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Abstract 
The interleukin-1 gene family in humans comprises eleven members (IL-1F1-
F11) that act as either functional agonists or antagonists of inflammation. Prior to this 
project, only two members of the IL-1 family had been identified and characterized in 
the chicken. The aim of this project was to identify, clone and characterise novel IL-1 
family members in this species.  
EST sequences representing IL-1F5 (IL-36RN) and the secretory and 
intracellular structural variants of IL-1 receptor antagonist (IL-1RN) were identified by 
their similarity with chicken IL-1β. 
Chicken IL-1RN (chIL-1RN) cDNAs were isolated from LPS-stimulated HD11 
cells. Two further putative splice variants (SVs) of both chIL-1RN structural variants 
were also isolated. Both full length variants of chIL-1RN exhibited biological activity 
resembling that of their mammalian orthologues. The four SVs, however, were not 
bioactive. ChIL-1RN was constitutively expressed in lymphoid and non-lymphoid 
tissues as well as several cell subsets. In response to bacterial and viral infection, chIL-
1RN expression was inducible. 
Chicken IL-36RN was cloned from a liver cDNA. In mammals, this cytokine is 
an IL-1RL2 receptor antagonist and downregulates LPS-mediated inflammation. IL-
1RL2 agonist ligands have not been identified in the chicken; therefore, an alternative 
bioassay to establish its function was attempted. Using a macrophage cell line, chIL-
36RN did not inhibit endotoxin-mediated inflammatory effects. Constitutive IL-36RN 
expression was found in all tissues and cell subsets examined. In response to viral 
infection, chIL-36RN expression was significantly downregulated.  
The eleven human IL-1 genes are encoded at three separate loci. Nine of these 
genes, including IL-1β, IL-1RN and IL-36RN, are present at a single locus. In the 
chicken genome, the equivalent locus contains only IL-1β. Neither IL-1RN nor IL-
36RN were identifiable anywhere in the chicken genome. Future work will seek to 
determine the true extent of the repertoire of chicken IL-1 family genes. 
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μ   Micro 
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Understanding the immune response in the chicken is of fundamental 
importance for both human health and the economy. Worldwide consumption of 
chicken is on an immense scale with around 50 billion chickens reared for meat and 
eggs every year. Farming of poultry is carried out in an industrialised manner, with a 
significant proportion of birds farmed under intensive conditions. With so many 
chickens in such close proximity to one another, the potential for disease outbreak is 
huge and has serious implications for both poultry and human health. Although many 
birds carrying disease may not survive the rearing process, others can carry subclinical 
disease whilst healthy birds may come into contact with faecal matter containing 
pathogens. This can lead to contamination of the final product. Food poisoning from 
zoonotic diseases such as salmonellosis and campylobacteriosis is a well-recognised, 
persistent problem caused mainly by contaminated poultry products. Avian-specific 
disease also leads to significant economic losses, despite routine vaccination against 
many different pathogens. Although many common avian diseases can be efficiently 
countered with a good vaccine, pathogens have developed several ingenious strategies 
for evading the host immune response. Resistance to a vaccine can therefore develop, 
causing widespread loss of birds thought to be protected. One striking example of this is 
Marek’s disease, where resistance to vaccination has driven the evolution of the virus to 
create novel strains with ever increasing virulence (Nair 2005). 
Understanding the underlying immunological mechanisms subverted by 
pathogens to nullify the host response is therefore crucial. This requires a 
comprehensive understanding of the basic immunobiology of the chicken, in particular 
identification of the immune gene repertoire it possesses. Once this has been 
established, deciphering which genes may have a significant contribution to 
immunopathogenesis can then feed into strategies for combating disease. Although 
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vaccination is clearly useful, selective breeding to incorporate, for example, particular 
allelic variants of genes which confer disease resistance, would be highly desirable. 
Likewise, removing alleles that increase disease susceptibility would be advantageous. 
Breeding more robust chickens that are better equipped to fight disease is undoubtedly a 
long term goal of the poultry industry. Understanding the innate immune response in 
Aves is clearly a major stepping stone towards effective disease prevention. The 
interleukin-1 (IL-1) family of genes plays a pivotal role in this innate response and can 
critically determine disease outcome and severity. Establishing exactly which IL-1 
genes are present in the chicken is therefore necessary.    
 
1.1 A general discussion on the difference between the human and 
chicken immune systems    
1.1.1 The innate immune response  
1.1.1.1 Humans  
The innate immune system acts as an initial barrier to prevent pathogens from 
invading a host and, in the event of physical defences being breached, to contain 
pathogens and limit the spread of infection. It is a collection of cells, proteins (receptors, 
cytokines, effector molecules) and anatomical barriers which provide the first line of 
defence. Innate responses are immediate and indiscriminate but do not confer inveterate 
protection to a host as the innate system has no capacity for immunological memory. 
Although generally considered as non-specific, innate recognition does differentiate 
between self and non-self and can also precisely identify different types of pathogen. 
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The innate response lasts up to around 96 hours post-infection after which time the 
adaptive system, if triggered, becomes more prominent. 
Physical barriers provide an initial affront to pathogens in the form of the 
various surface epithelia. Outer surface and internal mucosal membranes are tightly 
sealed to restrict pathogen entry. Cilia covering many surfaces can expel pathogens 
trapped in mucus by aiding its flow. Epithelia also secrete various substances to directly 
attack pathogens whilst reducing the opportunity for adherence. These include mucins, 
antimicrobial peptides such as the β-defensins, and enzymes such as lysozyme in tears 
and saliva. The GI tract is considerably microbicidal, with many fatty acids and 
enzymes in its upper region and a low pH in the stomach. Commensal bacteria also 
occupy most epithelia, competing with pathogens for space and nutrients whilst 
secreting their own antibacterial peptides.   
Should pathogenic organisms penetrate the epithelium, they become instantly 
recognised by macrophages which reside in many of the tissues that are close to 
epithelial surfaces. Further phagocytes, in the form of neutrophils, are attracted to areas 
of infection from the circulation. Neutrophils are a key component of the innate immune 
response as well as contributing significantly to the resolution of inflammation. 
Together, both cell types identify, engulf and eliminate a variety of pathogens. Several 
classes of preformed, germline-encoded receptors are expressed on the surface of 
phagocytes which directly recognise pathogens. The surfaces of bacteria and viruses 
consist of highly conserved repetitive structural motifs known as pathogen associated 
molecular patterns (PAMPs). The phagocyte receptors that detect PAMPs are 
collectively known as pattern recognition receptors (PRRs). The most extensively 
characterised group of PRRs are the Toll-like receptors (TLRs) which recognise a broad 
range of lipids, proteins, nucleic acids and sugars on the exterior of bacteria, viruses, 
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protozoa and fungi (Kawai and Akira 2010). Most TLRs are expressed on the surface of 
phagocytes; however, TLRs recognising viral (TLR3, 7, 8 and 13) and bacterial nucleic 
acids (TLR9) are found in intracellular endolysosomes. NOD-like receptors (NLRs) are 
another class of PRRs which sense bacterial, viral and protozoal PAMPs and also 
constitutive host molecules located in the cytoplasm of cells (Kumar, Kawai et al. 
2011). Cytoplasmic recognition of RNA viruses is further carried out by the RIG-I-like 
receptors (RLRs) RIG-I, MDA5 and LGP2, as well as AIM2, DAI, and RNA 
polymerase III (O'Neill and Bowie 2010). Other PRRs include the macrophage mannose 
receptor (MRC1) and scavenger receptors. MRC1 is a macrophage-specific C-type 
lectin present on the cell surface that detects carbohydrates present on bacteria and 
viruses. Scavenger receptors, present on the surface of phagocytes, recognize low 
density lipoproteins modified by acetylation or oxidation. Not all PRRs, however, are 
expressed on phagocytes, with some present as soluble proteins in blood and on 
epithelia. Examples of these include mannose-binding lection (MBL) and surfactant 
proteins.   
Binding of pathogen by PRRs on macrophages initiates a sequence of 
immunological effects which can eventually lead to priming the adaptive immune 
response. Pathogens can initially become phagocytosed and destroyed in 
phagolysosomes by acids, proteins and enzymes. Antimicrobial peptides, nitric oxide, 
hydrogen peroxide and superoxide are also synthesised within phagocytes to destroy 
engulfed pathogens. Production of superoxide is facilitated by NADPH oxidase via a 
mechanism termed the respiratory burst. Pathogen recognition also activates 
macrophages to initiate inflammation by releasing cytokines and chemokines. The 
purpose of inflammation is to increase the numbers of phagocytes at sites of infection, 
to kill invading microbes, to induce clotting of the microvasculature to limit the spread 
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of infection, and to repair damaged tissues. Engagement of PRRs initiates intracellular 
signalling pathways which leads to NF-κB-mediated pro-inflammatory cytokine 
production and IRF3/7-mediated production of type I interferons. Each different group 
of PRRs has its own specific intracellular signalling molecules, but this always 
culminates in activation of either NF-κB or IRF, irrespective of how a cell is stimulated 
(Kumar, Kawai et al. 2011). Activation of several NLRs by PAMPs, toxins or danger 
signals leads to assembly of the inflammasomes (Martinon, Mayor et al. 2009). The 
most comprehensively studied of these, known as NLRP3 (NALP3), plays a key role in 
the generation of mature IL-1β and IL-18 cytokines. NLRP3 is a complex of proteins 
which instigates the maturation of procaspase-1, leading to the activation of caspase-1. 
Mature caspase-1 then processes pro-IL-1β into its mature, bioactive form which is then 
secreted by cells (Figure 1.1) (Martinon, Mayor et al. 2009). 
Cytokines released by activated macrophages include the pro-inflammatory 
cytokines IL-1β, IL-6, IL-12 and TNF-α, the chemokine CXCL8 and the interferons 
IFN-α and IFN-β which induce scores of stimulatory effects. One important effect is the 
induction of co-stimulatory molecule expression on the surface of macrophages and 
dendritic cells (DCs). These cells then prime the adaptive response by presenting 
antigen to T cells. Neutrophils are attracted to sites of infection following stimulation 
with CXCL8. They adhere to endothelial surfaces in blood vessels by binding to 
selectins, which are highly expressed on endothelial cells during an inflammatory 
response. Neutrophils roll along the endothelium under the influence of CXCL8 before 
extravasating the endothelial wall by diapedesis and migrating through tissues down a 
CXCL8 concentration gradient to the site of infection.  Here, they phagocytose 
pathogens and participate in cellular crosstalk. They can also migrate to lymph nodes to 
affect the adaptive immune response  
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Figure 1.1 Assembly of the NALP3 (NLRP3) inflammasome. Activation of a cell 
leads to a fall in the intracellular concentration of K
+
 which initiates assembly of the 
NALP3 inflammasome. This induces the processing of procaspase-1, which in turn 
promotes the maturation of bioactive caspase-1. Caspase-1 enzymatically cleaves pro-
IL-1β/pro-IL-18 at a conserved aspartic acid residue, which generates mature IL-1β/IL-
18. The bioactive cytokine then leaves the cell. ASC = apoptosis-associated speck-like 
protein containing a C-terminal CARD domain; CARD = Caspase-activating 
recruitment domain; CARDINAL = CARD inhibitor of NF-κB-activating ligands; 
FIIND = function to find domain; LRR = leucine-rich repeat domain; NACHT = NAIP, 
CIITA, HET-E, TP-1 domain; NAD = NACHT-associated domain; PYR = pyrin 
domain. Figure adapted from Dinarello (2009).  
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(Mantovani, Cassatella et al. 2011). Many other pro-inflammatory effects are initiated 
by cytokines, and these are discussed in more detail in this Chapter, section 1.2.1.1.       
Another important component of innate immunity is the complement system, a 
cohort of plasma proteins which, through a series of sequential interactions with each 
other, operate to remove pathogens. Three major pathways have been identified which 
initiate complement activation: the classical pathway, the lectin pathway and the 
alternative pathway (Zipfel and Skerka 2009).  
An additional cellular contribution to the innate system comes from a small 
group of lymphocytes whose effector functions traverse both innate and adaptive 
immune responses. This group includes NK cells and the innate-like lymphocytes: B-1 
cells, γδ T cells and NKT cells. Finally, a novel innate effector cell population known as 
nuocytes have recently been described. They act as an early source of Th2 cytokines, 
priming the adaptive response against helminths (Neill, Wong et al. 2010). 
 
1.1.1.2 Chickens 
The innate immune response in the chicken could be accurately described as 
accommodating subtle differences amid general conformity with the system seen in 
humans. Both species have been separately evolving for over 300 million years, so this 
is perhaps to be expected. As with many areas of avian immunology, the availability of 
the chicken genome sequence has permitted the recent identification of a significant 
number of immune molecules previously “missing” in the chicken. Despite this, there 
are still many components of the human innate immune system for which an equivalent 
has yet to be recognised in the chicken.  
Avian macrophages appear to be phenotypically similar to those in mammals 
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although they have not yet been characterised to the same extent. Mammalian 
macrophages colonise tissues after migrating from the circulation, and this also appears 
to be the case for chicken macrophages. Here, they actively recognise, phagocytose and 
eliminate pathogens, similar to mammals. They contain anti-microbial proteins and 
enzymes in phagolysosomes, demonstrate respiratory burst activity and produce nitric 
oxide.  
Birds lack neutrophils and instead possess a functional equivalent known as the 
heterophil. These cells migrate to sites of infection more rapidly than other types and 
are the predominant subset in early innate responses. They phagocytose pathogens and 
eliminate them in phagolysosomes following degranulation. Unlike neutrophils, they do 
not contain myeloperoxidase and exhibit only modest respiratory burst activity. Similar 
to neutrophils, heterophils also have the ability to capture pathogens using extracellular 
traps (Chuammitri, Ostojic et al. 2009). 
Avian macrophages and heterophils express a different repertoire of PRRs 
compared with mammalian phagocytes. Those most well characterised are the TLRs, 
where notable species-specific differences are apparent. For example, the region of the 
human genome containing the TLR1, 6 and 10 genes has conserved synteny with a 
locus in the chicken containing a pair of genes named TLR1LA and TLR1LB (Kaiser, 
2010). In addition, the chicken genome contains two copies of TLR2 whereas only a 
single gene exists in humans. Bacterial PAMPs are recognised in humans by functional 
heterodimers of either TLR1 with TLR2, or TLR6 with TLR2 (Ozinsky, Underhill et al. 
2000). This cooperation between TLRs facilitates recognition of a wide range of 
bacterial TLR agonists. An equivalent mechanism has also been described in chickens 
whereby heterodimers form between TLR1LA and TLR2B, as well as between 
TLR1LB and TLR2A (Keestra, de Zoete et al. 2007; Higuchi, Matsuo et al. 2008). 
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There are also “missing” TLRs in the chicken with no obvious orthologues of huTLR9 
or huTLR11, whilst chTLR8 is a pseudogene (Philbin, Iqbal et al. 2005). Conversely, 
the chicken possesses genes for two TLRs (TLR15 and TLR21) which are absent in 
humans, although the latter is a direct functional equivalent of huTLR9 (Brownlie, Zhu 
et al. 2009). A comparison of the TLR repertoires of humans and chickens is provided 
in Table 1.1. Despite these striking differences between the species, there is no obvious 
loss of function in the chicken, which can deal with a comparable variety of PAMPs to 
those encountered by human TLRs.  
 
 Human Chicken chTLR identification 
 TLR1/6/10 TLR1LA and 
TLR1LB 
(Iqbal, Philbin et al. 
2005)a, (Yilmaz, Shen et 
al. 2005) 
 TLR2 TLR2A and TLR2B (Fukui, Inoue et al. 2001) 
Cell surface TLRs 
which 
TLR4 TLR4 (Leveque, Forgetta et al. 
2003) 
recognise cell 
surface PAMPs 
TLR5 TLR5 (Iqbal, Philbin et al. 
2005)b 
 TLR11 Not present  
 Not present TLR15 (Higgs, Cormican et al. 
2006) 
 TLR3 TLR3 (Iqbal, Philbin et al. 
2005)a 
Intracellular TLRs 
which  
TLR7 TLR7 (Philbin, Iqbal et al. 2005) 
recognise nucleic 
acids 
TLR8 Pseudogene (Philbin, Iqbal et al. 2005) 
 TLR9 TLR21 (functional 
equivalent ) 
(Roach, Glusman et al. 
2005) 
 
Table 1.1 The human and chicken Toll-like receptor families. 
 
Mannose-binding lectin and scavenger receptors are conserved in the chicken. 
However, many of the NLRs and RLRs found in humans are not. Notably, none of the 
NALPs have been identified in chickens, and NOD2 is also missing (Kaiser 2010). 
Additionally, RIG-I has yet to be found in the chicken (Barber, Aldridge et al. 2010). 
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However, MDA5 has been cloned and is functionally analogous to the human 
orthologue (Karpala, Stewart et al. 2011). The partial gene sequence for LGP2 
(DHX58) is apparent in the chicken genome (personal search), although it has missing 
exons at the N-terminal which are likely to be in the adjacent sequence gap. 
Although both NK and γδ T cells have been identified in the chicken, their 
contributions to the innate immune response have not been defined. A clear NKT cell 
population has yet to be described in the chicken (Rogers, Viertlboeck et al. 2008).  
All three complement pathways are present in the chicken (Nonaka and Kimura 
2006), although, fewer components of each have been isolated compared to mammals. 
1.1.2 The adaptive immune response  
1.1.2.1 Humans  
The adaptive immune response is required when innate defences are insufficient 
to clear invading pathogens. It is based around the central dogma of the recognition of 
specific antigen by lymphocytes bearing a distinct antigen receptor. Although the initial 
response to antigen is slow by comparison to the innate system, it confers long lasting 
protection which is both specific and rapid upon re-exposure to the same antigen.  
Two major types of lymphocytes are involved in adaptive immunity – T and B 
cells. Both express receptors that recognise a vast number of antigenic epitopes. This is 
the result of gene rearrangements which generate a hugely diverse repertoire of 
lymphocyte receptors. Both B and T cells originate from pluripotent haematopoietic 
stem cells in the bone marrow. B cells remain here and differentiate into immature B 
cells expressing immunoglobulin (Ig) on their surface. B cell precursors (pro-B cell) 
initially interact with stromal cells in the bone marrow leading to rearrangement of their 
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Ig genes. They then undergo negative selection where B cells which react strongly to 
self antigen are inactivated. Those that survive migrate to peripheral lymphoid organs, 
which, following activation by antigen and helper T cells, leads to their proliferation 
and differentiation into plasma or memory cells that secrete antibody (Ab). 
Immunoglobulins from a single B cell, either surface-bound as the B cell receptor 
(BCR) or as secreted Abs, have the same antigen specificity. Every Ig has the same 
basic Y-shaped structure comprising of a constant (C) region and a pair of variable (V) 
regions. The Fc portion of the C region of secreted Abs engage with immune cells to 
initiate effector mechanisms, however, membrane-bound BCRs expressed on the 
surface of B cells lack such an interaction. The V region is highly diverse and binds 
native antigen which has not required processing. Antibody structure is also defined by 
two heavy and two light chains which are comprised of both C and V regions. The two 
heavy chains are disulphide bonded to one another, and both are also attached to a light 
chain. The five different classes of immunoglobulin, IgA, IgD, IgE, IgG and IgM, are 
characterised by their different heavy chains, or isotypes, which confer specific 
functionality. Secreted antibodies perform three main functions which are to bind 
pathogens to neutralise them, to opsonise pathogens to facilitate phagocytosis by cells 
that recognise antibody, and to activate complement. 
T cells develop from lymphocyte progenitors in the bone marrow and then 
migrate to the thymus where they differentiate. Once in the thymus, their T cell receptor 
(TCR) genes become rearranged during a period of development and proliferation. 
Phases of thymocyte maturation can be distinguished by the presence of CD markers on 
the surface of developing cells. Thymocytes develop from double-negative (CD3
-
CD4
-
CD8
-) into one of two T cell lineages: either γδ+CD3+CD4-CD8- T cells or double-
positive αβ+CD3+CD4+CD8+ T cells which constitute the majority population 
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(Shortman and Wu 1996). Most thymocytes at the double positive stage then die after 
undergoing selection. Positive and negative selection determines whether T cells which 
recognise self MHC, but are not autoreactive to self antigen, survive. These cells are 
positively selected. Those which react too vigorously to self antigen are negatively 
selected and removed following apoptosis (Sebzda, Mariathasan et al. 1999). Positively 
selected cells mature into single-positive thymocytes (CD3
+
CD4
+
CD8
-
 or CD3
+
CD4
-
CD8
+
) which are then exported and migrate to peripheral lymphoid organs.  
DCs are potent antigen presenting cells (APCs) that reside in tissues and 
peripheral blood. Functionally, they traverse innate and adaptive immune responses to 
coordinate efficient pathogen clearance. Two major DC subsets, myeloid (mDC) and 
plasmacytoid (pDC), have been extensively characterised in mammals. They differ from 
one another in the numerous cell surface proteins they express, the cytokines they 
secrete and crucially, in the types of immune response they elicit. Adaptive responses 
are initially mobilised by activated DCs that have taken up antigen in peripheral tissues. 
They then migrate to lymphoid organs to present the processed antigen to naive T cells. 
Antigen recognition takes place when the membrane-bound TCR of a naive T cell 
identifies its antigen presented by major histocompatibility (MHC) molecules on the 
surface of antigen presenting cells (APC) (Germain 1994). MHC molecules are highly 
polymorphic and classed as either type I or type II based on the antigens they process 
and present. MHC Class I molecules are expressed by all nucleated cells in the body 
and present antigen from intracellular pathogens. Class II MHC molecules are found 
exclusively on the surface of antigen-presenting cells (DCs, B cells, macrophages) and 
display antigen from extracellular pathogens.  
Naive T cells which recognise their specific antigen undergo clonal expansion 
and differentiate into effector T cells. These can be divided into two major subsets – 
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CD8
+
 cytotoxic T cells which recognise antigen in the context of MHC I molecules, and 
CD4
+
 helper T cells that identify antigen presented by Class II MHC (Glimcher and 
Murphy 2000). Cytotoxic T cells drive a cell-mediated adaptive immune response 
where they secrete perforin and granzymes to directly kill infected cells, particularly 
those infected with virus. An ever-expanding group of CD4
+ 
helper T cells, which carry 
out a broad range of functions, has been identified. They are defined by the cytokines 
they secrete and transcription factors they express in addition to their surface phenotype 
(Glimcher and Murphy 2000). The best characterised of these are the Th1 and Th2 
subsets. Th1 cells secrete IFN-γ to activate macrophages which leads to the killing of 
cells infected with intracellular pathogens. Th2 cells secrete IL-4, IL-5 and IL-13 to 
promote antibody-mediated (humoral) responses against extracellular pathogens, but 
can also promote allergic immune responses (Glimcher and Murphy 2000). Other CD4
+ 
helper T cell subsets include Th17, Th9, Th22 and TFH (T follicular helper), which 
between them instigate a range of protective responses to clear pathogens. A further 
subset known as regulatory T cells (Treg) mediate immunosuppression by dampening 
inflammatory responses. Two major types of Treg cells have been identified in humans: 
natural Treg cells (nTreg), and inducible Treg cells (iTreg) of which there are two subsets, 
type 1 regulatory T cells (TR1) and T helper 3 T cells (Th3) (Bettini and Vignali 2010). 
Both nTreg and iTreg cells secrete IL-10 in order to mediate immunosuppression and 
tolerance; however, there are a number of key differences between these populations. 
The nTreg population is generated in the thymus, expresses the FoxP3 transcription 
factor and secretes IL-10 and TGF-β. By contrast, iTreg cells are generated in the 
periphery. Th3 cells express FoxP3 but TR1 cells do not. Th3 cells primarily secrete 
TGF-β, whereas TR1 cells secrete many more cytokines, including IL-5 and IFN-γ (in 
addition to IL-10 and TGF-β) (Bettini and Vignali 2010).  
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Lymphocytes which persist after an infection has been cleared are called 
memory cells and provide long-term protective immunity against further exposure to the 
same pathogen. Upon re-encountering this pathogen, relevant memory cells are rapidly 
activated to produce a more robust and faster response. Memory B cells secrete 
antibodies which have a higher affinity for the antigen, following rearrangement of their 
BCR variable region genes by somatic hypermutation. This ensures further exposure 
will lead to an even more specific response. Memory T cells are present in much greater 
abundance than naive T cells specific for the same antigen. They are long-lived and can 
be identified by a distinct cohort of cell surface proteins, the types of responses upon 
activation and expression of cell survival genes. Two types of memory T cells, effector 
and central, exist. Effector memory T cells, upon activation, differentiate into an 
effector T cell which secretes multiple cytokines and migrates to tissues. Central 
memory T cells are more slow acting, do not rapidly secrete cytokines and stay in 
peripheral lymphoid tissues following activation.    
1.1.2.2 Chickens  
Despite a number of prominent differences between the human and chicken 
adaptive immune systems, they generate a broadly similar response to infection. The 
chicken possesses both B and T cell populations; however, their development is 
different compared to that of mammalian lymphocytes. Chicken B cell precursors 
develop from stem cells in the para-aortic foci, the allantois, and the bone marrow 
during embryonic development. Within these haematopoietic tissues, they undergo Ig 
gene rearrangement before migrating to a specialised gut-associated lymphoid organ 
known as the bursa of Fabricius. The bursa is colonised in a single period from 
embryonic incubation days (EID) 8-15, after which it rapidly increases in size due to 
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intense B cell proliferation. Once a chick has hatched, the bursa further increases in size 
as B cells continue to proliferate until ~3 months post-hatch. At this point, the bursa 
begins to involute and has disappeared after 6 months. Chicken BCR diversity emerges 
through a different mechanism to the one described in mammals. In mammals, Ig gene 
rearrangement generates Ab diversity. In birds, rearrangement of Ig genes also takes 
place; however, Ab diversity is created by somatic gene conversion. This is a one-off 
event which provides a bird with its BCR repertoire for life. This is in stark contrast to 
mammals, where Ab diversity is continuously generated (Ratcliffe 2006).  
Compared with mammals, birds possess limited Ab isotype diversity, having 
only IgA, IgM and IgY. The latter is the functional equivalent of IgG in mammals but 
does not undergo subtype switching. Birds lack homologues of IgD and IgE (Ratcliffe 
2006).   
B cells emigrate from the bursa into the periphery; however, only ~5% of the 
total mature B cell population survives. Although the bursa has involuted fully after 6 
months, peripheral blood maintains a steady supply of B cells. These are known as 
extra-bursal cells and it is thought they derive from the spleen; however, in 
bursectomized birds, levels of this population are reduced, indicating the earliest 
precursors of this B cell population originate in the bursa (Paramithiotis and Ratcliffe 
1993). The activation of chicken B cells to stimulate antibody production is similar to 
mammals in that it requires both exposure to antigen and interaction with helper T cells 
(Vainio, Koch et al. 1984).  
Chicken T cell precursors originate in the blood before migrating to the thymus. 
These cells populate the thymus in three separate stages during embryonic development 
at EID6, 12 and 18 (Coltey, Bucy et al. 1989). Both the development of avian T cells 
and the generation of TCR diversity in the thymus appear to resemble the mechanisms 
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in mammals. Variability in the chicken TCR is therefore created through somatic DNA 
recombination. Three distinct lineages of mature T cells, characterized by the 
monoclonal antibodies that recognise them, develop in the thymus. These cells then 
leave the thymus in three separate stages. TCR1
+
 cells comprise the γδ T cell population 
which appear in the spleen at EID15.  Notably, they constitute a much bigger proportion 
of total peripheral lymphocytes in birds than the respective population in humans (20-
60% compared with 5-10%). The TCR2
+
 (αβ Vβ1 TCR) cells are the next to leave, and 
are localised in the spleen at EID19. Finally, the TCR3
+
 (αβ Vβ2 TCR) cells leave the 
thymus and appear in the spleen at 2 days post-hatch. As in mammals, the chicken αβ 
populations are double-positive CD4+CD8+ cells which are positively selected, mature 
into single-positive thymocytes (CD3
+
CD4
+
CD8
-
 or CD3
+
CD4
-
CD8
+
) (Davidson and 
Boyd 1992) and are then exported. 
A limited amount of evidence has shown that CD4
+
 helper T cells and CD8
+
 
cytotoxic T cells, that are MHC restricted, are present in the chicken. Based on cytokine 
secretion, the Th1/Th2 paradigm appears to be conserved in Aves (Gobel, Schneider et 
al. 2003; Degen, Daal et al. 2005). In addition, a Treg subset with immunosuppressive 
activity has recently been identified in the chicken (Shanmugasundaram and Selvaraj 
2011).   
As in humans, avian APCs process antigen and present it in the context of MHC 
molecules. The repertoire and genomic organization of MHC genes in the chicken, 
however, differs greatly from that in humans. Firstly, the chicken MHC (B locus) is 
around 20 times smaller than the human HLA locus, and is missing orthologues of 
many genes found in the human MHC (Kaufman, Milne et al. 1999). For example, most 
of the HLA Class III region is absent in the chicken. Of those genes found in the 
chicken, however, most have a direct orthologue in man. There are also some genes in 
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the avian MHC that lack human orthologues. The chicken contains only two class I and 
two class IIβ genes, with each class having a dominantly expressed, highly polymorphic 
major gene and a much less expressed, less polymorphic minor gene. The two class I 
genes flank the TAP1 and TAP2 genes in the chicken, whereas the TAP genes in 
humans are found in the class II region. The tapasin gene is situated between the two 
class IIβ genes in the chicken, but is separated from the class II genes by ~100 kb in 
mammals (Kaufman, Jacob et al. 1999). Finally, the class III region in humans separates 
the class I and II regions, but in the chicken, the class II and class III regions are 
separated by the class I region (Kaufman, Milne et al. 1999).      
1.1.3 Repertoires of cells and structural features 
Chickens possess the majority of the major populations of immune cells found 
in humans; however, several differences in the repertoires of the two species are 
apparent. Of the three types of granulocytes present in humans, chickens only possess 
basophils. They lack neutrophils; however, they possess a functional equivalent dubbed 
the heterophil which has demonstrated a prominent role in innate responses (Harmon 
1998). Chickens also lack a direct functional equivalent of human eosinophils, which 
suggest birds may have developed a mechanism to compensate for the key functional 
roles that this subset performs in mammals in allergic and Th2 cell responses. Chickens 
do, however, possess mast cells which also play a central role in the progression of 
many allergic responses. The three major classes of lymphocyte are present in chickens, 
although NKT cells and several of the novel subsets of Th cells identified in mammals 
have yet to be described in birds.   
There are a number of distinctive structural features of the avian lymphoid 
system. For example, chickens lack the classical lymph nodes found in man and instead 
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possess “dermal lymphoid nodules” (Igyarto, Lacko et al. 2006). These lymphoid 
aggregates bear very little resemblance to the human lymph node and, as such, it is not 
yet clear where antigen presentation takes place in the chicken. 
The chicken also contains bronchial associated lymphoid tissue (BALT) and 
several gut-associated lymphoid tissues (GALT) which are not present in man. One 
example is the caecal tonsils which are lymphoid tissue aggregates containing both 
lymphocytes and phagocytes found at the proximal end of the caecum, a blind pouch at 
the junction of the ileum and the colon. Within the jejunum of the chicken is a lymphoid 
organ known as Meckel’s diverticulum. It contains germinal centres and is a source of 
antibody-secreting plasma cells. Chickens also possess a Harderian gland which is 
found behind the eye, contains externally sourced lymphocytes, and appears to be a site 
of B cell differentiation.    
1.1.4 Cytokines  
1.1.4.1 Humans   
Cytokines are small signalling molecules that coordinate the functional 
properties of the cells involved in an immune response. They are typically produced in 
response to stimulation of a cell and can either be secreted by or retained within a cell to 
elicit their function. Secreted cytokines can affect cells in an autocrine, paracrine or 
endocrine manner. Collectively, cytokines have a diverse range of functions in both 
innate and adaptive immunity and have the capacity to either propagate or inhibit 
immune responses. Cytokines are classified according to their functional properties for 
which six major functional groups exist; interleukins (IL), colony-stimulating factors 
(CSF), interferons (IFN), transforming growth factors (TGF), tumour necrosis factors 
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(TNF) and chemokines. Interleukin, meaning “between leukocytes”, was originally 
coined to denote the fact they were produced by and acted upon white blood cells. This 
is now known to reflect only a small aspect of their biology as their synthesis is 
ubiquitous and they act on many different tissues. At present, around 40 interleukins 
have been identified in mammals, which are grouped into 6 major structural and 
functional subfamilies (IL-1, IL-10, IL-12, IL-17, T cell proliferative, and Th2) plus a 
small group of ILs which are sufficiently unique to remain unassigned. CSFs promote 
the differentiation of stem cells by directly activating them. IFNs stimulate 
macrophages and NK cells to elicit anti-viral immune responses. They can also increase 
the clearance of bacteria and viruses, as well as alerting the immune system to the 
existence of cancer. TGFs have several roles which include inhibiting cell growth, 
promoting cell survival and anti-inflammatory capability. The TNFs are pro-
inflammatory cytokines that restrict tumour growth and induce apoptosis. Chemokines 
are critically important during inflammation, where they orchestrate the activation and 
migration of phagocytes to sites of infection, and homeostasis.     
1.1.4.2 Chickens    
Considerable progress has been made over the past decade to decipher the 
number of different cytokine genes in the chicken (Kaiser 2010). Progress was initially 
slow due to a paucity of reagents and low sequence identity with mammalian 
orthologues making identification challenging. The availability of the genome sequence 
(Wallis, Aerts et al. 2004), however, has hastened the rate at which new genes have 
been uncovered. Birds appear to possess fewer members of each distinct cytokine 
family; however, novel genes continue to be discovered so it is likely the true extent of 
the avian cytokine repertoire has yet to be realised. To date, genomic and EST analysis 
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has identified the genes for 27 interleukins, all three TGFs, 12 TNFSF members, all 
three CSFs, 10 type I IFNs, IFN-γ, a single IFN-λ, and 24 chemokines (Kaiser 2010). Of 
those identified so far in the chicken, effector functions appear to be conserved despite 
relatively low amino acid identities (18-40%) with human homologues. Although 
lacking certain direct orthologues from each family, birds appear to possess most Th1, 
Th2, Th17 and IL-10 family cytokines found in humans, emphasizing the probable 
conservation of their distinct T cell lineages in birds. Of the pro-inflammatory 
cytokines, IL-1β and IL-6 are present but TNF-α, one of the major pro-inflammatory 
cytokines found in mammals, is notably absent. Strikingly, significantly fewer IL-1 
family cytokines have been identified in the chicken compared with the number of these 
genes discovered in mammals. This is discussed in more detail in this Chapter, section 
1.3.4.  
1.2 The Interleukin-1 gene family 
The interleukin-1 family consists of a large group of ligands and their receptors 
which have both pro- and anti-inflammatory activities. In humans, the family contains 
eleven ligand genes encoded at three separate loci. Nine of these, including IL-1 
receptor antagonist (IL-1RN), are present at a single locus on chromosome 2, whereas 
IL-18 and IL-33 lie on chromosomes 11 and 9 respectively. Ligands are named IL-1F1-
F11 (Sims, Nicklin et al. 2001), however, this nomenclature has recently been partially 
revised (Dinarello, Arend et al. 2010). Members IL-1F5-F9 are now named IL-36RN, 
IL-36α, IL-37, IL-36β, and IL-36γ, respectively (Dinarello, Arend et al. 2010).  
Ligand members have a broad and sometimes overlapping range of prominent 
roles in innate and adaptive immune responses. They have arisen following gene 
duplication which is reflected in their many shared characteristics. For instance, they are 
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structurally related to one another and encode three common exons which are at the C-
terminus of every IL-1F gene. Within the final exon is a 63 bp sequence motif which is 
highly conserved in all eleven genes and is the defining signature of the IL-1 family 
(Nicklin, Barton et al. 2002). This section describes the specific bioactivities, 
expression, regulation and genomic organisation for each of the different ligands and 
receptors.      
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1.2.1 IL-1 ligands in mammals 
1.2.1.1 IL-1F1 (IL-1α) and IL-1F2 (IL-1β) 
Unless specified otherwise, the term “IL-1” is usually used to denote both IL-1α 
and IL-1β. This is due to the fact that these pleiotropic, pro-inflammatory cytokines 
have identical bioactivities. Although they share the same function, they do differ from 
one another in many ways. This section will firstly describe their general, shared effects, 
followed by a description of their major differences. 
IL-1 affects multiple biological processes through its ability to act upon almost 
every tissue and cell type in the body. Its most prominent, well-characterised role is as a 
potent modulator of inflammation. It does this by increasing the transcription of a vast 
range of inducible genes (Dinarello 1996). IL-1 initiates the (intracellular) inflammatory 
cascade by upregulating transcription of the genes encoding the pro-inflammatory 
mediators cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and type 
II phospholipase A2 (PLA2). The consequent increase in abundance of these enzymes 
leads to a surge in the production of leukotrienes, nitric oxide, platelet-activating factor 
and prostanoids. It is these mediator molecules that are responsible for fever, 
inflammation, vasodilation and increased vascular permeability, hypotension, a reduced 
pain threshold and ultimately, the destruction of tissues (Dinarello 2000; Dinarello 
2009). Other important effects elicited by IL-1 include activation of JNK, p38, and 
members of the mitogen-activated protein kinase (MAPK) signalling pathway; 
increased transcription of pro-inflammatory genes via the transcription factors NF-κB, 
AP-1 and C/EBPβ; increased expression of endothelial surface adhesion molecules; 
increased synthesis of numerous chemokines, many other cytokines (particularly IL-6, 
TNF-α and CSF1-3) and their receptors, matrix metalloproteinases, acute phase proteins 
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in the liver, growth factors, lipids, extracellular matrix components; and the activation 
and migration of neutrophils (Dinarello 1996; Dinarello 2000). Many of these effects 
are brought about when IL-1 acts synergistically with either bradykinin, TNF-α/IL-
6/CSF or a growth factor (Dinarello 1996). The majority of these effects are instigated 
by the major target cell populations of IL-1 during the innate immune response, which 
are DCs, macrophages, monocytes, neutrophils, basophils and mast cells (Sims and 
Smith 2010).  
In addition to its major pro-inflammatory role, IL-1 also has the capacity to co-
stimulate T cells. For example, it influences the Th2-mediated immune response in 
asthma. In experimental mouse models, rodents that lack IL-1RI or have been injected 
with anti-IL-1β antibodies exhibit an attenuated reaction when challenged with allergen 
(Johnson, Yucesoy et al. 2005). IL-1 is indispensible for IL-17 production from Th17 
cells. Naive CD4
+
 T cells differentiate into Th17 cells following stimulation with either 
TGF-β plus IL-6 (Bettelli, Carrier et al. 2006) or IL-1β/α plus IL-23 (Chung, Chang et 
al. 2009). These early Th17 cells show relatively high expression of IL-1RI (Chung, 
Chang et al. 2009) and, following further stimulation with IL-1 plus a STAT3-inducing 
cytokine (IL-6, IL-21 or IL-23), become fully committed Th17 cells (Guo, Wei et al. 
2009). STAT3 induction with IL-1 stimulation induces RORγt in Th17 cells, leading to 
IL-17 production independently of TCR stimulation (Guo, Wei et al. 2009).  
IL-1 is able to affect a broad range of fundamental, physiological effects, and as 
such it is no surprise that it is strongly associated with a large number of different 
diseases. To date, IL-1 has been recognised as contributing to the pathogenesis of 
several forms of arthritis, type-2 diabetes, several forms of cancer, atherosclerosis, heart 
disease and heart failure as well as a growing number of autoinflammatory diseases 
(Dinarello 1996; Dinarello 2011).    
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The number of agents capable of inducing IL-1 production is vast. These include 
many cytokines (including IL-1 itself), other inflammatory agents (e.g. C5a, CRP), 
clotting factors (e.g. thrombin), cell matrix-associated factors (e.g. collagen), stress 
factors (e.g. hypoxia), neuroactive agents (e.g. melatonin), lipids (e.g. oxLDL), and 
many drugs. Most known viruses, bacteria and many fungi are also able to increase its 
production (Dinarello 1996). 
Both IL-1β and IL-1α signal through the IL-1RI. Upon receptor engagement, IL-
1RAcP, a co-receptor essential for IL-1 signalling, is recruited on the cell surface 
leading to signal transduction and increased transcription of inducible genes. Both 
ligands also share the same three dimensional structure, the β-trefoil. This is comprised 
of a 6 β-strand “barrel”, at one end of which a further 6 β-strands are located (Murzin, 
Lesk et al. 1992). The β-trefoil structure (Figure 1.2) is separated into 3 distinct trefoils, 
each of which consists of a hairpin loop and a β-sheet (Chavez, Gosavi et al. 2006). The 
crystal structure of the first IL-1 family member, IL-1β, was determined by (Priestle, 
Schar et al. 1989) at 2.0 Å resolution. Subsequent elucidation of the IL-1α structure 
(Graves, Hatada et al. 1990) reported substantial similarity to that of IL-1β, except for 3 
important differences. In addition to the 12 β-strands (of IL-1β), the IL-1α molecule has 
3 further secondary structure components: 2 extra β-strands (one close to the N-
terminus), and, between residues 101-105, 2 “turns” of a 310 helix. Having the extra β-
strand adjacent to the N-terminus results in this end of the protein being situated in a 
different position within IL-1α to where it is found in IL-1β (Graves, Hatada et al. 
1990). It has been proposed this may account for both precursor and mature forms of 
IL-1α being biologically active. 
IL-1α has a number of distinctive properties which set it apart from IL-1β. First, 
its synthesis and maturation is strikingly different from that of IL-1β. IL-1α is translated 
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Figure 1.2 The general β-trefoil protein structure. A. The 12 β strands which form 
the cap and barrel are coloured in blue and pink, respectively. B. When the protein is 
folded, β strands form three distinct trefoils with “three-fold pseudo-symmetry”. 
Diagram reproduced from Chavez, Gosavi et al. (2006). 
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as a biologically active precursor (Mosley, Urdal et al. 1987) containing a pro-domain 
which is then processed in one of two potential ways. Either it is cleaved by the 
membrane-associated cysteine protease calpain (Kobayashi, Yamamoto et al. 1990) or it 
is myristoylated (Stevenson, Bursten et al. 1993), which localises it to the plasma 
membrane where it becomes inserted (Kurt-Jones, Beller et al. 1985). The majority of 
IL-1α is retained intracellularly and is not secreted (Lonnemann, Endres et al. 1989). By 
contrast, IL-1β is synthesised as a biologically inactive molecule containing a pro-
domain (Jobling, Auron et al. 1988), which is cleaved by caspase-1 at a conserved 
aspartic acid residue (Black, Kronheim et al. 1988) facilitating secretion. The 
mechanisms underlying IL-1β processing and secretion are complicated and not fully 
understood. What is clear, however, is that caspase-1 activation is dependent upon 
assembly of the NALP3 inflammasome (Agostini, Martinon et al. 2004). Several 
alternative proteases, such as proteinase-3, are also able to process IL-1β (Figure 1.3) 
(Dinarello 2011). Secretion of the mature protein occurs thereafter via one of five 
possible mechanisms involving either vesicles, lysosomes, exosomes, membrane 
transporters or passive secretion upon lysis (Figure 1.4) (Qu, 2007), although exactly 
which process is correct is not known.   
Calpain protease cleavage of IL-1α yields the N-terminal propiece and the 
mature cytokine which are both bioactive. A recent study has elucidated the mechanism 
underlying secretion of IL-1α (Fettelschoss, Kistowska et al. 2011). Mature IL-1α is 
directly bound by IL-1β which acts as a shuttle to transfer IL-1α out of a cell. This 
process is dependent on activation of both the inflammasome and caspase-1, which are 
needed for IL-1β maturation. The presence of IL-1β is essential given that IL-1β-/- mice 
do not secrete mature IL-1α. The propiece along with full length pro-IL-1α, however, 
translocate to the nucleus - one of the major recognised features of IL-1α which 
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distinguishes it from IL-1β (Figure 1.5). Both IL-1α species possess a nuclear 
localisation sequence (KVLKKRR) which directs them across the nuclear membrane 
(Wessendorf, Garfinkel et al. 1993). Once intranuclear, IL-1α elicits a range of 
functional effects which can be broadly categorised into three main types of effects: on 
cellular growth/proliferation/death, on gene expression and on the  
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Figure 1.3 Non-caspase-1 processing of pro-IL-1β. Neutrophil proteases process pro-
IL-1β at residues (E111, Y113, and R120) near the caspase-1 cleavage site (D) in the 
human sequence (indicated with black arrows). The chicken sequence lacks a conserved 
aspartic acid residue at the corresponding site. However, bioassays have indicated chIL-
1β is cleaved in this region (Gyorfy, Ohnemus et al. 2003). Although similar proteases 
to those found in neutrophils have yet to be identified in avian heterophils, their cut sites 
are conserved in the chIL-1β amino acid sequence (indicated with blue arrows). The 
stippled green box indicates residues which belong to the pro-domain. The solid green 
box indicates the residues which belong to the mature protein. Figure adapted from 
Dinarello (2011). 
 
 
migration of cells (Luheshi, Rothwell et al. 2009). The exact mechanisms underlying 
these reported effects have yet to be thoroughly characterised. However, IL-1α directly 
binds to either RNA-binding proteins, histone acetyltransferases, IL-1RII, HS1-
associated protein X-1 (HAX-1) or necdin (Luheshi, Rothwell et al. 2009). To date, the 
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intranuclear effects of IL-1α have only been demonstrated in vitro. Some pro-IL-1α is 
myristoylated then inserted into the plasma membrane. 
IL-1 is produced by a range of different cells, including DCs, monocytes, 
macrophages, mast cells, neutrophils, B and T cells, endothelial cells, epithelial cells 
and cells undergoing lysis. IL-1α is produced (although not secreted) by the entire range 
of cells; however, IL-1β is predominantly secreted by monocytes and macrophages 
(Sims and Smith 2010). IL-1α is also constitutively expressed, whereas basal expression 
of IL-1β mRNA is very low (Dinarello 1996).  
A distinguishing feature of IL-1β is the discordance between transcription and 
translation. Several non-microbial ligands induce high levels of IL-1β transcription in 
monocytes; however, only a fraction of this mRNA is translated, with the majority 
being degraded (Dinarello 1996). A conserved “instability element” in the IL-1β coding 
region (functionally proven for IL-1F7b and inferred for IL-1β by alignment) is 
responsible for the lack of translation (Bufler, Gamboni-Robertson et al. 2004). 
Translation is significantly increased when these monocytes are subsequently 
stimulatedwith LPS or IL-1β (Schindler, Clark et al. 1990). It has been proposed that the 
3’ UTR of IL-1β mRNA is stabilised by these ligands (Dinarello 1996).  
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Figure 1.4 Potential mechanisms of mature IL-1β release. Pathway A indicates the 
formation of multivesicular bodies to release IL-1β in exosomes. Pathway B outlines the 
release of IL-1β by exocytosis from secretory lysosomes which fuse with the plasma 
membrane. Pathway C suggests IL-1β is released from cells in microvesicles which bud 
from the membrane. IL-1β is subsequently released from vesicles. Pathway D describes 
IL-1β release from a cell through ATP-activated membrane transporters. A fifth 
mechanism has suggested IL-1β is passively released when cells are lysed. Figure 
reproduced from (Qu, Franchi et al. 2007). Copyright 2007. The American Association 
of Immunologists, Inc. 
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Figure 1.5 Calpain-dependant processing and maturation of IL-1α. 
Cleavage of pro-IL-1α yields the N-terminal propiece and the mature cytokine (mIL-1α) 
both of which are bioactive. A very small amount of mIL-1α is released in an IL-1β, 
inflammasome and caspase-1-dependent manner. The NH2-terminal propiece 
translocates to the nucleus to mediate intracellular effects. Pro-IL-1α enters the nucleus 
or becomes myristoylated which promotes localisation to the plasma membrane for 
insertion. Figure reproduced from Gabay, Lamacchia et al. (2010).  
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1.2.1.2 IL-1F3 (IL-1RN) 
IL-1RN is an endogenous antagonist of inflammation. It physically blocks the 
IL-1RI preventing IL-1α and IL-1β from binding, which effectively limits 
inflammation. Target cells only require occupation of three to five IL-1RI with IL-1 to 
be fully stimulated. Such exceptional sensitivity combined with a relatively high 
abundance of IL-1RI on target cells means that a minimum of a 100-fold excess of IL-
1RN (over IL-1) is required to inhibit cell activation (Arend and Guthridge 2000). 
IL-1RN does not activate signal transduction (Dripps, Brandhuber et al. 1991), 
as it lacks the specific amino acids required to engage IL-1RAcP on the cell surface 
(Schreuder, Tardif et al. 1997; Wang, Zhang et al. 2010). Although IL-1RN binds to IL-
1RI with near equal affinity to that of IL-1α and IL-1β (Dinarello 1996), it does not act 
as an agonist, as administering a million-fold excess (over IL-1α and IL-1β) of the 
cytokine in humans has no biological effect (Granowitz, Porat et al. 1992).  
In mammals, there are two major structural variants of IL-1RN - secretory (sIL-
1RN) and intracellular (icIL-1RN). The sIL-1RN variant contains a 25 aa signal 
sequence that is cleaved by a signal peptidase to permit post-translational modification 
and secretion of the protein via the secretory pathway (Eisenberg, Evans et al. 1990; 
Walter and Johnson 1994). Intracellular IL-1RN is retained within the cell as it lacks a 
signal peptide. In mammals, three alternatively spliced isoforms of icIL-1RN have been 
described. The first intracellular variant to be described, icIL-1RN1, is formed through 
alternative splicing of an upstream exon into the N-terminus of the sIL-1RN mRNA 
(Haskill, Martin et al. 1991). An additional upstream exon is spliced in between exons 1 
and 2 of icIL-1RN1 to form icIL-1RN2 (Muzio, Polentarutti et al. 1995). The protein 
product of this variant has yet to be identified in vivo. The third intracellular variant, 
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icIL-1RN3, is created through use of an alternative translation initiation site located in 
exon 2 of the sIL-1RN transcript (Malyak, Guthridge et al. 1998). Although it has 
received no attention beyond the report describing its discovery, a fourth intracellular 
variant has been described (Holtkamp, de Vos et al. 1999), formed through yet another 
upstream exon which is spliced in between exons 1 and 2 of icIL-1RN2. Critically, this 
exon encodes an in-frame stop codon, which results in the predicted protein being 
significantly truncated to 27 amino acids in length. These variants are discussed in more 
detail in Chapter 5, section 5.1. 
The biological role of sIL-1RN appears to be limited to blocking IL-1RI on the 
cell surface. By contrast, the icIL-1RN isoforms may function through any of three 
different mechanisms. Firstly, icIL-1RN may suppress intracellular signalling in a non-
classical (non-IL-1R-dependent) manner (Banda, Guthridge et al. 2005). Secondly, 
icIL-1RN1 may compete with IL-1α in the nucleus to inhibit the effects of the agonist 
(Merhi-Soussi, Berti et al. 2005). Thirdly, icIL-1RN isoforms may be released from 
cells and bind to membrane- bound IL-1RI to limit IL-1 activity, in a similar way to 
sIL-1RN (Corradi, Franzi et al. 1995; Levine, Wu et al. 1997; Yoon, Zhu et al. 1999; 
Evans, Dower et al. 2006). These three possible mechanisms are discussed in more 
detail in Chapter 5, section 5.1.  
Global analysis of IL-1RN expression in tissues has been carried out in rabbits 
(Apostolopoulos, Ross et al. 1996; Matsukawa, Fukumoto et al. 1997), mice (Gabay, 
Porter et al. 1997), and rainbow trout (Wang, Bird et al. 2009), but not in humans. In 
rabbits, expression of the secretory transcript was constitutive in all of the tissues 
analysed. However, icIL-1RN expression was restricted to caecum, kidney, skin and 
thymus. In mice, sIL-1RN expression was undetectable and only skin contained 
constitutively expressed icIL-1RN. When LPS was used to stimulate mouse tissues, 
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intracellular transcripts were detected in the kidney, liver and spleen. Basal expression 
of IL-1RN in rainbow trout was ubiquitous.  
The expression of IL-1RN in distinct cell populations has been extensively 
characterised in humans and mice. Secretory IL-1RN is expressed in all cells able to 
transcribe IL-1α and IL-1β, with particularly high levels of expression found in 
monocytes, macrophages, neutrophils and fibroblasts (Eisenberg, Evans et al. 1990; 
Arend, Smith et al. 1991; Janson, Hance et al. 1991; Malyak, Smith et al. 1998). By 
contrast, expression of icIL-1RN is highly restricted, being found in only a limited 
range of cell types. Expression of each of the different intracellular isoforms has been 
determined in vivo. The icIL-1RN1 protein is predominantly found in endothelial cells, 
epithelial cells, fibroblasts, keratinocytes and macrophages (Haskill, Martin et al. 1991; 
Andersson, Bjork et al. 1992; Bigler, Norris et al. 1992; Hammerberg, Arend et al. 
1992). A single report has described icIL-1RN2 expression in fibroblasts, keratinocytes, 
monocytes and polymorphonuclear cells (Muzio, Polentarutti et al. 1995). However, the 
protein product of this variant has never been identified in vivo by any other groups. 
Neutrophils, PBMCs (Malyak, Smith et al. 1998) and hepatocytes (Gabay, Porter et al. 
1999) are the major cell types that express icIL-1RN3.  
A broad range of different agents induce IL-1RN expression, of which LPS, 
adherent IgG (Arend, Smith et al. 1991) and the cytokines GM-CSF (Roux-Lombard, 
Modoux et al. 1989; Shields, Bernasconi et al. 1990) and IL-4 (Fenton, Buras et al. 
1992; Vannier, Miller et al. 1992) are the most effective substances in vitro. A similarly 
vast number of agents induce IL-1RN production in vivo. These include almost all 
known bacteria and viruses, many fungi, as well as multiple cytokines, enzymes and 
plasma proteins (Dinarello 1996). IL-1RN protein levels are also increased in all disease 
states in which IL-1 is raised (Arend, Malyak et al. 1998).   
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1.2.1.3 IL-1F4 (IL-18)  
IL-18 induces scores of functional effects to regulate innate and adaptive 
immune responses. Most notably, it initiates both Th1-mediated and pro-inflammatory 
immune responses via its major target cell populations of Th1 cells, macrophages, DCs, 
basophils, NK cells and NKT cells (Smith 2011). IL-18 activates Th1 cells to proliferate 
and produce IFN-γ in the absence of TCR stimulation. In order to elicit the Th1 
response, cells must be co-stimulated with IL-12 or IL-15. Without one of these 
cytokines, IL-18 induces a Th2 response characterised by IL-4 and IL-13 production 
(Nakanishi, Yoshimoto et al. 2001). IL-18 activates its target cells to effectively clear 
bacteria, fungi, viruses and protozoa. Neutrophils and macrophages kill bacteria and 
fungi following activation by IL-18-induced IFN-γ (van de Veerdonk, Netea et al. 
2011). Anti-viral responses are coordinated following stimulation of antigen-specific 
CD8
+
 T cells, which leads to expansion of this population and downstream effector 
responses such as IFN-γ-mediated nitric oxide production (Gracie, Robertson et al. 
2003). The cytolytic properties of NK cells are enhanced by IL-18 stimulation (Smith 
2011), which can lead to effective antifungal activity (Gracie, Robertson et al. 2003). 
Bacteria and viruses can also be cleared, following increased innate responses, by NKT 
cells activated with IL-18. Multiple host-protective pro-inflammatory immune effects 
are modulated following stimulation of monocytes, macrophages, DCs and neutrophils 
by IL-18 (Smith 2011). IL-18 also has a pathological role in several autoimmune and 
inflammatory conditions (Nakanishi, Yoshimoto et al. 2001). 
IL-18 binds to the IL-18Rα, recruiting its co-receptor IL-18β (IL-18RAcP) to 
facilitate signal transduction. Its activity is regulated by an endogenous inhibitor, IL-18 
binding protein (IL-18BP) (Novick, Kim et al. 1999). It does not act as a receptor 
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antagonist but instead directly binds the cytokine to neutralise its activity. Several viral 
homologues of IL-18BP have been identified which act to restrict the host immune 
response in infected cells (Born, Morrison et al. 2000; Smith, Bryant et al. 2000; 
Calderara, Xiang et al. 2001; Xiang and Moss 2001).   
As befits a cytokine with such a broad spectrum of effector functions, it is 
widely expressed. It has been detected in adrenal cortex cells, DCs, intestinal epithelial 
cells, keratinocytes, Kupffer cells, macrophages, microglial cells, monocytes, 
osteoblasts and synovial fibroblasts (Gracie, Robertson et al. 2003). In contrast to IL-1β, 
it is also constitutively expressed, which may indicate a role in regulating homeostasis 
(Dinarello 2009).  
The IL-18 gene has been identified in nearly 40 species of mammals, birds, 
reptiles and fish, underlining its fundamental importance in immunity. The human gene 
consists of six exons, which encode three different transcripts. IL-18 is closely related to 
IL-1α and IL-33, with which it forms a distinct subgroup following phylogenetic 
analysis of the IL-1F ligand sequences (Smith 2011). Like IL- IL-18 is synthesised 
as an inactive precursor containing a pro-domain, which is cleaved by caspase-1 at a 
conserved aspartic acid to yield the bioactive mature form of the cytokine (Ghayur, 
Banerjee et al. 1997; Gu, Kuida et al. 1997).  
1.2.1.4 IL-1F5 (IL-36RN) 
IL-1F5 is an anti-inflammatory cytokine able to dampen the effects of a range of 
IL-1 agonist ligands as well as LPS. It acts as a receptor antagonist of IL-1RL2 (IL-
1Rrp2), preventing the agonists IL-1F6 (IL-36α), IL-1F8 (IL-36β) (Towne, Garka et al. 
2004) and IL-1F9 (IL-36γ) (Debets, Timans et al. 2001) from binding this receptor to 
initiate gene transcription via NF-kB and MAP kinases. Upon binding to this receptor, 
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IL-1F5 fails to recruit IL-1RAcP on the cell surface (Sims 2010), similar to the lack of 
an interaction when IL-1RN binds to IL-1RI.  
IL-1F5 can also downregulate inflammation through activation of the orphan 
receptor single Ig domain-containing IL-1 receptor-related molecule (SIGIRR). It is not 
known, however, if IL-1F5 directly binds SIGIRR, as its activation of this receptor has 
only been described as via an “interaction”. In mice and rats, both IL-1β- and LPS-
induced inflammation is antagonized by IL-1F5 in the brain, leading to an anti-
inflammatory response, characterised by increased IL-4 production. The ability of IL-
1F5 to mediate this effect is abolished in either SIGIRR
-/-
 or IL-4
-/- 
knockout mice. This 
function of IL-1F5 appears to be restricted to the brain and is not elicited in mouse 
macrophages or DCs (Costelloe, Watson et al. 2008).   
IL-1F5 is widely expressed in humans and mice, with transcripts detectable in 
all of the major organs investigated except for bone marrow, liver and the intestines 
(Mulero, Pace et al. 1999; Barton, Herbst et al. 2000; Busfield, Comrack et al. 2000; 
Smith, Renshaw et al. 2000). Many distinct populations of human cells also express IL-
1F5. These include THP-1 (monocytic leukaemia cell) ± PMA ± LPS, PBMCs ± PHA ± 
LPS, LPS-stimulated monocytes, in vitro differentiated macrophages, B cells ± 
stimulation, NK cells and LPS-stimulated DCs (Mulero, Pace et al. 1999; Barton, 
Herbst et al. 2000; Busfield, Comrack et al. 2000; Smith, Renshaw et al. 2000). IL-1F5 
is constitutively expressed in cultured human bronchial epithelial cells. Stimulation of 
these cells with IL-4 or IFN-γ significantly decreases its expression (Chustz, Nagarkar 
et al. 2011).  
Studies investigating the expression of IL-1F5 in vivo have been limited to 
inflammatory skin conditions. In several variants of human and mouse psoriasis, IL-1F5 
expression is significantly increased compared to levels found in control skin (Debets, 
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Timans et al. 2001; Blumberg, Dinh et al. 2007; Johnston, Xing et al. 2011). Following 
the treatment of chronic plaque psoriasis with etanercept (a TNF-α scavenger), IL-1F5 
expression is significantly decreased (Johnston, Xing et al. 2011). Inhibiting TNF-α 
leads to decreased activation of several genes and pathways controlling inflammation in 
psoriasis (Gottlieb, Chamian et al. 2005). This indicates IL-1F5 expression may be 
regulated by other pro-inflammatory cytokines. To date, there are no studies which have 
examined the expression of IL-1F5 following viral, fungal or parasitic infection. 
Expression in response to stimulation with bacterial agents (other than LPS) is also 
unknown. 
The importance of IL-1F5 in regulating inflammation has recently been 
emphasised in a study reporting a deficiency of IL-36RN due to mutation. In the cohort 
of patients expressing this aberrant protein, unregulated inflammation and chronic 
pustular psoriasis, which can be fatal, were prevalent (Marrakchi, Guigue et al. 2011).  
An IL-1F5 gene is present in almost all mammals with an available genome 
sequence (personal search). In humans, the IL-1F5 gene is comprised of six exons. Its 
first two exons (1a and 1b) are used alternatively to create two different five exon-
containing transcripts which encode the same protein and only differ in their 5′ UTRs. 
Compared to all of the IL-1 ligands, IL-1F5 is most similar to IL-1RN, with which it 
shares significant amino acid identity (47% and 52% with sIL-1RN and icIL-1RN, 
respectively) (Mulero, Nelken et al. 2000; Dinarello 2009). The positions of the exon-
intron boundaries are also highly conserved between both genes. This led to suggestions 
that IL-1F5 emerged following gene duplication of IL-1RN (Mulero, Nelken et al. 
2000). The crystal structure of mouse IL-1F5 adopts the same β-trefoil fold as IL-1α, 
IL-1β and IL-1RN, as well as containing two α-helices. These are situated in different 
positions and are of a different type to the two found in IL-1β (Dunn, Gay et al. 2003). 
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The mechanism of IL-1F5 secretion has so far remained elusive. The lack of an 
obvious signal peptide indicates it is unlikely to be processed by signal peptidase. 
Similarly, the absence of a clear pro-domain containing a caspase-1 cut site suggests it 
will not be activated by the inflammasome. Recent unpublished observations indicate 
N-terminally truncated IL-1F5 is significantly more bioactive than the full length 
molecule (Sims and Smith 2010). This suggests enzymatic cleavage may take place to 
produce a mature form of the protein. Alternatively, an atypical mode of secretion may 
be utilised. For instance, IL-1F5 expression in cultured COS-7 and JEG-3 cells leads to 
significantly more protein in the supernatants than in cell lysates (Barton, Herbst et al. 
2000). Importantly, analysis of both secreted and intracellular protein species revealed a 
product of equal size, suggesting a lack of enzymatic processing.  
1.2.1.5 IL-1F6 (IL-36α)  
IL-1F6 is a pro-inflammatory cytokine which activates NF-κB, ERK1/2, JNK 
and MAP kinases. After it binds to IL-1RL2 (IL-1Rrp2), IL-1RAcP is recruited, leading 
to signal transduction (Towne, Garka et al. 2004). This has been demonstrated with 
human and mouse IL-1F6 in, respectively, human (Jurkat and HepG2) and mouse 
(BA/F3) cell lines transfected with the receptor.  
The expression of IL-1F6 in vivo has been studied in several inflammatory skin 
diseases. Overexpression of IL-1F6 leads to an inflammatory skin phenotype in 
newborn transgenic mice. Resolution of this condition occurs after 3 weeks, during 
which a significant reduction in IL-1F6 expression is observed (Blumberg, Dinh et al. 
2007).  High levels of IL-1F6 expression have been consistently found in the skin of 
humans and mice with psoriasis (Blumberg, Dinh et al. 2007; Johnston, Xing et al. 
2011). Injecting anti-IL-1RL2 antibodies into human psoriatic skin transplanted onto 
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SCID (CB-17) mice led to disease resolution (Blumberg, Dinh et al. 2010). As IL-1F8 
and IL-1F9 are also both elevated in psoriasis skin (Johnston, Xing et al. 2011) and 
signal through IL-1RL2 (Towne, Garka et al. 2004), reduced inflammation in this model 
cannot be solely attributed to inhibiting IL-1F6.  
IL-1F6 is a pivotal member of the inflammatory cytokine network in psoriasis. 
Injecting the skin of mice with recombinant IL-1F6 led to statistically significant 
increases in the expression of IL-17A, IL-23, TNF-α and IFN-γ (Blumberg, Dinh et al. 
2010). In addition to significantly increasing its own expression, substantial increases 
were also observed in further pro-inflammatory cytokines (IL-1β, IL-1F9, IL-33 and IL-
6), IL-10 family cytokines (IL-19, IL-22, IL-24), other important cytokines (IL-12p35, 
CSF2, CSF3, LT- β), several chemokines, chemokine receptors, iNOS and matrix 
metalloproteinases (MMP) (Blumberg, Dinh et al. 2010). Conversely, when many of 
these same cytokines were injected into mice, il-1f6 expression increased significantly, 
suggesting a feedback mechanism may exist (Blumberg, Dinh et al. 2010). Synergistic 
increases in il-1f6 expression were found following the injection of certain cytokine 
combinations, with TNF-α and IL-23 showing the biggest induction (Blumberg, Dinh et 
al. 2010).  
IL-1F6 is evidently under the control of IL-17 and TNF-α. Normal human 
keratinocytes stimulated with IL-17A or IL-17A and IL-22 show significantly elevated 
IL-1F6 expression (Johnston, Xing et al. 2011). Bronchial epithelial cells cultured with 
IL-17A or TNF-α showed statistically significant increases in IL-1F6 expression, which 
was synergistically increased with both cytokines (Chustz, Nagarkar et al. 2011). 
Treatment with etanercept leads to a significant reduction in IL-1F6 mRNA (Johnston, 
Xing et al. 2011). IL-1F6 induces decreased PPARγ expression which inhibits the 
differentiation of adipocytes (van Asseldonk, Stienstra et al. 2010).  
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IL-1F6 has been identified in 22 mammals to date. The human gene consists of 
five exons, which are alternatively spliced to create two different transcripts. Compared 
with the rest of the IL-1 ligands, it is most closely related to IL-1F8 and IL-1F9, which 
is reflected in previous phylogenetic analyses of the family (Nicklin, Barton et al. 2002; 
Taylor, Renshaw et al. 2002).  
IL-1F6 lacks both a signal peptide and a caspase-1 cleavage site and so its mode 
of secretion differs from IL-1RN and IL-1β. Recent evidence indicates a truncated form 
of IL-1F6 (Arg8 as the first amino acid) exhibits ~10000-fold more bioactivity than the 
full length molecule (Blumberg, Dinh et al. 2010). This strongly suggests it is cleaved to 
yield a potent mature protein. An attempt to characterise a mechanism for its release 
was carried out in bone marrow-derived macrophages. Following overexpression, IL-
1F6 was passively released from cells stimulated with LPS and/or ATP. The cytokine 
was externalised via the ATP-dependent P2X7 receptor. IL-1F6 present in both 
conditioned medium and cell lysate was the same size (22 kDa) indicating it had not 
been proteolytically cleaved for export (Martin, Scholler et al. 2009).   
1.2.1.6 IL-1F7 (IL-37)  
The IL-1F7 gene has been found in twenty mammalian species to date. The 
human gene consists of six exons, which are alternatively spliced to create five different 
transcripts (Taylor, Renshaw et al. 2002). Of these, IL-1F7b is the longest, contains five 
of these exons, and has been the sole focus of functional studies on the gene. An IL-
1F7-IL-1F9 chimera, expressed in testis and placenta, has also been found, although has 
never been examined beyond its initial identification (Taylor, Renshaw et al. 2002).  
IL-1F7 is an anti-inflammatory cytokine that comprehensively inhibits the innate 
immune response. Its expression is increased in PBMCs stimulated with a range of TLR 
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ligands and pro-inflammatory cytokines, but suppressed by IL-4 and GM-CSF. In 
PBMCs transfected with either scrambled siRNA or siRNA against IL-1F7 (siIL-1F7), 
stimulation with LPS or Pam3Csk4 (a synthetic TLR1/2 agonist) led to a significant 
increase in the production of IL-1β, IL-6 and TNF-α in siIL-1F7 cells. In RAW 
macrophages, THP-1 cells (monocytic cell line), and A549 cells (epithelial cell line), 
overexpression of human IL-1F7b (huIL-1F7b) led to highly significant decreases in 
pro-inflammatory cytokine production, compared to controls, following LPS or IL-1β 
stimulation (Nold, Nold-Petry et al. 2010). These in vitro findings were replicated in 
vivo in mice transgenic for huIL-1F7b. Mice exhibited a marked reduction in the plasma 
concentration of 18 cytokines (significantly less IL-6, IL-17 and IL-1β were found) after 
LPS-induced shock. These mice were protected from endotoxic shock, displaying far 
less physiological damage than control mice (Nold, Nold-Petry et al. 2010). IL-1F7 
colocalises with Smad3 to facilitate anti-inflammatory activity in the nucleus of cells. 
Using either a specific Smad3 inhibitor (SIS3), shRNA coding for Smad3 or siRNA to 
silence Smad3, IL-1F7 activity was attenuated. For example, in RAW macrophages 
overexpressing IL-1F7, SIS3 treatment partially recovers the inflammatory phenotype 
(increased IL-1α and IL-6 expression) usually found following LPS-stimulation (Nold, 
Nold-Petry et al. 2010). IL-1F7 also inhibits pro-inflammatory cytokine expression 
following nuclear localisation (Sharma, Kulk et al. 2008). Evidence of its ability to 
restrict cancer was shown in mice with experimentally-induced fibrosarcoma. Repeated 
injections with adenoviral vectors expressing IL-1F7 resulted in substantial tumour 
regression (Gao, Kumar et al. 2003).  
IL-1F7 is ubiquitously expressed at very low levels except in the thymus, testis 
and uterus where expression is high. This experiment, however, did not differentiate 
between the five splice variant transcripts (Pan, Risser et al. 2001).    
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IL-1F7b binds to the IL-18 receptor (IL-18Rα) (Pan, Risser et al. 2001; Kumar, 
Hanning et al. 2002), and IL-18 binding protein (IL-18BP) (Bufler, Azam et al. 2002), 
although the functional significance of these interactions is unclear.  
IL-1F7 contains a caspase-1 cut site and is processed similarly to IL-1β and IL-
18 by the NALP3 inflammasome, yielding the mature form of the cytokine. It is also 
cleaved by caspase-4 (Kumar, Hanning et al. 2002). As indicated above, nuclear 
localisation of IL-1F7b led to a significant reduction in pro-inflammatory cytokine 
production (Sharma, Kulk et al. 2008). Nuclear localization of mature IL-1F7b is 
caspase-1 dependent, as introducing a specific inhibitor of this enzyme significantly 
decreases nuclear translocation of the cytokine (Sharma, Kulk et al. 2008).  
1.2.1.7 IL-1F8 (IL-36β)  
IL-1F8 binds to IL-1RL2, recruiting its co-receptor IL-1RAcP to initiate a pro-
inflammatory response. Signal transduction through the IL-1R heterodimer culminates 
in activation of NF-κB, ERK1/2, JNK and MAP kinases (Towne, Garka et al. 2004).  
Several cell types have increased IL-1F8 expression in vivo. Adipocytes express 
IL-1F8, although levels are not increased following LPS-stimulation. Stimulating 
primary human adipocytes with rIL-1F8 led to a significant rise in IL-6 and IL-8 
expression (van Asseldonk, Stienstra et al. 2010). IL-1F8 is expressed in glial cells in 
mice but stimulation of these same cells with recombinant IL-1F8 does not induce IL-6 
production or PGE2 release (Wang, Meinhardt et al. 2005). In contrast to these findings, 
human synovial fibroblasts and articular chondrocytes stimulated with rIL-1F8 secrete 
significantly higher amounts of IL-6, IL-8 and nitric oxide than untreated controls 
(Magne, Palmer et al. 2006). In human and mouse models of psoriasis, IL-1F8 
expression is increased (Johnston, Xing et al. 2011). It is also significantly increased in 
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normal human keratinocytes stimulated with TNF-α or IL-1α (Johnston, Xing et al. 
2011). As with other IL-1F genes, its expression is markedly reduced with etanercept 
treatment, confirming it is regulated by TNF-α (Johnston, Xing et al. 2011). 
Recent data revealed an additional function of IL-1F8 in psoriatic skin. 
Reconstituted human epidermal cultures stimulated with rIL-1F8 exhibited statistically 
significant increases in the expression of several antimicrobial peptides and MMPs. IL-
1α also induced this effect. However, IL-1F5, -F6 and -F9 did not (Johnston, Xing et al. 
2011).  
The ENSEMBL genome browser indicates a dozen mammalian species possess 
an IL-1F8 gene. The human orthologue consists of seven exons, which encode two 
transcripts of differing lengths, formed through the use of mutually exclusive exons. Its 
mechanism of secretion has not been described to date. NH2-terminally cleaved IL-1F8 
apparently exhibits increased bioactivity, although no data are available to show this 
(Sims and Smith 2010). 
1.2.1.8 IL-1F9 (IL-36γ)  
IL-1F9 induces inflammation in the skin. After binding its receptor IL-1RL2 
(Debets, Timans et al. 2001), IL-1RAcP is recruited, facilitating signal transduction 
(Towne, Garka et al. 2004). 
IL-1F9 mRNA expression has been detected in several tissues, most notably in 
the skin, where constitutive levels are high (Debets, Timans et al. 2001). Expression has 
also been found in embryonic tissues (Debets, Timans et al. 2001), oesophageal 
squamous epithelium, and LPS-stimulated monocytes (Kumar, McDonnell et al. 2000).  
IL-1F9 expression is regulated by other pro-inflammatory cytokines. TNF-α, 
IFN-γ (Kumar, McDonnell et al. 2000; Johnston, Xing et al. 2011), IL-1β (Debets, 
Chapter 1: Introduction and Aims 
66 
 
Timans et al. 2001), IL-1α, and IL-17A (± IL-22) (Johnston, Xing et al. 2011) induce 
IL-1F9 expression in keratinocytes.  
IL-1F9 is also highly expressed in psoriasis skin (Debets, Timans et al. 2001; 
Johnston, Xing et al. 2011). Its regulation in this condition is under the influence of 
TNF-α, as levels significantly decline in response to etanercept therapy (Johnston, Xing 
et al. 2011).  
Its central role in regulating the cytokine network in bronchial epithelial cells 
has been comprehensively described (Chustz, Nagarkar et al. 2011). IL-1F9 expression 
was significantly increased following stimulation with TNF-α, IL-1β, IL-17, dsRNA or 
FSL-1 (TLR2/6 agonist) (Chustz, Nagarkar et al. 2011). For IL-17 and dsRNA, 
increases in IL-1F9 expression were both dose-dependent and synergistic, increasing 
markedly by 24 hours post-stimulation (hps) before declining thereafter. IL-1F9 protein 
production correlates with mRNA expression in these cells, with protein detected in 
both lysate and supernatant. IL-1F9 also induces the production of other cytokines and 
chemokines in a dose-dependent manner. Following stimulation of lung fibroblasts, 
significantly elevated expression of IL-8, CSF3, CCL20 and CXCL3 was found 
(Chustz, Nagarkar et al. 2011). 
Increased IL-1F9 expression was also observed following infection with the 
dsRNA virus, rhinovirus type 16 (RV16) (Chustz, Nagarkar et al. 2011). Re-stimulation 
of these cells with RV16 following siRNA knockdown of RELA (NF-κB p65) led to 
significantly lower IL-1F9 expression compared with controls. IRF3 was also knocked 
down but this did not affect IL-1F9 levels. These results confirmed the dsRNA-induced 
increase in IL-1F9 expression is mediated via the NF-κB, but not the IRF3/7 (TRAF-3 
dependent), pathway (Chustz, Nagarkar et al. 2011). Infection with herpes simplex virus 
also increased IL-1F9 mRNA and protein expression (Kumar, McDonnell et al. 2000). 
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The mechanism of IL-1F9 secretion is unknown. Neither a signal peptide nor a 
pro-domain is present, similar to other IL-1F proteins, suggesting non-classical 
secretion. It may be cleaved at the N-terminus, however, as an IL-1F9 truncation mutant 
starting at Gly13 exhibits enhanced activity (Blumberg, Dinh et al. 2010). In ATP-
treated human epidermal cultures, significantly more IL-1F9 protein was found in the 
supernatant than intracellularly following IL-1α and TNF-α stimulation (Johnston, Xing 
et al. 2011). It is likely that protein export was due to passive diffusion through the 
ATP-dependent P2X7 receptor.  
The IL-1F9 gene has been located in 27 mammalian genomes. The human 
orthologue contains six exons which are alternatively spliced to produce three different 
transcripts. Following translation, three protein isoforms of differing lengths are formed. 
1.2.1.9 IL-1F10 
IL-1F10 was identified from screening a BAC clone (Bensen, Dawson et al. 
2001) and a cDNA library (Lin, Ho et al. 2001). To date, there have been no reports that 
characterise its function. IL-1F10 expression was detected in the heart, placenta, foetal 
liver, spleen, thymus, and tonsil and foetal skin (Bensen, Dawson et al. 2001; Lin, Ho et 
al. 2001). Although recombinant human IL-1F10 binds to soluble IL-1RI, it had a much 
lower binding affinity for this receptor than IL-1RN and IL-1β (Lin, Ho et al. 2001).  
The protein does not contain a signal peptide or a prodomain. Following 
transfection into CHO cells, equally sized protein species were detected in both 
supernatant and cell lysates (Lin, Ho et al. 2001), indicating non-classical secretion may 
occur.  
Despite a lack of functional evidence, IL-1F10 may act as a receptor antagonist 
as it is very similar to IL-1F5 and IL-1RN in a number of ways. The human gene is 
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situated between IL-1F5 (IL-36RN) and IL-1RN on chromosome 2 (Figure 1.6). 
Phylogenetic analysis of the human and mouse IL-1 family amino acid sequences 
results in a separate clade containing only IL-1F5, IL-1F10 and IL-1RN (Figure 1.7). 
IL-1F10 has much higher amino acid identity with IL-1F5 (41%) and IL-1RN (37%) 
than with the rest of the family (14-30%) (Lin, Ho et al. 2001). 
 
 
IL-1α IL-1β IL-37 IL-36γ IL-36α IL-36β IL-36RN IL-1F10 IL-1RN
113.53
Mb
113.89 
Mb
 
Figure 1.6 The IL-1 ligand gene cluster on human chromosome 2. Human IL-1F10 
lies between IL-1RN and IL-1F5 (IL-36RN). Diagram not to scale. 
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 mIL-1F11
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Figure 1.7 Phylogenetic analysis of the human and mouse IL-1 amino acid 
sequences. A separate “receptor antagonist” clade containing IL-1RN, IL-1F5 and IL-
1F10 is indicated (blue box). Figure constructed using the Neighbour-Joining (N-J) 
method. hu = human, mu = mouse.  
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 The gene structure of IL-1F10 is also similar to those of the two receptor antagonists. 
The positions of the exon-intron boundaries are highly conserved between all three 
genes (Lin, Ho et al. 2001). The coding region of IL-1F10 has four exons, which when 
translated, are very similar in size to those of IL-1F5 (11, 28, 43 and 70 amino acids 
compared to 10, 28, 43 and 74, respectively) (Bensen, Dawson et al. 2001). 
1.2.1.10 IL-1F11 (IL-33) 
The role of IL-33 has been described in a narrow range of disease states, each of 
which are characterised by a Th2 immune response. IL-33 initiates Th2-mediated 
immune responses via its major target cell populations, Th2 cells, mast cells, 
eosinophils, innate helper cells, macrophages, DCs, basophils, NK cells and NKT cells. 
It binds its receptor ST2, recruits IL-1RAcP, and facilitates signal transduction to 
activate Th2 cells in the absence of TCR stimulation (Smith 2011). IL-33 signalling has 
been partially defined in mast cells. Activation of ST2 facilitates intracellular 
recruitment of MyD88, IRAK1 and IRAK4 leading to mobilisation of two separate 
signalling pathways (Figure 1.8). In pathway 1, phospholipase D (PLD) and 
sphingosine kinase (SPHK) are activated, followed by an influx of Ca
2+
. This activates 
NF-κB causing mast cell degranulation and increased production of cytokines (IL-1β, 
IL-3, IL-6, TNF-α), chemokines (CXCL2, CCL2 and CCL3), and lipids (prostaglandin 
D2 and leukotriene B4) (Allakhverdi, Smith et al. 2007; Moulin, Donze et al. 2007; 
Pushparaj, Tay et al. 2009). In pathway 2, mitogen-activated protein kinase kinases 
(MAPKKs) are stimulated leading to activation of ERK, p38 and JNK. This initiates IL-
5, IL-13, CCL5, CCL17 and CCL24 production (Kurowska-Stolarska, Kewin et al. 
2008). End products of these pathways contribute to the two major functional roles of  
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Figure 1.8 Independent IL-33 signalling pathways in mast cells. Activation of ST2 
following IL-33 binding leads to recruitment of MyD88, IRAK1 and IRAK4. The 
MyD88 complex then activates two distinct signalling pathways by an unknown 
mechanism. Figure adapted from Liew, Pitman et al. (2010). 
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IL-33, in promoting host protection and aggravating allergic conditions.  
IL-33 protects the host against infections from parasitic worms and also against 
cardiovascular disease by reducing atherosclerosis. The cytokine exacerbates the 
inflammatory milieu in asthma, atopic allergy and anaphylaxis by activating mast cells. 
IL-33 also has pathological, pro-inflammatory roles in central nervous system disease 
and arthritis (Liew, Pitman et al. 2010). In addition to being released from cells, IL-33 
possesses intranuclear activity. Similar to IL-1α, it contains a nuclear localisation 
sequence which directs its nuclear translocation (Carriere, Roussel et al. 2007). 
IL-33 does not require co-stimulation with other cytokines to drive the Th2 
response, although it can stimulate Th1 cytokine production (Smithgall, Comeau et al. 
2008), in part due to activating target cells that are shared with IL-18 (Smith 2011). IL-
33 is expressed in numerous organs and cell populations, with relatively low levels 
found in monocytes, macrophages and DCs, whilst high levels are found in the brain 
and spinal cord (Oboki, Ohno et al. 2010).  
The IL-33 gene has been identified in 34 species of mammals. The human gene 
consists of eight exons, which encode three different predicted transcripts. An additional 
splice variant transcript has recently been identified (Hong, Bae et al. 2011). This 
transcript lacks the exon containing the putative caspase-1 cut site, yet retains 
functionality. There are conflicting findings regarding IL-33 processing. It was initially 
suggested that caspase-1 cleavage was required to yield a bioactive form of the cytokine 
(Schmitz, Owyang et al. 2005). Subsequent reports, however, have strongly disagreed 
with this (Ohno, Oboki et al. 2009; Talabot-Ayer, Lamacchia et al. 2009). One report 
has suggested caspase-1 cleavage actually inactivates IL-33 (Cayrol and Girard 2009). 
The splice variant that lacks the cleavage site but retains bioactivity supports the latter 
hypothesis. 
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1.2.2 IL-1 receptors and signal transduction in mammals  
The biological effects of the IL-1 ligands are mediated by members of the IL-1 
receptor (IL-1R) family which are expressed on the surface of target cells or secreted as 
soluble receptors. The family is comprised of eleven members (Table 1.2) that are 
characterised by an IgG-like extracellular domain and a cytoplasmic Toll/IL-1R (TIR) 
domain. The IL-1R family is part of a wider superfamily of TIR domain-containing 
receptors which includes the Toll-like receptors, intracellular molecules involved in 
signalling and recognising pathogens, and the Toll proteins of Drosophila (Boraschi and 
Tagliabue 2006).    
1.2.2.1 IL-1RI (IL-1R1) 
The type I IL-1 receptor (IL-1RI) contains three IgG domains in the extracellular 
portion and a cytoplasmic TIR domain (Sims, March et al. 1988). It binds the agonist 
ligands IL-1β, IL-1α and the antagonist IL-1RN. When IL-1β or IL-1α bind the 
receptor, its co-receptor IL-1RAcP is recruited on the cell surface forming a 
heterodimer. This ultimately leads to signal transduction and increased transcription of 
inducible genes. When IL-1RN binds IL-1RI, it physically occupies the receptor but 
does not initiate signal transduction. IL-1β has two binding sites termed A (bsA) and B 
(bsB). It binds Ig-like domains I & II of IL-1RI with bsA. Upon binding, these domains 
become firmly fixed in place by sulphide bonds leading to a conformational change 
which allows bsB to bind domain III of IL-1RI. This conformational change permits IL-
1RAcP to bind to IL-1RI, activating the intracellular signalling cascade. IL-1RN 
possesses bsA but lacks bsB. It therefore binds domains I and II of IL-1RI, blocking the 
receptor. The absence of bsB prevents any contact between IL-1RN and domain III of  
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Receptor 
Protein 
name 
Alternative 
names 
Soluble/ 
membrane 
bound 
 
Co-receptor Ligand(s) 
Interleukin-1 
receptor 1 
IL-1RI 
IL-1R1, IL1R, 
CD121A, 
D2S1473, IL-
1R-α, P80 
Both 
 
IL-1RAcP, 
TILRR 
IL-1β, IL-1α, 
IL-1RN 
Interleukin-1 
receptor 2 
IL-1RII 
IL-1R2 IL-1RB, 
CD121b, 
MGC47725 
Both 
 
IL-1RAcP IL-1β 
Interleukin-1 
receptor accessory 
protein 
IL-1RAcP 
IL-1R3, 
C3orf13, 
FLJ37788 
Both 
 
 
Interleukin-1 
receptor-like 1 
IL-1RL1/ 
ST2 
IL-1R4, IL-33α, 
T1, DER4, 
Fit-1, 
MGC32623 
Both 
 
 
IL-1RAcP 
IL-33 
Interleukin-1 
receptor-like 2 
IL-1RL2 
IL-1R6, 
IL-1Rrp2 
Membrane 
bound 
 
IL-1RAcP 
IL-36α, -β, -
γ, IL-36RN 
Interleukin-18 
receptor 
IL-18Rα 
IL-1R5, 
IL-1Rrp1, 
CD218a 
Both 
 
IL-18Rβ IL-18 
Interleukin-18 
receptor accessory 
protein 
IL-18Rβ 
IL-1R7, 
IL-18RAcP, 
IL18RAP, 
AcPL, CD218b 
CDw218b, 
IL18RB, 
MGC120589, 
MGC120590 
Both 
 
 
Three 
immunoglobulin 
domain-
containing IL1 
receptor-related-2 
TIGIRR-2 
 
IL-1RAPL1, 
IL-1R8, 
MRX10, 
MRX21, 
MRX34, 
OPHN4 
Membrane 
bound 
 
 
Unknown 
Unknown 
Three 
immunoglobulin 
domain-
containing IL1 
receptor-related-1 
TIGIRR-1 
IL-1RAPL2, 
IL-1R9 
Membrane 
bound 
 
 
Unknown Unknown 
Single 
immunoglobulin 
domain-
containing 
IL-1-related 
receptor 
SIGIRR 
TIR8, 
MGC110992 
Membrane 
bound 
 
 
Unknown 
Unknown 
 
Table 1.2 The IL-1 receptor family in humans. The family is comprised of eight 
receptors, and three co-receptors which are required for signalling. 
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IL-1RI, thus IL-1RAcP cannot be recruited, and signalling cannot take place (Gosavi, 
Whitford et al. 2008) (Figure 1.9). An additional factor underlying the inability IL-1RN 
to activate IL-1RI was recently described. Upon binding, the absence of an interaction 
between bsB of IL-1RN and domain III of IL-1RI causes an angle to form between 
domains II and III of IL-1RI. The relative location of domain III is therefore different to 
its location when IL-1β binds to IL-1RI. Thus, even if IL-1RAcP was able to be 
recruited following binding of IL-1RN, domain III of IL-1RI would be physically too 
far away from IL-1RAcP. The TIR domains of IL-1RI and IL-1RAcP would 
consequently not be close enough together to recruit MyD88, which is necessary for 
signal transduction (Sims 2010; Wang, Zhang et al. 2010). In mammals, a soluble form 
of IL-1RI has been identified. Its precise functional role is not clear, as conflicting 
reports have described both improved and worsening disease severity when it is 
administered (Subramaniam, Stansberg et al. 2004; Dinarello 2009). 
1.2.2.2 IL-1RII (IL-1R2)  
IL-1RII is a decoy receptor which acts to sequester excess IL-1β and IL-1α. It contains 
three Ig-like domains in the extracellular part of the receptor but crucially lacks a TIR 
domain; therefore signal transduction does not take place (Colotta, Dower et al. 1994). 
Upon ligand binding, IL-1RII can also recruit IL-1RAcP thereby competing with IL-
1RI to effectively diminish the responsiveness of a cell to IL-1 (Lang, Knop et al. 
1998). A soluble form of the receptor is generated following cleavage of the membrane-
bound form to further regulate IL-1 activity. A specific protease, aminopeptidase 
regulator of TNFR1 shedding (ARTS), is necessary for IL-1RII release from the cell 
surface (Cui, Rouhani et al. 2003). Soluble IL-1RII forms a complex with soluble 
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Figure 1.9 Ribbon diagrams of IL-1β and IL-1Ra bound to IL-1RI. A. IL-1β binds 
the Ig-like domains I and II of IL-1RI with bsA. Binding these domains leads to a 
conformational change allowing bsB to bind domain III of IL-1RI. This permits IL-
1RAcP to bind to IL-1RI, activating the intracellular signalling cascade. B. IL-1RN 
possesses bsA but lacks bsB. It binds domains I and II of IL-1RI with bsA, blocking the 
receptor. The absence of bsB prevents any contact between IL-1RN and domain III of 
IL-1RI, IL-1RAcP is not recruited, and signalling cannot take place. Figure reproduced 
from Gosavi, Whitford et al. (2008). 
 
IL-1RAcP which increases the affinity with which it binds IL-1β and IL-1α by ~100-
fold (Smith, Hanna et al. 2003). This does not affect its affinity for IL-1RN, which 
remains weak. 
 
1.2.2.3 IL-1RAcP (IL-1R3)  
IL-1RAcP is an essential co-receptor for the IL-1RI (Cullinan, Kwee et al. 
1998), ST2 (Ali, Huber et al. 2007; Chackerian, Oldham et al. 2007; Palmer, Lipsky et 
al. 2008) and IL-1RL2 (Towne, Garka et al. 2004) receptors. In order to modulate 
signalling through these receptors, recruitment of IL-1RAcP is fundamental. When IL-
1β or IL-1α bind to IL-1RI, IL-1RAcP is recruited to form a functional receptor 
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complex. However, it does not physically interact with bound ligand (Subramaniam, 
Stansberg et al. 2004). Once the heterotrimeric receptor complex is active, the TIR 
domains of IL-1RI and IL-1RAcP are in close proximity which permits recruitment of 
MyD88 and Tollip in the cytoplasm (Dinarello 2009). This is the first step in the 
initiation of intracellular signalling.  
A novel isoform, termed IL-1RAcPb, has recently been identified exclusively in 
the central nervous system. It alters the response to IL-1 in these cells by inhibiting the 
expression of some genes, whilst others remain unaffected (Smith, Lipsky et al. 2009).        
The soluble form of IL-1RAcP acts to regulate IL-1 activity by binding soluble IL-1RII 
which sequesters IL-1β and IL-1α (Smith, Hanna et al. 2003). 
1.2.2.4 ST2 (IL-1R4/IL-33Rα)  
The ST2 receptor possesses a three Ig domain-containing extracellular portion 
and an intracellular TIR domain. It binds IL-33 (Schmitz, Owyang et al. 2005) which 
leads to IL-1RAcP recruitment (Ali, Huber et al. 2007; Chackerian, Oldham et al. 2007; 
Palmer, Lipsky et al. 2008) and formation of a heterotrimeric receptor complex. Three 
splice variants of ST2 have been identified – ST2L, sST2 and ST2V. ST2L and ST2V 
are membrane-bound forms of the receptor, whilst sST2 is a soluble variant consisting 
of the extracellular portion of ST2L (Boraschi and Tagliabue 2006). In addition to its 
role as the IL-33 receptor, the membrane-bound form of ST2 also inhibits IL-1RI and 
TLR4 signalling through sequestration of the intracellular adaptors MyD88 and Mal 
(Brint, Xu et al. 2004).  
1.2.2.5 IL-18Rα (IL-1R5) and IL-18Rβ (IL-1R7/IL-1RAcP)  
IL-18Rα and IL-18Rβ (IL-18RAcP) bind IL-18 in a functionally equivalent 
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manner to the IL-1RI complex binding to IL-1β or IL-1α. IL-18Rα is a membrane-
bound TIR domain-containing receptor with three Ig-like extracellular domains. Upon 
binding IL-18, IL-18Rα forms a complex with its co-receptor, IL-18Rβ, on the cell 
surface. There is no physical interaction between IL-18 and IL-18Rβ; however, the 
recruitment of this co-receptor significantly increases the affinity of IL-18 for IL-18Rα. 
IL-18Rβ recruitment also leads to signal transduction, which cannot take place in its 
absence (Born, Thomassen et al. 1998; Debets, Timans et al. 2000). IL-1F7b also binds 
to the IL-18 receptor (IL-18Rα) (Pan, Risser et al. 2001; Kumar, Hanning et al. 2002) 
but the purpose of this interaction is unclear. 
1.2.2.6 IL-1RL2 (IL-1R6/IL-1Rrp2) 
IL-1RL2 is structurally related to most other IL-1Rs, having three Ig-like 
domains in the extracellular portion of the receptor and an intracellular part consisting 
of a TIR domain. It binds the agonist ligands IL-1F6, IL-1F8 and IL-1F9, and is blocked 
by a specific receptor antagonist, IL-1F5. Upon binding agonist ligand, IL-1RAcP is 
recruited leading to signal transduction and gene transcription (Debets, Timans et al. 
2001; Towne, Garka et al. 2004).  
1.2.2.7 TIGIRR-2 (IL-1R8/IL-1RAPL)  
Three Ig domain-containing receptor-related protein 2 (TIGIRR-2/IL-1RAPL) is 
an orphan receptor highly expressed in the brain (Carrie, Jun et al. 1999). Mutations in 
the IL-1RAPL gene are directly responsible for X-linked mental retardation (Carrie, Jun 
et al. 1999; Tabolacci, Pomponi et al. 2006). JNK activation by IL-1β in mature neurons 
is mediated by IL-1RAPL (Pavlowsky, Zanchi et al. 2010). 
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1.2.2.8 TIGIRR-1 (IL-1R9)  
TIGIRR-1 is an orphan receptor closely related to TIGIRR-2, and is highly 
expressed in foetal brain. Its extracellular domain does not bind IL-1α, IL-1β or IL-18 
(Sana, Debets et al. 2000).   
1.2.2.9 SIGIRR (TIR8) 
Single Ig IL-1 receptor-related protein (SIGIRR) is an orphan receptor with a 
unique structure within the IL-1R family. As its name indicates, it contains only a single 
Ig domain in the extracellular portion. Its intracellular TIR domain is also unique, being 
70 amino acids longer than those of the other IL-1Rs (Subramaniam, Stansberg et al. 
2004). Although largely considered to be an orphan, it has a functional interaction with 
IL-1F5 which led to an anti-inflammatory response in murine glial cells (Costelloe, 
Watson et al. 2008). To date, there is no recognised co-receptor for SIGIRR. Functional 
studies have shown SIGIRR is in fact an extremely important inhibitory receptor able to 
regulate multiple signalling pathways to dampen inflammation and Th cell 
differentiation. Of note, it regulates the activity of IL-1α, IL-1β, IL-18, IL-33 and 
several TLR agonists by inhibiting signalling through their respective receptors 
(Garlanda, Anders et al. 2009). 
1.2.2.10 Signal transduction   
When IL-1β or IL-1α bind to IL-1RI, its co-receptor IL-1RAcP is recruited on 
the cell surface, forming a heterodimer (Figure 1.10). The intracellular TIR domains of 
both receptor components are then in close proximity which leads to the recruitment of 
the myeloid differentiation 88 (MyD88) and Toll interacting protein (Tollip) adapter 
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molecules. Binding of MyD88 to the TIR domains of both receptor chains induces 
phosphorylation of the IL-1 receptor-associated kinases (IRAK)-1, -2 and -4, which in 
turn recruits the TNF receptor-associated factor 6 (TRAF6) to the protein complex 
(Figure 1.10). Both TRAF-6 and phosphorylated IRAK-1 then translocate to the plasma 
membrane to associate with TGF-β-activated kinase 1 (TAK1) and its binding proteins 
TAB1 (TAK1-binding protein) and TAB2. A four-component protein complex, 
consisting of TAK1, TAB1, TAB2 and TRAF-6, translocates back to the cytosol 
(Figure 1.10). Once there, TRAF-6 becomes ubiquitinated, followed by TAK-1 
phosphorylation. TAK1 then performs three functions - it activates the mitogen-
activated protein kinases (MAPK) p38 and JNK, as well as activating inhibitor of 
nuclear factor-κB kinase subunit β (IKKβ). Activated IKKβ phosphorylates IκB, a 
protein complex which inhibits NF-κB. Phosphorylation of IκB facilitates its 
degradation, which liberates NF-κB (Figure 1.10). This important transcription factor 
then moves into the nucleus to regulate gene expression (Dinarello 2009). 
1.2.3 Genomic organization and location  
Nine of the human IL-1 ligand genes are clustered in a region of ~360 kb on 
chromosome 2q13 (ENSEMBL coordinates; 2: 113,531,492-113,891,593). The gene 
order within the cluster, from centromere to telomere, is: IL-1α, IL-1β, IL-1F7, IL-1F9, 
IL-1F6, IL-1F8, IL-1F5, IL-1F10 and IL-1RN (Figure 1.6). Phylogenetic analysis 
indicates the specific order reflects the sequential incidence of divergence events 
(Nicklin, Barton et al. 2002). For example, IL-1F9, IL-1F6 and IL-1F8 branch together, 
as do IL-1F5, IL-1F10 and IL-1RN (Figure 1.7). The IL-1 gene order has been 
conserved through evolution except for the loss from the cluster of IL-18
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Figure 1.10 IL-1 signal transduction. Formation of the IL-1 receptor complex leads to 
approximation of the intracellular TIR domains of both IL-1RI and IL-1RAcP. This 
facilitates recruitment of MyD88 and Tollip adapter molecules. MyD88 binds to the 
TIR domains of both receptor chains inducing phosphorylation of IRAK-1, -2 and -4, 
which in turn recruits TRAF6 to the protein complex. Both TRAF-6 and phosphorylated 
IRAK-1 translocate to the plasma membrane and associate with TAK1 and its binding 
proteins TAB1 and TAB2. A protein complex consisting of TAK1, TAB1, TAB2 and 
TRAF-, translocates to the cytosol, whereby TRAF-6 becomes ubiquitinated, followed 
by TAK-1 phosphorylation. TAK1 then activates the MAPK p38 and JNK, as well as 
activating IKKβ. Activated IKKβ, phosphorylates IκB, a protein complex which inhibits 
NF-κB. IκB phosphorylation leads to its degradation, liberating NF-κB. Figure adapted 
from Dinarello (2009). 
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(Nicklin, Barton et al. 2002), which now resides on chromosome 11 (11: 112,013,974-
112,034,840). IL-33 is also not situated on chromosome 2, but is found at a discordant 
locus on chromosome 9 (9: 6,215,805-6,257,983) in the human genome. 
The nine gene IL-1 cluster is largely conserved in most mammalian species, 
except for in the mouse, where IL-1F7 is absent and IL-1β and IL-1α have become 
separated, by 105 Mb of sequence, from the rest of the cluster (IL-1RN, IL-1F5, -F6, -
F8, -F10) following rearrangement of chromosome 2. 
  The majority of the human IL-1 receptor genes (IL-1RII, IL-1RI, IL-1RL2, ST2, 
IL-18R, and IL-18RAcP) span a 460 kb region of chromosome 2q11.2-12.1 (2: 
102,608,306-103,069,025), with the remainder of the genes dispersed throughout the 
genome (Dale and Nicklin 1999). IL-1RAcP is on chromosome 3q28 (3: 190,231,840-
190,375,843); both TIGIRRs are on the X-chromosome (TIGIRR1: X: 103,810,996-
105,012,102; TIGIRR2: X: 28,605,516-29,974,840) whilst SIGIRR is on chromosome 
11p15 (11: 405,716-417,455). 
 
1.2.4 The chicken IL-1 family  
Compared with mammals, far fewer members of the IL-1 family have been 
identified in the chicken. To date, the ligands IL-1β and IL-18 as well as the receptors 
IL-1RI and ST2 are the only chicken orthologues that have been cloned. Expression 
analysis of chSIGIRR has been carried out but the cDNA has not been cloned. Chicken 
orthologues of IL-18Rα, IL-1RAcP and TIGIRR-1 have also been identified from EST 
libraries, but have not been fully characterised. 
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1.2.4.1 Chicken IL-1β 
The first chicken IL-1 (chIL-1) ligand to be cloned was IL-1β (Weining, Sick et 
al. 1998). Prior to this, a small number of reports were published describing 
characteristic IL-1-like activity in avian macrophages. This was originally described in 
culture supernatants from avian macrophages stimulated with endotoxin (Hayari, 
Schauenstein et al. 1982). IL-1 was also released from four different sources of E. coli- 
or S. aureus-stimulated macrophages, partially purified, and stimulated thymocyte co-
mitogenesis (Klasing and Peng 1987). Partial characterisation of signal transduction 
underlying IL-1 release from LPS-stimulated HD11 cells, a chicken macrophage cell 
line, was also carried out (Bombara and Taylor 1991), with findings similar to those 
reported in mice. Furthermore, the chicken orthologue of caspase-1 was cloned 
(Johnson, Bridgham et al. 1998), suggesting a mechanism of chIL-1 (and IL-18) 
maturation similar to that in mammals may exist.  
The chIL-1β cDNA was cloned from LPS-stimulated HD11 cells (Weining, Sick 
et al. 1998). It encodes a predicted protein of 267 amino acids which has 25% identity 
with the human orthologue and contains an NH2-terminal pro-domain. Unlike 
mammalian IL-1β proteins, it lacks a conserved aspartic acid at the predicted caspase-1 
cut site. Purified recombinant mature chIL-1β (lacking the pro-domain) exhibited 
biological activity which resembles that of its mammalian orthologues. In CEC-32 cells 
(a quail fibroblast cell line) stimulated with rchIL-1β, a dose-dependent increase in 
CXC chemokine expression was detected. Similar to mammalian IL-1β, an instability 
element was identified in the chIL-1β coding region (Weining, Sick et al. 1998).  
Compared with full length chIL-1β and three alternatively truncated forms, an N-
terminal truncation mutant of chIL-1β starting at Ala106 (the first residue after the 
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predicted caspase-1 cleavage site) exhibited significantly enhanced (100-fold) 
bioactivity (Gyorfy, Ohnemus et al. 2003). This suggests processing is required for 
maximal IL-1β activity, possibly mediated by caspase-1. In mammals, caspase-1-
independent processing of IL-1β is carried out by several neutrophil proteases. Adjacent 
to the caspase-1 site, single tyrosine and alanine residues have been recognised as the 
protease cut sites in mammals (Figure 1.3) (Dinarello 2011). Although avian 
equivalents of the neutrophil proteases have yet to be identified in heterophils, their 
putative cut sites are both conserved in chIL-1β. 
Expression of chIL-1β is increased in response to bacterial, viral and parasite 
challenge, consistent with its role as a rapidly induced pro-inflammatory mediator. In 
IFN-γ primed heterophils, stimulation with Salmonella Enteritidis led to statistically 
significant increases in IL-1β expression (Kogut, Rothwell et al. 2005). Similarly, in 
chicken embryonic fibroblasts (CEF), kidney cells and HD11 cells, stimulation with 
Salmonella-derived flagellin induced significant increases in IL-1β expression in all 
three cell types (Iqbal, Philbin et al. 2005). IL-1β expression is also increased in bursal 
cells from IBDV-infected chickens (Eldaghayes, Rothwell et al. 2006) as well as in 
HD11 cells stimulated with TLR7 agonists (Philbin, Iqbal et al. 2005). Intraepithelial 
lymphocytes removed from the jejunum of Eimeria maxima-infected chickens contain 
high levels of IL-1β mRNA compared with uninfected controls (Hong, Lillehoj et al. 
2006).  
The structure and genomic location of chIL-1β have been elucidated (Kaiser, 
Rothwell et al. 2004). The exon-intron structure of mammalian IL-1β is conserved in 
the chicken; however, the overall size of the chicken gene is substantially smaller than 
the human orthologue due to much shorter introns throughout. The genomic location of 
chIL-1β was determined using single-stranded conformational polymorphism, which 
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identified a telomeric region of chromosome 2 (Kaiser, Rothwell et al. 2004). In the 
2006 release (v2.0) of the chicken genome sequence, the genomic location was 
reassigned to chromosome 4 (Kaiser 2007). 
The crystal structure of chIL-1β has recently been resolved, which revealed the 
β-trefoil conformation of the human cytokine is conserved in the chicken. Significant 
differences were found between the chicken and human structures in the regions 
involved in receptor binding, providing a molecular explanation for the inability of 
these cytokines to cross-react (Cheng, Chen et al. 2011).  
1.2.4.2 Chicken IL-18 
A full length chicken IL-18 open reading frame (ORF) was identified in a bursal 
EST library and subsequently cloned from LPS-stimulated HD11 cells (Schneider, 
Puehler et al. 2000). The full length predicted protein contains 199 amino acids, has 
30% identity with mammalian chIL-18 sequences and includes a pro-domain at the N-
terminal. When aligned with mammalian sequences, a conserved aspartic acid is 
apparent at the predicted caspase-1 cleavage site, suggesting it may be processed by the 
enzyme. Purified recombinant mature chIL-18 (lacking the pro-domain) exhibited 
biological activity similar to that of mammalian IL-18. In primary chicken splenocytes 
stimulated with rchIL-18, a dose-dependent increase in IFN-γ production was detected 
(Schneider, Puehler et al. 2000). A conserved Th1 cell lineage similar to the one in 
mammals was subsequently proposed in the chicken. In chicken CD4
+
 T cells 
stimulated with chIL-18, cell proliferation, IFN-γ production and MHC class II 
expression were all increased (Gobel, Schneider et al. 2003). This was dependent upon 
the presence of macrophages in culture (Gobel, Schneider et al. 2003). 
Elevated levels of IL-18 mRNA have been detected in the spleen of birds 
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infected with Marek’s disease virus (Kaiser, Underwood et al. 2003), characteristic of a 
pro-inflammatory response to viral infection. IL-18 expression was also increased in the 
spleen of birds injected with Salmonella Typhimurium LPS (Sijben, Klasing et al. 2003) 
and the heterophils of chickens treated with corticosterone (Shini, Shini et al. 2010) 
reflecting the typical pro-inflammatory role of this cytokine.  
Neither the genomic location nor the structure of the chIL-18 gene has been 
published. 
 
1.2.4.3 Chicken IL-1RI  
The type I chicken IL-1 receptor (chIL-1RI) was cloned from a primary chicken 
fibroblast cDNA library. When compared with its human and mouse orthologues, amino 
acid identity of the five major protein domains varied from 19-61%, with the 
cytoplasmic domain the most highly conserved region (Guida, Heguy et al. 1992). A 
bioactive form of soluble chIL-1RI (sIL-1RI) has also been cloned (Klasing and Peng 
2001). Conditioned medium (CM) from LPS-stimulated HD11 cells contains chIL-1β 
that induces thymocyte co-stimulation. To establish biological activity, this CM was 
pre-incubated with partially purified sIL-1RI and then tested for its ability to co-
stimulate mitogenesis. Compared with controls, its capacity to stimulate thymocytes 
was significantly attenuated (Klasing and Peng 2001).   
The genomic location of the chIL-1RI gene has not been elucidated.  
1.2.4.4 Chicken ST2  
The chicken orthologue of the ST2 receptor was cloned from cDNA isolated 
from chicken embryos (Iwahana, Hayakawa et al. 2004). Three different cDNAs were 
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identified, designated ST2, ST2L and ST2 LV. ST2 is the secreted, soluble form of the 
receptor of which an equivalent has also been identified in humans. ST2L is a longer, 
membrane-bound isoform which contains a transmembrane domain, whilst ST2LV is a 
novel splice variant of the ST2L transcript. ST2LV lacks the transmembrane domain 
present in ST2L and as such is a secreted protein. To date, this novel splice variant has 
not been found in any mammalian species. ST2L has 39.3% and 38.3% identity with its 
respective human and mouse orthologues. In all three species, ST2L contains a signal 
peptide of similar length and all six cysteine residues are conserved in the Ig-like 
domain region. The structures of the human and chicken ST2 genes are very similar in 
composition (Iwahana, Hayakawa et al. 2004). The genomic location of the chST2 gene 
has not been determined. The ligand for this receptor, IL-33, has yet to be identified in 
the chicken. 
1.2.4.5 Chicken SIGIRR (TIR8)  
A full length chicken SIGIRR transcript which has 86% identity with human 
SIGIRR was identified in the NCBI nucleotide database (Riva, Polentarutti et al. 2009). 
Northern blotting analysis of twenty-one different chicken tissues revealed expression 
was ubiquitous with relatively high levels in the kidney, small and large intestine, 
caecum, liver, glandular stomach and cloaca (Riva, Polentarutti et al. 2009). A splice 
variant was identified exclusively in the adrenal gland. No further analyses of this gene 
were carried out.  
1.2.4.6 Other chIL-1 receptors  
Partial cDNAs for apparent chicken orthologues of IL-18Rα, IL-1RAcP and 
TIGIRR-1 receptors have been identified in the NCBI EST database (Huising, Stet et al. 
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2004). Comprehensive phylogenetic analysis of the IL-1 receptor family showed all 
three chicken sequences grouped with their mammalian orthologues (Huising, Stet et al. 
2004). 
 
1.3 The chicken genome 
When attempting to discover the avian orthologues of genes present in the 
human genome, it is crucial to fully appreciate the genetic differences between the 
human and the chicken. Therefore, the extent to which the evolution of these two 
species has changed the composition of their genomes needs to be carefully considered. 
As both species are eukaryotes, they will possess conserved molecular mechanisms for 
common functions which are likely to be controlled by the same set of orthologous 
genes. Despite this, chickens and humans have evolved separately for ~310 million 
years (Hedges, Parker et al. 1996) and this has led to the emergence of many 
differences. One major difference between the two is the organisation of species 
karyotype. The avian karyotype is made up of macro- and micro-chromosomes whose 
length differ substantially from one another. In total, the chicken has 38 autosomes and 
one pair of sex chromosomes, thus 2n = 78. In contrast to mammals, the male is 
homogametic (ZZ) whilst the female is heterogametic (ZW) (Griffin, Robertson et al. 
2007). 
Sequencing of the chicken genome (ICGSC 2004) has now allowed an even 
more detailed analysis of its genetic microarchitecture and how this compares to the 
human. For instance, the chicken and human genomes appear to contain roughly the 
same number of genes (~20-25,000), yet the chicken genome is ~3 times smaller than 
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the human. The chicken genome is composed, predominantly, of lengthy contiguous 
blocks of sequence that retain a lot of the ancient duplications. In both human and 
chicken genomes there is a relatively low incidence of chromosomal translocations; 
however, intrachromosomal rearrangements appear to be far more frequent in both 
species. When protein-coding gene sequences shared by the two species are aligned, 
exons show the highest conservation of sequence with very little homology between 
introns. The comparative analyses also showed ~60% of protein coding genes in the 
chicken have a sole orthologue in humans and that of these orthologous pairs, only 
~75.3% of amino acids are similar. Orthologous genes responsible for immune function 
are relatively less well conserved in the chicken compared with other essential 
functional sequences. Around 5-10% of all genes found in humans are either missing in 
the chicken or significantly truncated. There also appears to be a lot of genes that were 
present in the common ancestor, which are broadly conserved amongst many 
mammalian species, but are missing in the chicken. Of the vertebrates currently 
sequenced, the chicken appears to have lost more genes than it has gained, although the 
large number of sequence gaps in the chicken genome may contain some of these.  
Conservation of synteny is the term used to describe the conserved order of a 
defined cluster of genes on a single chromosome in different species. Many higher order 
eukaryotes have evolved from a common ancestor and this is reflected in the degree of 
similarity between their genomes. Although chromosomal rearrangements take place 
within a species through evolution, it is still common to observe large groups of 
orthologous gene clusters in different species. The degree of conserved synteny 
increases with the degree of relatedness between species. Despite the presence of a 
substantial number of regions of conserved synteny between the chicken and human 
genomes, the genetic composition of the two species differs markedly. 
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Since completion of the first draft of the chicken genome sequence in 2004 
(ICGSC 2004), comparative genomics have been widely used to define functional 
elements in the chicken, using the more extensively annotated human genome for 
comparison. Whilst a degree of genetic divergence is to be expected, e.g. in the genes 
that encode observable phenotypic differences such as the presence of feathers, 
sufficient genome sequence identity exists between the two species to be able to 
uncover novel orthologues in the chicken. It needs to be emphasized, however, that even 
after three separate genome builds; the quality of the chicken genome sequence is poor 
by comparison to that of the human genome. There are a significant number of regions 
on many of the chicken chromosomes which contain large sequence gaps. In some 
cases, such as with at least six of the micro-chromosomes, there is no sequence 
information for entire chromosomes. As such, it is difficult to know how many of the 
genes found in humans, which are presumed missing in the chicken, are genuinely 
absent.   
 
1.4 Aims of the project and experimental approach  
The ever expanding array of functional roles exhibited by IL-1 family cytokines 
in mammals emphasizes their importance in both innate and adaptive immunity. A 
group of eleven genes which encode the ligand members of the family are responsible 
for eliciting these biological functions. Determining whether an equivalent set of 
functional orthologues is conserved in the chicken is crucial for understanding the 
immune response in this species. Analysis of the first draft of the chicken genome 
sequence, however, provided no evidence of additional IL-1 ligand genes beyond the 
already described IL-1β and IL-18 (Kaiser, Poh et al. 2005). It was therefore not known 
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if the chicken possessed direct orthologues of the nine additional genes identified in 
man. Hence, the major aim of this project was to establish how many of these “missing” 
nine genes are present in the chicken. Once this was known, the aim was to characterise 
them fully at the genomic, mRNA and protein levels. Of these nine absent genes, six 
were discovered in man as recently as 2000 with a further gene found in 2005. 
Intriguingly, despite much active research into many non-mammalian species (of which 
several have a published genome sequence), these seven most recently discovered IL-1F 
genes have only been identified in mammals. Scientists have therefore speculated that 
these genes must have originated following duplication in the mammalian lineage 
(Mulero, Nelken et al. 2000). Birds and mammals have been evolving separately for 
~310 million years and have developed significant differences in the architecture of 
their genomes and specific gene content. Birds contain extra copies of certain immune 
function genes, e.g. TLR1, TLR2 and CXCL13, but are apparently missing others, such 
as TLR8, TLR9, NALP1 and IL-35. Discovery of direct orthologues of novel IL-1F 
genes in the chicken would thus not only suggest they have indispensible functions, it 
would also force a reappraisal of the evolution of this cytokine family. 
The starting point for this project was two EST sequences mined by a 
collaborator from the NCBI database. Both sequences had homology with chicken IL-
1β. From amino acid alignments they were clearly different members of the IL-1 family 
yet neither were identifiable in the chicken genome. The initial approach to the project 
involved screening every available eukaryotic genome sequence with BLAST to 
determine the exact identity of these two ESTs. Once this had been done, their predicted 
amino acid sequences and that of chIL-1β were used to screen build v2.1 of the chicken 
genome with BLAST. This was done for several reasons. Firstly, it was a different build 
to the previous two, and they had reported different genomic locations for IL-1β 
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(unplaced in v1.0, and chromosome 4 in v2.0). The genomic location had also been 
reported as chromosome 2 (Kaiser, Rothwell et al. 2004). It was thus necessary to 
establish if the most recent location, chromosome 4, was maintained in this new build. 
This was important because of the possible implications for finding further IL-1 genes 
in the chicken. In mammals, IL-1β is found at a locus containing a further eight IL-1 
genes. We therefore sought to establish if the human IL-1 locus shared conserved 
synteny with the chicken. The degree of conserved synteny for the IL-1 locus is high 
between different mammals. Except for in the mouse, where the locus has become 
divided into two, most mammals have retained the IL-1 locus as found in the human 
genome. Examining conserved synteny between the human and chicken genomes had 
previously been successfully used to isolate several chicken cytokines. For example, the 
Th2 cytokines (Avery, Rothwell et al. 2004) and CSF3 (Gibson, Kaiser et al. 2009) loci 
are largely conserved between mammals and the chicken. The two IL-10 family loci, 
despite a discrepancy in the exact gene content, are also conserved in synteny between 
the human and chicken genomes. A genome-wide analysis of conserved synteny 
between the chicken and humans has identified many conserved regions (Bourque, 
Zdobnov et al. 2005).  
Chicken IL-1β was found in the genome at a locus on chromosome 22, although 
no other chIL-1 genes were apparent. This locus did, however, contain the chicken 
orthologues of two non-IL-1 genes which flank the human IL-1 cluster suggesting a 
minimal degree of conserved synteny. As this locus did not contain further chIL-1 
genes, synteny was examined between the novel IL-1F genes in the human IL-1 cluster 
and other regions of the chicken genome. The chicken genome and the NCBI EST 
library were also screened with the amino acid sequences of all the novel IL-1F genes in 
humans. Despite a low degree of homology between chicken and human cytokine 
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genes, the IL-1 family contains a 21 amino acid signature motif which is unique to this 
family and highly conserved in all species (mammals, birds, and fish). It is therefore 
possible to identify IL-1 orthologues between species at this evolutionary distance, 
using this approach. 
The first main experimental aim of the project was to clone the full length CDS 
of each of the novel chicken IL-1 genes. The second aim was to thoroughly characterise 
their expression in the chicken at the basal level and in response to infection using 
quantitative real-time RT-PCR (TaqMan®). This would allow us to gain an insight into 
their roles in the avian immune response and whether these roles were similar to those 
of their functional orthologues in man and mouse. A third aim was to determine their 
genomic structures and location(s) in the chicken. This would provide a greater 
understanding of the evolution of this cytokine family and may also identify further IL-
1 genes at novel loci. A fourth aim was to express recombinant proteins for each novel 
IL-1 and to use cellular bioassays to characterise their precise function, to establish if 
these novel chicken cytokines are functionally analogous to their mammalian 
orthologues.   
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2.1 In silico materials 
2.1.1 Genomic sequence resources 
Nucleotide and amino acid sequences from eukaryotic species (listed in the 
Appendix) were accessed from a range of internet-based genome browsers and 
sequence databases. Chicken expressed sequence tag (EST) sequences were acquired 
from the National Center for Biotechnology Information (NCBI) chicken genome 
resources database 
(http://www.ncbi.nlm.nih.gov/projects/genome/guide/chicken/index.html). The 
sequences and genomic locations of individual genes or clusters of genes were accessed 
using the Ensembl genome browser (http://www.ensembl.org/index.html), the NCBI 
map viewer (http://www.ncbi.nlm.nih.gov/mapview/), and the University of California 
Santa Cruz (UCSC) genome browser (http://genome.ucsc.edu/). Chicken genomic 
sequences were accessed from the public database of The Genome Institute at 
Washington University in St.Louis (WUSTL) (http://genome.wustl.edu/).  
2.1.2 CodonCode aligner 
Codoncode aligner (CodonCode Corporation, MA, USA) is a software program 
that uses ClustalW to assemble nucleotide sequences into contigs. Base calling uses the 
Phred-Phrap algorithm to ensure that only high quality sequences become aligned. All 
sequencing results were analysed using Codoncode aligner.  
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2.1.3 ClustalX 
ClustalX is a software program that creates alignments of multiple nucleotide or 
amino acid sequences. Nucleotide or amino acid sequences from different species 
containing homologous genes or from variants of a gene within the same species were 
aligned using this software.  
2.1.4 SignalP 
SignalP3.0 (Center for Biological Sequence Analysis, Technical University of 
Denmark DTU; http://www.cbs.dtu.dk/services/SignalP/) is an online server that 
predicts the existence and position of signal peptides and the exact residues in an amino 
acid sequence where cleavage occurs. The analysis uses both artificial neural network 
and hidden Markov model algorithms to make a prediction. Information on the software 
can be found in (Bendtsen, Nielsen et al. 2004; Emanuelsson, Brunak et al. 2007). 
2.1.5 ProDom 
ProDom (http://prodom.prabi.fr/prodom/current/html/form.php) is a database 
containing protein domain families created following a large scale analysis of all 
available amino acid sequences. Protein sequences are derived from UniProt and 
organised into individual domain family records. BLASTP is used to search against this 
collection of domain families to indicate structural similarity of a protein to a pre-
existing characterized protein domain. Further information can be found in (Bru, 
Courcelle et al. 2005).  
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2.1.6 PSIPRED 
 PSIPRED (Department of Computer Science, University College London; 
http://bioinf.cs.ucl.ac.uk/psipred/) is an online server that predicts the secondary 
structure of a protein. The analysis uses two “feed-forward neural networks” which 
analyse the results of an initial PSI-BLAST search to make the prediction. 
2.1.7 SoftBerry 
SoftBerry (http://linux1.softberry.com/berry.phtml) is an online server that 
compares submitted sequences with a database of 8458 transcription factor binding site 
consensus motifs. The exact programme used was NSITE. 
 
2.2 In silico methods 
2.2.1 Identification of the extent of the chicken IL-1 gene family using the 
ENSEMBL database 
2.2.1.1 IL-1 ligand genes 
To establish the extent of the chicken IL-1 ligand gene family, a search of the 
ENSEMBL chicken genome browser using the terms “IL-1” and “IL-18”was carried 
out.  For all members of the human IL-1 family not identified in the chicken using this 
method, the full gene sequence, full amino acid sequence and the amino acid signature 
motif were analysed with BLAST against the chicken genome sequence using the 
ENSEMBL genome browser.  
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2.2.1.2 IL-1 receptor genes 
The extent of the chicken IL-1 receptor family at a conserved locus was 
identified by first searching for the known chIL-1 receptor, IL-1RI (Guida, Heguy et al. 
1992) in the ENSEMBL genome browser. Next, conserved synteny between the 
genomic location of chIL-1RI and its orthologue in the human genome was examined. 
This identified further chicken IL-1 receptor genes in a conserved locus in the chicken. 
For all members of the human IL-1 receptor gene family not identified in the chicken 
using this method, a search of their genomic locations in the human was carried out. 
Conserved synteny was then used to identify if/where chicken orthologues of these 
genes are located in the chicken genome.  
2.2.2 Identification of novel chicken IL-1 family members in the NCBI EST 
database 
A search of the NCBI Chicken Genome Resources expressed sequence tag 
(EST) database was performed in order to identify EST sequences for novel chicken IL-
1 genes using TBLASTN.  
2.2.3 Establishing the identity of novel chIL-1 genes using BLAST 
A sequence similarity search using BLAST was carried out to confirm the gene 
identities of novel chIL-1 EST sequences mined from NCBI. Nucleotide sequences 
were first translated followed by a TBLASTN search against all 39 eukaryotic animal 
genomes present in ENSEMBL release 50 (July 2008). For the full list of species 
queried, see Appendix I.  
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2.3 In vitro materials 
2.3.1 Restriction enzymes  
All restriction enzymes and buffers from Invitrogen unless stated otherwise. 
Buffer details are provided in Appendix III. 
Restriction enzyme Recognition site (5′→3′) Buffer 
 
AgeI (NEB) 
 
 
AˇCCGGT 
 
NEBuffer1 
BamHI GˇGATCC REact®3 
 
DdeI CˇTNAG REact®3 
 
EcoRI 
 
GˇAATTC REact®3 
HindIII AˇAGCTT REact®2 
 
HinfI GˇANTC REact®2 
 
KpnI 
 
GGTACˇC REact®4 
MluI (Roche) 
 
AˇCGCGT SuRE/Cut Buffer H 
NotI 
 
GCˇGGCCGC REact®3 
SalI GˇTCGAC REact®2 (75% activity) 
REact®10 (100%) 
XbaI 
 
TˇCTAGA REact®2 
XhoI CˇTCGAG REact®2 
 
2.3.2 Oligonucleotide primers 
All oligonucleotides were ordered from Sigma-Genosys. Primer sequences are 
provided in Tables I-III in Appendix II. 
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2.3.3 Vectors 
2.3.3.1 pCI-neo Mammalian Expression Vector (Promega E1841) 
pCI-neo is a 5.47 kb mammalian expression vector used for cloning cDNA 
fragments. Plasmid DNA clones can be either transiently or stably transfected into 
mammalian cells to produce high levels of constitutive expression. The vector contains 
a number of components that confer this functionality. A cytomegalovirus (CMV) 
immediate-early enhancer/promoter region acts to promote its expression in cells. A 
simian virus 40 (SV40) enhancer/early promoter region containing the SV40 origin of 
replication is also present, allowing any cell type expressing an SV40 large T antigen, 
e.g. COS-7 cells, to permit transient replication of pCI-Neo. A chimeric intron, located 
adjacent to the multiple cloning region, is used to augment expression of the cDNA 
insert. Inserts are directionally cloned with restriction sites into the multiple cloning 
region (MCR) which is flanked by T7 and T3 RNA polymerase promoters that facilitate 
sequencing of the insert. Downstream of the MCR is an SV40 late polyadenylation 
signal that promotes effective processing and increased amounts of RNA copies of the 
insert. Two selectable markers, the neomycin phosphotransferase and β-lactamase 
coding regions, confer resistance to G-418 and ampicillin antibiotics, respectively. 
 
2.3.3.2 pGEM-T® Easy (Promega A1360) 
pGEM-T® Easy is a linear 3.015 kb vector used to clone DNA fragments. This 
vector has single deoxythymidine bases located at both 3′ ends. Taking advantage of the 
single 3′ deoxyadenosine overhangs added to PCR products by Taq polymerase,  
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Figure 2.1 Map of the pCI-neo mammalian expression vector. 
 
complimentary TA base pairing permits efficient ligation of DNA inserts into this 
vector. Following transformation, positive recombinant clones can be identified by 
selection of white colonies on an agar plate. Colour screening is possible due to the 
location of the MCR within a lacZ gene. This gene encodes the α subunit of lacZ 
protein, which forms part of the enzyme β-galactosidase. Agar plates are spread with X-
gal, a sugar that becomes metabolised by β-galactosidase to form blue coloured 
bacterial colonies. DNA correctly inserted in the MCR inactivates lacZ, preventing 
functional β-galactosidase being produced so only white colonies are present. Blue 
colonies indicate no insert is present. The MCR contains T7 and SP6 RNA polymerase 
promoters facilitating RNA synthesis and sites for insert sequencing. An ampicillin 
resistance gene (amp
r
) permits selection of only the bacteria containing positive clones. 
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Figure 2.2 Map of the pGEM-T® Easy vector. 
 
2.3.3.3 pHLSec 
pHLSec is a 4.53 kb expression vector created following multiple modifications 
of the pCAGGS vector (Aricescu, Lu et al. 2006). Mammalian cells can be transiently 
transfected with pHLSec-cDNA clones to provide high level expression of constructs 
that become secreted. It contains a number of components that confer this functionality. 
It is comprised of a pLEXm backbone consisting of an origin of replication taken from 
the pBR322 vector. A CMV enhancer/chick β-actin promoter and a rabbit β-globin 
intron, adjacent to an MCR, enhance its expression in cells. A rabbit β-globin poly(A) 
signal adds a poly(A) tail to RNA transcripts of the insert, whilst an amp
r
 gene 
selectable marker allows visualisation of only positive clones following transformation. 
Several modifications were made to the MCR to permit the secretion of constructs from 
transfected cells. These include introducing a Kozak sequence (GCCACCATGG), a 
secretion signal sequence and a C-terminal K_His tag to facilitate protein purification. 
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Figure 2.3 Map of the pLEXm vector. pHLSec is comprised of the pLEXm backbone 
(top) with a modified MCR which was reduced to incorporate the signal sequence and 
HIS-tag (bottom). 
 
2.3.3.4 pTargeT™ Mammalian Expression Vector (Promega A1410) 
pTargeT™ is a 5.67 kb mammalian expression vector for TA cloning cDNA 
fragments which can be transiently or stably transfected into mammalian cells. This  
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Figure 2.4 Map of the pTargeT™ mammalian expression vector 
 
vector is, in effect, a chimera of the pCI-neo and pGEM-T® Easy vectors. It consists of 
a pCI-neo backbone combined with the pGEM-T® Easy feature of the MCR being 
located within a lacZ gene to allow blue/white screening of recombinants. A solitary T7 
RNA polymerase promoter facilitates RNA synthesis and a site for insert sequencing. 
 
2.3.4 Bacterial and viral strains 
Escherichia coli competent cells, JM109 strain (Promega L2001), were used to 
clone plasmid DNA. Chromosomal genotype: endA1, recA1, gyrA96, thi, hsdR17 (rk–, 
mk+), relA1, supE44, D(lac-proAB), [F¢, traD36, proAB, laqIqZDM15]. 
Salmonella enterica subsp. enterica ser. Typhimurium strain F98 Nal
R
. 
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Infectious Bursal Disease Virus strain 52/70. 
2.3.5 Cell lines 
2.3.5.1 COS-7 cells 
COS-7 cells are an adherent cell line that can be transiently transfected for high 
level expression of recombinant proteins (Aruffo 2002). To create the COS-7 cell line, a 
CV-1 cell line derived from African green monkey kidney cells was transformed by a 
mutant of SV40 encoding a wild type T antigen. SV40 origin-containing plasmids, such 
as pTargeT, experience high copy number replication at 48-72 h after transfection into 
COS-7 cells.  
2.3.5.2 HD11 cells 
HD11 cells are an adherent myelomonocytic cell line used widely as a means of 
investigating immune responses in chicken macrophages. To create the HD11 cell line, 
bone marrow-derived chick macrophages were transformed with the replication-
defective avian retrovirus, myelocytomatosis 29 (MC29) virus (Beug, von Kirchbach et 
al. 1979).  
2.3.5.3 HEK293T cells 
HEK293T cells are an adherent cell line with a wide range of experimental uses, 
mainly due to the ease with which they can be transfected, particularly to express 
recombinant proteins. The original 293 cell line was created by transforming human 
embryonic kidney (HEK) cell cultures with sheared adenovirus type 5 (strain Ad75) 
DNA (Graham, Smiley et al. 1977). HEK293T cells were created by expressing the 
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SV40 large T antigen to permit high copy number replication of SV40 origin-containing 
plasmids transfected into this line. 
2.3.6 Cell culture reagents 
All acquired from Sigma-Aldrich Ltd (Dorset, UK) unless otherwise stated. 
Reagent details are provided in Appendix IV. 
2.3.7 Recombinant protein  
Recombinant mature chIL-1β protein was purchased from AMS Biotechnology, 
Abingdon, UK. Full length chIL-1β (pro-chIL-1β) is a 267 amino acid precursor form of 
the cytokine which requires enzymatic cleavage to be converted into its mature, 
biologically active form. A previous study by Weining, Sick et al. (1998) identified the 
alanine at position 106 as the first residue of the mature form. We therefore amplified a 
cDNA encoding amino acids 106-267. AMSBio cloned the cDNA into the pET21a 
vector and HIS-tagged recombinant protein was expressed in E. coli. 
2.4 In vitro methods 
2.4.1 Sources of chicken tissues and cells  
2.4.1.1 Tissues and cells from specified-pathogen-free chickens 
Tissues were removed from a nine-week-old specified-pathogen-free (SPF) 
inbred line 72 chicken using a sterile scalpel and were immediately stabilised in 
RNAlater. Tissues taken were the thymus, spleen, bursa of Fabricius, Harderian gland, 
caecum, caecal tonsil, Meckel’s diverticulum, bone marrow, brain, muscle, heart, liver, 
Chapter 2: Materials and Methods 
107 
 
kidney, lung and skin.  
Further tissues (spleen, thymus and bursa of Fabricius) were removed from a 
six-week-old SPF inbred line 72 chicken. Splenocytes were divided equally into two 
groups. The first group of splenocytes, as well as all bursal cells and thymocytes, were 
stimulated as follows: splenocytes with 1 µg/ml Concanavalin A (ConA), bursal cells 
with 500 ng/ml phorbol myristate acetate (PMA), and thymocytes with 25 µg/ml 
phytohaemagluttinin (PHA). All stimulations were performed for 18 h as described 
(Wu, Hu et al. 2010). With the second group of splenocytes, specific lymphocyte 
subsets (CD4
+, CD8α+, CD8β, TCR1+, TCR2+, TCR3+, Bu-1+ and KUL01+ cells) were 
isolated as previously described (Wu, Hu et al. 2010). All tissues and sorted cell subsets 
were kindly supplied by Dr Zhiguang Wu (The Roslin Institute, University of 
Edinburgh, UK).  
Bone marrow-derived dendritic cells (BM-DCs), macrophages (BM-MФ) and 
blood-derived monocytes/macrophages (Bl-Mo/MФ) were isolated from 4-8-week-old 
SPF inbred line 72 chickens and stimulated with LPS or CD40L for 1, 2, 4, 8, 12, 24 or 
48 h as described (Wu, Hu et al. 2010). All cell populations were kindly supplied by Dr 
Zhiguang Wu. Unstimulated and LPS-stimulated heterophils were a gift from Dr Mike 
Kogut (USDA College Station, Texas, USA).  
2.4.1.2 Tissues and cells from SPF chickens challenged with bacteria or virus 
Six-week-old outbred SPF Rhode Island Red (RIR) chickens were orally 
challenged with 2.8 x 10
8
 cfu/ml S. Typhimurium strain F98 Nal
R 
or LB medium 
(control). Birds were killed at 3, 7, 14, 21 and 27 dpi, and whole spleens were removed 
and immediately stabilised in RNAlater. The experiment was carried out and tissues 
kindly supplied by Dr Claire Powers (IAH, Compton, UK). 
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Three-week-old resistant (line 61) and susceptible (Brown Leghorn) groups of 
inbred SPF chickens were challenged intra-nasally with either 10
1.3
 embryonic 
infectious dose (EID50) per 100 µl PBS of infectious bursal disease virus (IBDV) strain 
52/70, or PBS (control). Birds were killed at 2, 3, and 4 dpi, and whole spleens and 
bursas of Fabricius were removed. The experiment was carried out and tissues kindly 
supplied by Dr Jean-Remy Sadeyen (IAH, Compton, UK). 
2.4.2 Purification of nucleic acids 
2.4.2.1 Purifying total RNA from chicken tissues 
Total RNA was purified from chicken tissues using the RNeasy mini kit 
following the manufacturers’ protocol for purification of total RNA from animal tissues. 
Following dissection, fresh tissues were stabilised in RNAlater and frozen at -80
o
C. 
After thawing, tissues were lysed and homogenised using buffer RLT and a 
TissueLyser. Buffer RLT contains β-mercaptoethanol and guanidine thiocyanate which 
lyses the cells and protects the RNA by inactivating RNases. To homogenise a single 
sample, <30 mg tissue, 600 µl buffer RLT and a 5 mm stainless steel bead were placed 
in a 2 ml safe-lock tube. All sample tubes were then agitated for 4 min at 20 Hz using 
the TissueLyser bead mill. Homogenisation releases cellular RNA whilst shearing 
genomic DNA to decrease lysate viscosity. Further homogenization was achieved by 
passing tissue lysates through QIAshredder columns according to the manufacturers’ 
protocol. Ethanol was added to lysates to provide suitable binding conditions before 
samples were bound to RNeasy silica membranes (spin columns) by centrifugation at 
1300 x g for 15 s. A single buffer RW1 and two buffer RPE washes were carried out to 
remove contaminants. The final RPE wash had a 2 min centrifugation step to dry the 
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spin column by removing residual ethanol. Spin columns were transferred to clean 
collection tubes and centrifuged at 1690 x g for 1 min to eliminate all traces of ethanol. 
RNA was eluted into clean 1.5 ml tubes, using 30-50 µl RNase-free water, by 
centrifugation at 1300 x g for 15 s. Buffer contents are given in Appendix III. 
2.4.2.2 Purifying total RNA from cell lines 
Total RNA was purified from cell lines using the RNeasy mini kit following the 
manufacturers’ protocol for purification of total RNA from animal cells using spin 
technology. Cell lines were washed twice with PBS then directly lysed using 600 µl 
buffer RLT per 2 x10
6
 cells. RNA was extracted from cell lysates using the same 
method as described in section 2.4.2.1. 
2.4.2.3 Purifying genomic DNA from whole blood 
Genomic DNA was purified from whole blood using the DNeasy blood and 
tissue kit following the manufacturers’ protocol for purification of total DNA from 
animal blood or cells (spin-column). To lyse the cells, 20 µl of proteinase K were mixed 
with 10 µl anticoagulated chicken blood, and the volume adjusted to 220 µl with PBS. 
Proteinase K also digests contaminating proteins as well as degrading nucleases that 
could damage the DNA. Next, 200 µl of buffer AL were added to the reaction, mixed 
thoroughly by vortexing, then incubated for 10 min at 56 ºC. The guanidine 
hydrochloride (GndHCl) in buffer AL helps to lyse cells. To this, 200 µl of 100% 
ethanol were added and mixed by vortexing. The combination of ethanol with the 
GndHCl adjusts the buffer conditions for optimal DNA adsorption to a silica membrane. 
The mixture was then applied to a DNeasy mini spin column, in a 2 ml collection tube, 
and centrifuged at 1040 x g for 1 min. The column was transferred to a fresh collection 
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tube and washed with 500 µl of buffer AW1, followed by centrifugation at 1040 x g for 
1 min. The column was transferred to a fresh collection tube and washed with 500 µl of 
buffer AW2 then centrifuged at 1820 x g for 3 min. This long centrifugation step 
eliminated all traces of ethanol. The column was transferred to a clean microcentrifuge 
tube and 200 µl of buffer AE were added. After allowing 1 min for adsorption, DNA 
was eluted by centrifugation at 1040 x g for 1 min.  
2.4.2.4 Purifying genomic DNA from cell lines 
This protocol was identical to the purification from whole blood in section 
2.4.2.3 except for the first steps. When extracting DNA from cells, <5 x 10
6
 cells were 
pelleted by centrifugation at 300 x g for 5 min. The pellet was resuspended in 200 µl 
PBS then mixed with 20 µl proteinase K. The remainder of the protocol, beginning with 
the addition of 200 µl of buffer AL, was as described in section 2.4.2.3.  
2.4.3 Quantification of nucleic acids 
The concentration of pure RNA was determined using a NanoDrop ND1000 
spectrophotometer. Concentration is calculated as the absorbance of a 1 µl sample at 
260 nm which equates to 1 optical density (O.D.) unit = 44 µg/ml RNA. RNA 
concentration is automatically calculated in ng/µl, based on the Beer Lambert equation. 
RNA purity is also calculated as the ratio of absorbance at 260 nm and 280 nm 
(A260/A280). For pure RNA, this value should be in the range = 1.9-2.1. 
The concentration of DNA was calculated using the same method; however, 
with this template 1 O.D. = 50 µg/ml double-stranded DNA. DNA purity is also 
calculated using the A260/A280 ratio and, if pure, should ≈ 1.8. 
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2.4.4 DNA and RNA amplification 
2.4.4.1 Oligonucleotide primer design 
Oligonucleotide primers used to amplify genomic DNA or cDNA templates 
were designed using Primer3, an open access online design tool (Rozen and Skaletsky 
2000).  
2.4.4.2 One-step reverse transcriptase-polymerase chain reaction (RT-PCR) 
PCR products were generated from RNA templates in a single step using Illustra 
Ready-To-Go™ RT-PCR beads. Following first-strand cDNA synthesis, the 
RNA:cDNA heteroduplex is denatured to permit PCR amplification of the cDNA 
template. Beads are supplied containing most of the reagents required for both of these 
stages. The user is required to add first-strand primer, a pair of gene-specific PCR 
primers, the RNA template and DEPC-H2O, to a final volume of 50 µl. Reaction tubes 
were incubated on ice and beads were dissolved using 39 µl DEPC-H2O. Twenty pmol 
of both forward and reverse gene-specific primers (in DEPC-H2O) along with 1 µl RNA 
template were added to each tube to complete the reaction. Reverse strand gene-specific 
primers were always used as the first strand cDNA synthesis primer. The final 50 µl 
reaction contained 2 U Taq DNA polymerase, 10 mM Tris-HCl, 60 mM KCl, 1.5 mM 
MgCl2, 200 µM dNTPs, Moloney murine leukaemia virus reverse transcriptase (RT) 
and RNAguard ribonuclease inhibitor. Thermal cycling conditions were: 
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42ºC / 30 min  x1 cycle first strand synthesis 
95ºC / 5 min  x1 cycle inactivates the RT and denatures the template 
95ºC / 1 min 
*
55ºC / 1 min  x40 cycles 
72ºC / 2 min 
*
Annealing temperature is dependent on the Tm of the primers. The range of 
temperatures used was 55-70ºC. 
Thermal cycling was carried out using a Mastercycler (Eppendorf). Products 
were electrophoresed on a 1% agarose gel. 
2.4.4.3 Two step RT-PCR  
PCR products were generated from RNA templates in two separate reaction 
steps. In the first, cDNA was created from mRNA using Superscript II reverse 
transcriptase (RT). To a 0.2 ml nuclease-free centrifuge tube, the following reaction 
components were added: 1 µl 500 µg/ml oligo(dT)20, 1 ng – 5 µg total RNA, 1 µl 10 
mM dNTPs and sterile water to a total volume of 12 µl. The oligo(dT) primer 
hybridizes to the poly(A) tail of mRNA molecules to facilitate first strand cDNA 
synthesis using reverse transcriptase. The reaction mixture was heated to 65ºC for 5 min 
to enable the oligo(dT) to anneal to the mRNA template, then incubated on ice for 20 s. 
Next, the following components were added to the reaction: 4 µl 5X first-strand buffer 
and 2 µl 0.1 M DTT, followed by gentle agitation to mix. The first strand buffer 
contains MgCl2 which stabilizes ATP and supports transfer of the phosphate group 
during the extension step. DTT (dithiothreitol) is a reducing agent added to break 
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disulphide bonds in any RNases present. The tube was briefly incubated at 42ºC for 2 
min to bring the reaction to the required temperature. Next, 1 µl Superscript II RT was 
added and gently mixed by pipetting followed by incubation at 42ºC for 50 min to allow 
cDNA synthesis to take place. Finally, the RT was inactivated by heating the reaction at 
70ºC for 15 min.  
PCR was performed in a standard 25 µl reaction containing 2 µl of cDNA 
template, 0.4 mM dNTPs, 1 x final volume PCR buffer, 1.5 mM MgCl2, 0.625 U Go 
Taq® DNA polymerase and 0.2 µM of each primer. Thermal cycling conditions were: 
95ºC / 5 min  x1 cycle denatures the template 
95ºC / 20 s 
*
xºC / 20 s   x5 cycles touchdown i.e. annealing temperature decreases by  
72ºC / 1 min  1ºC per cycle 
95ºC / 20 s 
*
x-5ºC / 20 s  x25 cycles 
72ºC / 1 min 
*
Annealing temperature is dependent on the Tm of the primers. The range of 
temperatures used was 55-70ºC. 
Thermal cycling was carried out using an iCycler (Bio-Rad). Products were 
electrophoresed on a 1% agarose gel. 
2.4.4.4 DNA amplification by PCR 
Genomic DNA and cDNA were amplified by PCR in standard 25 µl reactions. 
Each reaction consisted of 50 ng DNA template, 0.4 mM dNTPs, 1 x final volume PCR 
buffer, 1.5 mM MgCl2, 1.25 U of Taq polymerase and 0.2 µM of each primer. Thermal 
cycling conditions were the same as the PCR in section 2.4.4.3. Thermal cycling was 
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carried out using an iCycler (Bio-Rad). Products were electrophoresed on a 1% agarose 
gel. 
2.4.4.5 5′ Rapid amplification of cDNA ends (RACE) 
5′ RACE was performed using the SMARTer™ RACE cDNA amplification kit 
(Clontech) following the manufacturer’s instructions.  
A brief explanation of the theory underpinning the method: 
 
   5′                                                   polyA 3′       mRNA 
                                                 Modified oligo(dT) primer 
 
First strand synthesis. PolyA+ RNA is reverse transcribed by SMARTscribe RT from a 
modified oligo(dT) primer. The primer has two degenerate nucleotides at its 3′ end 
causing it to anneal to the start of the polyA tail. 
                5′                                                   polyA 3′        mRNA 
            xxxx                                                                         cDNA 
5′        xxxx 
SMARTer IIA oligo 
Once the SMARTscribe has reached the 5′ end of the RNA, its terminal transferase 
activity adds 3-5 additional residues (xxxx) to the 3′ end of the synthesised cDNA 
strand. The SMARTer II A oligo contains a sequence of bases complementary to those 
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added by the RT enzyme, causing it to anneal to the cDNA tail. This permits the oligo 
to act as template for the RT. The RT jumps from the RNA to the oligo and copies the 
oligo sequence into the end of the cDNA.  
    5′         xxxx                                                   polyA 3′ 
                 xxxx 
The final product is a single-stranded full length cDNA with the SMARTer II A 
sequence (universal primer binding site) at the 5′ end.  PCR was performed using the 
universal primer (whose sequence is complementary to SMARTer II A) and a gene- 
specific reverse primer (GSP).  
                 xxxx                                                                Full length cDNA 
universal primer                                GSP 
 
2.4.4.5.1 First strand cDNA synthesis 
Buffer mix was made in multiples of 4 µl (depending on the number of reactions 
being set up) containing 2 µl 5X first strand buffer, 1 µl DTT (20 mM) and 1 µl dNTP 
(10 mM). Next, 5′ RACE cDNA was made by combining 1-2.75 µl RNA and 1 µl 5′ 
CDS Primer A (modified oligo (dT)), made up to 3.75 µl with sterile water. This 
reaction was incubated for 3 min at 72ºC, then 2 min at 42ºC. It was allowed to cool 
briefly before centrifugation at 1690 x g for 10 s to collect the tube contents. Next, 1 µl 
SMARTer II A oligo was added to each separate 5′ RACE reaction.  
Master mix was made consisting of 4 µl buffer mix (see above), 0.25 µl RNase 
inhibitor (40 U/µl) and 1 µl SMARTscribe RT (100 U/µl). This was added to the 4.75 
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µl RNA (from above) for a total volume of 10 µl. After gently mixing with a pipette, 
reactions were incubated for 90 min at 42ºC to facilitate cDNA synthesis followed by 
10 min at 70ºC to inactivate the RT. Reactions were diluted with 20-250 µl Tricine-
EDTA buffer and stored at -20ºC.  
2.4.4.5.2 5′ RACE PCR 
PCR mastermix was made in multiples of 41.5 µl containing 34.5 µl sterile 
water, 5 µl 10X Advantage 2 PCR buffer (1X final volume), 1 µl dNTP (10 mM) and 1 
µl 50X Advantage 2 polymerase mix (1X final volume). 5′ RACE PCR amplification 
was carried out in 50 µl reactions consisting of 2.5 µl 5′ RACE cDNA, 5 µl 10X 
universal primer mix (UPM) (1X final volume), 1 µl reverse GSP (10 µM) and 41.5 µl 
PCR mastermix. For each separate 5′ RACE PCR, 3 control reactions were also set up. 
A positive control PCR was the same as the 5′ RACE PCR except 4 µl sterile water and 
1 µl forward GSP (10 µM) were substituted for the UPM. This reaction ensured the 
cDNA of interest was contained within the template. Two negative controls were set up: 
a UPM control substituting 1 µl of sterile water for the reverse GSP; and a GSP control 
whereby 5 µl of sterile water was substituted for the UPM. Thermal cycling conditions 
were: 
If GSP Tm >70 ºC 
95ºC / 30 secs  x5 cycles 
72ºC / 3 mins 
94ºC / 30 secs     
70ºC / 30 secs             x5 cycles  
72ºC / 3 mins 
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94ºC / 30 secs   
68ºC / 30 secs            x20 cycles (polyA RNA) or 25 cycles (total RNA) 
72ºC / 3 mins 
 
If GSP Tm = 60-70ºC 
94ºC / 30 secs   
68ºC / 30 secs            x20 cycles (polyA RNA) or 25 cycles (total RNA) 
72ºC / 3 mins 
 
2.4.4.6 Real-time quantitative RT-PCR (TaqMan) 
Real-time quantitative RT-PCR (qRT-PCR) was used to measure the level of 
cytokine mRNA expression in a range of chicken cells and tissues. Expression levels of 
gene-specific transcripts were quantified alongside a house-keeping gene, 28S, for every 
sample that was assayed. The 28S ribosomal RNA gene encodes the RNA component 
of the large subunit found within ribosomes, so it is constitutively and relatively 
constantly expressed in all eukaryotic cells, and so is a suitable candidate to be used to 
normalize the expression levels of target genes. Standardization of the target gene 
quantity to the amount of RNA in a sample allows valid comparisons to be made 
between different samples.  
For each different gene that was analysed, a pair of primers and a probe were 
designed against the target template using the Primer Express software package 
(Applied Biosystems). Primers were acquired from Sigma, whilst probes were acquired 
from Eurogentec, Sigma and Applied Biosystems. Standard probes were labelled at the 
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5′ end with 5- or 6-carboxyfluorescein (FAM) fluorophore, and at the 3′ end with 
tetramethylrhodamine (TAMRA) quencher dye. MGB probes were also labelled with 
FAM at the 5′ end; however, the 3′ end was labelled with dihydrocyclopyrroloindole 
tripeptide minor groove binder ligand (MGB). These probes have higher melting 
temperatures and increased specificity. Primers and probe sets were designed according 
to seven strict criteria to enable optimal reaction efficiency. The melting temperature of 
the primers was 58-60ºC, with the probe Tm 10ºC higher than this. Primers and probes 
were 15-30 nucleotides in length, with the GC content in the range of 30-80%. To 
reduce non-specific priming, no more than 2 G or C bases were present in the final 5 
nucleotides at the 3′ end of a primer. Amplicons should ideally be 50-150 bp long and 
were never more than 400 bp. Probes did not contain consecutive identical nucleotides, 
in particular ≥4 guanines, as this can lead to mispriming. Probes also contained more 
C’s than G’s, and did not have a G at the 5′ end as this would have quenched the 
fluorophore. Finally, primer and probe sets were designed so that at least one of the 
oligonucleotides spanned a boundary between different exons. This ensured false-
positive results from the amplification of contaminating genomic DNA would not be 
obtained.  
The theory behind this assay is as follows: qRT-PCR probes are labelled at their 
5′ end with a reporter fluorophore and at their 3′ end with a quencher. The close 
proximity of these moieties allows the quencher to inhibit the fluorescence of the 
reporter dye, although not completely so some background fluorescence can be 
observed. During the PCR, the probe anneals to the template between forward and 
reverse primers. Upon primer extension, facilitated by Taq polymerase, template 
replication takes place. Upon reaching the bound probe, the 5′-3′ exonuclease activity of 
Taq degrades the probe releasing the reporter away from the close proximity of the 
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quencher. This leads to an increase in fluorescence intensity (see Figure 2.5). As this 
technique measures the number of copies of PCR product that have accumulated, the 
greater the fluorescence, the more transcripts are present in a sample. Results are 
presented as a cycle threshold (Ct) value, which represent the number of PCR cycles at 
which fluorescence emission of the reporter minus any background passes the threshold.  
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Figure 2.5 Real-time quantitative RT-PCR (qRT-PCR). A. Polymerization. A 
fluorescently labelled TaqMan probe hybridises to the target template between forward 
and reverse primers. Upon primer extension, template replication takes place, facilitated 
by Taq polymerase. B. Probe displacement. The elongated forward strand being 
synthesised, displaces the probe from the template. C. Probe degradation. The 5’-3’ 
exonuclease activity of Taq polymerase degrades the probe, releasing the fluorescent 
reporter dye. D. Fluorescence. Probe degradation allows the reporter to move away 
from its close proximity to the quencher. This leads to an increase in fluorescence 
intensity. 
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Before working with test samples, it was necessary to determine the optimal 
concentration of primer to be used in a reaction. Primer concentrations for IL-1β and 
28S were optimised prior to this study (Kaiser, Rothwell et al. 2000). For iNOS, primer 
concentrations were optimised prior to this study by Dr Bas Baaten (IAH, Compton, 
UK). For IL-1RN and IL-1F5, COS-7 cells were transfected with full length pTarget 
cDNA clones of both. RNA from these cells was diluted in the range 10
-2
-10
-7
 and 
analysed with a range of primer concentrations from 0.25-2.5 µM. RT-PCR was 
performed using the Taqman FAST Universal PCR Master Mix (kit 1) and TaqMan 
One-step RT-PCR mastermix (kit 2) reagent kits (Applied Biosystems). Samples were 
assayed in 10 µl reactions consisting of: 5 µl 2x FAST Master mix (kit 1), 0.5 µl primer 
mix, 125 nM probe, 0.25 µl 40X Multiscribe enzyme (kit 2), 1.5 µl DEPC-H2O and 2.5 
µl RNA. For the test sample RNA, 1:5 dilutions were made for the analysis of cytokine 
expression, and 1:500 dilutions for 28S analysis. All were assayed in triplicate. For IL-
1RN and IL-1F5, standard curves were created with serial dilutions of ex-COS RNA in 
the range 10
-2
-10
-6
. For 28S positive standard RNA, HD11 cells were stimulated with 
200 ng/μL LPS for 6 h, then total RNA extracted and diluted in the range 10-3-10-7. 
Amplification and quantification of products was carried out using the 7500FAST 
TaqMan machine (Applied Biosystems). Thermal cycling conditions were: one cycle of 
48ºC for 30 min, 95ºC for 20 s, then 40 cycles of 95ºC for 3 s, 60ºC for 30 s. Optimised 
primer concentrations for all assays are in Table II in Appendix II. 
2.4.5 Agarose gel electrophoresis of DNA 
DNA products from RT-PCR, standard PCR, RACE and restriction digestion 
reactions were visualised following electrophoresis. Five µl PCR or 10 µl restriction 
digest products were added to 6X Orange G loading buffer (1X final volume) and 
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electrophoresed on 1% agarose gels at 100 V for 3 h. Agarose gels were made by 
dissolving 1% w/v pure agarose in 50 ml 0.5X Tris-borate-EDTA (TBE) buffer to 
which 5 µl 10000X GelRed™ (1X final volume) was added. GelRed intercalates with 
DNA which enabled visualisation of all products using a UV transilluminator. 100 bp 
and 1 kb DNA size markers (Invitrogen) were used to estimate product sizes.   
2.4.6 Purification of PCR products 
2.4.6.1 PCR purification  
PCR products in solution were purified using the QIAquick PCR purification 
kit. Briefly, 5 volumes of buffer PB were added to 1 volume PCR product, mixed, 
applied to a spin column (in a 2 ml collection tube) and centrifuged at 1690 x g for 1 
minute. Spin columns contain a silica membrane to which DNA adsorbs at the optimal 
pH and salt concentrations provided by buffer PB. Contaminants were removed by 
adding 750 µl buffer PE and centrifuging at 1690 x g for 1 min. After discarding the 
flow through, the spin column was centrifuged at 1690 x g for an additional minute to 
eliminate all traces of ethanol. The column was transferred to a clean microcentrifuge 
tube and 35 µl of sterile water was added. After allowing 1 min for adsorption, DNA 
was eluted by centrifugation at 1690 x g for 1 min.  
2.4.6.2 PCR purification from agarose gel 
Multiple PCR products from a single reaction required separation by gel 
electrophoresis on a 0.8% agarose gel. Using a clean scalpel, individual DNA fragments 
were excised from the gel under UV transillumination and purified using the QIAquick 
gel extraction kit following the manufacturer’s protocol. Buffer QG was added at 3X 
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volume of the weight of the gel slice followed by incubation at 50ºC for 10 min. This 
incubation allows buffer QG to solubilise the gel whilst providing the optimal pH (≤7.5) 
and salt concentration (high) for DNA adsorption to the silica membrane. Optimal pH is 
determined by the pH indicator present in buffer QG. Where a high pH (>7.5) was 
found, 10 µl 3 M sodium acetate (pH 5.0) was added to adjust it for optimal DNA 
adsorption. Isopropanol was added to the sample at 1X gel volume, mixed, and applied 
to a QIAquick spin column (in a 2 ml collection tube). The sample was centrifuged at 
1690 x g for 1 min to facilitate DNA adsorption. After discarding the flow through, 500 
µl buffer QG were added to the spin column and centrifuged at 1690 x g for 1 min to 
remove any residual agarose. Next, the column was washed with 750 µl buffer PE and 
centrifuged at 1690 x g for 1 min to remove contaminants. After discarding the flow 
through, the column was centrifuged at 1690 x g for an additional minute to eliminate 
all traces of ethanol. The column was transferred to a clean 1.5 ml microcentrifuge tube 
to which 35 µl of sterile water was added. After incubating for 1 min to allow 
adsorption, DNA was eluted by centrifugation at 1690 x g for 1 min. 
2.4.7 Cloning and subcloning 
2.4.7.1 Vector preparation 
In order to directionally clone or subclone genes of interest into the pCI-neo 
mammalian expression vector, it first needed to be linearised by restriction digestion. 
Using EcoRI and MluI restriction enzymes, pCI-neo was digested at 37ºC for 2 h 
followed by electrophoresis of the products on a 0.8% agarose gel. Vector DNA was 
purified using the QIAquick gel extraction kit. 
Chapter 2: Materials and Methods 
123 
 
 
2.4.7.2 TA-cloning RT-PCR products 
Purified RT-PCR products were ligated into the pTargeT™ mammalian expression 
vector. The ligation reaction contained 60 ng of pTargeT™ vector, x ng DNA insert, 1 
µl of T4 DNA ligase and 1 x T4 DNA ligase buffer in a total volume of 10 µl. The 
concentration of insert was calculated using the following formula:  
60 ng vector x y kb insert 
        5.67 kb vector 
 
Ligations were incubated overnight at 4ºC. 
TA cloned RT-PCR products inserted into pTargeT™ in the incorrect orientation were 
directionally subcloned into pCI-Neo following release from pTargeT using EcoRI and 
MluI restriction enzymes. Ligation reactions were carried out exactly as for pTargeT™ 
except 60 ng of linearised pCI-neo and x ng DNA insert with EcoRI and MluI 
restriction sites were used. The concentration of insert was calculated using the 
following formula:  
60 ng vector x y kb insert 
        5.47 kb vector 
 
Ligations were incubated overnight at 4 ºC 
 
2.4.7.4 Directional sticky end cloning into an expression vector 
Purified PCR products with AgeI and KpnI restriction site overhangs were 
X 1.4 = x ng insert 
X 1.4 = x ng insert 
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directionally cloned into the linear pHLSec mammalian expression vector, kindly 
supplied by James Birch (IAH, Compton, UK). The ligation reaction contained 40 ng 
pHLSec, 40-200 ng DNA insert, 1 µl of T4 DNA ligase and 1x T4 DNA ligase buffer in 
a total volume of 10 µl. Ligations were incubated for 1 h at room temperature.  
2.4.7.5 Transformation and screening 
JM109 competent cells were thawed on ice for 5 min. To a chilled 1.5 ml 
eppendorf tube containing 2 µl ligation mix, a 50 µl aliquot of the cells was added and 
gently mixed by stirring with a pipette tip. The DNA/cells were incubated for 20 min on 
ice then heat shocked at 42ºC for 50 s. This creates small holes in the bacterial cell 
membrane allowing the DNA to be taken up. Cells were then returned to ice for a 
further 2 min. A 950 µl aliquot of room temperature SOC medium was added to the 
cells and gently mixed by inversion. Cells were incubated at 37ºC with shaking at 170 
rpm for 90 min. Next, cells were pelleted by centrifugation at 863 x g for 10 min. The 
supernatant was discarded and cells were resuspended in 200 µl room temperature SOC 
medium. The transformed cells were plated out in 100 µl aliquots onto LB agar plates 
containing 100 µg/ml ampicillin, 80 µg/ml Xgal and 0.5 mM IPTG. Plates were 
inverted and incubated overnight at 37ºC. Positive recombinant clones in all vectors 
were indicated by white colonies, whilst blue colonies denoted an empty vector for 
pGEM-T® Easy or pTargeT clones.  
 
2.4.8 Restriction digestion  
Restriction digestions were carried out using the restriction enzymes and buffers 
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(buffer components in Appendix) listed in section 2.3.1 to release DNA inserts from 
cloning vectors, to linearise and create sticky ends in cloning vectors, and to digest 
BAC DNA. Digestions were carried out in 10 µl reactions containing 1 µg DNA, 1 µl 
10X buffer (1X final volume), 1 µl restriction enzyme and made up to the final volume 
with sterile water. Reactions were incubated at 37ºC for 90 min. Large scale digestions 
containing several enzymes were incubated at 37ºC overnight (16 h) to ensure complete 
digestion.  
2.4.9 Plasmid DNA purification 
2.4.9.1 Small scale (mini) plasmid DNA preparation 
Mini preps use an alkaline lysis method to purify DNA and were carried out 
following the manufacturer’s protocol. In order to screen plasmid DNA clones, bacterial 
cells were picked and used to inoculate 5 ml LB medium supplemented with 100 µg/ml 
of ampicillin (LB/Amp100). Cultures were grown overnight at 37ºC with shaking at 170 
rpm. The next day, cells were pelleted by centrifugation at 1942 x g for 10 min at 4ºC. 
Cell supernatants were discarded and the cells resuspended in 250 µl of cold buffer P1 
containing RNase A and LyseBlue reagent. Next, the cells were lysed by adding 250 µl 
of buffer P2 and mixing by inversion. The addition of buffer P2 to buffer P1 in the 
presence of LyseBlue causes the cell suspension to turn blue. Buffer P2 contains SDS 
and NaOH that encourage lysis as follows: SDS solubilises the protein and phospholipid 
bilayer of the cytoplasmic membrane releasing cell contents. NaOH provides high 
alkaline conditions that denature chromosomal DNA, plasmid DNA and proteins. Next, 
350 µl buffer N3 were added and mixed by inversion. The blue appearance of the lysate 
disappeared indicating the SDS from buffer P2 had been precipitated. Buffer N3 
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neutralised the reaction whilst adjusting it to high salt conditions that led to precipitation 
of chromosomal DNA, denatured proteins and cellular debris. Plasmid DNA which is 
smaller by comparison, becomes renatured and remains in solution. The reaction was 
centrifuged at 1690 x g for 10 min to pellet precipitants. Supernatant containing plasmid 
DNA was applied to a spin column (in a 2 ml collection tube) and centrifuged at 1690 x 
g for 1 min. The column contains a silica membrane to which DNA adsorbs at the 
optimal high salt concentration. The column was washed with 500 µl buffer PB and 
centrifuged at 1690 x g for 1 min to remove contaminants and residual endonucleases. 
A further wash with 750 µl buffer PE was carried out. After discarding the flow 
through, the spin column was centrifuged at 1690 x g for an additional minute to 
eliminate all traces of wash buffer. The column was transferred to a clean 1.5 ml tube 
and DNA was eluted in 50 µl sterile water by centrifugation at 1690 x g for 1 min. Kit 
components are listed in the Appendix.  
2.4.9.2 Large scale (maxi) plasmid DNA preparation 
Maxi preps also use an alkaline lysis method to purify DNA and were carried 
out following the manufacturer’s protocol. To synthesise a sufficient quantity of 
plasmid DNA for transfection, a 5 ml LB/Amp100 seeder culture was set up as described 
in section 2.4.9.1 and incubated for 8 h at 37ºC with shaking at 170 rpm. Next, a 100 ml 
aliquot of LB/Amp100 was inoculated with 200 µl of the seeder culture and cultured 
overnight at 37ºC with shaking at 170 rpm. The next day, cells were pelleted at 6000 x g 
for 15 min at 4ºC. Cell resuspension, lysis and neutralisation steps followed the same 
method as for mini preps, using 10 ml of each of buffers P1, P2 and P3, respectively. 
After this, however, the maxi prep method differs. Cell lysates were added to a 
QIAfilter maxi cartridge and incubated at room temperature for 10 min to allow the 
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precipitated genomic DNA, proteins and detergent to float to the surface. Lysates were 
then filtered into a clean, endotoxin-free 50 ml tube to which 2.5 ml endotoxin removal 
buffer ER was added followed by incubation on ice for 30 min. During this incubation, 
a QIAgen tip 500 was equilibrated with 10 ml buffer QBT. This tip contains an anion 
exchange resin that binds plasmid DNA under optimal low pH and salt conditions. The 
filtered lysate was applied to the tip and passed through by gravity flow facilitating 
DNA binding. Contaminants and impurities were removed with 2 x 30 ml washes of 
medium salt buffer QC. DNA was eluted with 15 ml high salt buffer QN into a 30 ml 
endotoxin-free tube. Concentration, desalting and precipitation of the DNA was carried 
out by adding 0.7 volumes room temperature isopropanol. DNA was pelleted by 
centrifugation at 15000 x g for 30 min at 4ºC. After discarding the supernatant, the 
pellet was washed with 5 ml 70% ethanol, centrifuged at 15000 x g for 10 minutes and 
dried. Finally, the pellet was resuspended in 500 µl endotoxin-free buffer TE.  
2.4.9.3 Very large scale (mega) plasmid DNA preparation 
Mega preps also use an alkaline lysis method to purify DNA and were carried 
out following the manufacturer’s protocol, identical to the maxiprep protocol in section 
2.4.9.2 except for the following differences. Volumes of buffers used were: 50 ml of 
buffer P1 containing RNase A and LyseBlue reagent, 50 ml of buffer P2, 50 ml of 
buffer P3, 50 ml of buffer FWB2, 12.5 ml of buffer ER, 35 ml of buffer QBT, 200 ml of 
buffer QC and 35 ml of buffer QN. Bacterial culture was carried out on a larger scale: a 
500 ml aliquot of LB/Amp100 was inoculated with 1 ml of a 5 ml LB/Amp100 seeder 
culture set up as described in section 2.4.9.1. Cell lysates were added to a QIAfilter 
mega-giga cartridge and incubated at room temperature for 10 min to allow 
contaminants to float to the surface. Lysates were then filtered into a collection vessel 
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beneath the mega-giga cartridge using a vacuum pump. Once all the liquid had passed 
through, the vacuum was switched off and 50 ml of buffer FWB2 were added. 
Precipitates were stirred after restarting the vacuum pump to aid the flow of liquid 
through the filter. A QIAgen tip 2500 was subsequently used to bind the DNA. 
Volumes of isopropanol for DNA precipitation and 70% ethanol to wash the pellet were 
scaled up accordingly. Finally, DNA pellets were resuspended in 1 ml endotoxin-free 
buffer TE.  
2.4.9.4 Large scale BAC DNA preparation 
BAC clones were acquired as bacterial cells and re-streaked onto solid LB 
medium supplemented with 12.5 μg/ml of chloramphenicol (ChP12.5) then incubated 
overnight at 37ºC. From this LB plate, a single colony of cells was picked and used to 
inoculate 5 ml LB/ChP12.5 as described in section 2.4.9.1, then incubated for 8 h at 37ºC 
with shaking at 170 rpm. The culture was used to seed a 500 ml aliquot of LB/ChP12.5 
and this large culture was incubated at 37°C overnight. Bacterial cells were pelleted by 
centrifugation at 5000 x g for 10 min at 4°C. BAC DNA was purified from the pelleted 
bacteria using the NucleoBond® BAC 100 kit (Macherey-Nagel) following the 
manufacturer’s instructions. This kit also uses a modified alkaline/SDS lysis method to 
purify BAC DNA. Cell supernatants were discarded and the cells resuspended in 24 ml 
of buffer S1 containing RNase A. Next, the cells were lysed by adding 24 ml of buffer 
S2 and mixing by inversion. Buffer S2 contains SDS and NaOH that encourage lysis 
whilst providing high alkaline conditions that denature chromosomal and plasmid DNA. 
The reaction was then neutralised by the addition of 24 ml of buffer S3. Buffer S3 
contains 2.8 M potassium acetate that precipitates the denatured chromosomal DNA 
whilst plasmid DNA becomes renatured and remains in solution. During 5 min 
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incubation on ice, a NucleoBond filter was folded and placed in a funnel. The lysate 
was then clarified by loading onto the filter to remove SDS and cellular debris. This 
step is an alternative to centrifugation which can lead to large constructs such as BACs 
becoming sheared. During filtration, a BAC 100 column was equilibrated with 5 ml of 
buffer N2. The clarified lysate was loaded onto the column and passed through by 
gravity flow, facilitating DNA binding. Contaminants and impurities were then 
removed with 3 x 12 ml washes of buffer N3. DNA was eluted from the column with 6 
ml of buffer N5 which had been pre-heated to 50ºC. Purified BAC DNA was 
precipitated with 0.7 volumes of isopropanol and centrifuged at 15000 x g for 30 min at 
4ºC. After discarding the supernatant, the DNA pellet was washed with 0.35 volumes of 
cold 70 % ethanol and centrifuged at 15000 x g for 10 min at 4ºC. Finally, the pellet 
was air dried for 30 min and resuspended in 200 µl buffer EB (Qiagen).  
2.4.10 Sequencing 
Sequencing was carried out using the Beckman Coulter CEQ™ 8000 Genetic 
Analysis System (Beckman Coulter, Bucks, UK). Samples were analysed by capillary 
electrophoresis sequencing using dye terminator cycle sequencing chemistry 
(GenomeLab DTCS with quick start kit, Beckman Coulter). This chemistry is based on 
classical chain termination by dideoxynucleotide triphosphates (ddNTPs), each of 
which is labelled with a fluorescent dye that emits light at different wavelengths.   
2.4.10.1 Sequencing PCR 
One quarter standard sequencing reactions were set up containing 2 µl quickstart 
master mix, 1.5 µl sequencing reaction buffer, 4 pmol primer, 10-400 ng DNA and 
sterile water to 20 µl. Difficult, GC-rich templates were pre-heat treated at 96ºC for 2 
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min to destabilise DNA secondary structure, then sequenced using the methods 
development kit (Beckman Coulter). One quarter GC-rich sequencing reactions were set 
up containing 10-100 ng DNA, 4 pmol primer, 2 µl 10X reaction buffer, 1 µl dNTP(G) 
mix, 2 µl ddUTP dye terminator, 3 µl ddGTP dye terminator, 2 µl ddCTP dye 
terminator, 2 µl ddATP dye terminator, 1 µl DNA polymerase and sterile water to 20 µl. 
This kit contains all of the reagents found in the standard sequencing kit with the 
exception of the dNTP solution. In a standard sequencing reaction, dNTP(I) mix is used, 
whereas dNTP(G) mix is used to sequence through difficult GC-rich regions. Thermal 
cycle sequencing conditions were: 
 
96ºC / 20 secs   
50ºC / 20 secs            x 30 cycles (dITP standard sequencing) 
60ºC / 4 mins 
 
96ºC / 20 secs   
50-68ºC / 20 secs       x 30 cycles (dGTP difficult sequencing) 
68-72ºC / 2 mins 
 
Custom primers were used to sequence PCR products, with vector primers used to 
sequence clones (sequences in the Appendix).  
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2.4.10.2 Ethanol precipitation of products 
Reactions were terminated using 5 µl stop solution consisting of 2 µl of 100 mM 
EDTA, 2 µl of 3 M sodium acetate (pH 5.2), and 1 µl glycogen. To each reaction, 60 µl 
of ice-cold 95% ethanol was then added and vortexed thoroughly. Precipitated DNA 
was pelleted by centrifugation at 1690 x g for 15 min at 4ºC. After decanting the 
supernatant, pellets were washed twice with 200 µl ice cold 70% ethanol and 
centrifuged after each wash at 1690 x g for 5 min 4ºC. Pellets were air-dried for 30 min 
and resuspended in 40 µl sample loading solution (SLS). After waiting 1 min to allow 
the SLS to become absorbed, samples were vortexed thoroughly. Finally, reactions were 
overlaid with a drop of mineral oil. Analysis was carried out immediately using a 
CEQ8000 sequencer or samples were frozen at -20ºC and analysed later.  
2.4.11 Chicken BAC library screening 
In order to uncover the genomic location of novel chIL-1 genes, four high-
density BAC filters representing the Red Jungle Fowl genome sequence (CHORI-261 
chicken BAC library) were acquired from the Children’s Hospital Oakland Research 
Institute (CHORI), California, USA. The library was constructed from Red Jungle Fowl 
genomic DNA. High molecular weight DNA fragments were digested with EcoRI 
endonuclease, modified with EcoRI methyltransferase and directionally cloned into 
pTARBAC2.1. Transformation was carried out by electroporating DH10B cells. Each 
BAC filter contains 18432 different BAC clones taken from 48 microtitre plates and 
each spotted in duplicate.  
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2.4.11.1 Pre-hybridisation 
Chicken BAC filters were moistened with pre-hybridisation solution (200 μg per 
ml DNA in 10X SSC, 10X Denhardt's solution) (Sigma). Each filter was then rolled 
between two thin plastic meshes and placed in a glass roller bottle. A further 10 ml pre-
hybridisation solution was added to each bottle and incubated overnight at 65ºC in a 
hybridisation oven. Tubes were arranged symmetrically in a rotating rotisserie wheel to 
allow the filters to unwind. Pre-hybridisation solution contents are listed in Appendix 
III.  
2.4.11.2 Synthesising a radio-labelled DNA probe  
Using the random-primed DNA labelling kit (Roche), radio-labelled DNA 
probes were generated for BAC filter hybridisation. The theory behind this method is as 
follows: random hexanucleotide primers, present in all possible sequence combinations, 
anneal to denatured template DNA. This ensures templates are labelled equally along 
their entire length. Complementary strand synthesis then takes place from the 3′ end of 
the hybridised primers using Klenow. During this synthesis, deoxycytidine triphosphate 
(dCTP) modified with 
32
P becomes incorporated into the newly formed complimentary 
strand.   
Probe templates were generated by PCR amplification of genomic DNA or 
restriction digestion to release cDNA clones from a vector. They were then purified 
using the Qiaquick PCR purification kit. Templates were quantified by 
spectrophotometry, as described in section 2.4.3, and for each probe ≥25 ng DNA was 
denatured for 10 min at 99ºC and then chilled on ice. This step created single- stranded 
DNA molecules.  
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To a 500 µl eppendorf tube on ice, the following were then added: 6 µl dATP, dGTP 
and dTTP (by mixing 2 µl of each of solutions 2, 4 and 5), 4 µl reaction mixture 
(solution 6; hexanucleotide primer mix in 10X reaction buffer), 18 µl denatured DNA, 2 
µl Klenow enzyme (1 U/µl; solution 7) and 10 µl α32P-dCTP (7.40 MBq). The reaction 
was incubated for 30 min at 37ºC. The DNA was then denatured and the reaction 
stopped by incubating for 10 min at 95ºC.  
2.4.11.3 Hybridisation and washing 
One quarter (10 µl) of the radio-labelled probe reaction mix was added to each 
of the four roller bottles containing CHORI-261 BAC filters 1-4, respectively. Bottles 
were incubated overnight at 65ºC with rotation to facilitate hybridisation. Three washes 
with increasing stringency were performed following hybridisation. This was done to 
limit the amount of background radiation from unincorporated probe. Wash buffers 
were pre-warmed to 65ºC and used to wash the filters as follows: wash 1: 2X SSC, 
0.1% SDS; wash 2: 1X SSC, 0.1% SDS; and wash 3: 0.1X SSC, 0.1% SDS. Each wash 
was carried out at 65ºC for 30 min. BAC filters were then removed from their roller 
bottles, sealed in plastic bags and placed in exposure cassettes containing two 
intensifying screens. Sealed filters were each overlaid with a single sheet of BioMax™ 
MR film (Kodak) before cassettes were transferred to -80ºC for overnight exposure. 
Films were developed after 24 h using an X-ograph compact X4 automatic processor.  
2.4.11.4 Identification of positive clones 
Each BAC filter contains a total of 18432 distinct clones spotted in duplicate. 
Each filter was divided into 6 large panels and within each panel, a total of 384 boxes 
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(24 x 16) were present. Within each individual box there were a total of 8 clones spotted 
in duplicate. Hence 16 (spots) x 384 (boxes) x 6 (panels) = 36864 spots (18432 clones 
in duplicate) per filter. Each panel on any individual filter contained clones from 8 
plates; hence 48 microtitre plates were represented on each filter. So for filter 1, plate #1 
is spotted in panel 1, plate #2 is spotted in panel 2, plate #7 is spotted in panel 1 etc…up 
to plate #48 being spotted in panel 6. This pattern was maintained in the other 3 filters; 
for example, plate #49 is spotted in filter 2, panel 1, etc. To be able to interpret positive 
signals, a plastic overlay representing the gridded template described above was placed 
against a filter autoradiograph, using the label position for correct orientation. A 
positive hybridisation was denoted by a double spot within an individual box as each 
clone is spotted in duplicate within the same box. The relative orientation of positive 
duplicate spots in a box determined the range of plates where the clone came from. 
Combined with the panel and filter numbers, the exact plate could be identified. As each 
panel row is labelled 1-24, and column labelled A-P, the well coordinates of a positive 
clone could be determined. The exact identity of a positive clone was therefore 
established using the notation: plate number, column letter, and row number, e.g. clone 
132E6. Positive clone ID’s were submitted to CHORI, who supplied the clones in the 
form of bacterial cells on an agar plug. BAC DNA was purified as described in section 
2.4.9.4.  
2.4.12 Cell culture 
2.4.12.1 Resurrecting cryopreserved cell lines 
Cells were removed from liquid nitrogen and rapidly thawed in a 37ºC water 
bath. They were then resuspended in 10 ml warm (37ºC) growth medium and pelleted 
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by centrifugation at 216 x g for 5 min. After discarding the supernatant, cell pellets were 
washed in another 10 ml growth medium and centrifuged as before. Cells were then 
seeded at 1 x 10
6
/25 cm² flask in 5 ml growth medium, with cell densities scaled up 
accordingly for larger flasks. HD11 cells were routinely cultured in growth medium 
(contents listed in the appendix) at 41ºC, 5% CO2, whilst COS-7 cells were cultured in a 
different growth medium (contents listed in Appendix IV) at 37ºC, 5% CO2. 
2.4.12.2 Passaging cells 
Both HD11 and COS-7 cell lines were adherent and typically passaged every 2-
3 days once flasks had become confluent. To passage cells, they were first washed with 
2 x 10 ml warm PBS followed by a 1 in 10 solution of 0.25% trypsin/versene. For a 25 
cm² flask, 5 ml trypsin/versene were added, with volumes scaled up for larger flasks. 
Trypsinisation detached adherent cells during a 4-5 min incubation at 37ºC, after which 
trypsin was neutralised by adding a 2X volume of growth medium. Cells were pelleted 
by centrifugation at 216 x g for 5 min, supernatants discarded, and cells resuspended in 
10 ml warm growth medium. Cell viability was determined using a 0.4% w/v solution 
of trypan blue, which is excluded by live cells but taken up by dead ones. A 20 µl 
aliquot of cell suspension was diluted 1 in 2 with trypan blue and cells were counted 
using a haemocytometer. Cells were reseeded at 1 x 10
6
/25 cm² flask in 5 ml growth 
medium.  
2.4.12.3 Transfecting cells with pure chicken DNA 
2.4.12.3.1 Transient protein expression in COS-7 cells 
COS-7 cells were transiently transfected with chicken cDNA clones by the 
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DEAE/dextran method. The theory behind this method is as follows: DEAE/dextran is a 
positively charged polymer that binds to negatively charged DNA very tightly. This 
creates a DNA:polymer complex with an overall net positive charge. As cell membranes 
are negatively charged, this enables the complex to come into close contact with cell 
membranes facilitating uptake by endocytosis. DNA that has been taken up resides in 
endosomes that are capable of being acidified. This would lead to degradation of the 
DNA and therefore chloroquine is added to the transfection reagent to prevent this from 
happening. 
To transfect, COS-7 cells were trypsinised, counted and re-seeded at 6 x 10
6
 
cells/75 cm² flask. Cells were then cultured for 18-24 h at 37ºC, 5% CO2. For each 
separate cDNA, a transfection mix for a 75 cm² flask was made containing: 15 ml 
serum-free medium, 112.5 µg DNA, 258 μg/ml chloroquine and 600 μg/ml 
DEAE/dextran. Cells were washed with 2 x 10 ml warm PBS followed by the addition 
of the transfection mix. Cells were incubated for 3 h at 37ºC, 5% CO2 to facilitate DNA 
uptake. The transfection mix was discarded and cells were washed with another 10 ml 
warm PBS. Next, a solution of PBS containing 10% DMSO was added for 2 min to 
shock the cells, increasing the efficiency of the transfection. The PBS/DMSO was then 
discarded and replaced with 15 ml growth medium. After incubating the cells for 16-24 
h at 37ºC, 5% CO2, growth medium was changed for serum-free medium. Cell 
supernatants were harvested 72 h later. Some recombinant cytokines were not secreted 
and remained intracellular. Where this was suspected, COS-7 cells were trypsinised, 
resuspended in serum-free medium and frozen at -80ºC. Cell lysates containing 
recombinant cytokines were generated by 3 repeated freeze-thaw cycles.   
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2.4.12.3.2 HEK293T cells 
HEK293T cells were transiently transfected with chicken cDNA clones by the 
method of Aricescu, Lu et al. (2006) using polyethylenimine (PEI) transfection reagent. 
PEI, like DEAE/dextran, is also a cationic polymer so initiates transfection by the same 
method. It is also believed to buffer the endosomal pH, preventing acidification thus 
abrogating the need for chloroquine. HEK293T cells were routinely cultured in growth 
medium (contents listed in Appendix IV) at 37ºC, 5% CO2 and seeded at 90% 
confluence in 150 cm
2
 flasks. For transfection, 50 μg pure plasmid DNA were added to 
5 ml serum-free medium and mixed (scalable as necessary). Next, 75 μl of 1 mg/ml PEI 
were added, briefly mixed by inversion then incubated at room temperature for 10 min 
to permit DNA-PEI association. During this incubation, HEK293T growth medium was 
changed for 2% serum-containing growth medium. The DNA-PEI containing medium 
was added to the cells to finish. After 3 days, culture supernatants were harvested and 
replaced with fresh 2% serum-containing growth medium. This second batch of 
conditioned medium was harvested another 3 days later.   
2.4.13 Purification of HIS-tagged recombinant proteins 
2.4.13.1 Under native conditions 
Crude HEK293T cell supernatants were concentrated in a stirred ultrafiltration 
cell using YM10 ultrafiltration membranes (NMWL: 10000) (both Millipore) followed 
by a buffer exchange with PBS. Concentrated proteins were purified under native 
conditions using 1.25 ml HIS-Select® high flow columns (Sigma). To purify, a column 
was mounted on a clamp stand and solutions were passed through at 1 ml/min using an 
EP-1 Econo Pump (Bio-rad). A modified version of the manufacturer’s instructions was 
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followed as described. The storage solution was first removed using 10 ml sterile water. 
Next, the column was equilibrated with 10 ml wash buffer (20 mM imidazole in 0.3 M 
sodium chloride and 50 mM sodium phosphate at pH 8.0). Concentrated protein was 
then applied to the column followed by 10 ml of the same wash buffer to remove 
unbound proteins and impurities. The column was washed with increased stringency 
using 10 ml of a second wash buffer (30 mM imidazole in 0.3 M sodium chloride and 
50 mM sodium phosphate at pH 8.0). Finally, pure proteins were eluted using 10 ml of 
elution buffer (250 mM imidazole in 0.3 M sodium chloride and 50 mM sodium 
phosphate at pH 8.0). All eluted fractions were saved for analysis.  
2.4.13.2 Under denaturing conditions 
The procedure was identical to purification under native conditions except for 
the following differences. Crude HEK293T cell supernatants were concentrated and 
buffer exchanged as above then solubilised using 8 M urea. Column equilibration and 
washes were carried out with a single denaturing wash buffer (0.1 M sodium phosphate 
at pH 8.0 with 8 M urea). Pure proteins were eluted using a denaturing elution buffer 
(250 mM imidazole in 0.1 M sodium phosphate at pH 8.0 with 8 M urea). Proteins were 
then refolded by stepwise dialysis against PBS for 24 h. Samples were dialysed to 
remove urea and imidazole using Slide-A-Lyzer G2 Dialysis Cassettes (10K MWCO) 
(Thermo Scientific).   
2.4.14 Analysis of HIS-tagged recombinant proteins 
2.4.14.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE analysis of pure recombinant proteins was carried out using a Mini-
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PROTEAN® II electrophoresis cell (Bio-rad). To prepare the samples, 15 µl of protein 
were mixed with an equal volume of SDS-PAGE sample buffer (contents in the 
appendix) then denatured at 95ºC for 5 min before being placed on ice. During the 
incubation step, a precast Tris-HCl Ready Gel, 4-15% (Bio-rad) was fitted into the 
clamp assembly and placed into the electrophoresis cell. Running buffer containing 25 
mM Tris, 192 mM glycine and 0.1% SDS was added to the cell. Samples were loaded 
alongside a 6xHIS protein ladder (Qiagen) and electrophoresed at 150 V for 45 min.   
2.4.14.2 Western blotting 
Following electrophoresis, proteins were electroblotted onto a piece of Hybond 
ECL nitrocellulose membrane (Amersham) using a Mini Trans-Blot electrophoretic 
transfer cell (Bio-Rad). The SDS-PAGE gel was placed against the nitrocellulose 
membrane then sandwiched between double layers of 3 MM filter paper (Whatman), 
pre-soaked with transfer buffer. This assembly was sandwiched between pre-soaked 
fibre pads and secured in the gel holder cassette. The cassette was secured in the 
electrode module and placed in the buffer tank with the nitrocellulose membrane closest 
to the anode. Chilled transfer buffer containing 25 mM Tris.HCl, 192 mM glycine and 
25% methanol was added to fill the tank. Electrophoresis was carried out at a constant 
250 mA for 45 min. Proteins were then detected using the QIAexpress system (Qiagen) 
following the manufacturer’s protocol. All incubations were performed at room 
temperature with shaking. After removal from the transfer cell, the membrane was 
washed twice with TBS buffer (see Appendix III) for 10 min each time. The membrane 
was then blocked for 1 h in blocking buffer (3% BSA (w/v) in TBS buffer). Two 10 min 
washes in TBS-Tween/Triton buffer (see Appendix III) were next followed by a 10 min 
wash in TBS. The membrane was then incubated for 1 h in a 1/2000 dilution of Penta-
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HIS antibody (BSA-free; Qiagen) in blocking buffer. Two further 10 min washes in 
TBS-Tween/Triton buffer were next followed by another 10 min wash in TBS to 
remove unbound antibody. A secondary antibody (rabbit anti-mouse IgG conjugated to 
horseradish peroxidise (HRP); DAKO) was diluted 1/1000 in a solution of 10% non-fat 
dried milk in TBS. The membrane was then incubated in this antibody solution for 1 h 
followed by four further 10 min washes in TBS-Tween/Triton buffer. Proteins were 
detected by enhanced chemiluminescence using ECL™ Western Blotting Detection 
Reagents and Hyperfilm ECL (both Amersham). The HRP conjugated to the secondary 
antibody catalyses the oxidation of luminol, which becomes oxidised further by 
hydrogen peroxide and a chemical enhancer. This creates triplet carbonyl groups which 
decay to form single carbonyl groups that emit light. The membrane was covered with 
equal volumes of Detection Reagents solutions 1 and 2, incubated for 1 min and the 
excess drained off. After covering it in plastic wrap (Saran), the membrane was overlaid 
with a single sheet of Hyperfilm ECL and exposed for 30 s to 10 min at room 
temperature. The film was developed using an X-ograph compact X4 automatic 
processor. 
2.4.15 HD11 bioassay 
2.4.15.1 Pilot study 
A pilot experiment was set up to determine the responsiveness of the HD11 cell 
line to recombinant mature chicken IL-1β as described in Weining, Sick et al. (1998). 
Serial dilutions of recombinant mature chicken IL-1β (kindly provided by Dr Benjamin 
Schusser, University of Munich, Germany) were pre-incubated for 2 h at 41ºC with or 
without 30 µl of anti-IL-1β antibody (kindly provided by Dr Benjamin Schusser). HD11 
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cells were routinely cultured in growth medium at 41ºC, 5% CO2 as described in section 
2.4.12.1 and then passaged and counted as outlined in section 2.4.12.2. Cells were 
reseeded at 1 x 10
6
/well in 1 ml growth medium in flat-bottomed 24-well culture plates. 
Cells were then cultured for 12-48 h at 41ºC, 5% CO2 in the presence of either serial 
dilutions of recombinant mature chicken IL-1β pre-incubated with or without anti-IL-1β 
antibody or media only. After 12-48 h, three 100 μl aliquots of cell supernatant/well 
were harvested. The rest of the supernatant was discarded, cells were washed twice with 
warm PBS and trypsinised as outlined in section 2.4.12.2. Cells were pelleted by 
centrifugation at 1040 x g for 5 min and total RNA was extracted using the RNeasy 
mini kit (Qiagen). 
2.4.15.2 Quantifying the biological response 
2.4.15.2.1 Griess assay 
Culture supernatants were harvested for the measurement of nitrite (NO2
-
), the 
stable derivative product of nitric oxide (NO) breakdown, by the Griess reaction. 
Samples to create a standard curve were prepared by making a 1:200 dilution of 6.9 
mg/ml NaNO2 then double-diluting the stock a further 6 times. To a 96-well sterile 
culture plate, 100 µl of six standard dilutions, alongside eighteen 100 µl (i.e. one 24-
well plate row (6 wells) of triplicate 100 µl aliquots) aliquots of culture supernatant per 
individual treatment group were added. Griess reagent was prepared by mixing equal 
volumes of NED (Naphthylethylenediamine, 0.3 g/100 ml in 2.5% H3PO4) and 
sulphanilamide (1 g/100 ml in 2.5% H3PO4) reagents (both from Sigma) then adding 
100 µl to each well to be tested. Absorbance was measured after 5 min at 543 nm using 
a Biotek Elx 808 spectrophotometer (Biotek, Winooski, Vermont, USA).  
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2.4.15.3 Optimised bioassay conditions 
2.4.15.3.1 Optimising the [pure rIL-1β]  
A preliminary assay was carried out to establish the optimal concentration of 
recombinant (mature) chicken IL-1β (rchIL-1β) (AMSBio, Abingdon, UK) to use in 
subsequent bioassays. To do this, HD11 cells were routinely cultured in growth medium 
at 41ºC, 5% CO2 as described in section 2.4.12.1 and then passaged and counted as in 
section 2.4.12.2. Cells were reseeded at 1 x 10
6
/well in 1 ml growth medium in flat-
bottomed 24-well culture plates. Cells were then cultured for 12 h at 41ºC, 5% CO2 in 
the presence of a serial two-fold dilution of pure rchIL-1β at a starting concentration of 
166.6 ng/ml. Cell supernatant was assayed (in triplicate) for nitrite (NO2
-
) using the 
Griess assay, as before. 
2.4.15.3.2 Final bioassay conditions 
To determine the antagonistic properties of recombinant chIL-1RN, bioassays 
were set up as follows: 1x10
6
 HD11 cells/well were seeded in flat-bottomed 24-well 
culture plates in 250 μl medium with or without 500 μl serial two-fold dilutions of ex-
COS rIL-1RN (crude cell supernatant or cell lysate), purified rsIL-1RN or ricIL-1RN, 
ex-COS pCI-Neo (mock-transfected negative control) or media alone. To create the 
starting dilutions of pure chIL-1RNs, 500 μl aliquots of both were concentrated to 30 μl 
by centrifugation at 14000 x g for 15 min at 4ºC using Amicon Ultra-0.5 centrifugal 
filters (Millipore). Starting dilutions were made by adding 15 μl of concentrated protein 
to 985 μl of growth media. After 4 h incubation at 41ºC, 5% CO2, 250 μl of 40 ng/ml 
pure rIL-1β (AMSBio) were added to all wells (except for 1 row of cells in media 
alone), followed by a further incubation for 12 h.  
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Cell supernatant was assayed (in triplicate) for nitrite (NO2
-
) using the Griess 
assay, as before. Cells were harvested, RNA extracted and IL-1β, iNOS and 28S 
expression quantified by qRT-PCR (TaqMan®) as before.  
2.4.16 HD11 time course stimulation assay 
To determine the expression of chIL-1RN over a time course, HD11 cells were 
seeded in 25 cm² flasks at 2 x 10
6
 in 5 ml growth medium, then stimulated for 0 
(baseline control), 1, 2, 6, 12, 24 and 48 h with 200 ng/μl LPS (Sigma) at 41ºC, 5% 
CO2. At each time-point, culture supernatant was discarded; cells were washed twice 
with warm PBS and lysed with 1.8 ml buffer RLT (Qiagen). Total RNA was extracted 
from cell lysates using the RNeasy mini kit (Qiagen). IL-1RN, IL-1β and 28S mRNA 
levels were quantified by real-time quantitative RT-PCR (TaqMan®) as described in 
section 2.4.4.6. Results were standardized and calculated as previously.  
2.4.17 Statistics 
Statistical analyses were carried out using the Mann-Whitney U test within the 
Graphpad Prism software package. Tests were performed between different treatment 
groups within the HD11 bioassay. Within the gene expression analyses, tests were 
performed between groups of birds of different infection status. Statistical significance 
was determined with a P value ≤ 0.05.  
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3.1 Introduction 
Cytokines are protein molecules produced by and able to act upon almost every 
cell in the body. They have an exceptionally broad repertoire of functions that influence 
numerous biological processes. Although widely acting, research into their function has 
been largely centred on their immune-related effects. Interleukins, a major subgroup of 
cytokines, were initially discovered and named according to their described production 
by and influence upon leukocytes. The first interleukin, IL-1, was described as a fever-
inducing cytokine with multiple pro-inflammatory biological effects. Subsequent 
advances in molecular biology have lead to the identification of genes for a further ten 
IL-1 family cytokines. All eleven ligands are structurally related; some have 
overlapping complementary functions, and others act to specifically antagonise these 
functions. The functional effects of the IL-1 ligands are mediated via a large group of 
IL-1 receptors and co-receptors that are characterised by a conserved intracellular 
Toll/IL-1R (TIR) domain. Novel IL-1 genes were originally discovered in humans and 
mice; however, annotation of latterly available mammalian genomes has identified most 
of these IL-1 ligands and receptors in other mammals. Some of these IL-1 genes in 
other mammals have been cloned, but most were identified in silico. Nine of these IL-1 
genes are located in a cluster which is highly conserved across most mammalian 
species, except for mice, where il-1f7 is absent and il-1α and il-1β genes are separated 
from the other six genes (Nicklin, Barton et al. 2002; Taylor, Renshaw et al. 2002). 
Similarly, over half of the IL-1 receptor genes are located at a single locus (Dale and 
Nicklin 1999). Due to a paucity of genomic and sequence resources, the extent of the 
IL-1 gene family in non-mammalian species is only beginning to become apparent. In 
birds, an IL-1β gene was discovered in the chicken several years ago (Weining, Sick et 
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al. 1998); however, other avian orthologues were not found until more recently. The 
coding region of IL-1β has now been cloned in duck, goose, turkey and pigeon (Wu, 
Liu et al. 2007). An IL-1β orthologue has been found in several species of fish 
(Secombes, Wang et al. 2011), some of which encode more than one gene. IL-1β has 
also been cloned in the African clawed frog (Zou, Bird et al. 2000).  
Only one other IL-1 family ligand, IL-18, has been found in multiple non-
mammalian species. The chicken IL-18 gene (Schneider, Puehler et al. 2000) was the 
first avian orthologue found, closely followed by turkey (Kaiser 2002). A partial IL-18 
CDS has also been identified in the duck (Kaiser 2002). Compared with IL-1β, fewer 
fish possess an identifiable IL-18 gene as only Fugu (Huising, Stet et al. 2004) and 
rainbow trout (Zou, Bird et al. 2004) orthologues have been cloned.  
In addition to IL-1β and IL-18, mammals possess up to a further nine IL-1 
ligand genes. These genes have so far not been found in the chicken or in other non-
mammalian species. The exception to this trend is in the rainbow trout where a novel 
IL-1F gene has been recently identified (Wang, Bird et al. 2009). Biologically, it 
functions as a receptor antagonist, although its gene structure, nt and aa sequences and 
overall size are markedly different from any of the mammalian IL-1RN genes.  
To date, a total of eight IL-1 receptors and three IL-1 co-receptors have been cloned in 
mammals. In the human genome, six of these reside in a cluster on chromosome 2 with 
the rest at discrete loci on different chromosomes. In the chicken, only two IL-1 
receptors, chIL-1RI (Guida, Heguy et al. 1992) and chST2 (Iwahana, Hayakawa et al. 
2004), have been cloned to date. Expression analysis of a further chIL-1R, 
SIGIRR/TIR8 (Riva, Polentarutti et al. 2009) has been carried out, although the cDNA 
was not cloned. Partial ESTs for the chicken IL-18Rα, IL-1RAcP and TIGIRR-1 
receptors have also been identified (Huising, Stet et al. 2004). In at least one species of 
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fish, the genes for the IL-1RI, IL-1RII, ST2 and IL-18Rβ receptors have been identified 
(Huising, Stet et al. 2004) so far.  
Although fewer IL-1 family genes have been cloned in the chicken compared to 
mammals, there are clear discrepancies between the ligand and receptor genes found. 
For instance, a chIL-18 gene has been cloned, but the IL-18RAcP (IL-18β) gene has 
not. Similarly, the chST2 cDNA has been isolated, but a gene for its ligand, IL-33, has 
yet to be identified.  
In this Chapter the full extent of the IL-1 gene family in the most up-to-date 
assembled version (v2.1) of the chicken genome is described. Using a conserved 
synteny approach, several chIL-1 family receptor genes which have never been 
described in the literature were identified.  
 
3.2 Methods 
The ENSEMBL genome browser was initially screened using the search terms 
“IL-1” and “IL-18”. For all members of the human IL-1 family not identified in the 
chicken using that method, the full nt and aa sequences as well as the aa signature motif 
were used in BLAST searches. For the human IL-1 family genes which remained absent 
in the chicken, conserved synteny between their locations in the human genome and 
possible locations in the chicken were examined.  
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3.3 Results 
3.3.1 IL-1 ligand genes in the chicken 
The human IL-1 family consists of 11 ligand genes. To ascertain the extent of 
the chicken IL-1 ligand gene family, a search of the ENSEMBL chicken genome 
browser (v2.1) using the term “IL-1” was carried out. This identified the gene for 
chicken IL-1β, located on chromosome 22, but did not provide evidence of any other 
ligand genes. The existence of this gene was already established (Weining, Sick et al. 
1998). However, this search suggested a different genomic location to that given in 
previous reports. The gene was initially mapped to chromosome 2 (Kaiser, Rothwell et 
al. 2004), then reassigned to chromosome 4 in the 2006 release (v2.0) of the genome 
sequence (Kaiser 2007). In the v2.1 assembly, a limited degree of conserved synteny 
exists between the locus containing chicken IL-1β and the human IL-1 gene cluster on 
chromosome 2. The human orthologues of two genes (SLC20A1 and CKAP2L) which 
flank the chIL-1β gene are located adjacent to the huIL-1 gene locus (Figure 3.1). 
Neither of the previous attempts to map the chIL-1β gene identified syntenic genes 
conserved with the human IL-1 locus. Whereas the huIL-1 gene cluster contains a 
further eight IL-1 ligand genes, these are all absent at the chicken locus. To determine if 
the avian orthologues of these other eight huIL-1 genes are located elsewhere in the 
chicken genome, TBLASTN searches of the chicken genome (v2.1) were carried out 
using full length and IL-1 family signature motif amino acid sequences. These did not 
identify any other chIL-1 genes.  
The human genome contains genes for two other IL-1 ligands, IL-18 and IL-33, 
which are located on chromosomes 11 and 9, respectively. Searching the chicken 
genome in ENSEMBL with “IL-18” identified the only other known (Schneider, 
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Puehler et al. 2000) chicken ligand gene, IL-18, in this family on chicken chromosome 
24 (location previously unknown). The amount of conserved synteny between the 
chicken and human IL-18 gene loci was examined and found to be substantial. A total 
of twelve genes including IL-18 are syntenically conserved at these loci. 
Searching the chicken genome with “IL33” did not return any results. Similarly, 
a TBLASTN search of the chicken genome with the huIL-33 amino acid sequence did 
not return any significant results. The “multi-species view” tool in ENSEMBL showed 
that the huIL-33 gene is located in a region of the genome which lacks conserved 
synteny with any region of the chicken genome.   
 
SLC20A1 NT5DC4 CKAP2L IL-1α IL-1β IL-1F7 IL-1F9 IL-1F6 IL-1F8 IL-1F5 IL-1F10 IL-1RN
SLC20A1 OGDH NUDCD3YKT6IL-1βCKAP2LnovelADRA1A
Human Chr. 2
Chicken Chr. 22
113.4 
Mb
113.89 
Mb
3.824 
Mb
3.934 
Mb
 
 
Figure 3.1 Schematic depicting an IL-1 gene family locus conserved between 
humans and chickens. A limited degree of conserved synteny exists between these two 
species at this region. The human locus on chromosome 2 contains nine IL-1 family 
genes, whereas only a single IL-1 family gene, IL-1β, is found on chicken chromosome 
22. Previous attempts to map the chIL-1β gene did not identify the flanking genes 
SLC20A1 and CKAP2L present at both loci. 
 
3.3.2 IL-1 receptor genes in the chicken 
The human IL-1 family consists of eight receptor and three co-receptor genes. A 
search of the chicken genome (v2.1) in ENSEMBL with the term “IL-1” identified three 
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receptor genes present on chromosome 1: IL-1RI, IL-1RII and IL-1RL2. Searching with 
“IL-18” identified the IL-18Rα gene at the same locus on chicken chromosome 1. In 
humans, IL-1RII, IL-1RI, IL-1RL2, ST2, IL-18Rα and IL-18Rβ genes lie in a cluster on 
chromosome 2 in that order. Further examination of the chicken locus showed that this 
IL-1R gene cluster is fully conserved in the chicken on chromosome 1 (1: 137,942,100-
138,163,150) (Figure 3.2). Previous studies reported the identification and cloning of 
the chIL-1RI (Guida, Heguy et al. 1992) and chST2 (Iwahana, Hayakawa et al. 2004) 
genes; however, neither provided a genomic location. A partial IL-18Rα EST had 
already been identified (Huising, Stet et al. 2004). Chicken orthologues of IL-1RII and 
IL-18Rβ have never been described.  
 
MAP4K4 IL-1R2 IL-1R1 IL-1RL2 ST2 IL-18Rα IL-18Rβ SLC9A4 SLC9A2
MAP4K4 IL-1R2 IL-1R1 IL-1RL2 ST2 IL-18Rα IL-18Rβ SLC9A4 SLC9A2
Human Chr. 2
Chicken Chr. 1
137.81 
Mb
138.26 
Mb
102.31 
Mb
103.32 
Mb
 
Figure 3.2 Schematic depicting an IL-1 receptor gene family locus conserved 
between humans and chickens. Complete conserved synteny exists between these two 
species at this region.  
 
As the other members of the huIL-1R family reside elsewhere in the genome, 
conserved synteny between the two species was used to identify the remaining chIL-1R 
genes. The chicken gene for SIGIRR/TIR8 was found on chromosome 5, at a locus 
which is highly conserved with the SIGIRR/TIR8 locus on human chromosome 11. The 
chicken SIGIRR/TIR8 gene was identified following genome annotation by 
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ENSEMBL, but has never been cloned in vitro. Despite this, its global expression in the 
chicken has been analysed (Riva, Polentarutti et al. 2009). Full length chicken cDNAs 
of two other IL-1R (TIGIRR1, TIGIRR2) and two IL-1 co-receptors (IL-1RAcP and 
TILRR), present in humans, have never been isolated. Conserved synteny was used to 
identify these genes in the chicken. They were dispersed across the genome, as they are 
in humans. Human TIGIRR1/IL-1RAPL2, found on human chromosome X, has a 
chicken orthologue on chromosome 4 (4: 17,149,659-17,318,676). A partial chTIGIRR-
1 EST had been previously identified (Huising, Stet et al. 2004). Human TIGIRR2/IL-
1RAPL1, which is also found on chromosome X, has an orthologue in the chicken 
genome on chromosome 1 (1: 119,540,327-120,167,775). Human IL-1RAcP is found 
on chromosome 3 at a locus syntenic with a region of chicken chromosome 9 which 
contains the chIL-1RAcP gene (9: 14,947,157-14,967,542). A partial chIL-1RAcP EST 
had been previously identified (Huising, Stet et al. 2004). TILRR, a novel IL-1RI co-
receptor recently discovered in human and mouse genomes, also has a chicken 
orthologue. The human gene lies on chromosome 9, with the chicken gene present on 
chromosome Z (Z: 31,415,596-31,473,831). An overview of the IL-1 receptor gene 
family in the human and chicken genomes is provided in Table 3.1.  
Finally, a gene encoding the IL-18 binding protein (IL-18BP), a soluble protein 
which binds IL-18 to regulate its activity, is present on human chromosome 11. When 
conserved synteny with the chicken genome was examined, orthologues of three genes 
(NUMA1, RNF121 and XRCC1) which immediately flank the huIL-18BP gene were 
identified at a conserved locus on chicken chromosome 1. Between NUMA1 and 
XRCC1, where the chIL-18BP gene would be expected to be found is a large sequence 
gap spanning 2342 bp (Figure 3.3). The chIL-18BP gene may be present in this gap.  
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 Human  Chicken  
Gene Genomic location Gene Genomic location cDNA 
clone 
IL-1RII 2: 102,608,306-102,645,006 IL-1RII 1: 137,942,627-137,952,233  
IL-1RI 2: 102,681,004-102,796,334 IL-1RI 1: 138,002,937-138,026,152 Guida 
(1992) 
IL-1RL2 2: 102,803,433-102,856,462 IL-1RL2 1: 138,039,834-138,053,899  
ST2 2: 102,927,962-102,968,497 ST2 1: 138,087,256-138,111,381 Iwahana 
(2004) 
IL-18Rα 2: 102,927,989-103,015,218 IL-18Rα 1: 138,122,441-138,139,234  
IL-18Rβ 2: 103,035,149-103,069,025 IL-18Rβ 1:138,147,956-138,161,221  
SIGIRR 11: 405,716-417,455 SIGIRR 5:1,574,130-1,578,868  
TIGIRR1 X: 103,810,996-105,012,102 TIGIRR1 4: 17,149,659-17,318,676  
TIGIRR2 X: 28,605,516-29,974,840 TIGIRR2 1: 119,540,327-120,167,775  
IL-1RAcP 3: 190,231,840-190,375,843 IL-1RAcP 9: 14,947,157-14,967,542  
TILRR 9: 14,734,664-14,910,993 TILRR Z: 31,415,596-31,473,831  
 
Table 3.1 The IL-1 receptor gene family in humans and chickens. Six members of 
the family are found at a locus with conserved synteny between human and chicken. 
2.34 kb
Contig coverage
XRCC1
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RNF121 NUMA1
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199.10
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Figure 3.3 Schematic depicting the IL-18BP locus in humans and a region of the 
chicken genome with which it shares limited conserved synteny. Chicken 
chromosome 1 contains a large sequence gap where the chicken orthologue of IL-18BP 
may reside. The blue bars depict contig coverage in that part of the chromosome whilst 
the locations of the genes along the contig are indicated immediately above. 
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3.4 Discussion 
To date, only two chIL-1 ligand cDNAs have been cloned: IL-1β and IL-18. 
BLAST searches with the chIL-1β and huIL-1F1-F11 sequences showed that no further 
members of IL-1 ligand family are present in v2.1 of the genome assembly. Examining 
conserved synteny between human and chicken chromosomes showed the nine IL-1 
gene human cluster is represented by only a single chicken IL-1 gene, IL-1β, at the 
equivalent chicken locus. In both the rainbow trout and puffer fish, a similar conserved 
locus encoding only IL-1β exists. Both these fish also contain a gene encoding an IL-
1RN-like protein, nIL-1F. These two genes are found at divergent loci in the two fish, 
on chromosomes 5 and 12, respectively. No other IL-1 genes are present at either locus 
in these fish. If the chicken contains any other IL-1 ligand genes, assuming the 
assembly of chicken chromosome 22 is correct, they may also lie at different loci, 
presumably in regions that are poorly assembled. The locus containing chIL-1β does 
contain a number of sequence gaps. However, the equivalent locus in the zebra finch 
has the identical gene content and no sequence gaps.  
Examining conserved synteny between the human IL-33 gene locus and the 
chicken genome did not identify an avian orthologue. Despite this, conserved synteny 
between large numbers of genes flanking huIL-33 and a region on chicken chromosome 
Z was evident. When evaluating the exact orthologous pairings between both species, it 
is clear that a chromosomal breakpoint has occurred and a potential chIL-33 gene has 
been lost or relocated. Avian orthologues of the two human genes (RANBP1 and 
TPD52L3) which immediately flank huIL-33 are located on chicken chromosomes 1 
and 20, respectively. All other genes flanking this three gene cluster in both directions 
are completely syntenically conserved between human chromosome 9 and chicken 
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chromosome Z (Figure 3.4). 
In stark contrast to the number of chIL-1 ligand genes, the chIL-1 receptor gene 
family contains all of the orthologues found in the human genome. Every receptor is 
located in a region of conserved synteny between both species. Some of the identified 
chIL-1R genes were assumed to exist because of their essential functional roles. For 
example, once a chicken IL-18 gene had been identified, it was inevitable the IL-
18RAcP gene would exist. Likewise, with both IL-1β and IL-1RI genes already present, 
it was likely the IL-1RAcP gene, essential for IL-1β function, would be found. It is 
particularly interesting that the IL-1RL2 and ST2 receptors are found in the chicken. In 
mammals, IL-1F5, -F6, -F8 and -F9 bind to IL-1RL2, whilst IL-1F11 binds to ST2. This 
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Figure 3.4 Schematic depicting the IL-33 locus in the human genome and a 
syntenic region of the chicken genome. Although considerable synteny exists at this 
locus, avian orthologues of two of the genes (RANBP6 and TPD52L3) on human 
chromosome 9 lie elsewhere in the chicken genome. An IL-33 gene has yet to be 
identified in the chicken genome. Pairs of orthologous genes are indicated with lines 
and have identical shading. 
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suggests the chicken may also possess genes encoding these IL-1F ligands. It is also 
interesting to observe that both TIGIRR-1 (IL-1RAPL2) and TIGIRR-2 (IL-1RAPL1) 
genes are encoded in the chicken. The exact functional roles of these orphan receptors 
have yet to be comprehensively defined in humans, although IL-1RAPL1 appears to 
have a role in brain development as mutations in this gene are strongly associated with 
mental retardation (Pavlowsky, Zanchi et al. 2010). The existence of avian orthologues 
of both suggests they form part of a fundamental signalling network with important 
downstream functions.  
The fact that all the receptors are present in the chicken but only two of the 
ligands have been found presents a somewhat paradoxical situation. It is possible that 
the chicken and human IL-1 ligand genes evolved from a single gene in a common 
ancestor which became duplicated at a single locus. Both species may have retained all 
eleven IL-1 genes, with nine of these remaining intact at a single locus in humans. 
Although the chicken may have retained all eleven genes, intense selective pressures 
may have led to significant chromosomal rearrangement, scattering the genes in the IL-
1 locus across the genome. Should this be true then these genes presumably reside in 
areas of the genome which are too difficult to sequence with the current methods 
available. To date, a number of regions of the chicken genome have not been 
sequenced; in particular, coverage of the microchromosomes is negligible. 
Alternatively, the chicken may contain 2-3 separate IL-1 loci (in addition to 
those identified) each containing several IL-1 genes. In mouse, the nine IL-1 genes 
clustered on human chromosome 2 are found on two separate loci. Assuming the three 
IL-1 loci in the human genome constitute regions containing paralogous genes, their 
inception could be traced to a single ancestral locus which underwent duplication. This 
primordial locus could have contained 2-3 IL-1 genes, which upon subsequent genome 
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duplication formed several paralogous IL-1 loci each encoding a copy of these few IL-1 
ligand genes. Further duplications in the human genome may have expanded the size of 
the IL-1 gene family at one locus, whilst the other two loci may have contracted, 
conceivably leaving only single IL-1 gene loci containing IL-33 and IL-18. In the 
chicken, two of the loci could have respectively retained only single IL-1F genes, with 
IL-1β at one locus and IL-18 at the other. Additional IL-1 loci could have lost these 
ligand genes, retained others and possibly undergone further duplications. If all nine (or 
even a few) of these “missing” genes are present in the chicken genome, their 
distribution would be atypical, compared to what is normally seen when comparisons 
are made with the human genome. In general, the distribution of the genes in a cytokine 
family in the human genome is mirrored in the chicken genome. For example, the IL-17 
cytokine gene family is dispersed across the genomes of both species (Kaiser 2007). 
Similarly, the IL-10 family, although not completely conserved in the chicken, has the 
same pattern of gene distribution as that found in the human genome (Kaiser 2007).  
An alternative hypothesis to explain gene absence is that the chicken has lost or 
is in the process of losing its IL-1 ligand genes and the receptors will also disappear 
over time. Considering the presumably indispensible functions of the IL-1 family to 
combat disease and ultimately sustain life, it is difficult to imagine functional 
redundancy leading to gene loss. Both humans and mice lacking the IL-1RN gene, for 
example, present with gross inflammatory disorders, which can be fatal in man. In mice 
overexpressing il-1f6, the prevailing inflammatory phenotype is significantly worsened 
when il-1f5 is knocked out (Blumberg, Dinh et al. 2007). A further hypothesis is that 
the chicken has only ever had a limited IL-1 ligand family. Based on the approximate 
mutational rate of IL-1RN, it has been proposed that IL-1F5 is only found in mammals 
(Mulero, Nelken et al. 2000). This appears to be unlikely, however, given the presence 
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in the chicken genome of the receptor for IL-1F5, -F6, -F8 and -F9 (IL-1RL2).
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4.1 Introduction 
For decades after its initial discovery in the 1940s, a substance described as 
“endogenous pyrogen” was known to induce fever when injected into animals. 
Advances in molecular biology eventually permitted the identification of two ligand 
genes responsible for these effects. Named IL-1β (Auron, Webb et al. 1984) and IL-1α 
(Lomedico, Gubler et al. 1984), these two agonist ligands were the first described 
members of the interleukin-1 cytokine family. Around the same time, several reports of 
a substance shown to inhibit IL-1 were published, prompting much research into its 
function. After showing its effects were IL-1 receptor-specific (Hannum, Wilcox et al. 
1990), its cDNA (Eisenberg, Evans et al. 1990) was cloned and sequenced. Sequence 
analysis indicated a third IL-1 family gene had been found. Subsequent characterization 
of its bioactivity (Carter, Deibel et al. 1990) showed it specifically inhibited the actions 
of IL-1β and IL-1α, and was accordingly named IL-1 receptor antagonist (IL-1RN). 
Further studies confirmed that two major structural variants of this gene, secretory and 
intracellular, are formed through alternative splicing. Three protein isoforms of the 
intracellular variant (Haskill, Martin et al. 1991; Muzio, Polentarutti et al. 1995; 
Malyak, Guthridge et al. 1998) exist whose roles, whilst clearly antagonistic, remain 
inadequately defined. Since its discovery in humans, IL-1RN orthologues have been 
identified in 35 other mammalian genomes according to the ENSEMBL genome 
browser (personal search). However, it has continued to be absent in non-mammalian 
species, although an IL-1RN-like gene has recently been described in rainbow trout 
(Wang, Bird et al. 2009). Given the remarkable potency of IL-1β in immune responses, 
it is difficult to conceive that any species possessing this gene would lack IL-1RN.  As 
discussed in Chapter 3, examination of conserved synteny between human and chicken 
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chromosomes suggests that the chicken does not encode any other members of the IL-1 
cytokine family at the relevant locus, including IL-1RN. However, we know that birds 
and mammals have evolved separately for ~310 Mya, and over time this has led to a 
striking divergence in the number, organisation and architecture of their chromosomes. 
Conservation of synteny therefore only indicates that the nine gene IL-1 cluster found in 
humans is absent at the equivalent genomic location in birds, apart from IL-1β.  
Significant progress has been made over the past decade to elucidate the 
repertoire of immune function genes in the chicken (Kaiser 2010). In particular, 
knowledge of the number of cytokine genes it possesses has grown rapidly, accelerated 
by the availability of the genome sequence (Wallis, Aerts et al. 2004). Whilst birds 
typically possess fewer members of individual cytokine gene families (Kaiser 2010), the 
essential functional role of IL-1RN made its existence likely in the chicken.  
As comparative genomics would be a redundant approach for finding this gene, 
given its absence at the equivalent locus in the chicken, alternative sources of sequence 
information needed to be investigated. Around the time of the chicken genome sequence 
publication, several chicken EST sequencing projects were conducted (Savolainen, 
Fitzsimmons et al. 2005), providing thousands of novel transcript sequences.  
In this Chapter the identification and molecular cloning of chicken IL-1RN is 
described. The procedure for screening EST databases which led to the identification of 
several novel chicken IL-1 sequences is also outlined. Further in silico characterization 
showed a number of these chIL-1 ESTs were most similar to the IL-1RN gene found in 
many other species. Once satisfied that chIL-1RN had been identified, RT-PCR was 
used to amplify chicken orthologues of the two major structural variants of IL-1RN 
found in mammals. Analyses of the chIL-1RN gene structure, as well as attempts to 
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determine its genomic location, were also carried out.  
4.2 Methods 
A combination of in silico and in vitro techniques were used to identify and 
clone a novel cytokine, chicken IL-1RN. General methods were carried out as outlined 
in Chapter 2. Additional methods and alterations to those described in Chapter 3 are 
detailed here. 
4.2.1 In silico techniques  
The NCBI EST database was initially screened as described in Chapter 2, 
section 2.2.2. This identified three putative chicken cytokine EST sequences from the 
IL-1 family. These sequences had significant homology with chIL-1β, but were clearly 
different. A full length open reading frame cDNA was derived from combining two of 
these ESTs, which overlapped. Its nucleotide and predicted amino acid sequences were 
analysed and BLAST was used to confirm its identity as described in Chapter 2, section 
2.2.3. Next, this amino acid sequence was used to attempt to uncover further chIL-1 
ESTs. An EST with high identity to the query chIL-1RN sequence was identified which 
had an obviously different 5′ end sequence and lacked a start codon. Latterly, a database 
of novel sequence reads, from efforts to resequence the chicken genome, became 
available. This database was screened, uncovering the missing start codon from this 
reciprocally mined EST sequence. Potential promoter regions were analysed with 
Softberry, a web-based tool which compares submitted promoter sequences with a 
database of published binding site consensus motifs. Further characterisation of chIL-
1RN nucleotide and amino acid sequences was carried out to confirm the identity and 
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similarity of the chicken protein isoforms to their respective huIL-1RN sequences. 
Bioinformatics tools described in Chapter 2, section 2.1 were used for this analysis.  
4.2.2 In vitro techniques  
Using RT-PCR, both cDNA coding sequences were amplified, sequenced and 
cloned into the pTarget mammalian expression vector. For the RT-PCR, RNA isolated 
from LPS-stimulated HD11 cells was chosen as the template. HD11 cells were 
stimulated for 6 h with 200 ng/µl LPS (E. coli, Sigma). Sequence-specific primers for 
icIL-1RN and sIL-1RN (Table I in Appendix II) were designed from EST and Galgal 
3.0 sequences. Cycling conditions were as described in Chapter 2, sections 2.4.4.2 
(icIL-1RN) and 2.4.4.3 (sIL-1RN), with an annealing temperature of 60ºC. HD11 cells 
are a chicken macrophage cell line (Beug, von Kirchbach et al. 1979), and were selected 
because monocytes and macrophages are the cells that predominantly express IL-1RN 
in mammals (Arend, Malyak et al. 1998). Of the many agents that induce mammalian 
IL-1RN expression, LPS is one of the most potent (Arend, Malyak et al. 1998). In a 
previous study, LPS activated NF-κB via chicken Toll-like receptor 4 (chTLR4) in 
HD11 cells (Keestra and van Putten 2008).  
PCR amplification of chIL-1RN introns used custom primers designed from the 
coding sequence and optimised thermal cycling annealing temperatures. Details of both 
are in Table I in Appendix II.  
To determine the genomic location of chIL-1RN, PCR analysis of the locus 
containing chIL-1β used a specific BAC clone (TAM32-21N6) for the template. This 
was acquired from the Institute for Plant Genomics & Biotechnology (Texas A&M 
University, Texas, USA) as a bacterial colony plug. A single colony of E. coli was 
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picked and used to inoculate 5 ml LB medium (containing 12.5 μg/ml chloramphenicol) 
which was incubated for 8 h at 37ºC with shaking. This culture was used to seed 200 ml 
LB medium (+ 12.5 μg/ml chloramphenicol) followed by incubation at 37ºC with 
shaking for 12 h. BAC DNA was purified from the bacterial cell pellet using the 
Nucleobond® PC100 kit (Macherey-Nagel) as described in Chapter 2, section 2.4.9.4. 
PCR amplification of chIL-1β and chIL-1RN used custom primers designed from the 
coding sequences and optimised thermal cycling annealing temperatures. Details of both 
are in Table I in Appendix II. An additional experiment to discover the genomic 
location of chIL-1RN used a 
32
P-labelled (random-primed) probe to hybridize against 
BAC library filters. Four high-density BAC filters representing the complete v2.1 Red 
Jungle Fowl genome (CHORI-261 chicken BAC library) were acquired from the 
Children’s Hospital Oakland Research Institute (CHORI), California, USA. IL-1RN 
probe templates were generated by EcoRI restriction digests to release the icIL-1RN and 
icIL-1RN SV2 clone inserts from pTargeT. Restriction digests (40 µl) containing 28 µl 
dH2O, 4 µl EcoRI and 8 µl DNA were incubated for 1 h at 37ºC. Products were 
electrophoresed on an agarose gel at 100 V for 2 h and gel-purified using the QIAquick 
gel extraction kit (Qiagen). Purified DNA templates were quantified by 
spectrophotometry using the NanoDrop ND1000, radiolabelled and subsequently 
hybridised against the 4 BAC filters. Details of the filter preparation, probe preparation 
and hybridisation protocol are in Chapter 2, section 2.4.11. 
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4.3 Results 
4.3.1 Identification and analysis of novel chIL-1 expressed sequence tag (EST) 
sequences 
The starting point for this project was a TBLASTN search of the NCBI EST 
database by a collaborator, Dr Steve Bird (University of Aberdeen). He identified three 
chicken ESTs representing putative IL-1 genes, which were described as “similar to 
chicken IL-1β”. Two of these ESTs (Acc. Nos: CK613932 and BX257557) were 
combined to create a 554 bp sequence with potential start and stop codons as well as a 
polyadenylation (polyA) signal (AATAAA). I translated this combined EST and found 
the predicted protein sequence contained the IL-1 family signature motif (consensus: 
[FC]-x-S-[ASLV]-x(2)-P-x(2)-[FYLIV]-[LI]-[SCA]-T-x(7)-[LIVM]; Bird, Zou et al. 
(2002)). Furthermore, the sequence had 20.6% identity with chIL-1β, but was missing 
from v2.1 of the genome sequence. This predicted sequence was used to perform a 
TBLASTN analysis against all of the other eukaryotic genomes in ENSEMBL, which 
identified IL-1RN as the best hit in 22 other species (results in Table I in Appendix I). 
To determine whether any further members of the chIL-1 family were present in 
the NCBI EST database, reciprocal BLASTP analysis of this database using the 
predicted chIL-1RN amino acid sequence was performed. This uncovered twelve 
further EST sequences with significant homology (Table II in Appendix I). Three of 
these sequences were identical to the query IL-1RN sequence; however, one EST 
(BU214831.1) was similar but clearly differed at the 5′ end. This 669 bp sequence also 
lacked a potential start codon. Unassembled, uncurated nucleotide sequence reads from 
the third build (Galgal 3.0) of the chicken genome were subsequently made available. A 
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TBLASTN search against these sequences was carried out and two contigs were 
identified (designated 81757.1 and 113837.1) from the “removed data” reads containing 
the majority of the coding sequence of chIL-1RN as well as some intronic sequence. 
Contig 81757.1 was aligned with the BU214831.1 EST sequence and additional 5′ 
sequence was determined (that differed from the CK613932 and BX257557 ESTs) 
containing a single start codon (Figure 4.1). 
4.3.2 Signal peptide analysis of predicted chIL-1RN amino acid sequences 
Two similar chIL-1RN ESTs had been identified by screening the NCBI EST 
database. One of these ESTs (BU214831.1) was subsequently supplemented with 
further 5′ end sequence from a contig (113837.1) mined from Galgal 3.0 (unassembled) 
sequence reads. Translating these two original ESTs produced two predicted chIL-1RN 
protein sequences that did not align at their NH2-termini (Figure 4.2). The human IL-
1RN gene is differentially spliced to create two structural variants that are identical to 
one another except for their 5′ ends. This suggested that different structural variants may 
also exist in the chicken. Human IL-1RN structural variants are classified as either 
secretory or intracellular based on the existence of a signal peptide in the former. To 
determine if similar structural variants are synthesised in the two chIL-1RN sequences, 
they were analysed for the presence of a signal peptide using SignalP (Figure 4.3). The 
BU214831.1 EST (supplemented with further 5’ end sequence from contig 113837.1) 
contained a 17 amino acid signal peptide and was designated secretory IL-1RN (sIL-
1RN). The combined chIL-1RN EST (CK613932 & BX257557), however, did not 
contain a signal sequence and was therefore named intracellular IL-1RN (icIL-1RN) to 
reflect its likely identity.  
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Figure 4.1 Nucleotide alignment between chIL-1RN EST BU214831.1 and Contig 
81757.1. The single start codon missing from the EST is marked on the contig 
sequence. Once identified, it was then possible to design a forward primer against this 
EST/genomic sequence to amplify a full length CDS.  
 
 
Figure 4.2 Amino acid alignment between 2 chIL-1RN ESTs differing at their 5’ 
ends. 
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Figure 4.3 SignalP analysis of chIL-1RN amino acid sequences. Top, SignalP 
analysis of chicken sIL-1RN identifies a 17 amino acid signal peptide. Bottom, SignalP 
analysis of chicken icIL-1RN indicates no signal peptide is present.
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4.3.3 Amplification and molecular cloning of chIL-1RN protein coding cDNA 
sequences 
Primers were designed against the predicted sIL-1RN and icIL-1RN protein 
coding nucleotide sequences (CDS) derived from the ESTs. A full length icIL-1RN 
CDS was amplified by one-step reverse transcription-polymerase chain reaction (RT-
PCR) using RNA from LPS-stimulated HD11 cells and ConA-stimulated splenocytes. 
Gel electrophoresis of the RT-PCR products revealed a double band consisting of a 
band of the expected size and a smaller additional band (see Figure 4.4). Both bands 
were gel-purified and TA-cloned into the pTarget mammalian expression vector. Clones 
were then screened by EcoRI restriction digestion. Agarose gel electrophoresis of 
released clone inserts suggested the small band present on the initial gel (Figure 4.4) 
was actually a doublet, as two clones with apparently different mobilities were isolated 
for this PCR product (Figure 4.5). All clones were sequenced by chain termination 
sequencing using T7 and revT7 (a custom reverse primer) vector primers (see Table 1 in 
the Appendix). Analysis of the clone sequences for the full length icIL-1RN CDS 
showed it was 492 bp in length and a 100% match with the IL-1RN EST sequence. 
Analysis of the clone sequences for the smaller band confirmed the existence of two 
distinct splice variants (SV) of the full length. Both aligned with the full length 
sequence but had regions where sequence was absent (Figure 4.6). As these truncated 
variants were specific, they were termed icIL-1RN SV1 and SV2. Their respective 
lengths were 400 bp and 420 bp. 
A full length sIL-1RN ORF cDNA was amplified by PCR using cDNA made 
from LPS-stimulated HD11 RNA as template (Figure 4.7). As with icIL-1RN, agarose 
gel electrophoresis of the RT-PCR products revealed a double band - one at the 
expected size and a smaller additional band. Again, both bands were gel purified and  
Chapter 4: Identification, cloning and characterisation of chicken IL-1RN 
 
169 
 
500
400
300
200
100
M     H     S     
492
420
bp
 
Figure 4.4 Agarose gel showing RT-PCR products from the amplification of the 
icIL-1RN CDS using ConA-stimulated splenocyte (S) and LPS-stimulated HD11 
(H) macrophage cell line RNA as template. Expected band size = 492 bp. Both icIL-
1RN splice variants are present in the smaller band at ~420 bp. M = 100 bp DNA 
ladder.  
TA-cloned into the pTarget vector, followed by EcoRI restriction digestion to screen the 
clones. Agarose gel electrophoresis of the released clone inserts identified two splice 
variants of sIL-1RN in addition to the full length variant. Sequencing all of the clones 
with T7 and revT7 vector primers showed the two splice variants were specific and 
identical to those of the intracellular SVs at all of the splice sites, differing only in their 
5′ end sequences (Figure 4.8). This suggested a similar mechanism had led to their 
formation and they were subsequently named sIL-1RN SV1 and SV2. The CDS of full-
length sIL-1RN is 522 bp in length, whilst SV1 and SV2 are 430 bp and 450 bp in 
length, respectively. 
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Figure 4.5 Agarose gel showing icIL-1RN splice variant clones released from 
pTargeT by restriction digestion. Two different fragments are evident on this gel – 
SV1 and SV2. Size marker = 100 bp DNA ladder.  
 
4.3.4 In silico analysis of chIL-1RN nucleotide and amino acid sequences 
The full length chIL-1RN amino acid sequences were further characterized in silico. 
The sIL-1RN and icIL-1RN ORF cDNAs encode predicted proteins of 173 and 163 
amino acids, respectively, although sIL-1RN contains a predicted 17 amino acid signal 
peptide, so its predicted secreted mature protein is 156 amino acids. When aligned with 
mammalian IL-1RN sequences (Figure 4.9), both chIL-1RN sequences show relatively 
high amino acid identity for avian cytokines. Chicken sIL-1RN is very similar in length 
to the human and mouse sIL-1RN, sharing 38.3% and 37.9% sequence identity, 
respectively. Its predicted molecular weight (Mw) is 19.372 kDa with an isoelectric 
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Figure 4.6 Alignment between icIL-1RN (icFL), SV1 and SV2 CDS cDNA 
sequences using ClustalX. Blocks are shaded black to denote identical bases in all 
three sequences and grey to highlight identical bases in two of the sequences. This 
allows the exact locations of the splice junctions to be viewed more easily. 
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Figure 4.7 Agarose gel showing RT-PCR products from the amplification of the 
sIL-1RN CDS using LPS-stimulated HD11 (H) macrophage cell line RNA as 
template. Expected band size = 522 bp. Two sIL-1RN splice variants are present in the 
smaller band at ~450 bp. M = 100 bp DNA ladder.  
 
point (pI) of 8.68. Chicken icIL-1RN, most similar to the human icIL-1RN1 isoform, 
has 38.2% and 40.4% amino acid identity with the respective human and mouse 
sequences. Its Mw is calculated as 18.299 kDa, with an identical pI to sIL-1RN of 8.68. 
The secondary structures of human and mouse IL-1 proteins have been characterized as 
β-trefoil folds comprised of 12 β-strands. Using PSIPRED, the secondary structure of 
chIL-1RN was predicted to have the same three-dimensional configuration, with the 12 
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Figure 4.8 Alignment between the six chIL-1RN CDS cDNA sequences in ClustalX. 
Previous page Both secretory and intracellular splice variant sequences are identical at 
all of the splice sites. Blocks are shaded black to denote identical bases in all sequences 
and grey to highlight identical bases in four of the sequences. 
 
β-strands located in almost identical regions to the huIL-1RN sequence (Figure 4.9). 
These regions are the most highly conserved between species reflecting their likely 
functional/structural importance. Of the five cysteine residues in the chIL-1RN 
sequences, three of these are conserved in mammals, located in β-strands 6 and 10, and 
two will likely form disulphide bonds. A single potential N-glycosylation site (NGT) is 
found in icIL-1RN at positions 76-78 (86-88 in sIL-1RN); however, it is not conserved 
in mammalian sequences. Both chIL-1RN sequences were analysed for structural 
similarity to known protein domains in the ProDom database. Both sequences were 
most closely related to domains PDA1I6T8 (domain I.D: IL-1Ra; closest domains: rat 
IL-1Ra (to ch icIL-1RN) and rabbit IL-1Ra (to ch sIL-1RN); e-values: 2x10
-9
 and 4x10
-
9
 for residues 2-62 and 15-69; with 49% and 52% amino acid identity, respectively); and 
PD002536 (IL-1; mouse IL-1F10; 2x10
-18
; 32-161/42-171; 37%).    Upon examination 
of the IL-1RN SV nucleotide sequences, SV1 transcripts were apparently formed 
through use of an atypical splice donor site (GG). This resulted in the predicted protein 
sequence being out of frame and significantly truncated compared to the full length 
sequence (Figure 4.10). The modified amino acid sequence following the frameshift 
consists of a higher proportion of hydrophobic residues which may significantly affect 
the biochemical properties of the molecule. β-strands 2 and 3 have also been removed 
and the conserved cysteines found in the full length sequences are absent. The SV2 
transcripts are apparently formed through use of an alternative splice acceptor site, with 
the predicted protein sequence in frame with the full length molecule. Although in  
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Figure 4.9 Amino acid alignment of chicken sIL-1RN and icIL-1RN with human 
(secretory and intracellular variant 1), mouse, cow, and platypus IL-1RN 
sequences. Identical residues between all five species at the same position are shaded 
black; identical residues between four species are shaded dark grey, those between three 
species shaded light grey; similar (structure) residues are shaded light grey. The 
secondary structure of IL-1 family proteins consists of 12 β-strands. The specific amino 
acid residues that comprise these 12 β-strands in humans (Schreuder 1997) are indicated 
by white blocks beneath the sequence. Their locations in the chicken, predicted by 
PSIPRED, are indicated by black blocks.  
 
frame, the truncated sequence lacks β-strand 8 which may affect protein folding. 
Using the full length chicken icIL-1RN and sIL-1RN amino acid sequences, 
phylogenetic analysis was carried out to determine an evolutionary relationship with 
mammalian IL-1RN. The initial large scale analysis incorporated the maximum number 
of known IL-1 amino acid sequences from the following species: human, mouse, 
platypus, chicken, zebra finch and lizard. The unrooted phylogenetic tree that was 
created showed both chicken IL-1β and IL-18 sequences grouped within the major 
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Figure 4.10 Amino acid alignment between predicted icIL-1RN (icFL), SV1 & SV2 
sequences. Due to use of an atypical splice donor site, the SV1 amino acid sequence is 
out of frame and truncated compared to the full length sequence.    
 
clades for those genes, as previously shown (Huising, Stet et al. 2004). Both chIL-1RN 
formed a separate branch within the major IL-1 receptor antagonist subgroup (IL-1RN, 
IL-1F5 & IL-1F10) clade (Figure 4.11). A smaller scale analysis was carried out using 
only IL-1β, IL-1RN, IL-1F5 and IL-1F10 from species possessing these genes, which 
again produced the same groupings. All IL-1 genes contain 3 highly conserved common 
exons which are always the last 3 in any transcript. The final common exon encodes the 
IL-1 family signature motif so is the most highly conserved region between all IL-1 
genes across all species with identified orthologues. In an attempt to determine if chIL-
1RN would group closer to its direct mammalian orthologues, analysis using only the 
amino acid sequence of common exon 3 was carried out. However, a similar tree 
topology to that previously seen was generated (data not shown). 
 
4.3.5 Structural determination of chIL-1RN by PCR amplification, sequencing 
and in silico analysis 
 A combination of PCR and in silico analyses allowed the genomic structure of  
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Figure 4.11 Phylogenetic analysis of chIL-1RN amino acid sequences using MEGA 
v5.0. Analysis was performed using the Neigbour-Joining (N-J) method. hu = human, m 
= mouse, Pl = platypus, ch = chicken, Lz = lizard, Zf = zebra finch. IC = intracellular; 
SEC = secretory.  
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chIL-1RN to be determined. The human IL-1RN gene consists of six exons, which, 
through differential splicing of the first three exons (ic1, ic2 and s1), creates three 
different transcripts: sIL-1RN, icIL-1RN1 and icIL-1RN2. All 3 transcripts include the 
common exons 2-4; and either all (sIL-1RN) or part (icIL-1RN1 and icIL-1RN2) of 
exon s1. The icIL-1RN1 transcript contains a further upstream exon (ic1) that is spliced 
into exon s1through use of an internal splice acceptor site located within s1. This splice 
acceptor site is situated towards the 3’ end of the sequence encoding the signal peptide, 
hence the icIL-1RN1 transcript does not possess a signal sequence. The icIL-1RN2 
transcript contains all of the exons present in the icIL-1RN1 sequence, in addition to 
which a 63 bp exon (ic2) is inserted between ic1 and s1 (Figure 4.12). As the 
chromosomal location of the chIL-1RN gene remains unknown, the structure and full 
gene sequence are not present in any of the chicken genome browsers.  
Avian cytokine genes are structurally very similar to their mammalian 
orthologues (Kaiser, 2004), so it is likely that the structure of the chIL-1RN gene 
resembles that of the huIL-1RN gene. Using knowledge of the huIL-1RN gene 
structure, the human and chicken IL-1RN cDNA sequences were aligned to predict the 
locations of the chicken introns (Figure 4.13). Primers were then designed from the 
exon sequences flanking the predicted intron-exon boundaries of the chicken transcripts. 
Only two chicken introns were successfully amplified using this approach. Using 
genomic DNA from lines 61 and N, a 354 bp PCR product was generated (the 
equivalent cDNA amplicon would be 161 bp) (Figure 4.14). Sequencing revealed this 
amplicon was comprised of intron 2, exon 3 and intron 3 of chIL-1RN. The size and 
sequence of exon 3 was already known, allowing the sizes of introns 2 and 3 to be 
accurately determined as being 88 bp and 105 bp in length, respectively. The 
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corresponding introns in the huIL-1RN gene are substantially larger, at 1835 bp and 
1380 bp, respectively. 
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Figure 4.12 The structures and identified protein coding transcripts of chicken and 
human IL-1RN genes. 
 
The subsequent availability of Galgal 3.0 unassembled sequence reads 
confirmed the sequencing results generated for introns 2 and 3 of chIL-1RN. Alignment 
of the chicken CDS with the genomic sequence in contigs 81757.1 and 113837.1 
allowed the identification of the exact locations of each of the exons. The alignment 
also confirmed the full sequence of exons ic1, s1 and 2-4 and introns 1-3 (Figures 4.15 
and 4.16), thus the only outstanding intron yet to be amplified was intron 4. Using 
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Figure 4.13 Alignment of human and chicken transcript sequences created to 
predict the locations of the chicken gene introns. Previous page Vertical lines 
indicate the location of introns in both species. In the chicken, the locations of primers 
used to amplify the 4 introns are indicated. Introns 1-4 were amplified with IL-1RN 
Int1-2L1 and IL-1RN 130R primers. Introns 2 and 3 were amplified with IL-1RN Int2-
3L2 and IL-1RN Int3-4R2 primers. 
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Figure 4.14 Agarose gel of PCR products containing intron 2, exon 3 and intron 3 
of chIL-1RN. Products were amplified with IL-1RN Int2-3L2 and IL-1RN Int3-4R2 
primers (see Fig 4.13). Lane M = 100 bp DNA ladder. Lanes 1-8 = products amplified 
from lines 61, 72, 15I, W, P, 0, RIR & N genomic DNA respectively. 
 
previously unknown sequence from contig113837.1, several primer pairs were designed 
to generate a PCR product containing the “missing” intron 4. A ~1500 bp PCR product 
was amplified with Int1-2L1 and 130R primers (Figure 4.17), cloned and sequenced. 
Intron 4 of chIL-1RN is ~770 bp in length, ~1020 bp shorter than its human equivalent. 
In summary, the structure of chIL-1RN was found to be similar to that of its human 
orthologue (Figure 4.12). The coding region is comprised of five exons, which when 
translated are very similar in size to their corresponding human sequences. The introns 
of chIL-1RN, however, are significantly smaller than their human equivalents, resulting 
in the overall length of the gene being around one tenth (10.5%) that of huIL-1RN.  
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F  K  H  E  L  Q  P  V  I  M  G  I  R  N  G  T  R  C  L  A  C  P  A  A
CACAGCCCACCCTGCAGCTCCAGGTGGGGCACGGGGGG
P  Q  P  T  L  Q  L  Q
Intron 1
Exon 2
Exon 3
secExon 1
icExon 1
Intron 2
Intron 3
5’UTR
 
Figure 4.15 Structure of exon/intron 1-3 of chIL-1RN. Above Splicing that leads to 
the formation of SV1 transcripts is indicated. Intron 2 is usually spliced at the GT splice 
donor site (in bold), however, it is spliced 1 G nucleotide earlier in SV1 (splice site 
marked by an arrow) making CC the final nucleotides in the coding sequence. Intron 3 
is usually spliced at the AG splice acceptor site (in bold), however, it is spliced 2 
nucleotides later at the alternative but incorrect AG, making AA the first nucleotides in 
the continuing coding sequence. Several motifs associated with exon skipping in 
mammals are underlined in introns 2 and 3.  
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Below Exon skipping alters the reading frame of the amino acid, introducing a 
premature stop codon. Residues out of frame are shaded blue. 
 
ATGGCGCTCACCATCGCCCTCCTCCTCCTCCACGCA
M  A  L  T  I  A  L  L L L H  A
GAGGCTGCCGGATCGGTGCCGTGCCGCGCGCCCGCG
E  A  A G  S  V  P  C  R  A  P  A
CTGCAAACCAAAGTCTTCAAATACCAAGGTGTTTTG
L  Q  T  K  V  F  K  Y  Q  G  V  L
GGTGCCCAACCGCTTCTTCAAGCACGAGCTGCAGCC
G  A  Q  P  L  L Q  A  R  A  A A
CGTCATCATGGGCATCCGCAACGGCACCCGCTGCCT
R  H  H G  H  P  Q  R  H  P  L  P
GGCCTGCCCGGCGGCCCCACAGCCCACCCTGCAGCT
G  L  P  G  G P  T  A  H  P  A  A
CCAGGACGCCGACATCACGGAGCTGCCCCGCAGCGG
P  G  R  R H  H G  A  A P  Q  R
CGCCGCCTCCGCGCCGTTCACCTTCTTCCGCACCTA
R  R L  R  A  V  H  L  L P  H  L
TAAGGACGGGCTGTGGCGCTTCGAGTCGGCCGCCAA
*
CCCCGGATGGTTCCTCTGCACCTCCGCCCGCGCCCA
CCAACCCCTGGGGCTCTCCCGGCGCCCCGACGCCGC
CCACGTCCTGGATTTCTACTTCCAGCTGTGCTGA
 
 
Establishing the genomic structure of chIL-1RN (above) allowed the sequences 
of the chIL-1RN splice variants to be revisited to decipher the alternative splicing 
events that generated them. SV1 was missing exon 3 and was formed through use of an 
atypical splice donor site (GG). This resulted in the predicted protein sequence being 
out of frame and significantly truncated compared to the full length amino acid (Figure 
4.15). Analysis of the intron sequences flanking this missing exon identified several 
conserved sequence motifs associated with exon skipping in mammals (Miriami, 
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Margalit et al. 2003). These motifs were predominantly G-rich (AGGG or GGG(A/T)), 
with only a single C-rich (CTCC) motif present. Analysis of the type and position of 
these two motifs in mammalian intron sequences led to the proposal of a consensus 
pattern describing how they are arranged relative to a skipped exon (Miriami, Margalit 
et al. 2003). Complementary motifs appear in the same relative positions to one another 
in flanking introns, e.g. if, in the 5’ direction from an exon there were a G-rich motif at -
20 nt, a C-rich motif at -30 nt, a C-rich motif at -38 nt and a G-rich motif at -55, then in 
the 3’ direction from the same exon you would see a C-rich motif at +20 nt, a G-rich 
motif at +30 nt, a G-rich motif at +38 nt and a C-rich motif at +55 nt. There is some 
leniency with this pattern,so the exact number of complementary motifs and the spacing 
may vary. The motifs in these chicken introns which are all G-rich except for a single 
C-rich motif (Figure 4.15) therefore do not fit this described pattern.  
The SV2 transcript sequence was formed through use of an alternative splice 
acceptor site (AG) within exon 5 located 72 bp from its 5’ end. In contrast to SV1, 
removal of this short stretch of nucleotides did not introduce a frameshift in the 
predicted protein sequence (Figure 4.15).  
Contig 81757.1 also provided sufficient sequence at the 5’ end of the gene to 
clarify how alternative splicing creates the two major structural variants of chIL-1RN. 
The icIL-1RN1 variant in humans is created following alternative splicing of an 
upstream exon into the 3’ end of exon 1 of sIL-1RN, utilising an internal splice acceptor 
site. Analysis of Contig 81757.1 indicated that a similar mechanism takes place in the 
chicken, whereby an upstream exon is used to create the chicken icIL-1RN CDS 
previously identified (Figure 4.18).  
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AGGGCTGGGATGTGAGGGCTGAGCCGTGGTGCGGCGCTGCCAGCAGGACGCCGACATCAC
D  A  D  I  T  
GGAGCTGCCCCGCAGCGGCGCCGCCTCCGCGCCGTTCACCTTCTTCCGCACCTATAAGGA
E  L  P  R  S  G  A  A S  A  P  F  T  F  F R  T  Y  K  D 
CGGGCTGTGGCGCTTCGAGTCGGCCGCCAACCCCGGATGGTTCCTCTGCACCTCCGCCCG
G  L  W  R  F  E  S  A  A N  P  G  W  F  L  C  T  S  A  R  
CGCCCACCAACCCCTGGGGCTCTCCCGGCGCCCCGACGCCGCCCACGTCCTGGATTTCTA
A  H  Q  P  L  G  L  S  R  R P  D  A  A H  V  L  D  F  Y 
CTTCCAGCTGTGCTGAGCCCATCCCCGGGCAATAAAGGCGCTCTGCTCCCCGTTGGGTGG
F  Q  L  C  *
CACCGGCGTCGGTGCGCGGCGTTACCCCACCGCGGCTGACGTGGGTGGTGGGGCTGCCCC
GAAAGGGATGGGCACGGCCCTAAAATGGATGGGCACGGCCCTAAAATGGATGGGCACGGC
CCTAAAATGGATGGGCACGGCCCCGAAAGGGATGGGCACGGCCCCTTCCCGG
Exon 4
3’ end of Intron 4
 
Figure 4.16 Structure of exon/intron 4 of chIL-1RN. Above Splicing that leads to the 
formation of SV2 transcripts is indicated. Intron 4 is usually spliced at the AG splice 
acceptor site (in bold). However, in SV2 it is spliced at an alternative splice acceptor 
site (in blue, arrow indicates splice) within exon 4. The polyadenylation signal 
(AATAAA) downstream of the final exon is underlined.  
Next page Use of the alternative splice acceptor site in exon 4 truncates the amino acid 
sequence compared to that of full-length chIL-1RN. 
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ATGGCGCTCACCATCGCCCTCCTCCTCCTCCACGCA
M  A  L  T  I  A  L  L L L H  A
GAGGCTGCCGGATCGGTGCCGTGCCGCGCGCCCGCG
E  A  A G  S  V  P  C  R  A  P  A
CTGCAAACCAAAGTCTTCAAATACCGGATCTGGGAT
L  Q  T  K  V  F  K  Y  R  I  W  D
ATGAACCAGCAGTCGCTGTACCTGCGCGATGATCAG
M  N  Q  Q S  L  Y  L  R  D  D Q
CTGGTGGCCGGGCACCTGCAGGGCGCCAACGCCGCG
L  V  A  G  H  L  Q  G  A  N  A  A
CTGGAGGAGAAGGTGTTTTGGGTGCCCAACCGCTTC
L  E  E K  V  F  W  V  P  N  R  F
TTCAAGCACGAGCTGCAGCCCGTCATCATGGGCATC
F  K  H  E  L  Q  P  V  I  M  G  I
CGCAACGGCACCCGCTGCCTGGCCTGCCCGGCGGCC
R  N  G  T  R  C  L  A  C  P  A  A
CCACAGCCCACCCTGCAGCTCCAGGACGCCGACATC
P  Q  P  T  L  Q  L  Q
ACGGAGCTGCCCCGCAGCGGCGCCGCCTCCGCGCCG
TTCACCTTCTTCCGCACCTATAAGGACGGGCTGTGG
D  G  L  W
CGCTTCGAGTCGGCCGCCAACCCCGGATGGTTCCTC
R  F  E  S  A  A N  P  G  W  F  L
TGCACCTCCGCCCGCGCCCACCAACCCCTGGGGCTC
C  T  S  A  R  A  H  Q  P  L  G  L
TCCCGGCGCCCCGACGCCGCCCACGTCCTGGATTTC
S  R  R P  D  A  A H  V  L  D  F
TACTTCCAGCTGTGCTGA
Y  F  Q  L  C  *
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Figure 4.17 Agarose gel of PCR products containing introns 1-4 of chIL-1RN. 
Products were amplified with IL-1RN Int1-2L1 and IL-1RN 130R primers (see Fig 
4.13). Lane 1-3 = products amplified from line N genomic DNA in each lane with 
identical thermal cycling conditions except for differing annealing temperatures of 
54.0°C, 52.8°C and 52.0°C respectively. Lane M = 50 bp DNA ladder.  
 
In humans, both first exons of ic and s variants are preceded by large promoters 
of 1680 bp and 1894 bp in length, respectively. Between exon 1 of icIL-1RN and exon 
1 of sIL-1RN is a large intragenic region spanning 9.6 kb (Figure 4.12). In the chicken, 
however, examination of contig 81757.1 shows the genomic organization at the 
corresponding region of chIL-1RN differs markedly from this. Here only 129 bp 
separate the first exons of both variants. Analysis of this sequence using software that 
characterizes promoter sequences identified a TATA box at 40 nt upstream of the sIL-
1RN start codon. This suggests this region may contain a minimal promoter sequence. 
No other known sequence motifs representing defined promoter elements were 
identified here (Figure 4.18). Three potential transcription factor binding sites (Sp1 and 
NF-IL-6 on the forward strand, PU.1 on the complementary strand) were identified 
upstream of the icIL-1RN start codon at -41 (PU.1), -69 (NF-IL-6) and -88 (Sp1). They 
may be part of the promoter controlling the sIL-1RN structural variant (Figure 4.18).  
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GTCGTCCCGGCGATGGACGGCACCCAGGGGCGGGACGTGCGGGCGGTGTGGCAACACTCTGCGCCCTTCCTTCC
TCCCTCCTTCCCCAGGCTCCAGGGCGGGTGGCCTCCATTGGGGCATCTCATGGGTGGTGAGCCGGGGGGCGCCG
M  G   
GGACGGGAAGTGGAACCGGCGGGAGGGGAGTCACGGACAGGGGAGGGGGGGGAGCGAATATAGAGTATAAAGGG
CCCCCCAACCCCGCACCGTGCCCCACAGCCCGCCCCATGGCGCTCACCATCGCCCTCCTCCTCCTCCACGCAGA
M  A  L  T  I  A  L  L L L H  A  E
GGCTGCCGGATCGGTGCCGTGCCGCGCGCCCGCGCTGCAAACCAAAGTCTTCAAATACCGGTAATGGGGTGAGG
A  A G  S  V  P  C  R  A  P  A  L  Q  T  K  V  F  K  Y  R   
GGGGGATATGGGGGGGCTGTATGGGGGGAGCGGGGTGGGCTGTCCGGCACTGCGTCCCTCCGTCCCCCCCGCAG
GATCTGGGATATGAACCAGCAGTCGCTGTACCTGCGCGATGATCAGCTGGTGGCCGGGCACCTGCAGGGCGCCA
ACGCCGCGCTGGAGGGTGAGCGGTCCCTTTAAGGGGCACTGGGAGGGGGGGGGGGACACACACGACACGTGGGG
GGGAGGGCTGATGGTGTGTGTGTGTGTGTCCCCCGCGTACACACAGAGAAGGTGTTTTGGGTGCCCAACCGCTT
CTTCAAGCACGAGCTGCAGCCCGTCATCATGGGCATCCGCAACGGCACCCGCTGCCTGGCCTGCCCGGCGGCCC
CACAGCCCACCCTGCAGCTCCAGGTGGGGCACGGGGGG
sExon 1
icExon 15’UTR
Sp1 NF-IL-6
PU.1
 
Figure 4.18 The 5’ end of the chIL-1RN gene. The locations of the first exons of icIL-
1RN and sIL-1RN transcripts are marked with boxes. To create the icIL-1RN structural 
variant, a splice acceptor site (AG, in bold and underlined) located within the first exon 
of the sIL-1RN transcript is utilised. A TATA box at -40 nt from the sIL-1RN start 
codon indicates a possible minimal promoter. Three potential transcription factor 
binding sites (SP-1 and NF-IL-6 on the forward strand; PU.1 on the complementary 
strand) identified upstream of the icIL-1RN start codon are underlined and labelled 
above and may form part of a possible icIL-1RN promoter.  
 
Further upstream genomic sequence is required for a thorough analysis of the potential 
promoters. 
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4.3.6 Identification of the genomic location 
Nine of the human IL-1 genes (ordered centromere to telomere: IL-1α, IL-1β, 
IL-1F7, IL-1F9, IL-1F6, IL-1F8, IL-1F5, IL-1F10 and IL-1RN) are located in a cluster 
on human chromosome 2, with IL-18 (chromosome 11) and IL-1F11 (chromosome 9) 
located elsewhere in the genome. According to the chicken genome (v2.1), the chIL-1β 
gene is encoded on chromosome 22 at a locus that possesses limited conserved synteny 
with the human IL-1 gene cluster on chromosome 2 (Chapter 3, Figure 3.1). The avian 
orthologues of two genes (SLC20A1 and CKAP2L) that flank the human IL-1 gene 
cluster are located adjacent to chicken IL-1β, but no other genes are shared by the two 
loci. A TBLASTN search of this version of the chicken genome with both chIL-1RN 
amino acid sequence variants did not identify any positive hits. As this gene is present 
in the IL-1 gene cluster on human chromosome 2, it indicated that the present assembly 
of the chicken genome does not contain such an obvious locus containing multiple IL-1 
family genes. A TBLASTN analysis of the chicken genome (v3.0, unassembled) with 
both full length chIL-1RN amino acid sequence variants identified two contigs (I.Ds: 
81757.1 and 113837.1) containing the majority of the coding sequence as well as novel 
sequence flanking the first and final exons. These contigs, however, were mined from 
“removed data” sequence reads and are thus unplaced in the assembled genome; as 
such, the genomic location of chIL-1RN remains unknown.  
Close examination of the locus containing chIL-1β in build v.2.1 revealed the 
presence of four sequence gaps immediately adjacent to the 5′ end of the gene. The sizes 
of sequence gaps in the v2.1 genome build are only estimated as 489, 100, 445 and 98 
bp in length, respectively. The presence of further chIL-1 family genes in these gaps 
was investigated by PCR using a BAC, TAM32-21N6, which covers the entire region, 
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as template. To confirm specific amplification in the region covered by BAC TAM32-
21N6, a control PCR to amplify chIL-1β using this template was included. Positive 
control PCRs were also set up to amplify chIL-1β and chIL-1RN using genomic DNA 
from line 0, 72 & 15I chickens, using the same primer pairs. The results confirmed the 
presence of chIL-1β at this locus but chIL-1RN did not amplify, suggesting it is 
encoded elsewhere (Figure 4.19). A further BLASTN analysis of the v3.0 chicken 
genome build using the original 8.8 kb of sequence from v2.1, including these gaps, was 
carried out (Figure 4.20). This indicated 1147 bp of this region has been assigned to a 
contig in v3.0 but the remainder has yet to be assembled and is spread across numerous 
short contigs in the “removed data” (results not shown). It is not clear from this BLAST 
search, therefore, whether these sequence gaps will also be present in the third build of 
the genome.  
Following confirmation by PCR that the chIL-1RN gene does not lie adjacent to 
that encoding IL-1β, a BAC library representing the Red Jungle Fowl genome was 
screened with a 
32
P-labelled 420 bp icIL-1RN SV2 CDS clone. No positive clones were 
identified. This experiment was repeated using the full length 492 bp icIL-1RN CDS as 
a probe, again without success.  
 
4.3.7 Characterization of the 5’ untranslated regions (5′ UTRs) of icIL-1RN 
and sIL-1RN cDNA sequences 
Attempts were made to determine the 5′ UTRs of both chIL-1RN structural variants 
using 5′ RACE, to accurately determine the exact sizes of both secretory and 
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IL-1RN255
Line 0 Line 72 Line 15I BAC
IL-1β330
bp
 
Figure 4.19 Agarose gel electrophoresis of IL-1β and IL-1RN PCR products in 
lines 72, 15I & 0 genomic DNA and TAM32-21N6 BAC DNA. Examination of the 
locus containing chIL-1β shows four sequence gaps are present immediately adjacent to 
the 5’ end of the gene. The gaps were examined for further chIL-1 family genes by PCR 
using purified TAM32-21N6 bacterial artificial chromosome (BAC) clone DNA, which 
covers the entire region. To confirm specific amplification in the region covered by the 
BAC, a control PCR to amplify chIL-1β using this template was included. Positive 
control PCRs were set up to amplify chIL-1β and chIL-1RN in lines 0, 72 & 15I 
genomic DNA, using the same primer pairs as for the BAC DNA PCRs.  
 
 
 
Contig 112.4
Contig 112.3
Contig 112.2 Contig 112.1
Contig 2297.1
~8.8 kb
Sequence gaps:      489 bp                   100 bp                    445 bp                                      89 bp
chIL-1β
 
Figure 4.20 Diagram of the locus on chicken chromosome 22 (v2.1) containing IL-
1β and 4 adjacent sequence gaps. Estimated sizes of these gaps are indicated. Blue 
blocks denote contigs of known sequence. The black box denotes the location of chIL-
1β. The red line indicates coverage of the sequence used to perform a BLASTN search 
against v3.0 of the unassembled chicken genome sequence reads.  
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intracellular first exons and to establish how much of the 129 bp separating these exons 
was 5′ UTR, as this could clarify if this region contains a promoter. Prior sequencing of 
s and ic coding regions revealed that only a very short amount of both 5′ ends does not 
align. The first 36 bp of sIL-1RN and first 6 bp of icIL-1RN are dissimilar, after which 
the transcripts are identical. Therefore uncovering further unaligned 5′ end sequence 
could provide sufficiently large regions to which variant-specific TaqMan primers and 
probes could be designed.  
A pair of gene-specific primers was designed to amplify a product spanning part 
of exons 2-4 of the chIL-1RN coding sequence. The reverse primer was used to PCR 
amplify the 5′ UTR, whilst the forward primer created a 219 bp amplicon with the 
reverse that acted as a positive control to ensure the target transcript was present in the 
cDNA template. Using RNA from LPS-stimulated HD11 cells as template, the icIL-
1RN 5′ UTR was amplified along with the positive control. Agarose gel electrophoresis 
of the PCR products revealed two bands, a larger band at ~ 480 bp and a smaller band at 
~ 430 bp (Figure 4.21). Both bands were gel purified and TA-cloned into the pTarget 
mammalian expression vector; clones were screened by EcoRI restriction digestion and 
sequenced. Sequencing revealed both bands were icIL-1RN clones, with the smaller of 
the two corresponding to the icIL-1RN SV1 transcript previously identified. The 
chicken icIL-1RN 5′ UTR was found to be 50 bp in length. This novel sequence was 
absent in all chIL-1 EST sequences mined from NCBI. By comparison, the 5′ UTR of 
both human icIL-1RN1 and RN2 transcripts is longer at 122 bp. The PCR was repeated 
to attempt to elucidate the 5’ UTR of the sIL-1RN transcript. To ensure the RACE PCR 
template contained this transcript, an RT-PCR using the total RNA isolated from LPS-
stimulated HD11 cells was carried out in advance. The same primers and conditions  
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Figure 4.21 Agarose gel electrophoresis of 5′ RACE PCR products. cDNA was 
made from RNA from LPS-stimulated HD11 cells using Superscript II reverse 
transcriptase. PCR was carried out to amplify the 5′ UTR of chIL-1RN using gene-
specific primers. M = 100 bp DNA ladder; T = test reaction. The 5′ UTR of chicken 
icIL-1RN was amplified with the universal forward primer and the gene- specific 
reverse primer. C = positive control reaction to ensure the target transcript was present 
in the template used to make cDNA. ChIL-1RN was amplified from the cDNA template 
using a pair of gene-specific primers. N = negative control. The PCR set up for this 
reaction was identical to the test reaction except for the absence of the universal primer. 
 
used to previously amplify the full length sIL-1RN coding region cDNA were used 
again, confirming this mRNA was present in the sample (Figure 4.22). Despite this, I 
was unable to subsequently amplify this 5′ UTR, as this particular RACE PCR appears 
to always preferentially amplify the icIL-1RN variant. 
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Figure 4.22 Agarose gel electrophoresis of sIL-1RN RT-PCR products. For the 5′ 
RACE PCRs, cDNA was made from RNA from LPS-stimulated HD11 cells. Repeated 
attempts were unable to amplify the sIL-1RN 5′ UTR using this template. To ensure the 
RACE PCR template contained the sIL-1RN transcript, RT-PCR using the total RNA 
isolated from HD11 cells was carried out in advance of cDNA synthesis. The same 
primers and thermal cycling conditions used to amplify the full length sIL-1RN coding 
region cDNA were used. M = 100 bp DNA ladder.  
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4.4 Discussion 
The genomes of many eukaryotic species contain a pair of genes, IL-1α and IL-
1β, whose proteins are responsible for multiple immune activities. Of these, their ability 
to induce inflammation has been the focus of most research efforts to characterise their 
biology. A naturally occurring receptor antagonist, IL-1RN, inhibits the bioactivity of 
IL-1α and IL-1β through cell surface receptor blocking. Subsequently identified 
isoforms act intracellularly to limit inflammation. The gene for IL-1RN has been found 
in many mammalian species and for years was considered to have arisen following gene 
duplication in the mammalian lineage.  
In this Chapter, the identification and characterization of both secretory and 
intracellular variants of interleukin-1 receptor antagonist in the chicken is described. 
Whilst obvious similarities between the chicken gene and its mammalian orthologues 
exist, a number of notable differences were identified. 
Given the potency of IL-1β in immune responses, its regulation by IL-1RN is 
essential to avoid possible physical damage to the host organism. Humans either lacking 
or possessing mutations in the IL-1RN gene can die prematurely in the absence of 
treatment with synthetic IL-1RN (Aksentijevich, Masters et al. 2009). Following the 
identification of IL-1β in the chicken (Weining, Sick et al. 1998), it was therefore likely 
that IL-1RN would also be present. The conserved locus containing chIL-1β exhibits 
limited synteny with the human IL-1 gene locus but lacks any further IL-1 genes. 
TBLASTN analyses of the chicken genome with the chIL-1β amino acid sequence did 
not reveal any further IL-1 gene loci. Using the chIL-1β amino acid sequence, the NCBI 
databases were mined for ESTs encoding apparent novel chicken IL-1 genes. Using the 
predicted amino acid sequences of the ESTs, TBLASTN analysis identified them as the 
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chicken orthologue of IL-1RN. Further analysis of two IL-1RN ESTs differing at the 5’ 
end identified both secretory and intracellular variants of the gene. Chicken sIL-1RN 
contains a predicted 17 amino acid signal peptide and is presumably secreted by the 
endoplasmic reticulum/golgi secretory pathway (Eisenberg, Evans et al. 1990; Walter 
and Johnson 1994). A relatively high degree of amino acid identity between the 
predicted chIL-1RNs and mammalian homologues was found. Further in silico analyses 
confirmed both chicken sequences are genuine IL-1 family members. Phylogenetic 
analysis was able to confirm they are distantly related to mammalian IL-1RN.  
As both structural variants of human IL-1RN are expressed by macrophages 
(Arend, Malyak et al. 1998), RNA from LPS-stimulated HD11 cells (a macrophage-like 
cell line) was used to amplify full length chicken sIL-1RN and icIL-1RN CDS 
sequences. Two additional splice variants of both, designated SV1 and SV2, were 
identified upon examination of the resulting RT-PCR products. Both SV1 transcripts 
appear to be formed following exon skipping, whilst the SV2s utilise an alternative 
splice acceptor site in the final exon of the gene. A number of conserved sequence 
motifs synonymous with exon skipping (Miriami, Margalit et al. 2003) were identified 
in the introns adjacent to the spliced exon in SV1, although their relative locations and 
abundance did not conform to the described patterns found in mammalian introns. This 
exon skipping event caused the predicted amino acid sequence to change reading frame, 
introducing a premature stop codon, significantly truncating the molecule. Although the 
predicted SV2 amino acid sequences are in frame, potentially important residues 
corresponding to two β-sheets of the secondary structure have been removed by this 
splicing event. As yet, there are no reports of truncated splice variants of IL-1RN in 
mammals, suggesting a novel mechanism of regulating this gene has been found. 
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Alternatively, chIL-1RN may be prone to introducing splicing errors at the pre-mRNA 
stage.  
Attempts to determine the genomic location of chIL-1RN were unsuccessful. 
Despite this, the identification on chromosome 22 of an IL-1 gene locus sheds new light 
on what is known regarding the evolution of this cytokine gene family. Firstly, the 
existence of IL-1RN in the chicken (in addition to IL-1β) supports Eisenberg, Brewer et 
al. (1991) who predicted IL-1RN and IL-1β evolved from a common ancestral gene 
~350 million years ago. It is believed that the chicken and human have evolved 
separately for ~310 million years (Hedges, Parker et al. 1996). Results obtained in this 
study, however, do not support a straightforward explanation of IL-1 gene family 
evolution from a common ancestor. BLAST data confirmed both chicken gene variants 
are unquestionably IL-1 receptor antagonists. This was supported by clear evidence of 
secretory and intracellular variants and structural similarity with the human gene. 
However, chIL-1RN did not group with the orthologous mammalian genes in 
phylogenetic analysis. There are several hypotheses to explain this. It is possible that 
chIL-1RN and mammalian IL-1RN emerged by species-specific convergent evolution. 
Alternatively, the IL-1RNs evolved from a common ancestor followed by sequence, and 
possibly functional, divergence in the avian lineage. Although either is possible, I 
believe the latter is most likely given the number of structural similarities between the 
chicken and human genes. Cytokine genes are under extreme selective pressure and 
tend to evolve rapidly, so it is not surprising that avian cytokines exhibit limited 
sequence homology with mammalian equivalents. This has been a fundamental 
stumbling block to finding novel chicken cytokine orthologues, and as such, progress 
has been slow in this area compared to mammals (Kaiser, Poh et al. 2005). I therefore 
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believe the phylogenetic analysis reflects substantial sequence divergence in the genuine 
avian IL-1RN orthologue rather than the identification of a novel avian IL-1F gene.  
The presence of IL-1RN in the chicken at a location elsewhere from IL-1β 
suggests the evolution of the nine gene IL-1 cluster took place before the diversification 
of birds and mammals. An alternative hypothesis of differential gene loss within 
different species may also explain how IL-1RN has arisen at discordant loci in humans 
and chickens. Assuming the three human IL-1 loci constitute regions of the genome 
containing paralogous genes, their origins could be traced to a single ancestral locus 
which underwent duplication. This ancient locus could have contained both IL-1β and 
IL-1RN, which upon subsequent genome duplication formed several paralogous IL-1 
loci each encoding a copy of both genes. Additional duplications in the human genome 
may have expanded the size of the IL-1 gene family at one locus, whilst the other may 
have contracted, conceivably leaving only IL-33. In the chicken, one locus could have 
lost IL-1RN, whilst retaining IL-1β; with the opposite scenario taking place at a second 
locus.  
It is interesting to observe that whilst the IL-1 locus in the chicken has become 
fragmented, it has remained relatively intact in most mammalian species for >300 
million years. It would be interesting to investigate whether the human IL-1 locus has 
remained intact through genetic linkage. Additionally, the locus may also be under a 
degree of global regulation, such as that provided by an upstream locus control region.  
In either instance, the chicken presumably lacks any equivalent linkage or control 
mechanisms affecting its IL-1 ligand genes.  
Elucidation of the chIL-1RN gene structure provided an interesting insight into 
how its regulation may differ from its mammalian orthologue. The expression of human 
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sIL-1RN is controlled by a 1680 bp promoter; however, the anticipated location of an 
equivalent promoter in the chicken, between exon 1 of sIL-1RN and exon 1 of icIL-
1RN, was only 129 bp in length. A TATA box at -40 nt from the chicken sIL-1RN start 
codon suggested this variant may be driven by a minimal promoter sequence with a 
maximum length of 89 nt. No other known sequence motifs representing defined 
promoter elements were identified within this 89 nt region, suggesting different 
potential mechanisms for regulation of this chIL-1RN variant. Firstly, the human sIL-
1RN promoter contains three LPS responsive elements (LRE) comprised of NF-κB and 
PU.1 binding sites. These are completely absent between the TATA box and exon 1 of 
icIL-1RN in the chicken sequence. This sequence may not actually represent a promoter 
and chIL-1RN may, in fact, have evolved a different regulatory mechanism whereby 
both variants are controlled by a single promoter preceding exon 1 of icIL-1RN. The 
TATA box could, thus, be the remnants of where a promoter used to be. Alternatively, 
chicken sIL-1RN may only require a very short minimal promoter and may not, in 
contrast to mammals, need LREs to respond to LPS stimulation. Analysis of regulatory 
elements upstream of the icIL-1RN start codon identified three potential transcription 
factor binding sites (Sp1 and NF-IL-6 on the forward strand; PU.1 on the 
complementary strand) suggestive of a promoter sequence (Figure 4.18). Both Sp1 and 
NF-IL-6 binding sites were identified within the human icIL-1RN promoter (Jenkins, 
Drong et al. 1997). Further upstream genomic sequence is required for a thorough 
analysis of the potential promoter. It remains to be determined if this region only 
controls icIL-1RN transcripts or is also able to direct transcription of the sIL-1RN 
structural variant. In mammals, sIL-1RN and icIL-1RN expression are independently 
driven by separate promoters located proximally to their transcripts’ first exons (see 
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Figure 4.12). It will be interesting to determine if chIL-1RN has evolved to 
accommodate a more promiscuous promoter. Interestingly, IL-1α is an important 
regulator of icIL-1RN transcription in mouse keratinocytes (La, 2001). C/EBP and NF-
κB binding sites are essential for the modulation of this function. A chicken IL-1α gene 
has yet to be identified, and neither C/EBP nor NF-κB response elements are located in 
the first 123 bp upstream of the icIL-1RN start codon. Once the full genome sequence 
upstream of chIL-1RN is available, potential promoter regions could be cloned and 
functionally characterized in a reporter gene assay.  
Further analysis of the chIL-1RN gene structure indicated the chicken may 
possess a relatively limited repertoire of IL-1RN protein isoforms compared to humans. 
Chicken icIL-1RN is most similar to human icIL-1RN1, containing a single upstream 
exon spliced into the 5’ end of the sIL-1RN mRNA. Human icIL-1RN2 contains a 
further upstream exon spliced in between exons 1 and 2 of icIL-1RN1. This exon in the 
huIL-1RN gene is located between the first exons for icIL-1RN1 and sIL-1RN, but 
there is no equivalent in the chicken. This suggests the existence of a chicken icIL-
1RN2-like transcript is unlikely. Human icIL-1RN3 is formed through use of an 
alternative translation initiation site within exon 1 of the sIL-1RN transcript. Amino 
acid alignments between the chicken and human show the chicken sequence contains a 
methionine separated by 7 residues from the icIL-1RN3 initiation site in the human 
sequence. At present, there is no evidence that a chicken icIL-1RN3 isoform exists. 
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5.1 Introduction 
Inflammation is an important process which forms part of an organism’s 
response to restrict the impact of invading pathogens in order to maintain homeostasis. 
IL-1α and IL-1β are two examples of cytokines that induce inflammation by priming the 
innate immune response (Dinarello 2009). Their functional effects are exerted through a 
common, shared receptor, IL-1 receptor I (IL-1RI). In excess and without regulation, 
inflammation mediated by IL-1α and IL-1β can cause significant damage to the host. 
Their production at both mRNA and protein levels is therefore precisely controlled. In 
addition to this, a naturally occurring antagonist, IL-1 receptor antagonist (IL-1RN), 
acts to reduce IL-1 effects by physically occupying the IL-1RI (Carter, Deibel et al. 
1990; Eisenberg, Evans et al. 1990; Hannum, Wilcox et al. 1990). This prevents signal 
transduction (Dripps, Brandhuber et al. 1991) and consequently gene transcription, as 
IL-1RN lacks the specific amino acids required to engage IL-1RAcP on the cell surface 
(Schreuder, Tardif et al. 1997; Wang, Zhang et al. 2010). The only apparent function of 
IL-1RN is to limit inflammation. It does not act as an agonist, as demonstrated by the 
lack of a response observed after administering humans with a million-fold excess (over 
IL-1 α and IL-1β) of IL-1RN (Dinarello 1996).  
In mammals, there are two major structural variants of IL-1RN – secretory (sIL-
1RN) (Eisenberg, Evans et al. 1990) and intracellular (icIL-1RN). Alternative splicing 
of the IL-1RN gene gives rise to three protein isoforms of icIL-1RN in humans (Haskill, 
Martin et al. 1991; Muzio, Polentarutti et al. 1995; Malyak, Guthridge et al. 1998). The 
biological activity of IL-1RN has been quantified using a number of different methods. 
The first study to demonstrate IL-1RI-specific binding by sIL-1RN showed both 
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recombinant and native forms inhibited the binding of 
125
I-labelled IL-1α to EL4-6.1 
cells, a murine thymoma cell line which is responsive to IL-1 stimulation (Hannum, 
Wilcox et al. 1990). An alternative bioassay was subsequently described, showing sIL-
1RN inhibited IL-1α and IL-1β-mediated proliferation of PHA-stimulated murine 
thymocytes (Arend, Welgus et al. 1990). Characterisation of icIL-1RN1 bioactivity was 
based on the same principal (IL-1RI blocking), and showed this protein inhibited IL-1β-
mediated IL-2 production from the LBRM-33-1A5 murine thymoma cell line (Haskill, 
Martin et al. 1991). Recombinant icIL-1RN1 was expressed in COS-7 cells and both 
supernatants and lysates were tested in the assay. Results showed significantly more 
activity in the lysate, confirming this protein was a genuine intracellular isoform. The 
second major icIL-1RN isoform to be discovered (icIL-1RN2) inhibited the IL-1β-
mediated expression of E-selectin on cultured endothelial cells (Muzio, Polentarutti et 
al. 1995). As with icIL-1RN1, this cDNA was expressed in COS-7 cells with the 
majority of the protein found in the lysate. Of note, this protein has never been detected 
in vivo (Arend, Malyak et al. 1998; Arend, Palmer et al. 2008) beyond the original paper 
describing its discovery. Finally, the bioactivity of icIL-1RN3 (referred to as IL-1RaII 
in the paper) was established (Malyak, Guthridge et al. 1998) using the identical murine 
thymocyte proliferation assay previously described (Arend, Welgus et al. 1990).  
Whilst the biological role of sIL-1RN appears to be limited to the blocking of 
IL-1RI on the cell surface, the icIL-1RN isoforms seem to function through any of three 
possible mechanisms. Firstly, icIL-1RN may exert intracellular effects in a non-classical 
(non-IL-1R-dependent) manner. For instance, when keratinocytes are cultured in the 
presence of IL-1α, icIL-1RN1 binds to the third component of the COP9 signalosome, 
an important protein kinase involved in signal transduction. This causes inhibition of 
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downstream pro-inflammatory cytokine production (Banda, Guthridge et al. 2005). 
Secondly, icIL-1RN1 may act within the nucleus to inhibit the effects of IL-1α. Briefly, 
either full length IL-1α (preIL-1α) or its N-terminal propiece (NIL-1α) increased the 
motility of ECV304 cells, a human endothelial cell line, following stable transfection. 
This effect was significantly attenuated when icIL-1RN was co-expressed with either 
(Merhi-Soussi, Berti et al. 2005). Thirdly, icIL-1RN isoforms may be released from 
cells and act in a similar way to sIL-1RN by antagonising membrane-bound IL-1RI 
(Corradi, Franzi et al. 1995; Levine, Wu et al. 1997; Yoon, Zhu et al. 1999; Evans, 
Dower et al. 2006). 
The expression of IL-1RN has been studied in substantial depth in humans and 
mice and also in other mammals, although less thoroughly. Interestingly, although sIL-
1RN mRNA has been predicted to be expressed in any cells able to transcribe IL-1α and 
IL-1β (Arend, Malyak et al. 1998), a global assessment of its expression in humans has 
never been carried out. The vast majority of studies have focussed on its expression in 
monocytes, macrophages, neutrophils and fibroblasts (Arend, Malyak et al. 1998). The 
expression of mammalian icIL-1RN is highly restricted, being found in only a narrow 
range of cell types. The icIL-1RN1 protein is predominantly found in endothelial cells, 
epithelial cells, fibroblasts, keratinocytes, and macrophages (Arend, Palmer et al. 2008), 
whereas icIL-1RN3 is mainly found in neutrophils, PBMCs (Malyak, Smith et al. 1998) 
and hepatocytes (Arend, Palmer et al. 2008). Although its expression in vivo has never 
been reported beyond the original study, icIL-1RN2 transcripts were detected in 
fibroblasts, keratinocytes, monocytes and polymorphonuclear cells (Muzio, Polentarutti 
et al. 1995).  
The only published studies to date investigating global IL-1RN expression were 
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carried out in rabbits (Apostolopoulos, Ross et al. 1996; Matsukawa, Fukumoto et al. 
1997) and mice (Gabay, Porter et al. 1997). Expression of sIL-1RN was constitutive in 
all nine tissues analysed in rabbits, with expression of icIL-1RN found in only caecum, 
kidney, skin and thymus (Matsukawa, Fukumoto et al. 1997). In mice, expression of IL-
1RN was not ubiquitous, with sIL-1RN undetectable in unstimulated tissues and icIL-
1RN only expressed in skin. LPS stimulation of the same tissues induced sIL-1RN 
expression in liver, lung and spleen and increased the amount of icIL-1RN expression in 
skin (Gabay, Porter et al. 1997). This study used a ribonuclease protection assay to 
quantify expression levels and so may have lacked the degree of sensitivity obtained 
with real-time qRT-PCR. Although the data were not shown, icIL-1RN transcripts were 
also amplified by RT-PCR in kidney, liver and spleen tissues stimulated with LPS 
(Gabay, Porter et al. 1997). Expression of a novel IL-1F gene (IL-1RN-like) was 
quantified by real-time qRT-PCR in rainbow trout and was constitutive in the eight 
tissues examined (Wang, Bird et al. 2009).  
An enormous number of different agents induce IL-1RN expression with LPS, 
adherent IgG and the cytokines GM-CSF and IL-4 the most effective substances in vitro 
(Arend, Malyak et al. 1998). A similarly broad number of agents induce IL-1RN 
production in vivo. These include virtually all known bacteria and viruses, many fungi, 
as well as numerous cytokines, enzymes and plasma proteins (Dinarello 1996). IL-1RN 
protein levels also increase in many disease states including autoinflammation, 
autoimmunity, allergies, and injury (amongst others) (Arend, Malyak et al. 1998).  
Of the many agents known to increase IL-1RN expression, the response to LPS-
stimulation is the most comprehensively understood. In particular, the kinetics of IL-
1RN expression in vitro has been resolved in detail. After LPS stimulation, human 
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blood monocytes rapidly express sIL-1RN, with protein apparent in the Golgi around 4-
6 h later as transcript levels begin to decline. After 12 h, icIL-1RN expression starts to 
increase, becoming the predominant transcript by 24 h (Dinarello 1996). In monocytes 
and macrophages stimulated with LPS for a sustained period, tolerance develops 
leading to decreased cytokine production upon subsequent stimulation. Unlike certain 
cytokines, such as IL-10 and TNFα whose levels decline, the expression of IL-1RN 
remains unaffected, continuing to increase in response to endotoxin challenge (Randow, 
Syrbe et al. 1995). 
The differential expression of IL-1RN and IL-1β has also been examined in 
LPS-stimulated leukocytes. In freshly isolated monocytes, mRNA and protein levels of 
both IL-1RN and IL-1β are almost identical following LPS stimulation. Following in 
vitro differentiation into macrophages, relative mRNA expression levels alter markedly 
in these cells. Increased constitutive expression of IL-1RN is observed; however, IL-1β 
expression is lower both constitutively and after LPS stimulation (Arend, Smith et al. 
1991).   
In this Chapter, thorough analyses of both chIL-1RN expression and biological 
activity are described. 
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5.2 Methods 
5.2.1 Sources of chicken tissues and cells 
All chicken tissues and cells were acquired, sorted and stimulated as described 
in Chapter 2, section 2.4.1.1. Tissues and cells were acquired from SPF chickens 
challenged with bacteria or virus as described in Chapter 2, section 2.4.1.2.  
5.2.2 HD11 time course stimulation 
HD11 cells were routinely cultured as described in Chapter 2, section 2.4.12.1 
and 2.4.12.2. Cells were stimulated with LPS as described in Chapter 2, section 2.4.16.  
5.2.3 Transfecting cells with pure chicken DNA 
5.2.3.1 Transient protein expression in COS-7 cells 
COS-7 cells were transiently transfected by the DEAE/dextran method with 
endotoxin-free chicken sIL-1RN SV1, sIL-1RN SV2, icIL-1RN, icIL-1RN SV1 and 
icIL-1RN SV2 clones (in pTargeT) and pCI-neo (lacking an insert) as described in 
Chapter 2, section 2.4.12.3.1. COS cell lysates were generated as described in Chapter 
2, section 2.4.12.3.1. 
5.2.3.2 Transient protein expression in HEK293T cells 
HEK293T cells were transiently transfected with endotoxin-free chicken mature 
sIL-1RNpHLSec and icIL-1RNpHLSec clones as described in Chapter 2, section 
2.4.12.3.2. 
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5.2.4 Purification and analysis of HIS-tagged recombinant proteins 
Recombinant mature sIL-1RNpHLSec and icIL-1RNpHLSec proteins were 
purified from crude HEK293T culture supernatants under native conditions as described 
in Chapter 2, section 2.4.13.1. Proteins were analysed by SDS-PAGE and Western 
blotting as described in Chapter 2, sections 2.4.14.1 and 2.4.14.2. Pure proteins were 
quantified using the Bradford assay. Briefly, a series of protein standards (0, 250, 500, 
750 and 1500 µg BSA/ml) in 0.15 M NaOH (both Sigma) and a 10-fold serial dilution 
series of the chIL-1 proteins were generated. To a 100 µl aliquot of each of the standard 
and test samples, 5 µl of Coomassie Brilliant Blue (Bio-rad) were added, mixed, and the 
absorbance measured at 595 nm. ChIL-1 protein concentrations were calculated from 
the standard curve.  
5.2.5 HD11 bioassay 
5.2.5.1 Pilot assay set up 
To determine the suitability of the HD11 cell line for characterisation of chIL-
1RN bioactivity, a pilot study was carried out, testing the ability of the cell line to 
respond to stimulation with chIL-1β as described in Chapter 2, section 2.4.15.1.  
The optimal concentration of recombinant chicken IL-1β (rchIL-1β) (AMSBio) 
to use in “test” assays was determined. HD11 cells were seeded in a 24-well plate at 
1x10
6
 cells/well. The cells were stimulated with a double dilution series of rchIL-1β 
(range: 166.6-5.21 ng/ml) and cultured overnight at 41°C, 5% CO2. The next day, 
culture media was tested for nitrite using the Griess reaction as outlined in Chapter 2, 
section 2.4.15.2.1.  
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To test the ability of rchIL-1β (AMSBio) to stimulate HD11 cells and sustain IL-
1β mRNA levels for 24 h, seven T25 flasks of HD11 cells were seeded at 2x106/flask 
and cultured overnight at 41°C, 5% CO2. The next day, culture media were replaced 
with fresh media containing 200 ng/ml LPS and cells were stimulated for 0, 1, 2, 4, 8, 
12 and 24 h. At each time-point, cells were lysed with 600 µl RLT buffer (Qiagen) and 
lysates frozen at -80°C.  
5.2.5.2 Final bioassay conditions 
Optimal bioassay conditions were determined empirically and all assays 
described in this Chapter were carried out under these conditions as outlined in Chapter 
2, section 2.4.15.3.2. 
5.2.5.3 Quantifying the biological response 
The concentration of nitrites (NO2
-
) was measured in HD11 culture supernatants 
by the Griess reaction as outlined in Chapter 2, section 2.4.15.2.1. IL-1β and iNOS 
mRNA levels were quantified by TaqMan® as described in Chapter 2, sections 2.4.4.6 
and 2.4.15.3.2 and this Chapter, section 5.2.6. Primer and probe sequences are provided 
in Appendix II. 
5.2.6 Total RNA isolation and real-time qRT-PCR (TaqMan®) analysis of 
chicken mRNA expression 
RNA was extracted from the tissues and cells used in this Chapter as described 
in Chapter 2, sections 2.4.2.1 and 2.4.2.2.  
Primers and probes to detect expression of IL-1β, iNOS and 28S were designed 
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using Primer Express (Applied Biosystems) as described in Chapter 2, section 2.4.4.6. 
For chIL-1RN, it was not possible to design TaqMan® assays with sufficiently long 
amplicons to distinguish between each of the 6 identified variants. This was due to a 
combination of the GC-rich nature of chIL-1RN transcripts and the stringent primer and 
probe design parameters. Three different TaqMan® primer/probe sets were designed to 
detect expression of full-length (IL-1RNfl), splice variant 1 (IL-1RNSV1) and splice 
variant 2 (IL-1RNSV2) transcripts. Standard probes labelled at the 5’end with 5- or 6-
carboxyfluorescein (FAM) fluorophore, and at the 3’end with tetramethylrhodamine 
(TAMRA) quencher dye were used to detect IL-1RNfl expression. Probes used to detect 
IL-1RNSV1 and IL-1RNSV2 transcripts were labelled with FAM at the 5’ end and 
dihydrocyclopyrroloindole tripeptide minor groove binder (MGB) at the 3’ end. Assays 
were performed as described in Chapter 2, section 2.4.4.6.  
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5.3 Results 
5.3.1 Analysis of IL-1RN mRNA expression in unstimulated tissues by real-
time qRT-PCR  
The expression of IL-1RNfl mRNA was determined in a broad range of chicken 
tissues by qRT-PCR (Figure 5.1). Expression of full-length IL-1RN was ubiquitous, 
with highest levels in lymphoid tissues in the bone marrow and blood. These findings 
are consistent with IL-1RN production in mammals which is highest in monocytes and 
macrophages (Arend, Malyak et al. 1998). In non-lymphoid tissues, expression was 
highest in brain and lung. Constitutive expression of IL-1RN has been detected in rat 
brain (van Dam, Poole et al. 1998) and human bronchial epithelial cells (Coulter, 
Wewers et al. 1999). 
5.3.2 Analysis of IL-1RN mRNA expression by real-time qRT-PCR in sorted 
lymphocyte subsets  
Constitutive expression of IL-1RNfl was detected in the entire cell panel. Of the 
20 different populations investigated, KUL01
+
 cells (macrophages) and blood-derived 
monocytes (with or without LPS stimulation) showed the highest expression levels 
(Figure 5.2). Stimulation of several cell subsets with LPS did not lead to an increase in 
expression levels except in the monocyte population. In bone marrow-derived dendritic 
cells (BM-DC) and bone marrow-derived macrophages (BM-MØ), LPS stimulation 
decreased expression levels of IL-1RNfl. LPS-stimulation had no effect on expression 
levels in heterophils. 
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Figure 5.1 IL-1RNfl expression in lymphoid and non-lymphoid tissues as measured 
by real-time qRT-PCR. Results are expressed as corrected 40-Ct +SEM of three 
replicates from a single sample. Lymphoid: 1, bursa of Fabricius; 2, caecal tonsil; 3, 
Meckel’s diverticulum; 4, spleen; 5, thymus; 6, Harderian gland; 7, bone marrow; 8, 
blood; Non-lymphoid: a, lower gastrointestinal tract (GIT); b, mid-GIT; c, upper GIT; 
d, kidney; e, lung; f, heart; g, muscle; h, brain; i, skin; j, caecal wall; k, liver.  
 
5.3.3 Analysis of IL-1RN mRNA expression across a time course in three 
different populations of stimulated macrophages  
To gain an understanding of IL-1RN mRNA expression across a time course, 
three different populations of macrophages were stimulated in culture. Expression was 
assessed in in vitro cultured HD11 cells stimulated with LPS from 0-24 h. Expression 
was also measured in two ex vivo populations, bone marrow-derived macrophages (BM- 
MØ) and blood monocyte-derived macrophages (Mo-MØ), stimulated with LPS or 
CD40L for 1-48 h. 
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Figure 5.2 IL-1RNfl expression in sorted chicken lymphocyte subsets as measured 
by real-time qRT-PCR. Results are expressed as corrected 40-Ct +SEM of three 
replicates from a single sample. Bars represent expression in: 1, splenocytes; 2, bursal 
cells; 3, PMA-stimulated bursal cells; 4, thymocytes; 5, CD4+ cells; 6, CD8α+ cells; 7, 
CD8β+ cells; 8, TCR1+ cells; 9, TCR2+ cells; 10, TCR3+ cells; 11, Bu-1+ cells; 12, 
KULO1+ cells; 13, BM-DC; 14, LPS-stimulated BM-DC; 15, BM-MФ; 16, LPS-
stimulated BM-MФ; 17, blood-derived monocytes; 18, LPS-stimulated blood-derived 
monocytes; 19, heterophils; 20, LPS-stimulated heterophils. 
 
In the HD11 macrophage cell line, full length IL-1RN (IL-1RNfl) expression 
remained constant from 0-24 h (Figure 5.3), seemingly unaffected by the presence of 
LPS at any of the time-points investigated. At 48 h post-stimulation (hps), substantial 
cell death had occurred (data not shown), effectively ending the assay. By contrast, the 
expression of IL-1β in the same cells was significantly affected by LPS, increasing by 
>300-fold after 1 hps. Expression remained constant from 1-12 hps, and began to 
noticeably decrease by 24 hps.  
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Figure 5.3 Expression of IL-1RNfl, IL-1RNSV1 and IL-1β in the HD11 macrophage 
cell line following stimulation with LPS as measured by real-time qRT-PCR. 
Results are expressed as corrected 40-Ct ± SEM of three samples from single flasks. 
 
In primary BM-MØ stimulated with LPS or CD40L, IL-1RNfl expression did not 
significantly increase when compared with unstimulated controls over the entire 48 h 
period (Figure 5.4). IL-1RN splice variant 1 expression (IL-1RNSV1), whilst relatively 
lower at all of the time-points, exhibited a similar expression profile to IL-1RNfl (Figure 
5.5). At 2 hps, IL-1RNSV1 expression in both LPS-stimulated and CD40L-stimulated 
cells was >2-fold greater than control cells; however, this difference was not statistically 
significant. A similar magnitude of difference in IL-1RNSV1 expression was observed 
between LPS-stimulated and control cells at 4 hps, which again was not significant. 
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Figure 5.4 Expression of IL-1RNfl in BM-MØ stimulated with LPS or CD40L. 
Results are expressed as corrected 40-Ct ± SEM of three replicates from a single 
sample. hps = hours post-stimulation. 
 
A similar profile to that for BM-MØ was also observed for IL-1RNfl expression in Mo-
MØ stimulated with LPS or CD40L (Figure 5.6). A noticeable difference in expression 
(2.6-fold) was seen between control cells and cells stimulated for 24 h with CD40L, 
however, it was not statistically significant. At all other time-points with both stimuli, 
there were no statistically significant differences in expression levels from those in 
control cells. The expression of IL-1RNSV1 mRNA in Mo-MØ (Figure 5.7) was 
distinctly different to its expression in BM-MØ and to IL-1RNfl expression in the same 
cells. LPS-stimulation at 1, 2, 8 and 12 hps led to a large increase in expression (from 3- 
to 4.3-fold) compared with controls, although this was not statistically significant. At 4 
hps, however, LPS-stimulated Mo-MØ exhibited lower IL-1RNSV1 mRNA expression. 
By 24 h, IL-1RNSV1 expression levels were 2.8-fold lower in LPS- stimulated Mo-MØ  
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Figure 5.5 Expression of IL-1RNSV1 in BM-MØ stimulated with LPS or CD40L. 
Results are expressed as corrected 40-Ct ± SEM of three replicates from a single 
sample. hps = hours post-stimulation. 
 
compared to control cells. This difference was even greater at 48 hps, being equivalent 
to a 3.95-fold decrease. Following CD40L stimulation, IL-1RNSV1 expression was 
higher than in control cells at 4, 8 and 12 hps, although relative increases were lower 
than in LPS-stimulated Mo-MØ. As with LPS, expression levels following CD40L 
stimulation were much lower than in control cells at 48 hps.  
5.3.4 Analysis of IL-1RN expression in vivo by qRT-PCR following bacterial or 
viral challenge  
IL-1RN mRNA expression was determined by qRT-PCR in a common viral and 
a common bacterial challenge model. 
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Figure 5.6 Expression of IL-1RNfl in Mo-MØ stimulated with LPS or CD40L for 1-
48 h. Results are expressed as corrected 40-Ct ± SEM of three replicates from a single 
sample. hps = hours post-stimulation. 
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Figure 5.7 Expression of IL-1RNSV1 in Mo-MØ stimulated with LPS or CD40L for 
1-48 h. Results are expressed as corrected 40-Ct ± SEM of three replicates from a single 
sample. hps = hours post-stimulation. 
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5.3.4.1 Infectious Bursal Disease Virus  
Birds known to be either resistant (line 61) or susceptible (Brown Leghorn, BrL) 
to infectious bursal disease virus (IBDV) were challenged as outlined in Chapter 2, 
section 2.4.1.2. At 2 days post-infection (dpi), levels of expression of IL-1RNfl were not 
statistically significantly different between infected and control birds of either line. By 3 
dpi, relative expression in both groups of infected birds had increased compared to the 
controls, but again the differences were not statistically significant. At 4 dpi, the 
difference in IL-1RNfl expression between infected and uninfected birds had increased 
even further in both lines. In the resistant birds, expression was 2.1 Ct greater (4.3-fold) 
which was statistically significant. A 1.7 Ct (3.3-fold) difference was observed in the 
susceptible line birds (Figure 5.8), but this was not statistically significant.  
By comparison, there were no statistically significant differences in IL-1RNSV1 
expression between both groups of infected and uninfected birds at any time-point 
(Figure 5.9). The pattern of IL-1RNSV2 expression was almost identical to that for IL-
1RNfl expression (Figure 5.10). At 2 dpi there were no statistically significant 
differences between control and infected birds in both groups. By 3 dpi, however, 
greater levels of expression (2.7-fold) were found in both groups of infected birds 
compared with respective control groups, although neither was statistically significant. 
The biggest differences were observed between infected and control birds at 4 dpi. In 
line 61 birds, mRNA expression was 2.5-fold higher in the infected subgroup, which 
was statistically significant. Although a 3.2-fold difference in expression was found 
between the two groups of BrL birds, this was not significant due to a single infected 
bird skewing the results (Figure 5.10).  
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Figure 5.8 Expression of IL-1RNfl mRNA in bursal cells from line 61 (resistant) 
and BrL (susceptible) chickens infected with IBDV. Results are expressed as mean 
corrected 40-Ct ± SEM of five birds per individual group. **P<0.01.  
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Figure 5.9 Expression of IL-1RNSV1 mRNA in bursal cells from line 61 (resistant) 
and BrL (susceptible) chickens infected with IBDV. Results are expressed as mean 
corrected 40-Ct ± SEM of five birds per individual group. dpi = days post-infection.  
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Figure 5.10 Expression of IL-1RNSV2 mRNA in bursal cells from line 61 
(resistant) and BrL (susceptible) chickens infected with IBDV. Results are expressed 
as mean corrected 40-Ct ± SEM of five birds per individual group. *P<0.05. dpi = days 
post-infection.  
 
5.3.4.2 Salmonella Typhimurium strain F98 Nal
R 
  
The expression of IL-1RNfl, IL-1RNSV1, and IL-1RNSV2 transcripts was assessed 
following oral infection with Salmonella Typhimurium (S.Typhi) strain F98 Nal
R 
across 
a 28 day period (Figure 5.11). Splenocyte RNA from infected and uninfected age-
matched outbred RIR birds was assayed at 3, 7, 14, 21 and 28 dpi. IL-1RNfl mRNA 
expression was 1.93-fold higher in the spleen of infected birds compared to the 
uninfected controls at 3 dpi, which was statistically significant. By 7 dpi, however, 
expression levels in both groups of birds were similar and remained so for the duration 
of the experiment. A comparable pattern of IL-1RNSV1 expression was observed, with a  
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Figure 5.11 IL-1RN expression in splenocytes from RIR chickens following 
infection with Salmonella Typhimurium strain F98 Nal
R
. Blue bars = IL-1RNfl 
expression, green bars = IL-1RNSV1 expression, yellow bars = IL-1RNSV2 expression. 
Results are expressed as mean corrected 40-Ct ± SEM of four birds per individual 
group. *P<0.05. dpi = days post-infection.  
 
2.7-fold increase (infected compared to uninfected) at 3 dpi. Between 7 and 28 dpi, 
there were no statistically significant differences in IL-1RNSV1 expression between the 
groups. Again, a similar pattern of expression was found for the IL-1RNSV2 variant, 
with the largest differences at 3 dpi between infected and control birds. A 3.5-fold 
difference was measured, which was statistically significant. As with the other two IL-
1RN splice variants, IL-1RNSV2 expression in both groups of birds was similar by 7 dpi 
and remained so until 28 dpi. 
5.3.5 Characterization of the bioactivity of chIL-1RN  
The antagonistic activity of chIL-1RN was determined by its ability to 
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effectively inhibit the IL-1β-mediated upregulation of IL-1β and iNOS genes in HD11 
cells. In several different types of human cells, IL-1β induces its own production 
(Schindler, Ghezzi et al. 1990). The amount of IL-1β mRNA in IL-1β-stimulated cells 
remains high for over 24 h. By contrast, IL-1β mRNA levels begin to fall after 4 h in 
LPS-stimulated cells (Dinarello 2009).  
We initially sought to establish whether the HD11 cell line was responsive to IL-
1β stimulation, and if this also induced IL-1β expression over a sustained period as is 
seen in mammals.   
5.3.5.1 Pilot study 
As the chicken HD11 cell line had never previously been used to carry out such 
an assay, a pilot experiment was performed to establish its suitability. Its ability to 
respond to stimulation with rchIL-1β was tested. As a control, a doubling dilution series 
of rchIL-1β was incubated for 2 h with a uniform volume of neutralizing antibody. 
HD11 cells were then either stimulated for 24 h with rchIL-1β ± antibody or cultured in 
media only. Both IL-1β and iNOS mRNA expression were upregulated in rchIL-1β-
stimulated cells compared with no stimulation. In cells cultured with rchIL-1β + 
antibody, IL-1β and iNOS mRNA expression were initially equivalent to rchIL-1β-
stimulated cells; however, sufficient dilution of the cytokine allowed the antibody to 
neutralize its activity. This resulted in a decrease in IL-1β and iNOS expression to levels 
equivalent to those in unstimulated cells (Figure 5.12).  
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Figure 5.12 IL-1β and iNOS expression in IL-1β-stimulated HD11 cells. A doubling 
dilution series of recombinant chIL-1β was pre-incubated ± a uniform volume of anti-
IL-1β antibody for 2 h at 41°C. HD11 cells were then either stimulated for 24 h with 
rchIL-1β ± antibody or cultured in media only. RNA was extracted from the HD11 cells 
and assayed for IL-1β and iNOS expression by real-time qRT-PCR.  
 
To ensure the optimal rchIL-1β concentration was used in subsequent bioassays, 
HD11 cells were stimulated with a doubling dilution series of rchIL-1β as described in 
this Chapter, section 5.2.5.1. Culture supernatants were tested for nitrite content by the 
Griess reaction as outlined in Chapter 2, section 2.4.15.2.1. A rchIL-1β concentration of 
10 ng/µl was deemed optimal (Figure 5.13). 
For all subsequent “test” assays, a commercially produced stock of rchIL-1β was 
purchased from AMSBio (Abingdon, UK). To test its ability to stimulate HD11 cells 
and sustain IL-1β mRNA levels for 24 h, HD11 cells were cultured as described in 
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Figure 5.13 Establishing the optimal [rchIL-1β] required to stimulate HD11 cells. 
HD11 cells were routinely cultured and stimulated overnight with a doubling dilution 
series of rchIL-1β as indicated. The next day, supernatants were assayed using the 
Griess reaction. Bars denote the O.D. of culture supernatants at 540 nm, as a 
representation of the [NO2
-
]. O.D540 (media only control) = 0.118. 
 
Chapter 2, section 2.4.12.1, and stimulated as described in this Chapter, section 5.2.5.1. 
IL-1β expression levels were determined at 0, 1, 2, 4, 8, 12 and 24 hps by real-time 
qRT-PCR (Figure 5.14). Results indicated the stock of rchIL-1β was able to stimulate 
HD11 cells, increasing IL-1β expression. Increased IL-1β mRNA levels were sustained 
across a 24 h period. 
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Figure 5.14 IL-1β mRNA expression in IL-1β-stimulated HD11 cells. HD11 cells 
were routinely cultured at 41°C, 5% CO2 for 0, 1, 2, 4, 8, 12 and 24 h in medium 
supplemented with 10 ng/µl rchIL-1β. RNA was extracted from the HD11 cells and 
assayed for IL-1β expression by real-time qRT-PCR. Results are represented as mean 
corrected 40-Ct ± SEM of two samples from individual flasks. hps = hours post-
stimulation.  
 
5.3.5.2 Characterization of the bioactivity of pure secretory and intracellular IL-1RN 
(purified recombinant proteins) 
Recombinant chicken sIL-1RN and icIL-1RN were successfully expressed in 
HEK293T cells (Figure 5.15). The ability of rchIL-1RN to inhibit the biological activity 
of IL-1β was assessed in a HD11 cell bioassay. The antagonistic activity of both chIL-
1RN was determined by their ability to effectively inhibit the IL-1β-mediated 
upregulation of IL-1β and iNOS genes. In HD11 cells incubated for 4 h with either sIL- 
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Figure 5.15 Western blot of purified recombinant chIL-1RN proteins expressed in 
HEK293T cells. Samples were electrophoresed by SDS-PAGE on a 4-15% Mini-
PROTEAN TGX gel. Lane 1 = recombinant mature sIL-1RNpHLSec; calculated Mw = 
21.857 kDa. Lane 2 = recombinant icIL-1RNpHLSec; calculated Mw = 22.329 kDa. 
Lane 3 = 6xHIS protein ladder (Qiagen). 
 
1RN or icIL-1RN prior to the addition of rchIL-1β, the upregulation of IL-1β and iNOS 
mRNA expression levels was effectively inhibited (Figure 5.16). In cells stimulated 
with IL-1β alone, IL-1β and iNOS mRNA expression levels increased significantly 
compared to expression levels in unstimulated cells. The antagonistic effect of both 
chIL-1RN gradually declined as they were titrated out in the presence of a fixed 
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concentration of rchIL-1β. Griess assay results correlated with the qRT-PCR data 
throughout the experiment (Figure 5.17).  
5.3.5.3 Characterization of the bioactivity of ex-COS secretory and intracellular IL-
1RN splice variant proteins 
The biological activity of the four identified splice variants of chIL-1RN was 
tested in the same HD11 bioassay. The bioactivities of cell supernatants and lysates 
from COS cells transfected with each IL-1RN splice variant were compared with similar 
mock-transfected controls of pCI-neo vector lacking a cDNA insert. At their highest 
concentration, ex-COS lysates containing either icIL-1RN SV1 or SV2 gave greater 
inhibition of IL-1β-mediated upregulation of proinflammatory genes than their 
respective supernatants. When compared with ex-COS lysates of pCI-neo controls, 
however, no significant differences in IL-1β and iNOS expression were found following 
rchIL-1β stimulation (Figures 5.18-5.21). When titrated out, there were no differences 
in bioactivity between any of the icIL-1RN SV cell lysates and their respective pCI-neo 
controls. Lysates and supernatants (ex-COS) of both sIL-1RN splice variants, similarly, 
showed no bioactivity when compared with pCI-neo controls. These results indicate all 
four splice variants of chIL-1RN do not act as functional antagonists of IL-1β in this 
bioassay. 
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Figure 5.16 Full length chIL-1RNs are bioactive as determined by TaqMan. 
Previous page. Both secretory and intracellular variants of purified recombinant chIL-
1RN antagonise the stimulatory effects of recombinant chIL-1β in HD11 cells, in a 
dose-dependent manner. Doubling dilutions of recombinant proteins from 225 μg/ml 
(sIL-1RN) and 194 μg/ml (icIL-1RN). Bars denote IL-1β and iNOS expression in HD11 
cells pre-incubated with either pure sIL-1RN (s) or icIL-1RN (ic) for 4 h prior to the 
addition of rchIL-1β for 12 h. Results are represented as the mean corrected 40-Ct ± SD 
of three independent experiments. U = unstimulated cells. IL-1β = cells stimulated with 
IL-1β without IL-1RN. *P<0.05 of the rchIL-1β + IL-1RN treatment groups compared 
to the rchIL-1β only treatment.  
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Figure 5.17 Full length chIL-1RNs are bioactive as determined by the Griess assay. 
Both secretory and intracellular variants of purified recombinant chIL-1RN antagonise 
the stimulatory effects of recombinant chIL-1β in HD11 cells, in a dose-dependent 
manner. Bars denote O.D. of culture supernatant from HD11 cells pre-incubated with 
either pure sIL-1RN (s) or icIL-1RN (ic) for 4 h prior to the addition of rchIL-1β for 12 
h. Results are represented as the mean ± SEM of 9 replicates (triplicate measurements 
from three independent experiments). U = unstimulated cells. IL-1β = cells stimulated 
with IL-1β without IL-1RN.  
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Figure 5.18 Chicken icIL-1RN splice variants do not antagonise IL-1β-mediated 
IL-1β expression. Bars indicate IL-1β expression in HD11 cells pre-incubated with 
either ex-COS icIL-1RN SV1 or SV2 (cell lysate (L) or supernatant (S)) or ex-COS cell 
lysate or supernatant (mock transfected cells, M) for 2 h prior to the addition of rchIL-
1β for 12 h. Dilutions of crude ex-COS supernatants and lysates are indicated beneath 
the x-axis. Results are represented as mean corrected 40-Ct ± SEM of three independent 
experiments.  
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Figure 5.19 Chicken icIL-1RN splice variants do not antagonise IL-1β-mediated 
iNOS expression. Bars indicate iNOS expression in HD11 cells pre-incubated with 
either ex-COS icIL-1RN SV1 or SV2 (cell lysate or supernatant) or ex-COS cell lysate 
or supernatant (mock transfected cells, M) for 2 h prior to the addition of rchIL-1β for 
12 h. Dilutions of crude ex-COS supernatants and lysates are indicated beneath the x-
axis. Results are represented as mean corrected 40-Ct ± SEM of three independent 
experiments.  
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Figure 5.20 Chicken sIL-1RN splice variants do not antagonise IL-1β-mediated IL-
1β expression. Bars indicate IL-1β expression in HD11 cells pre-incubated with either 
ex-COS sIL-1RN SV1 or SV2 (cell lysate or supernatant) or ex-COS cell lysate or 
supernatant (mock transfected cells, M) for 2 h prior to the addition of rchIL-1β for 12 
h. Dilutions of crude ex-COS supernatants and lysates are indicated beneath the x-axis. 
Results are represented as mean corrected 40-Ct ± SEM of three independent 
experiments.  
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Figure 5.21 Chicken sIL-1RN splice variants do not antagonise IL-1β-mediated 
iNOS expression. Bars indicate iNOS expression in HD11 cells pre-incubated with 
either ex-COS sIL-1RN SV1 or SV2 (cell lysate or supernatant) or ex-COS cell lysate 
or supernatant (mock transfected cells, M) for 2 h prior to the addition of rchIL-1β for 
12 h. Dilutions of crude ex-COS supernatants and lysates are indicated beneath the x-
axis. Results are represented as mean corrected 40-Ct ± SEM of 3 independent 
experiments.  
Chapter 5: Characterisation of expression and bioactivity of chicken IL-1RN 
 
235 
 
5.4 Discussion 
The biological activity of human and mouse IL-1RN has been repeatedly 
characterised in assays which show it acts as an antagonist of IL-1RI. It physically 
occupies this receptor preventing IL-1β or IL-1α from binding. However, this does not 
lead to signal transduction. Although IL-1RN is sufficiently similar to IL-1β to facilitate 
IL-1RI binding, several key differences account for its inability to activate signalling. 
IL-1β has two binding sites termed A (bsA) and B (bsB). It binds domains I and II of 
IL-1RI with bsA leading to a conformational change allowing bsB to bind domain III of 
IL-1RI. This activates the intracellular signalling cascade. IL-1RN has bsA but lacks 
bsB. It therefore only binds domains I and II of IL-1RI, facilitating blocking (Gosavi, 
Whitford et al. 2008). This binding event leads to the creation of an angle between 
domains II and III of IL-1RI which prevents any contact between IL-1RN and domain 
III of IL-1RI. This completely abolishes its capacity to recruit MyD88 to activate 
signalling (Sims and Smith 2010). In addition, IL-1RN lacks the specific amino acids 
required to engage IL-1RAcP on the cell surface (Schreuder, Tardif et al. 1997; Wang, 
Zhang et al. 2010). The extent to which IL-1RN is similar to the agonist IL-1β has been 
shown following site-directed mutagenesis of IL-1RN at a single codon. The resulting 
substitution, making IL-1RN differ from the wild type by only a single amino acid, 
conferred partial agonist activity (Ju, Labriola-Tompkins et al. 1991). 
Both full length chicken sIL-1RN and icIL-1RN recombinant proteins were able 
to antagonize the IL-1β-mediated upregulation of IL-1β and iNOS genes, and as such 
exhibited biological activity analogous to their mammalian orthologues.  
Bioinformatic analysis of the four chIL-1RN SVs in Chapter 4, section 4.3.4 
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suggested they would be functionally redundant given the potential importance of 
missing residues. Ex-COS recombinant SV proteins were tested in the HD11 bioassay 
in parallel with vector controls, and lacked any biological activity. Although ex-COS 
lysates of both SV1 and SV2 proteins contained more activity than their respective 
supernatants, when compared with mock control ex-COS lysates, differences were not 
statistically significant. Any differences between lysates and supernatants were 
therefore unlikely to be IL-1-mediated. These bioassay results suggest a possible control 
mechanism may exist to regulate chIL-1RN expression, and hence bioactivity, by 
creating SV transcripts that encode functionally redundant proteins. It is possible the SV 
proteins were misfolded in COS-7 cells and subsequently degraded by the ubiquitin-
proteasome system (Hershko and Ciechanover 1998). Alternatively, SV mRNAs may 
have been inefficiently translated which could have led to defective protein synthesis. 
To determine whether this occurred, a polysome profile of the transfected COS-7 cells 
followed by Northern blotting could be carried out (Beilharz and Preiss 2004). 
Expression of IL-1RNfl is ubiquitous and constitutive in the range of cells and 
tissues examined, although the assay does not differentiate between sIL-1RN and icIL-
1RN mRNAs. Previous studies have assessed global IL-1RN expression in mice 
(Gabay, Porter et al. 1997) and rabbits (Apostolopoulos, Ross et al. 1996; Matsukawa, 
Fukumoto et al. 1997), and found it was not constitutive in all mouse tissues. Analyses 
in mice used an RNase protection assay which lacks sensitivity compared to TaqMan, 
so IL-1RN expression may be more widespread than reported in that species. As in 
humans, rabbit sIL-1RN expression was ubiquitous but icIL-1RN expression was 
restricted. The highest levels of chicken IL-1RNfl expression were found in monocytes 
and macrophages. Human equivalents of these leukocytes also exhibit high levels of 
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huIL-1RN expression, suggesting the predominance of chIL-1RN in these cells reflects 
a similar requirement at sites of immune activation in vivo. 
Chicken IL-1RNfl expression is increased in vivo following bacterial or viral 
infection, reflecting a typical response to that seen in experimental models of disease in 
mammalian species. For IBDV, IL-1RNfl expression was highest at 4 dpi, which was 
also observed for IL-1β expression in the bursae of out-bred RIR chickens infected with 
the same strain of virus (Eldaghayes, Rothwell et al. 2006).  
Stimulation of three distinct monocyte/macrophage populations with LPS did 
not affect the expression of IL-1RNfl, a response that differs from previous observations 
in human monocytes. Following LPS stimulation, human blood-derived monocytes 
express sIL-1RN in less than an hour, with detectable levels of protein present after 4 h. 
The icIL-1RN1 transcript is subsequently expressed after ~12-15 h, and is the principal 
IL-1RN isoform after 24 h (Dinarello 1996). Despite our assay being unable to 
distinguish structural variants, it was somewhat unexpected that LPS did not increase 
the expression of IL-1RNfl up to 24 hps in any of the macrophage populations. In the 
HD11 cell line, LPS robustly activates NF-κB via chicken Toll-like receptor 4 
(chTLR4) (Keestra and van Putten 2008). We were satisfied a similar LPS response had 
taken place in the HD11 cells in this experiment, reflected by the vast increase in IL-1β 
expression after only 1 h. The pattern of IL-1RNSV1 expression was consistent with IL-
1RNfl expression in HD11 cells, showing no increase following exposure to LPS. Given 
that both chicken sIL-1RN and icIL-1RN cDNAs were amplified from LPS-stimulated 
HD11 cells, it must be assumed the promoter region of chIL-1RN and cell machinery 
required to initiate chIL-1RN transcription are intact in HD11 cells. Thus, the apparent 
non-existent response to LPS in these cells is surprising and demonstrates the 
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transcriptional response of chIL-1RN in vitro is strikingly different from findings in 
mammals.  
In contrast to HD11s, IL-1RNSV1 expression in both BM-MØ and Mo-MØ was 
noticeably upregulated following LPS stimulation at 2 and 4 hps, and 1, 2, 4 and 12 hps, 
respectively. It is interesting to observe the contrast with IL-1RNfl expression in these 
cells perhaps lending weight to the idea that a control mechanism is regulating chIL-
1RN expression. For instance, the chicken may be preferentially splicing a significant 
proportion of full length transcripts into SV transcripts in response to stimulation. It 
seems rather futile to be deliberately splicing full length transcripts that normally 
encode proteins which are biologically inert, unless of course chIL-1RN is functionally 
promiscuous. This was not apparent in the bioassay, although the assay may not provide 
an accurate reflection of alternative function(s).  
Another interesting observation in these stimulated BM-MØ and Mo-MØ was 
the apparently large differences in expression of the same transcript in the two different 
cell types. In Mo-MØ, IL-1RNfl expression was, compared with the levels determined in 
BM-MØ, relatively lower. A difference of around 2-3 Ct values (4 to 8-fold) was 
evident at any of the given time-points. The absolute Ct values for IL-1RNSV1 mRNA 
expression in Mo-MØ were also considerably smaller than those determined in BM-
MØ. Although it is difficult to imagine why chIL-1RN expression is much lower in 
cells isolated from the blood than the bone marrow, it is undoubtedly an observation 
with implications for experimental interpretation. Considering the wide-reaching 
influence of IL-1-mediated effects in macrophages, it may be important to consider that 
the activation status of a cell, cell surface marker expression, motility, and production of 
many other cytokines (amongst countless other effects) is being innately suppressed to a 
Chapter 5: Characterisation of expression and bioactivity of chicken IL-1RN 
 
239 
 
greater extent in blood-derived Mo-MØ.  
In conclusion, in vitro analyses of IL-1RN expression did not identify any 
statistically significant differences between stimulated and unstimulated cell 
populations. By contrast, in two distinct in vivo challenge models, significant 
differences in IL-1RN expression were found between infected and uninfected birds. 
Specifically, the expression of both full length and SV2 transcripts were statistically 
significantly elevated in birds infected with either IBDV or S.Typhi compared with 
uninfected controls. It was not evident why there was such a discrepancy between in 
vitro and in vivo models, and consequently, it warrants further investigation. 
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6.1 Introduction 
Rapid advances in genomics-based molecular techniques vastly increased the 
availability of sequence data around the start of this century. This led to the emergence 
of the human genome sequence, and greatly expanded our knowledge of the repertoires 
of genes we possess. Screening EST and cDNA sequence databases prior to the human 
genome assembly led to many novel genes being discovered. This was the case with the 
IL-1 gene family which up until 1999 was only thought to contain four genes (IL-1β, 
IL-1α, IL-1RN and IL-18). Studies conducted by several different groups culminated in 
concurrent reports of six “new” genes in the huIL-1 family, all of which clustered with 
IL-1β, IL-1α and IL-1RN on chromosome 2 (Mulero, Pace et al. 1999; Barton, Herbst et 
al. 2000; Kumar, McDonnell et al. 2000; Smith, Renshaw et al. 2000; Bensen, Dawson 
et al. 2001; Lin, Ho et al. 2001; Pan, Risser et al. 2001). These were named IL-1F5-F10 
(Sims, Nicklin et al. 2001), although this has since been replaced with an updated 
nomenclature (Dinarello, Arend et al. 2010). Some degree of biological function has 
been assigned to all of these except for IL-1F10. The number of published studies 
looking at these cytokines, however, remains very small and it is possible they may 
possess additional, as yet undefined functions.  
IL-1F5 is evidently an antagonistic cytokine – its two major roles being as a 
receptor antagonist of IL-1RL2 (Debets, Timans et al. 2001) and a suppressor of 
inflammation through an (as yet unelucidated) interaction with the orphan receptor, 
SIGIRR (Costelloe, Watson et al. 2008). Since its discovery in humans, IL-1F5 
orthologues have been identified in 31 other mammalian genomes according to the 
ENSEMBL genome browser (personal search). However, it remains absent in non-
mammalian species, although an apparent IL-1F5 orthologue is present in the Anole 
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lizard genome (unpublished observations). The proximity of these nine IL-1 genes at a 
single locus, their phylogeny, and their similar sequences and structures suggest they 
arose by gene duplication. Analysis of the IL-1α, IL-1β and IL-1RN sequences 
proposed that IL-1RN arose through gene duplication ~350 Mya, after which a 
successive duplication ~285 Mya formed the IL-1β and IL-1α genes. Using the 
calculated mutational rate of IL-1RN since it was formed (Eisenberg, Brewer et al. 
1991), it was predicted that IL-1F5 emerged later, at ~190-210 Mya (Mulero, Nelken et 
al. 2000). If accurate, this would have precluded its existence in non-mammalian 
species. The apparent absence of a large multigene IL-1 locus in non-mammalian 
species with an assembled genome sequence lends weight to this hypothesis.  
This chapter describes the identification and molecular cloning of chicken IL-
1F5. After screening EST databases to find a novel IL-1 sequence, it was 
comprehensively characterised in silico, which showed it was most similar to the IL-
1F5 gene found in mammals. Once this EST had been unequivocally identified as chIL-
1F5, it was amplified by PCR directly from its cDNA clone. Analyses of the chIL-1F5 
gene structure, genomic location and chicken-specific sequence features were also 
carried out. 
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6.2 Methods 
General methods were carried out as outlined in Chapter 2. Additional methods 
and alterations to those described in Chapter 2 are detailed here. 
Both in silico and in vitro techniques were used to identify and clone a novel 
cytokine, chicken IL-1F5. The NCBI database was initially screened as described in 
Chapter 2, section 2.2.2. This identified a putative chicken cytokine EST sequence from 
the IL-1 family. The sequence had significant homology with chIL-1β and chIL-1RN; 
however, it appeared to lack the IL-1 signature motif and was truncated at the 3’ end. 
Analyses of its nucleotide and predicted amino acid sequence were carried out whilst 
BLAST was used to confirm its identity as described in Chapter 2, section 2.2.3. Its 
amino acid sequence was used to identify further chIL-1 ESTs.  
In order to obtain a full-length clone of IL-1F5, the original EST clone 
(ChEST734c4/ BU247129.1) was ordered from MRC geneservice 
(http://www.geneservice.co.uk/products/cdna/chickenEST.jsp). The clone was provided 
as a bacterial stab and re-streaked onto solid LB medium (+ 50 µg/ml carbenicillin) then 
incubated overnight at 37ºC. Ten single colonies were picked and grown in LB broth (+ 
50 µg/ml carbenicillin + 8% glycerol) overnight with shaking at 37ºC. A 1.5 ml stock of 
each culture was then frozen at -70ºC for 24 h. All 10 stock cultures were streaked out 
onto solid LB (+ 100 µg/ml ampicillin) and incubated overnight at 37ºC. Ten single 
colonies were picked and grown in LB broth (+ 100 µg/ml ampicillin) and incubated 
overnight at 37ºC. Plasmid DNA was isolated using the QIAprep spin miniprep kit 
(Qiagen). Clones were sequenced using the M13 and revM13 sequencing primers 
(Sigma-Genosys) on the CEQ™ 8000 Genetic Analysis System (Beckman Coulter). 
Using PCR, the IL-1F5 CDS was amplified, sequenced and cloned into the pTargeT 
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mammalian expression vector. For the PCR, the EST clone was used as the template 
and thermal cycling conditions were: one cycle of 94ºC for 2 min, then 30 cycles of 
94ºC for 30 s, 69ºC for 30 s, and 72ºC for 2 min. Sequence-specific primers (Table 1 in 
the Appendix) were designed from the full-length EST sequence (missing sequence in 
the NCBI submission was obtained from sequencing the clones with M13 and revM13 
sequencing primers). 
Further bioinformatic characterization of chIL-1F5 nucleotide and amino acid 
sequences was carried out to confirm the avian gene’s identity and similarity to the 
orthologous human and mouse IL-1F5 sequences. PCR amplification of chIL-1F5 
introns used custom primers designed from the coding sequence (Table 1 in the 
Appendix). Cycling conditions were as described in Chapter 2, section 2.4.4.3 with an 
initial annealing temperature of 70ºC for the five touchdown cycles. 
To determine the genomic location of chIL-1F5, PCR analysis of the locus 
containing chIL-1β was performed using a specific BAC clone (TAM32-21N6) for the 
template as described in Chapter 4, section 4.2.2. An additional experiment to discover 
the genomic location of chIL-1F5 used a 
32
P-labelled (random-primed) probe to 
hybridize against BAC library filters as described in Chapter 4, section 4.2.2. 
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6.3 Results 
6.3.1 Identification and analysis of a novel chIL-1 EST sequence 
A TBLASTN search of the NCBI expressed sequence tag (EST) database by a 
collaborator, Dr Steve Bird (University of Aberdeen), identified a chicken EST 
representing a putative novel chicken IL-1 gene. This EST (Acc. No. BU247129.1) was 
an 811 bp sequence with 3 potential start codons but lacked both a stop codon and a 
polyA signal. Translation of this EST showed that the predicted protein sequence did 
not contain the highly conserved IL-1 family motif, but had significant identity with 
chIL-1β (17.5%) and ic chIL-1RN (32.4%) amino acid sequences when aligned using 
ClustalX. Next, TBLASTN analysis against all of the genomes in ENSEMBL showed it 
was missing from the chicken genome (v2.1), but exhibited significant identity with IL-
1F5 (IL-36RN) in 19 other species (results in Table III in Appendix I). When aligned 
with the human, macaque, mouse and cow IL-1F5 sequences, the chicken sequence was 
clearly truncated at the 3′ end (Figure 6.1). Several unsuccessful attempts were made to 
amplify the 3′ end of the IL-1F5 cDNA using 3′ RACE.  
To determine whether any similar chIL-1 family sequences were present in the 
NCBI EST database; a reciprocal BLASTP analysis of this database using the predicted 
chIL-1F5 amino acid sequence was carried out. This did not identify any further ESTs 
with significant homology, other than those already identified in this study (listed in 
Table II in Appendix I). 
The NCBI record for this EST 
(http://www.ncbi.nlm.nih.gov/nucest/BU247129.1) indicated it had only been 
sequenced from the 5′ end. Therefore, it was possible the BU247129.1 EST 
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Figure 6.1 Amino acid alignment of truncated chicken IL-1F5 with the full length 
human, macaque, mouse, cow and platypus IL-1F5 sequences. Identical residues 
between all 5 species at the same position are shaded black; identical residues between 4 
species are shaded dark grey, those between 3 species shaded light grey; similar 
(structure) residues are shaded light grey. The chicken sequence is incorrect as the IL-1 
family signature motif (indicated with a box) is not conserved. The chicken sequence is 
also incomplete as it is truncated at the 3′ end.  
 
 (ChEST734c4) was longer than the published 811 nt sequence. The cDNA clone was 
acquired, fully sequenced and found to be 1059 nt in length. Sequence analysis 
identified the previously missing stop codon and polyA signal. It also uncovered a 
number of errors in the submitted BU247129.1 sequence towards the 3′ end (Figure 
6.2). Consequently, translation of the correct EST sequence altered the reading frame of 
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Figure 6.2 Nucleotide sequence alignment between the 3’ end of the chIL-1F5 EST 
(BU247129.1) present in the NCBI database and the clone of the identical EST 
(ChEST734c4) after being fully sequenced in both directions. A number of incorrect, 
missing or inserted nucleotides in the BU247129.1 sequence were identified. They are 
indicated with an asterisk below the alignment.  
 
the protein sequence such that a conserved IL-1 signature motif was now apparent 
(Figure 6.3). This predicted chIL-1F5 amino acid sequence now had higher identity 
with the chIL-1β (20.4%) and chIL-1RN (34.1%) sequences, as well as with the 19 
other species to which it was previously aligned. Figure 6.3 shows the correct chicken 
sequence aligned with human, mouse, cow, macaque & platypus IL-1F5 sequences. 
Unassembled, uncurated nucleotide sequence reads from the third assembly 
(Galgal 3.0) of the chicken genome were subsequently made available. A TBLASTN 
analysis of these sequences was carried out which identified two contigs (designated 
110035.1 and 162436.1) from the “removed data” reads containing ~80% of the coding 
region of chIL-1F5 as well as some intronic sequence. A third contig (designated 
166095.1) was identified which contained two exons from the apparent 5′ UTR of the 
gene. This contig aligned with the 5' end of the full-length EST clone sequence. 
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Figure 6.3 Amino acid alignment of chicken IL-1F5 with the human, macaque, 
mouse, cow and platypus IL-1F5 sequences. Identical residues between all 5 species 
at the same position are shaded black; identical residues between 4 species are shaded 
dark grey, those between 3 species shaded light grey; similar (structure) residues are 
shaded light grey. The original translation of the chIL-1F5 EST was truncated at the 3’ 
end and did not contain the conserved IL-1 family signature motif (Figure 6.1). Both 
errors and missing sequence were identified following full-length sequencing of the 
chIL-1F5 EST. Translation of the correct full length CDS sequence changed the reading 
frame such that the IL-1 family signature motif (indicated with a blue box) was now 
well conserved. The secondary structure of IL-1 family proteins consists of 12 β-
strands. The specific amino acid residues that comprise these 12 β-strands in humans 
(Schreuder 1997) are indicated by black blocks beneath the sequence. Their locations in 
the chicken, predicted by PSIPRED, are indicated by white blocks.  
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6.3.2 Characterization of the putative processed form of chIL-1F5 
Human IL-1F5 lacks a signal peptide and apparent pro-domain, and its mode of 
secretion thus remains unknown. Despite this, unpublished observations indicate human 
IL-1F5 truncated at the N-terminus has increased biological activity. The predicted 
chIL-1F5 amino acid sequence was, therefore, examined for potential cleavage sites that 
may indicate a particular mechanism of secretion. Analysis using PeptideCutter 
(ExPASy) predicted that chicken IL-1F5 would not be cleaved by signal peptidase or 
caspase-1, i.e. it does not contain either a signal peptide or a pro-domain. Although 
chIL-1F5 possesses aspartic acid (D) residues (caspase-1 cut site) at positions 6, 34 and 
44 at the NH2-terminus, adjacent residues do not conform to any of the published 
consensus sequences for this enzyme. None of the other 17 enzymes queried with 
PeptideCutter were predicted to process chIL-1F5. These findings correlate with a 
similar analysis for huIL-1F5.  
 
6.3.3 Amplification and molecular cloning of the chIL-1F5 coding sequence 
cDNA 
The translated ChEST734c4 sequence contained three potential start codons. 
Alignment of the predicted chIL-1F5 amino acid sequence with 19 other species 
indicated only one likely candidate for the genuine initiation codon. Primers were 
designed against the predicted IL-1F5 CDS sequence derived from the EST. A full 
length 516 bp IL-1F5 CDS cDNA was amplified by PCR using purified ChEST734c4 
DNA. This EST clone was generated from a liver cDNA library. Several initial attempts 
were made to amplify the full length CDS by RT-PCR in skin, spleen, lung and bone 
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marrow; however, these were unsuccessful. It was therefore amplified directly from the 
EST clone. Gel electrophoresis of the PCR products revealed a single band of the 
expected size (Figure 6.4). Products were TA-cloned into the pTarget mammalian 
expression vector, and clones were screened by EcoRI restriction digestion. All clones 
were sequenced by chain termination sequencing using T7 and revT7 vector primers. 
Analysis of the clone sequences revealed a 100% match with the IL-1F5 ChEST734c4 
sequence. 
600
400
300
200
516500
100
M
bp
 
Figure 6.4 Agarose gel showing PCR products from the amplification of the IL-1F5 
CDS using ChEST734c4 DNA as template. Expected band size = 516 bp. Size marker 
= 100 bp DNA ladder.  
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6.3.4 In silico analysis of the chIL-1F5 amino acid sequence 
The full length chIL-1F5 amino acid sequence was further characterized in 
silico. The CDS cDNA encodes a predicted protein of 171 amino acid residues in 
length. When aligned with mammalian IL-1F5 sequences (Figure 6.3), chIL-1F5 shares 
31.2% amino acid identity with both its human and mouse homologues. The chicken 
sequence, however, is significantly longer (>20 aa) at its 5’ end when compared with 
the human and mouse proteins, which may affect its function. Its calculated Mw is 
18.748 kDa with a theoretical pI of 6.52. The secondary structures of human and mouse 
IL-1 proteins have been elucidated as β-trefoil folds comprised of 12 β-strands. The 
crystal structure of mouse IL-1F5 has been resolved, with the analysis showing this 
cytokine also adopts the same β-trefoil fold. In addition, the study identified several 
major differences between the composition and conformation of the other structural 
features of IL-1F5 compared to those found on IL-1RN and IL-1β. Using PSIPRED, the 
secondary structure of chIL-1F5 was predicted to contain 12 β-strands, located in almost 
identical regions to the mouse IL-1F5 sequence (Figure 6.3). Three cysteine residues are 
present in the chIL-1F5 sequence, although only one of these is conserved with 
mammals, located in β-strand 6. The mouse IL-1F5 sequence contains four cysteine 
residues of which two are linked by a disulphide bond. These are found at the NH2- and 
COOH-termini (Cys8 and Cys155, respectively) of the protein. When aligned with 
mouse IL-1F5, one of the cysteines in chIL-1F5 is located 12 amino acids in the 3′ 
direction from Cys8. However, neither of the other 2 cysteine residues (Cys76 and 
Cys91) in the chicken sequence is situated close to the C-terminus. This makes it 
difficult to speculate with any confidence which two cysteines will form a disulphide 
bond in the chicken amino acid. No potential N-linked glycosylation sites were located 
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in chIL-1F5, consistent with their absence in mammalian sequences. The chIL-1F5 
sequence was analysed for structural similarity to known protein domains in the 
ProDom database. The sequence was most closely related to domain PD002536 
(domain I.D: IL-1; closest domain: human IL-1F5; e-value: 1x10
-13
 for residues 78-170; 
amino acid identity: 39%). The sequence was further examined for other functional 
motifs. Using the NetNES prediction server, chIL-1F5 was found to possess a nuclear 
export sequence (LQLEEVKLLDL) at positions 99-109. Analysis of both human and 
mouse IL-1F5 sequences did not detect a similar motif in either species. This motif may 
be non-functional, as most proteins <50 kDa are able to diffuse freely across nuclear 
membranes.  
Using the full length chicken IL-1F5 amino acid sequence, phylogenetic analysis 
was performed to determine an evolutionary relationship with mammalian IL-1F5. 
Analysis was performed exactly as described in Chapter 4, section 4.3.4. As shown in 
Figure 4.11, chIL-1F5 formed a separate branch (with the chIL-1RN sequences) within 
the major IL-1 receptor antagonist subgroup (IL-1RN, IL-1F5, IL-1F10) clade.   
6.3.5 Structural determination by PCR amplification, sequencing and in silico 
analysis 
A combination of PCR and in silico analyses allowed the genomic structure of 
chIL-1F5 to be partially determined. The human IL-1F5 gene consists of six exons, 
which through use of alternative first exons (1a and 1b), creates two different five exon-
containing transcripts (Figure 6.5D). These transcripts only differ in their 5′ UTRs and 
encode exactly the same protein sequence. As the chromosomal location of the chIL-
1F5 gene remains unknown, the structure and full gene sequence is not present in any of 
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Figure 6.5 Determination of the gene structure of chicken IL-1F5.  
Previous page A. Agarose gel of PCR products containing Intron 4 of chIL-1F5. 
Products were amplified from genomic DNA from line 61 with IL-1F5 332L and IL-1F5 
437R primers. M = 100 bp DNA ladder. B. Agarose gel of PCR products containing 
Intron 5 of chIL-1F5. Products were amplified with IL-1F5 Int5F and IL-1F5 Int5R 
primers. M = 100 bp DNA ladder, lanes 1 & 3 = products amplified from lines 61 and N, 
respectively, lane 2 = empty. C. Agarose gel of PCR products containing Intron 1 of 
chIL-1F5. Products were amplified with IL-1F5 Int1F and IL-1F5 Int1R primers. M = 
100 bp DNA ladder, lanes 1-3 = products amplified from lines 61, N and 15I 
respectively. D. The structures and identified protein coding transcripts of chicken and 
human IL-1F5 genes. The chicken gene structure is only partially known.  
 
the chicken genome browsers. 
A similar approach to the one employed for the chIL-1RN gene was used to 
establish the locations of the chIL-1F5 introns. The cDNA sequences of human, 
platypus and chicken IL-1F5 were aligned to verify the approximate intron-exon 
boundaries in the chicken. Platypus cDNAs were aligned because the chicken and 
platypus transcripts encode an additional 16 and 25 amino acids respectively at their 
NH2-termini that are absent in other mammalian sequences (Figure 6.3). It was possible 
any platypus introns in this region may also be present in the chicken. As before, 
primers were designed from the exon sequences flanking the predicted chicken exon-
intron boundaries.  
This approach enabled three chicken introns to be successfully amplified. Using 
genomic DNA from line 61 as a template, a ~280 bp PCR product was amplified (the 
equivalent cDNA amplicon would be 205 bp) with the primers IL-1F5 332L and 437R 
(Figure 6.5A). Sequencing revealed this amplicon contained a 71 bp intron of chIL-1F5. 
Its location indicated it was intron 4 and was thus much smaller than the 1186 bp human 
intron 4. To amplify a second intron, the primers IL-1F5 Int5 F and IL-1F5 Int5 R were 
used. A ~4 kb PCR product (the equivalent cDNA amplicon would be 117 bp) was 
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generated using genomic DNA from line N as template (Figure 6.5B). This product was 
TA-cloned into pTarget and sequenced from both ends with T7 and revT7 vector 
primers to confirm it was specific. Its location in the gene indicated it was intron 5 and 
was therefore substantially larger than its 201 bp human equivalent. The subsequent 
availability of Galgal 3.0 sequence reads confirmed the sequencing results for intron 4 
of chIL-1F5. For intron 5, 381 bp at the 5′ end and 90 bp at the 3′ end were also 
verified.  
Previous BLASTN analysis with the full length ChEST734c4 sequence against 
Galgal3.0 reads identified a contig (166095.1) containing the likely 5′ UTR sequence. 
This contig is 531 bp long comprising, 5′-3′, 170 bp of upstream (possible promoter) 
sequence, an 84 bp exon, a 118 bp intron, a 118 bp exon and finally 41 bp of (likely) 
intron sequence. To verify that the 118 bp intron sequence was correct, it was amplified 
by PCR and then sequenced. Using genomic DNA from lines 61, N and 15I as template, 
a 247 bp PCR product was generated (the equivalent cDNA amplicon would be 129 bp) 
with the primers IL-1F5 Int1 F and IL-1F5 Int1 R (Figure 6.5C). Sequencing the line 61 
product revealed a 100% match with the sequence in contig 166095.1. It was already 
known this was intron 1 and is thus much smaller than its 364 bp human equivalent. 
Alignment of the combined chicken CDS and intron sequences with the genomic 
sequence in contigs 110035.1, 162436.1 and 166095.1 allowed the exact locations of 
four of the exons to be identified. From the initial alignment of chicken, human, mouse 
and platypus transcript sequences, it was apparent the chIL-1F5 gene would be likely to 
contain four exons. With the addition of two further 5′ UTR exons, it is likely that the 
chIL-1F5 gene, as with that of mammals, consists of six exons in total. This means that 
up to two further introns, separating coding region exons, have yet to be amplified.   
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The incomplete chIL-1F5 gene structure is shown in Figure 6.5D. In summary, 
the exact sizes of two exons (designated exons 4 and 5) at the 3′ end of the chIL-1F5 
coding region are known. When translated, the amino acid sequences of these two exons 
are very similar in size to the corresponding human sequences. Chicken exon 5 is much 
smaller than its human homologue which contains a long 3′ UTR. The polyadenylation 
signal in exon 5 of chIL-1F5 is found 24 nt after the stop codon. RNA is usually cleaved 
10-30 nt after the polyA signal. Therefore, the 3′ UTR of chIL-1F5 is very short 
compared to the 3’ UTR of huIL-1F5 (which is 2071 nt long). The probable chIL-1F5 5′ 
UTR is encoded by two exons, which are both smaller than their equivalents in human. 
Both of these exons appeared in the chIL-1F5 EST, which is in contrast to the situation 
in humans, in which 2 different transcripts, each containing only one of two alternative 
5′ UTR exons, are encoded. The mouse, however, encodes an IL-1F5 transcript 
containing both its 5′ UTR exons. The introns of chIL-1F5 are generally smaller than 
their human equivalents, except for intron 5 which is much larger (4 kb compared to 
201 bp). The overall length of chIL-1F5 is no shorter than 4.8 kb, so it is atypically (for 
a chicken cytokine gene) similar in size to the 5.29 kb huIL-1F5 gene.  
 
6.3.6 Identification of the genomic location 
An identical procedure to that carried out for chIL-1RN in Chapter 4, section 
4.3.6 was used to elucidate the genomic location of chIL-1F5. A TBLASTN search of 
the chicken genome (v2.1) with the chIL-1F5 amino acid sequence did not return any 
positive hits. This offered further indication that the present assembly of the chicken 
genome does not contain an IL-1 gene cluster resembling the locus found in humans. A 
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TBLASTN search of the chicken genome (Galgal3.0, unassembled) with the full length 
chIL-1F5 amino acid sequence identified two contigs (110035.1 and 162436.1) 
containing the coding sequence from residues 35-171, the 71 bp intron and 184 bp novel 
sequence beyond the stop codon. An additional BLASTN search with the full length 
ChEST734c4 sequence against the same reads identified a further contig (166095.1) 
containing the likely 5′ UTR sequence. These contigs were mined from “removed data” 
sequence reads and are thus unplaced, indicating the third build of the genome sequence 
may not provide the location of chIL-1F5.  
As for chIL-1RN, the four sequence gaps adjacent to chIL-1β were analysed for 
the presence of chIL-1F5 by PCR using purified TAM32-21N6 BAC clone DNA. 
Specific amplification in the region covered by BAC TAM32-21N6 was confirmed with 
a control PCR to amplify chIL-1β using this template. Positive control PCRs were also 
set up to amplify chIL-1β and chIL-1F5 in genomic DNA from line 61 using the same 
primer pairs. The results confirmed the presence of chIL-1β at this locus but chIL-1F5 
did not amplify from the BAC, suggesting it is encoded elsewhere (Figure 6.6). 
Following confirmation by PCR that the chIL-1F5 gene does not lie adjacent to 
chIL-1β, the CHORI261 BAC library was screened with a radiolabelled DNA probe. To 
synthesise the probe, IL-1F5 was amplified by PCR from genomic DNA from line 61 as 
template with primers IL-1F5 332L and IL-1F5 437R, yielding a product of 276 bp. 
This probe identified three apparent positive clones (Figure 6.7) which corresponded to 
the following BAC clones: 70B9, 132E6 & 161B7. Two of these clones had previously 
been placed in the chicken genome at chr2:96,686,393-96,852,271 (70B9) and 
chr2:55,324,685-55,545,707 (132E6). In the genome, the region covered by BAC 70B9 
is fully sequenced except for two gaps predicted to span 784 bp and 810 bp,  
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Figure 6.6 Agarose gel electrophoresis of IL-1β and IL-1F5 PCR products in lines 
72, 15I, 0 (IL-1β) and line 61 (IL-1F5) genomic DNA and TAM32-21N6 BAC DNA. 
Examination of the locus containing chIL-1β shows four sequence gaps are present 
immediately adjacent to the 5’ end of the gene. The gaps were examined for further 
chIL-1 family genes by PCR using purified TAM32-21N6 bacterial artificial 
chromosome (BAC) clone DNA, which covers the entire region, as template. To 
confirm specific amplification in the region covered by the BAC, a control PCR to 
amplify chIL-1β using this template was included. Positive control PCRs were set up to 
amplify chIL-1β and chIL-1F5 in genomic DNA, using the same primer pairs as for the 
BAC DNA PCRs. 
 
 
 
 
Figure 6.7 Screening a BAC library to elucidate the genomic location of chIL-1F5. 
The CHORI261 BAC library was screened with a radiolabelled DNA probe 
corresponding to 276 bp of chIL-1F5. This probe identified 3 apparent positive clones 
which corresponded to the following BAC clones: a) 70B9, b) 132E6 & c) 161B7. 
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respectively. Again, for BAC 132E6 the genome sequence coverage is extensive but the 
locus also contains gaps of predicted size 640 bp, 312 bp and 1058 bp. BAC 161B7 is 
unplaced in the current build of the chicken genome (v2.1). All three BAC clones were 
acquired from CHORI and DNA was purified as described in the methods. BACs were 
screened by PCR to establish whether the identified sequence gaps contained chIL-1F5. 
Although all of the gaps at both loci on chromosome 2 are much smaller than the full 
length chIL-1F5 gene, the specified sizes of sequence gaps in the genome build are only 
estimates. Using the same primers from which the probe was synthesised, five PCRs 
were set up; a positive control to amplify genomic DNA from line 61; a no template 
control, and reactions with the three BAC DNA templates. A single band of the correct 
size was apparent following agarose gel electrophoresis of the positive control and test 
(BAC) PCR products (Figure 6.8). When repeated using brand new PCR reagents and 
new BAC DNA preparations, this product was no longer amplified from BAC DNA, 
but continued to be synthesised from genomic DNA (Figure 6.9). None of the clones 
corresponding to positive hybridisation signals, therefore, contained the chIL-1F5 gene.  
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Figure 6.8 Agarose gel showing PCR products from the amplification of IL-1F5 
using BAC DNA and genomic DNA from line 61. Products were amplified with the 
IL-1F5 332L & 437R primers. A negative (no template) control reaction was also set 
up. Lane 1 = negative control, 2 = 100 bp DNA ladder, 3 = 50 bp DNA ladder, 4 = 
clone 70B9, 5 = clone 132E6, 6 = clone 161B7 (prep 1), 7 = clone 161B7 (prep 2), 8 = 
positive control (line 61 genomic DNA), M = 1 kb ladder. 
 
Chapter 6: Identification, cloning and characterisation of chicken IL-1F5 
 
261 
 
1     2     3    4    5     6    M
600
500
400
300
200
100
bp
 
 
Figure 6.9 Agarose gel showing PCR products from the repeated amplification of 
IL-1F5 using BAC DNA and genomic DNA from line 61. Products were amplified 
with the IL-1F5 332L & 437R primers. A negative (no template) control reaction was 
also set up. Lane 1 = negative control, 2 = clone 70B9 (original prep), 3 = clone 132E6 
(new prep), 4 = clone 161B7 (new prep), 5 = 161B7 (original prep), 6 = positive control 
(line 61 genomic DNA), M = 100 bp ladder.  
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6.4 Discussion 
Early studies into the interleukin-1 gene cytokine family identified and 
characterized the protein products of three ligand genes: IL-1β, IL-1α and IL-1RN. For 
almost another decade, only a single novel IL-1 ligand (IL-18) (Okamura, Tsutsi et al. 
1995) was found. However, during this same period an increasing number of orphan 
receptors with IL-1R-like features were discovered. The availability of the human 
genome sequence revealed a further six IL-1 family ligand genes (IL-1F5-F10) 
clustered with the original three members on human chromosome 2. Subsequent work 
has attributed most of these ligands to IL-1 family receptors, with some formerly 
orphaned receptors now having defined roles. One of these more recently discovered 
members, IL-1F5 (IL-36RN), suppresses inflammation through its role as a receptor 
antagonist of IL-1RL2 (IL-1Rrp2) (Debets, Timans et al. 2001). This prevents the 
agonists IL-1F6 (IL-36α), IL-1F8 (IL-36β) and IL-1F9 (IL-36γ) from binding this 
receptor to initiate gene transcription via NF-kB and MAP kinases. As with IL-1RN, IL-
1F5 fails to recruit IL-1RAcP on the cell surface. IL-1F5 can also downregulate 
inflammation through an (as yet unelucidated) interaction with the orphan receptor, 
SIGIRR (Costelloe, Watson et al. 2008). The gene for IL-1F5 is present in the genome 
sequence of many mammalian species and is considered to have arisen following gene 
duplication from IL-1RN in the mammalian lineage. 
This Chapter describes the identification and characterization of IL-1F5 in the 
chicken. Whilst many similarities between the chicken gene and its mammalian 
orthologues exist, several contrasting features were identified.  
The locus containing chIL-1β exhibits limited conserved synteny with the 
human IL-1 gene locus but lacks any further IL-1 genes. TBLASTN searches of the 
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chicken genome with the chIL-1β amino acid sequence did not reveal any further IL-1 
gene loci. The same sequence was also used to mine the NCBI database for ESTs 
encoding novel chicken IL-1 genes. This search identified a novel EST, whose predicted 
amino acid sequence was shown to most closely resemble IL-1F5 following subsequent 
BLASTP analysis. A moderate degree of amino acid identity (31.2%) between the 
predicted chIL-1F5 sequence and human and mouse IL-1F5 was found. Chicken 
cytokines typically share 25-40% amino acid identity with their mammalian 
homologues. Additional in silico analyses supported the BLASTP results to 
unequivocally establish the identity of the gene. Phylogenetic analysis was able to 
confirm it is distantly related to mammalian IL-1F5. Analysis of the predicted 
secondary structure of chIL-1F5 identified 12 β-strands located in almost identical 
regions to the mouse IL-1F5 sequence; the only experimentally resolved IL-1F5.  
Attempts to determine the genomic location of chIL-1F5 were unsuccessful. 
PCR results indicated chIL-1F5 does not lie adjacent to chIL-1β as it does in mammals. 
Despite this, limited conserved synteny with the human, anole lizard and zebrafish 
genomes implies the IL-1 locus on chicken chromosome 22 may have had a common 
ancestral origin with the larger IL-1 loci in those species. For example, the avian 
orthologues of 2 genes (SLC20A1 and CKAP2L) that flank the human cluster are 
located adjacent to chicken IL-1β, although no other genes are shared by the two loci 
(see Chapter 3, Figure 3.1). Similarly, the avian orthologues of three genes (YKT6, 
NUDCD3 and OGDH) situated next to the lizard IL-1 cluster (containing IL-1RN, IL-
1F5, IL-1F10) are located adjacent to chicken IL-1β. In the zebrafish, NUDCD3 and 
OGDH are also found adjacent to its IL-1β gene. How these loci have arisen and 
evolved to represent their current compositions, however, cannot be explained with a 
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simple answer. Perhaps the most logical explanation is that all IL-1 genes evolved from 
a common ancestor followed by substantial sequence divergence within each species. 
The majority of single locus multigene families are conserved between humans and 
chickens and are likely to have arisen this way. As this is not the case with the chIL-1 
family, significant chromosomal rearrangement must have taken place in the chicken at 
some point, leading to the separation of IL-1F5 (and IL-1RN) from IL-1β. If the IL-1 
family has emerged this way, then gene duplication from a common ancestral gene 
would have to precede the divergence of birds and mammals which took place ~310 
Mya. This would comprehensively disprove Mulero, Nelken et al. (2000) who 
speculated IL-1F5 evolved following divergence from the IL-1RN sequence around the 
time mammals emerged ~200 Mya. An alternative hypothesis for the origin of IL-1F5 in 
three species as diverse as human, chicken and lizard, is species-specific convergent 
evolution. Despite the number of similar structural features between the human and 
chicken IL-1F5 genes appearing to be relatively low (compared with similarities 
between huIL-1RN and chIL-1RN genes), this would still represent an extraordinary 
occurrence.  
A hypothesis of differential gene loss within different species may also explain 
how IL-1F5 has arisen at discordant loci in humans and chickens. Assuming the three 
human IL-1 loci constitute regions of the genome containing paralogous genes, their 
origins could be traced to a single ancestral locus which underwent duplication. This 
ancient locus could have contained both IL-1β and IL-1F5, which upon subsequent 
genome duplication formed several paralogous IL-1 loci each encoding a copy of both 
genes. Additional duplications in the human genome may have expanded the size of the 
IL-1 gene family at one locus, whilst the other may have contracted, conceivably 
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leaving only IL-33. In the chicken, one locus could have lost IL-1F5 (and IL-1RN), 
whilst retaining IL-1β; with the opposite scenario taking place at a second locus.  
Efforts to elucidate the mechanism by which the IL-1F5, F6, F8 and F9 proteins 
are secreted from cells have so far been inconclusive. None of the four genes encode a 
signal peptide like IL-1RN, nor have an obvious pro-domain like IL-1β and IL-1α. Only 
a single report to date has described the secretion of IL-1F5, from trophoblastic JEG-3 
cells, although the mechanism remains unknown (Barton, Herbst et al. 2000). Another 
study has attempted to characterize the mechanism by which murine IL-1F6 is released 
from bone marrow-derived macrophages (Martin, Scholler et al. 2009). It revealed 
export was not constitutive, but was increased significantly in response to LPS/ATP 
stimulation of cell surface P2X7 receptors. No evidence of proteolytic cleavage was 
found as IL-1F6 from conditioned medium was exactly the same size as that found in 
cell lysates. Unpublished observations in two other recent papers imply proteolytic 
cleavage may take place to yield mature proteins with increased specific activity. For 
instance, a truncated mutant of murine IL-1F6 with Arg8 as its first amino acid has 
~10000-fold greater specific activity than the full length molecule (Blumberg, Dinh et 
al. 2010). Likewise, an IL-1F9 truncation mutant starting at Gly13 exhibits similarly 
enhanced activity (Blumberg, Dinh et al. 2010). NH2-terminally cleaved IL-1F5 and IL-
1F8 also exhibit increased bioactivity (Sims and Smith 2010). The fact that neither IL-
1F6 nor IL-1F9 mutants are cleaved at an aspartic acid residue (the caspase-1 cleavage 
site) may mean they are processed independently of the inflammasome. The classical 
model of enzymatic cleavage incorporates this consensus sequence: P4-P3-P2-P1|P1’-
P2’-P3’-P4’, whereby the protein is cleaved between P1 and P1’. The chIL-1F5 protein 
is not predicted to be cleaved by caspase-1 as it does not contain any sites that fully 
Chapter 6: Identification, cloning and characterisation of chicken IL-1F5 
 
266 
 
conform to the published P4-P1 consensus ([F/W/Y/L]-N-[H/A/T]-D for human 
proteins). Despite this, it does contain three aspartic acid residues at positions 6, 34 and 
44 at the N-terminus. The P4-P1 sequences are ALFD, AVRD and CLRD at these sites, 
respectively. A degree of homology is shared between these sites and the caspase-1 cut 
sites of huIL-1β and IL-33. The two IL-1β cut sites are FEAD and YVHD. Examining 
the four residues at the Asp34 site of chIL-1F5 shows those at the P3 (V) and P1 (D) 
positions are identical to those within the YVHD huIL-1β sequence. Even greater 
similarity exists between the huIL-33 caspase-1 cut site of ALHD and the Asp6 site of 
chIL-1F5 (ALFD), which are identical at positions P4, P3 and P1. Caspase-1 cleavage 
of IL-33 at this site inactivates this cytokine (Cayrol and Girard 2009), although there 
still remains much contention and conflicting evidence concerning exactly how it is 
processed (Sims and Smith 2010). The published consensus sequence for caspase-1 is 
for human proteins and it may be the case that chicken caspase-1, with which it shares 
41% identity, exhibits moderately divergent substrate specificity for residues P4-P2 
when P1 = D.  
A number of striking differences between the chicken and human sequences at 
both nt and aa levels were noted during this study. For instance, the chIL-1F5 aa 
sequence has a much longer NH2-terminus than the human protein, which may have a 
functional consequence. The platypus IL-1F5 aa also has a longer 5′ end, although, this 
is uncharacteristically predicted (for this cytokine) to contain a signal peptide. The 
chIL-1F5 aa sequence contains a nuclear export sequence (NES). This motif may not be 
functional as most proteins <50 kDa are able to diffuse freely across nuclear membranes 
(Fahrenkrog and Aebi 2003). However, proteins with defined nuclear roles are 
considered to be transported in a controlled manner (la Cour, Kiemer et al. 2004). 
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Whether this NES is functional will have to be investigated in vitro. This would also 
raise the question as to how IL-1F5 accumulates in the nucleus such that it is required to 
be exported and why? To date, within the IL-1 family, only huIL-1α is actively 
transported across the nuclear membrane, although in the opposite direction, as it 
contains a nuclear localization signal (NLS) (Wessendorf, Garfinkel et al. 1993). 
Human IL-1β, IL-1F7b and IL-33 also have nuclear functionality, although how they 
arrive in the nucleus is not known (Luheshi, Rothwell et al. 2009). 
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7.1 Introduction 
Discovery of the novel IL-1F genes expanded the repertoire of cytokines 
coordinating innate and inflammatory immune responses, increasing our knowledge of 
the depth and complexity of this highly sophisticated signalling network.  
A high degree of sequence identity with IL-1RN suggested IL-1F5 would be an 
antagonist; however, initial studies examining its biology were unable to ascribe an 
obvious function. The purified recombinant form did not, for instance, possess either 
agonist or antagonist activity in NF-κB reporter assays, bioassays conducted in primary 
osteoblasts or in any T cell lines used in earlier assays characterizing IL-1 bioactivity 
(Busfield, Comrack et al. 2000). Similarly, using either fibroblasts or endothelial cells, 
IL-1F5 did not stimulate IL-6 production or attenuate IL-1α/IL-1β-mediated 
upregulation of the same proinflammatory cytokine. It also failed to either stimulate 
IFN-γ production in the human myelomonocytic KG-1 cell line, or suppress its 
induction following PHA/IL-18 co-stimulation (Barton, Herbst et al. 2000). 
Interestingly, both these studies expressed IL-1F5 in COS-7 cells and found 
significantly more recombinant protein in the supernatants than was present in the 
lysates. Supernatant from cultured JEG-3 cells, a human tumour cell line which 
constitutively expresses IL-1F5, was also found to contain much more rIL-1F5 than the 
lysate following immunoprecipitation (Barton, Herbst et al. 2000). As IL-1F5 lacks a 
signal peptide, pro-domain and N-linked glycosylation sites, this consistent observation 
strongly implies an unorthodox mode of secretion.  
A major breakthrough only a year later conclusively determined the biological 
function of IL-1F5 as a receptor antagonist of the IL-1RL2 (IL-1Rrp2) (Debets, Timans 
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et al. 2001). In this study, Jurkat T cells transiently transfected with IL-1RL2 were 
stimulated with IL-1F9, leading to NF-κB activation. This response was effectively 
antagonized by IL-1F5. Typically, a 100- to 1000-fold excess of IL-1RN over IL-1β/IL-
1α is required to effectively antagonise IL-1RI, whereas this study showed equimolar 
concentrations of IL-1F5 and IL-1F9 were sufficient for inhibition of IL-1RL2 
activation (Debets, Timans et al. 2001). This work also highlighted the short comings of 
previous studies (Barton, Herbst et al. 2000; Busfield, Comrack et al. 2000) which 
failed to investigate orphan receptors or novel IL-1F agonist ligands. Another of the 
original papers describing the novel IL-1F members disagreed with the findings of 
Debets, Timans et al. (2001). These studies investigated ligand-receptor binding 
interactions between orphan receptor Fc fusion proteins and IL-1F5-F8 but were unable 
to observe any, including IL-1F5 being unable to bind to IL-1RL2 (Smith, Renshaw et 
al. 2000). In another study, Towne, Garka et al. (2004) only found partial IL-1RL2 
antagonism by IL-1F5 in Jurkat cells transfected with the receptor, and this was not 
consistently observed. Interestingly, although IL-1F6, -F8 and -F9 activated NF-κB and 
MAPKs in a reporter assay using IL-1RL2 transfected cells, none of the ligands bound 
this receptor when it was fixed on a BIAcore chip (Towne, Garka et al. 2004). In 
synovial fibroblasts and articular chondrocytes stimulated with IL-1F8, antagonism of 
this response by IL-1F5 was only transient (Magne, Palmer et al. 2006). A subsequent 
study provided a more robust assessment of the role of IL-1F5, examining the effects of 
knocking the gene out. In transgenic mice overexpressing il-1f6, an abnormal skin 
phenotype develops. The severity of this phenotype is worsened in il-1f5 deficient mice, 
underlining its role as an antagonist of inflammation (Blumberg, Dinh et al. 2007). It is 
possible the previous evidence investigating the role of IL-1F5 was inconsistent due to 
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inadequate or suboptimal experimental conditions. It is difficult, however, to argue with 
the results of the knockout model.  
A recent review has stated IL-1F5 is definitely a receptor antagonist, binding IL-
1RL2 and preventing recruitment of IL-1RAcP, although these are unpublished 
observations (Sims and Smith 2010). Its nomenclature has now been revised to IL-36 
receptor antagonist (IL-36RN) to reflect this function (Dinarello, Arend et al. 2010). 
Since the review by Sims and Smith (2010) was published, two more recent reports 
have provided further evidence of the antagonistic role of IL-36RN.  In a cohort of 
patients containing a homozygous missense mutation in IL-36RN, an aberrant protein 
which has lower affinity for IL-1RL2 is expressed at low levels. This leads to 
unregulated inflammation and chronic pustular psoriasis, which can be fatal (Marrakchi, 
Guigue et al. 2011). More recently, a new study appears to have comprehensively 
shown that IL-36RN is definitely the antagonist of IL-1RL2 (Vigne, Palmer et al. 2011). 
Multiple stimulatory effects induced by IL-36α, -β and -γ in bone marrow-derived DCs 
and CD4
+
 T cells were dose-dependently antagonised by IL-36RN (Vigne, Palmer et al. 
2011). In the same cells stimulated with IL-1β, preincubation with IL-36RN has no 
effect on the induction of proinflammatory effects (Vigne, Palmer et al. 2011). An 
additional, as yet unpublished, study (referred to in the discussion of Vigne, Palmer et 
al. 2011) has also characterised IL-36RN and observed the same general effect (Towne, 
unpublished). 
The second major functional role of IL-1F5 is as an anti-inflammatory cytokine 
able to downregulate IL-1 - and LPS-mediated immune responses. This has so far been 
exclusively reported in the brain of mice and rats, and apparently does not take place in 
mouse macrophages or DCs. This effect appears to be mediated through its interaction 
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with the orphan receptor SIGIRR which induces IL-4 production. Both the SIGIRR 
interaction and the production of IL-4 are integral to this particular function of IL-1F5, 
as it is abrogated in either IL-4
-/-
 or SIGIRR
-/-
 mice (Costelloe, Watson et al. 2008).  
There have been no further studies investigating the function of IL-1F5. Despite 
only a small number of reports, with some discordant findings, IL-1F5 is evidently 
involved in downregulating the immune response.  
IL-1F5 appears to be broadly expressed in humans and mice with transcripts 
detectable in most major organs and several cell subsets. Initial studies used Northern 
blotting and in situ hybridisation to quantify expression as restricted to a very narrow 
range of tissues, namely skin, placenta, uterus, thymus and keratinocytes (Barton, 
Herbst et al. 2000; Busfield, Comrack et al. 2000). Subsequent analyses using RT-PCR 
and both EST and cDNA library screening identified significantly more tissues 
expressing the cytokine (Barton, Herbst et al. 2000; Smith, Renshaw et al. 2000). To 
date, only bone marrow, liver and small and large intestine have failed to show IL-1F5 
expression. Distinct populations of human cells expressing IL-1F5 include THP-1 
(monocytic leukaemia cell) ±PMA ±LPS, PBMCs ±PHA ±LPS, LPS-stimulated 
monocytes, in vitro differentiated macrophages, B-cells ± SAC and CD40L and IL-4, 
NK cells and LPS-stimulated dendritic cells (Mulero, Pace et al. 1999; Barton, Herbst et 
al. 2000; Busfield, Comrack et al. 2000; Smith, Renshaw et al. 2000). In human 
bronchial epithelial cells, both IL-4 and IFN-γ significantly decrease IL-1F5 expression 
(Chustz, Nagarkar et al. 2011).  
The expression of IL-1F5 in vivo has been incompletely studied with only a very 
small number of reports available to date. Initial studies showed IL-1F5 was highly 
expressed in skin (Debets, Timans et al. 2001) and this observation has seemed to direct 
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the focus of further studies making inflammatory skin conditions the only disease model 
examined. In various forms of human psoriatic skin, IL-1F5 expression is greatly 
increased compared with levels found in normal skin (Debets, Timans et al. 2001; 
Blumberg, Dinh et al. 2007; Johnston, Xing et al. 2011). Similarly, in the inflammatory 
psoriasis-like skin condition which develops in il-1f6 transgenic mice (Blumberg, Dinh 
et al. 2007), and the involved skin of mouse psoriasis (Johnston, Xing et al. 2011), IL-
1F5 is highly expressed. The expression of IL-1F5 following viral, fungal or parasitic 
infection has not been described. Beyond stimulation with LPS, responses to other 
bacterial agents are also unknown. 
In this Chapter, thorough analyses of both chIL-1F5 expression and biological 
activity are described. Attempts to characterise the bioactivity of full length 
recombinant chicken IL-1F5 were unsuccessful. The transcriptional profile of chIL-1F5 
provided some novel observations on possible regulation of the cytokine at sites of 
immune activation and, in particular, disease states. 
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7.2 Methods 
7.2.1 Sources of chicken tissues and cells 
All chicken tissues and cells were acquired, sorted and stimulated as described 
in Chapter 2, section 2.4.1.1. Tissues and cells were acquired from SPF chickens 
challenged with bacteria or virus as described in Chapter 2, section 2.4.1.2.  
7.2.2 HD11 time course stimulation 
HD11 cells were routinely cultured as described in Chapter 2, section 2.4.12.1 
and 2.4.12.2. Cells were stimulated with LPS as described in Chapter 2, section 2.4.16.  
7.2.3 Transfecting cells with pure chicken DNA 
HEK293T cells were transiently transfected with a pure chicken IL-1F5pHLSec 
CDS clone as described in Chapter 2, section 2.4.12.3.2. 
7.2.4 Purification and analysis of HIS-tagged recombinant proteins 
Recombinant IL-1F5pHLSec protein was purified from crude HEK293T culture 
supernatants under denaturing conditions as described in Chapter 2, section 2.4.13.2, as 
initial attempts to purify under native conditions repeatedly resulted in loss of the 
protein (determined by SDS-PAGE and Western blotting). Purified proteins were 
analysed by SDS-PAGE and Western blot as described in Chapter 2, sections 2.4.14.1 
and 2.4.14.2. Pure proteins were quantified using the Bradford assay as described in 
Chapter 5, section 5.2.4. 
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7.2.5 HD11 bioassay 
7.2.5.1 LPS optimisation assay  
A pilot study was set up to quantify the optimal concentration of LPS to use in 
subsequent “test” assays. Two rows of a 24-well plate were seeded with 5x105 HD11 
cells/well and cultured overnight at 41°C, 5% CO2. The next day, HD11 cells were 
stimulated with LPS (strain: Kleibsiella pneumoniae) across the following concentration 
range: 5000, 2500, 1000, 500, 250, 100, 50, 25, 10 and 1 ng/ml, and incubated for 12 h 
overnight. The concentration of nitrites (NO2
-
) was measured in HD11 culture 
supernatants by the Griess reaction as outlined in Chapter 2, section 2.4.15.2.1.  
7.2.5.2 Final bioassay conditions 
HD11 cells were seeded in a 24-well plate at 1x10
6
 cells/well and cultured with 
a doubling dilution series of pure rIL-1F5 (range: 625-19.53 µg/ml) for 4 h at 41°C, 5% 
CO2.  Next, cells were stimulated with 200 ng/ml LPS and cultured overnight at 41°C, 
5% CO2. The next day, culture media was tested for nitrites by the Griess reaction as 
outlined in Chapter 2, section 2.4.15.2.1. The rest of the supernatant was discarded, 
cells were lysed with 600 µl RLT buffer and lysates were used immediately or frozen at 
-80°C. Optimal bioassay conditions were determined empirically and all assays 
described in this Chapter were carried out under these conditions. 
7.2.5.3 Quantifying the biological response 
The concentration of nitrites (NO2
-
) was measured in HD11 culture supernatants 
by the Griess reaction as outlined in Chapter 2, section 2.4.15.2.1. IL-1β and iNOS 
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mRNA levels were quantified by TaqMan® as described in Chapter 2, sections 2.4.4.6 
and 2.4.15.3.2 and this Chapter, section 7.2.6.  
7.2.6 Total RNA isolation and real-time qRT-PCR (TaqMan®) analysis of 
chicken mRNA expression 
RNA was extracted from the tissues and cells used in this Chapter as described 
in Chapter 2, sections 2.4.2.1 and 2.4.2.2.  
Primers and probes to detect expression of IL-1F5, IL-1β, iNOS and 28S were 
designed using Primer Express (Applied Biosystems) as described in Chapter 2, section 
2.4.4.6. Standard probes labelled at the 5′ end with 5- or 6-carboxyfluorescein (FAM) 
fluorophore, and at the 3′ end with tetramethylrhodamine (TAMRA) quencher dye were 
used to detect IL-1β, iNOS and 28S expression. The probe used to detect IL-1F5 
transcripts was labelled with FAM at the 5′ end and dihydrocyclopyrroloindole 
tripeptide minor groove binder ligand (MGB) at the 3′ end. Assays were performed as 
described in Chapter 2, section 2.4.4.6.  
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7.3 Results 
7.3.1 Analysis of IL-1F5 mRNA expression in unstimulated tissues by real-time 
qRT-PCR  
The expression profile of chIL-1F5 was examined in a broad range of chicken 
tissues and cells by qRT-PCR (TaqMan®) (Figure 7.1). Expression was ubiquitous with 
highest levels, in lymphoid tissues, in the blood, spleen and thymus. In non-lymphoid 
tissues, expression was highest in lung and skin. By contrast, the expression of 
mammalian IL-1F5 appears to be restricted to skin, brain, spleen, leukocytes (Mulero, 
Pace et al. 1999), and placenta, thymus, macrophages and LPS-stimulated monocytes 
(Barton, Herbst et al. 2000). 
 
7.3.2 Analysis of IL-1F5 mRNA expression by real-time qRT-PCR in sorted 
cells which were either unstimulated or stimulated  
Constitutive expression of IL-1F5 was detected in all 20 subsets of sorted 
chicken lymphocytes. In heterophils (± LPS stimulation) and LPS-stimulated blood-
derived monocytes, IL-1F5 expression was substantially higher than in the rest of the 
panel (Figure 7.2). DCs and macrophages derived from bone marrow were also 
stimulated with LPS; however, this did not lead to an increase in IL-1F5 expression.  
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Figure 7.1 IL-1F5 expression in lymphoid and non-lymphoid tissues as measured 
by real-time qRT-PCR. Results are expressed as corrected 40-Ct +SEM. Lymphoid: 1, 
bursa of Fabricius; 2, caecal tonsil; 3, Meckel’s diverticulum; 4, spleen; 5, thymus; 6, 
Harderian gland; 7, bone marrow; 8, blood. Non-lymphoid: a, lower gastrointestinal 
tract (GIT); b, mid-GIT; c, upper GIT; d, kidney; e, lung; f, heart; g, muscle; h, brain; i, 
skin. j, caecal wall; k, liver.  
 
7.3.3 Analysis of IL-1F5 mRNA expression across a time course by real-time 
qRT-PCR in three different populations of stimulated macrophages  
As described in Chapter 5, section 5.3.3, three different populations of 
macrophages were stimulated in culture from 0-48 h. IL-1F5 expression was assessed in 
in vitro cultured HD11 cells stimulated with LPS from 0-24 h. Expression was also 
measured in two ex vivo populations; bone marrow-derived macrophages (BM-MØ) and 
blood monocyte-derived macrophages (Mo-MØ), stimulated with LPS or CD40L for 1-
48 h. In the HD11 macrophage cell line, IL-1F5 expression increased by 1.75-fold at 1 
hps. This level of expression was sustained at 2 hps, but then noticeably declined by 6 
hps, being 2.6 fold lower. The level of expression then remained constant for the  
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Figure 7.2 IL-1F5 expression in sorted chicken lymphocyte subsets as measured by 
real-time qRT-PCR. Results are expressed as corrected 40-Ct ± SEM. Bars represent 
expression in: 1, splenocytes; 2, bursal cells; 3, PMA-stimulated bursal cells; 4, 
thymocytes; 5, CD4+ cells; 6, CD8α+ cells; 7, CD8β+ cells; 8, TCR1+ cells; 9, TCR2+ 
cells; 10, TCR3+ cells; 11, Bu-1+ cells; 12, KULO1+ cells; 13, BM-DC; 14, LPS-
stimulated BM-DC; 15, BM-MФ; 16, LPS-stimulated BM-MФ; 17, blood-derived 
monocytes; 18, LPS-stimulated blood-derived monocytes; 19, heterophils; 20, LPS-
stimulated heterophils. 
 
duration of the experiment (Figure 7.3).  
In BM-MØ, large differences in IL-1F5 expression were observed between LPS-
stimulated and unstimulated control cells. At 1 hps, mRNA expression was 1.5-fold 
higher in stimulated cells. By 2 and 4 hps, an even bigger difference was observed as 
expression had increased to 3.2-fold higher than in control cultures (Figure 7.4). At 8 
hps, however, LPS-stimulated BM-MØ exhibited identical IL-1F5 expression to the 
control cells, an inconsistent result relative to the sampled time-points before and after. 
Expression was again increased in LPS-stimulated cells at 24 h and 48 h to levels ~1.6-
fold higher than the controls. Stimulation with CD40L, however, did not affect IL-1F5 
Chapter 7: Characterisation of expression and bioactivity of chicken IL-1F5 
 
280 
 
0
5
10
15
20
25
0 1 2 6 12 24
Corrected 
40-Ct
hps
IL-1β
IL-1F5
 
Figure 7.3 Expression of IL-1F5 and IL-1β in the HD11 macrophage cell line 
following stimulation with LPS as measured by real-time qRT-PCR. Results are 
expressed as corrected 40-Ct ± SEM of three samples from single flasks. hps = hours 
post-stimulation.  
 
expression in this population. None of the observed differences in expression were 
statistically significant. 
A similar, albeit delayed response to LPS was observed in Mo-MØ. Here, LPS-
stimulation led to 1.5 and 1.7-fold increases at 1 and 2 hps compared with unstimulated 
cells. A substantial increase in expression was apparent after 4 h (7.2-fold), which 
remained high at 8 h (4.4-fold) post-stimulation, but declined thereafter. In contrast to 
the findings in BM-MØ, CD40L stimulation led to an upregulation in IL-1F5 expression 
in Mo-MØ throughout the experiment (Figure 7.5). A gradual rise in expression was 
observed in stimulated cells at 1, 2 and 4 hps, increasing by 1.9, 2.6 and 4.2-fold 
respectively, relative to controls. Expression was no higher than in unstimulated cells at 
8 hps (1.1-fold). However, at both 12 h and 24 h a difference of >2-fold was apparent in 
CD40L-stimulated cells, compared to control cultures. Again, none of the observed  
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Figure 7.4 Expression of IL-1F5 in BM-MØ stimulated with LPS or CD40L. 
Results are expressed as corrected 40-Ct ± SEM of three replicates from a single 
sample. hps = hours post-stimulation.  
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Figure 7.5 Expression of IL-1F5 in Mo-MØ stimulated with LPS or CD40L. 
Results are expressed as corrected 40-Ct ± SEM of three replicates from a single 
sample. hps = hours post-stimulation.  
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differences in expression were statistically significant. 
 
7.3.4 Analysis of IL-1F5 expression in vivo by real-time qRT-PCR following 
bacterial or viral challenge 
7.3.4.1 Infectious Bursal Disease Virus  
Chickens which have either increased resistance (line 61) or susceptibility (BrL) to 
infectious bursal disease virus (IBDV) were challenged as outlined in Chapter 2, section 
2.4.1.2. RNA was extracted from bursae of Fabricius and assayed for IL-1F5 expression 
at 2, 3 and 4 dpi (Figure 7.6). In contrast to the pattern of IL-1RNfl expression found in 
this tissue (Chapter 5, section 5.3.4.1), IBDV infection consistently downregulated IL-
1F5 mRNA expression throughout the experiment. At 2 dpi there was no statistically 
significant difference (-1.23-fold) in expression between line 61 infected and control 
birds. By contrast, a statistically significant decrease in IL-1F5 expression in infected 
BrL birds compared with controls was observed (-4.24-fold). Again at 3 dpi, differences 
between control and infected line 61 birds were not statistically significant, although 
expression was lower in the infected birds by 1.4-fold. A bigger difference in expression 
between both groups of BrL birds was again apparent at 3 dpi, being 3.46-fold lower in 
the infected cohort. This was also statistically significant. Finally, at 4 dpi, the largest 
differences in mRNA expression between control and infected birds of both lines were 
found. For the resistant line, 2.86-fold lower expression was detected in the infected 
birds relative to controls; whilst the infected susceptible birds exhibited a 6.65-fold 
decrease in expression compared with uninfected birds. At this time-point, 
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Figure 7.6 Expression of IL-1F5 mRNA in bursal cells from line 61 (resistant) and 
BrL (susceptible) chickens infected with IBDV. Results are expressed as mean 
corrected 40-Ct ± SEM of five birds per individual group. *P<0.05. dpi = days post-
infection.  
 
differences in expression were again only statistically significant in the BrL line.  
7.3.4.2 S. Typhimurium strain F98 Nal
R
  
The expression of IL-1F5 mRNA, as with IL-1RN, was assessed following 
infection of outbred RIR chickens with S. Typhimurium strain F98 Nal
R 
across a 28 day 
period (Figure 7.7). Splenocyte RNA from infected and uninfected age-matched RIR 
birds was quantified at 3, 7, 14, 21 and 28 dpi. A similar expression profile to that seen 
with IL-1RN (Chapter 5, section 5.3.4.2) was observed for this gene. At 3 dpi, IL-1F5 
mRNA expression was 4.52-fold higher in the spleen of infected birds compared to the 
uninfected controls. This result was statistically significant. For the remainder of the  
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Figure 7.7 IL-1F5 expression in splenocytes from RIR chickens following infection 
with S. Typhimurium strain F98 Nal
R
. Results are expressed as mean corrected 40-Ct 
± SEM of four birds per individual group. *P<0.05. dpi = days post-infection.  
 
experiment, differences in expression between infected and uninfected birds were small 
(range: -1.6 to 1.3-fold) and not statistically significant. 
7.3.5 Characterization of the bioactivity of IL-1F5 
7.3.5.1 Characterization of the bioactivity of pure IL-1F5  
Recombinant chicken IL-1F5 was successfully expressed in HEK293T cells 
(Figure 7.8). Full length chIL-1F5 was cloned into the pHLSec expression vector as 
described in Chapter 2, section 2.4.7.4. Following transfection into HEK293T cells, 
recombinant chicken IL-1F5 was initially detected in crude cell supernatant by western 
blot (Figure 7.8A, lane 2). However, following concentration of the supernatant and 
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Figure 7.8 Western blot of pure recombinant chIL-1F5 protein expressed in 
HEK293T cells. Samples were electrophoresed on a 4-15% Mini-PROTEAN TGX gel 
under denaturing conditions then purified under denaturing conditions. Urea was 
removed by stepwise dialysis. A. Lane 1 = 6xHIS protein ladder (Qiagen); Lane 2 = 
crude HEK293T culture supernatant containing rchIL-1F5pHLSec. B. Lane 1 = 6xHIS 
protein ladder (Qiagen); Lane 2 = crude HEK293T culture supernatant containing 
rchIL-1F5pHLSec (precipitated); Lane 3 = Denatured re-solubilised crude rchIL-
1F5pHLSec in PBS + 8M urea (the identical sample from lane 2 with added urea); Lane 
4 = Purified rchIL-1F5pHLSec (in PBS with imidazole and urea). C. Lane 1 = 6xHIS 
protein ladder (Qiagen); Lane 2 = crude HEK293T culture supernatant containing 
rchIL-1F5; Lane 3 = dialysed, urea-free purified rchIL-1F5pHLSec. Purification and 
dialysis led to a loss of protein as shown by the unclear band in this lane. Protein 
concentration = 2 mg/ml. Calculated Mw (chIL-1F5pHLSec) = 22.8 kDa. 
 
buffer exchange with PBS, the recombinant protein became precipitated and was no 
longer detectable by western blot (Figure 7.8B, lane 2). It was therefore necessary to 
purify chIL-1F5 under denaturing conditions. To do this, precipitated rchIL-1F5 was 
initially denatured with 8 M urea, which resolubilised the protein (Figure 7.8B, lane 3).  
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Following washing, purified rchIL-1F5 was detectable by western blot (Figure 7.8B, 
lane 4). To remove the urea and refold rchIL-1F5, the sample was dialysed against PBS 
then detected by western blot (Figure 7.8C, lane 3). This confirmed that dialysis had not 
caused precipitation of the protein. 
In mammals, IL-1F5 acts as an antagonist of the IL-1RL2 receptor. 
Proinflammatory immune responses are modulated via this receptor by the agonists IL-
1F6 (IL-36α), IL-1F8 (IL-36β) and IL-1F9 (IL-36γ). As yet, these ligands have not been 
identified in the chicken, so it was not possible to determine the antagonistic activity of 
chIL-1F5 in a straightforward ligand-receptor interaction bioassay. Transgenic 
technology is in its infancy in this species, ruling out the use of knockout chickens to 
establish function. Although unsuccessful in mouse macrophages, we assessed the 
ability of pure recombinant chIL-1F5 to downregulate LPS-mediated inflammation in a 
HD11 (macrophage) cell bioassay. The activity of IL-1F5 was determined by its ability 
to abrogate the LPS-mediated upregulation of IL-1β and iNOS genes. In cells stimulated 
with LPS alone, IL-1β and iNOS mRNA expression increased significantly compared to 
expression levels in unstimulated cells (Figure 7.9). Preincubation with different 
dilutions of rchIL-1F5 for 4 h prior to the addition of LPS had no effect, in that levels of 
IL-1β and iNOS mRNA expression were the same as in those cells stimulated with LPS 
alone. 
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Figure 7.9 Full length chIL-1F5 does not downregulate LPS-induced inflammation 
in HD11 cells. Doubling dilution of rchIL-1F5 from 250 μg/ml. Bars denote IL-1β and 
iNOS expression in HD11 cells pre-incubated with pure rchIL-1F5 for 4 hours prior to 
the addition of LPS for 12 hours. Results are represented as the mean corrected 40-Ct ± 
SD of 3 independent experiments. U = unstimulated cells. LPS = cells stimulated with 
LPS without IL-1F5.  
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7.4 Discussion  
The biological activity of human and mouse IL-1F5 has been characterised in 
NF-κB reporter assays showing it acts as an antagonist of IL-1RL2 (Debets, Timans et 
al. 2001), although not all groups are able to replicate these findings (Towne, Garka et 
al. 2004; Magne, Palmer et al. 2006). It is assumed to physically occupy this receptor 
preventing IL-1F6, -F8 and -F9 from binding (Sims and Smith 2010). Although 
bioassays have shown it does not initiate signal transduction, resolution of its crystal 
structure actually suggested it was more likely to operate as an agonist (Dunn, Gay et al. 
2003). As IL-1F6, -F8 and -F9 ligands remain absent in the chicken, it was not possible 
to determine the antagonistic activity of chIL-1F5 in a ligand-receptor interaction 
bioassay. Other potential methods of investigation such as a knockout model to 
establish function are also unavailable in the chicken at present. We therefore sought to 
replicate a previous assay carried out in mice, by preincubating cells in culture with IL-
1F5 prior to the addition of LPS. In mouse glial cells, IL-1F5 potently downregulated 
the effects of subsequent LPS-stimulation; however, this effect was not observed in 
macrophages or DCs (Costelloe, Watson et al. 2008). With limited scope for an 
alternative, we investigated the ability of pure recombinant chIL-1F5 to downregulate 
LPS-mediated inflammation in a HD11 (macrophage) cell bioassay. Chicken IL-1F5 
contains an additional 16 amino acids (than mouse IL-1F5) at its NH2-terminus, a 
potential nuclear export sequence, and exceptionally low amino acid identity with 
mouse IL-1F5 at both NH2- and COOH-termini. It therefore cannot be assumed to 
possess identical biological function to the mammalian protein. It did not suppress LPS-
mediated increases in IL-1β and iNOS mRNA expression.  
Purification of chIL-1F5 was initially unsuccessful under native conditions due 
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to precipitation. This was predicted to be due to the theoretical pI of chIL-1F5 being 
very similar to the pH of the HEK293T culture medium.  Purification of chIL-1F5 was 
therefore performed under denaturing conditions. This meant stepwise dialysis was 
required to purge the sample of urea and to refold the recombinant protein. It is possible 
the protein did not refold properly, which would make it unable to bind its receptor. It is 
also possible HD11 cells do not express IL-1RL2 or SIGIRR. ChIL-1F5 may just not 
function in these cells even if it is able to downregulate LPS-induced inflammation in 
other cell types. The IL-1RL2 agonist ligands are required to facilitate a more 
comprehensive assessment of function. 
Expression of IL-1F5 was ubiquitous and constitutive in the range of cells and 
tissues examined. Previous studies have assessed global IL-1F5 expression in humans 
and mice (Mulero, Pace et al. 1999; Barton, Herbst et al. 2000; Busfield, Comrack et al. 
2000; Smith, Renshaw et al. 2000) and found it was not present in all tissues. The 
highest constitutive levels of chicken IL-1F5 expression were in blood, thymus and 
spleen, reflecting a likely requirement for high levels of IL-1F5 production from 
leukocytes upon activation. Similar to IL-1RN, IL-1F5 was also highly expressed in 
KUL01+ cells and LPS-stimulated blood-derived monocytes, although expression in 
heterophils was markedly divergent. In these avian-specific cells, IL-1RNfl exhibited 
relatively low expression whereas high levels of IL-1F5 were found. As heterophils 
migrate to sites of infection more rapidly than other cell types (Wu and Kaiser 2011), 
being the dominant subset during the first 6-12 h post-infection (Harmon 1998), large 
amounts of IL-1F5 are likely to be produced during acute inflammation. There are no 
reports as yet of IL-1F5 expression in neutrophils, the mammalian equivalent of avian 
heterophils.  
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Stimulation of three distinct monocyte/macrophage populations with LPS led to 
large increases in the expression of IL-1F5 in BM-MØ and Mo-MØ, sharply contrasting 
with IL-1RNfl expression in the identical samples, which was unaffected. In both of 
these ex vivo populations, expression was much higher than the controls at 4 hps, as 
well as at 2 hps in BM-MØ and at 8 hps in Mo-MØ. At all time-points after 8 hps, IL-
1F5 mRNA levels were similar in control and LPS-stimulated cells. These novel 
findings suggest IL-1F5 is a bona fide innate immune response gene in the chicken. 
Expression of IL-1F5 has never been examined over a time course in vitro in any other 
species. As was seen for IL-1RNfl and IL-1RNSV1, IL-1F5 expression did not 
significantly increase after LPS-stimulation in the HD11 cell line.  
Chicken IL-1F5 expression was significantly increased following infection with 
S. Typhimurium. As befits an innate immune response gene, expression was much 
higher in infected than uninfected splenocytes at 3 dpi. By 7 dpi, expression was similar 
in both groups following the onset of the adaptive immune response. This expression 
profile correlated with that of IL-1RNfl in these samples.  
Infection with IBDV led to a striking decrease in IL-1F5 mRNA expression in 
both lines throughout the entire experiment. In the resistant line, differences between 
infected and uninfected birds were modest at 2 and 3 dpi. By 4 dpi, expression was 
much lower in the infected birds relative to the uninfected group, although not 
significantly so. In the susceptible line, the differences in IL-1F5 expression between 
infected and uninfected birds were much bigger than differences in the resistant line. 
Relative differences were statistically significant at 2, 3 and 4 dpi in the susceptible 
birds. It is interesting to observe such a discrepancy between the two lines of birds. It is 
not possible to say whether differences in IL-1F5 expression are caused by differential 
Chapter 7: Characterisation of expression and bioactivity of chicken IL-1F5 
 
291 
 
resistance to IBDV, whether expression differences lead to disease resistance or whether 
neither is causative. The IL-1F5 gene or genes which regulate its expression in brown 
Leghorn birds may contain certain polymorphisms which affect the amount of mRNA 
produced. Whatever the cause, these are significant and novel findings when compared 
with the results obtained for IL-1RNfl and IL-1RNSV1, and with IL-1F5 expression 
following S. Typhimurium infection, and from them we can form certain hypotheses. 
Firstly, there is some degree of regulation of IL-1F5 expression which must 
differ from the control of IL-1RN (and IL-1β) expression. It may be possible that some 
form of subversion or downregulation of the intracellular signalling pathway is taking 
place. If so, this would suggest an alternative pathway to that regulating IL-1β or IL-
1RN is being utilised as expression of both these genes is increased following IBDV 
infection (Eldaghayes, Rothwell et al. 2006). However, the likelihood of this is difficult 
to predict. 
Secondly, a viral-specific factor, either directly or indirectly, may regulate IL-
1F5 expression, for example a secreted protein binding to its promoter. The IL-1F5 gene 
may be directly influenced in response to viral infection. As its expression has never 
been assessed in response to any type of virus in any other species, there are no simple 
models for how this could occur. IL-1F5 may be at the end of a cascade of gene-gene 
interactions and so would be indirectly influenced by IBDV, but again, there is no 
precedent for this. Related to both original points, IBDV may encode a microRNA 
which degrades IL-1F5 mRNA, leading to reduced expression levels in infected birds. 
Regardless of the cause, these findings represent the first ever study of IL-1F5 
expression in response to viral infection. 
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8.1 Discussion   
The major aim of this study was to determine the extent of the IL-1 gene family 
in the chicken. Once novel chIL-1 genes had been identified, the aim was to clone and 
thoroughly characterise them at the genomic, transcriptional and translational levels. In 
humans, eleven IL-1 ligand genes encoding proteins with both pro- and anti-
inflammatory activities have been identified. Prior to this study, avian orthologues of 
only two IL-1 family agonist ligands, IL-1β and IL-18, had been characterised. None of 
the anti-inflammatory IL-1 genes, or any of the IL-1F agonists most recently discovered 
in man, had been identified in the chicken. The number of IL-1 receptor genes identified 
in the chicken was similarly small when compared with the size of the IL-1R family in 
mammals. Due to the exceptional potency of IL-1 agonist ligands such as IL-1β, it was 
surprising that the chicken appeared to lack any of the genes encoding IL-1 ligands and 
receptors that regulate inflammation. In particular, the absence of IL-1RN and the IL-
1RII and SIGIRR receptors was conspicuous, given their critical functional roles in 
limiting IL-1 activity.  
An initial examination of the IL-1 ligand and receptor gene repertoires in the 
chicken used conserved synteny and BLAST searches to fully interrogate the most up-
to-date (although incomplete) assembly (v2.1) of the chicken genome. This failed to 
uncover any further ligands beyond the two already known, but did identify a different 
genomic location to those previously reported for IL-1β. This appeared to be a genuine 
IL-1 locus, as it shared a limited degree of conserved synteny with the major IL-1 
ligand gene locus in the human genome. The human locus contains a further eight IL-1 
ligand genes, but the chicken locus clearly does not. No other areas of the chicken 
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genome provided any evidence of IL-1 ligand genes. This indicated the chicken either 
lacks these genes entirely or that some or all of them are present in areas of the genome 
that have yet to be sequenced. The latter scenario was predicted to be the most likely, 
based on the absence of fundamentally important members of the family. At the 
genomic level, this would represent an atypical situation in the chicken, assuming the 
v2.1 build was assembled correctly. In general, although chickens characteristically 
possess fewer members of multigene families than are found in mammals, their 
genomic locations tend to be conserved. Clearly, this does not extend to the IL-1 family 
in the chicken. 
In contrast to the small number of identifiable IL-1 ligand genes, all of the IL-1 
receptor genes identified in the human genome are present in v2.1 of the chicken 
genome. Additionally, they are all found in regions of conserved synteny between both 
species. The degree of conserved synteny at each of these loci is very high and strongly 
suggests this receptor family was formed in a common ancestor prior to the divergence 
of birds and mammals. Assuming this is true, the persistence in the chicken of the IL-
1RL2 and ST2 receptors over 300 million years later implies they may continue to serve 
a purpose. This provides compelling evidence for the existence of avian orthologues of 
their ligands, IL-1F5, -F6, -F8, -F9 and -F11.   
Whilst comparative genomics did not identify additional IL-1 ligand genes in the 
chicken, EST library screening uncovered sequences for IL-1RN and IL-1F5. Thorough 
analyses of both genes showed they retained certain features that were similar to those 
found in their mammalian orthologues, alongside some quite significant differences.  
The coding sequences of both secretory and intracellular IL-1RN cDNAs were 
present in the NCBI chicken EST library. Both were subsequently cloned from RNA 
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from LPS-stimulated HD11 cells and examined in silico. The predicted amino acid 
sequences were analysed by SignalP, confirming the two major structural variants of the 
mammalian gene are conserved in the chicken. Both protein sequences contain the IL-1 
signature motif, have a similar secondary structure to human IL-1RN, and share 
relatively high amino acid identity (for a chicken cytokine) with their human isoforms. 
Functionally, they both comprehensively antagonised IL-1β activity.  
The full chIL-1RN gene sequence was obtained by PCR and sequence reads 
from the latterly available unassembled third build of the chicken genome. This 
revealed a number of significant differences with the human gene, most prominently at 
the 5′ end. In this region of the chicken gene, there are two exons, ic1 and s1, separated 
by only 129 bp. By contrast, the human gene contains exons ic1, ic2 and s1 with 2.1 kb 
separating the intracellular exons and 7.5 kb between ic2 and s1. This latter region 
contains a 1.6 kb promoter proximal to s1 which drives transcription of the secretory 
transcript. Within the chicken gene, there is no obvious secretory-specific promoter in 
the respective location. This suggests the regulation of chIL-1RN transcription may 
differ from that of the human orthologue. The absence of upstream sequence in the 
genome meant it was not possible to fully characterise any putative promoter upstream 
of ic1 in the chicken. The chicken gene was also evidently missing an ic2 exon, 
suggesting fewer intracellular isoforms are present in this species. These key differences 
show the evolution of IL-1RN in the chicken has been distinctively different to that of 
the human orthologue. IL-1RN was predicted to emerge around 350 Mya, following 
duplication of an ancestral gene (Eisenberg, Brewer et al. 1991). As the major 
speciation event which led to the formation of birds and mammals happened around 40 
million years later, this suggests both human and chicken IL-1RN evolved from a 
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common ancestor. This implies that the ic2 exon was either present in the original gene 
and was then lost in birds, or it was gained independently during the evolution of 
mammals. 
Examination of the other 33 mammalian IL-1RN sequences indicates that they 
are, not surprisingly, much more closely related to huIL-1RN than chIL-1RN. Despite 
this similarity, only three of these mammals (chimpanzee, gibbon and gorilla) appear to 
possess the ic2 exon. The gene structures of the other 30 mammals may have been 
incorrectly predicted or curated. Alternatively, this exon has arisen in the primate 
lineage; however, this theory is inconsistent as orang-utans, which lack ic2, diverged 
from their ancestor after the divergence of gibbons but before the divergence of gorillas 
and chimpanzees. Clearly, the identification of IL-1RN in many more non-mammalian 
species is required to determine whether ic2 is genuinely confined to the mammalian 
lineage.  
Identification and characterisation of IL-1F5 (IL-36RN) in the chicken provided 
some novel observations as well as expanding the current thinking on evolution of the 
IL-1 cytokine family. Initial BLAST and phylogenetic analyses provided unequivocal 
confirmation of the exact identity of the cytokine. IL-1F5 in mammals acts as an 
antagonist of the IL-1RL2 receptor. As yet, the agonists of this receptor, IL-1F6, -F8 
and -F9, have not been identified in the chicken, which eliminated the possibility of 
demonstrating receptor blockade with IL-1F5. With limited alternatives, the ability of 
chIL-1F5 to downregulate LPS-mediated inflammation in a macrophage cell line 
(HD11 cells) was examined. This particular property of IL-1F5 had only previously 
been shown in rodent glial cells but not in macrophages or DCs. Although pre-
incubating cells with chIL-1F5 did not abrogate the effects of subsequent LPS 
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stimulation, it did not invoke a response prior to endotoxin exposure, confirming it lacks 
agonist activity. Despite a previous lack of reproducibility in studies carried out by 
different research groups, a new study has comprehensively shown that IL-1F5 is 
definitely the antagonist of IL-1RL2 (Vigne, Palmer et al. 2011). Multiple stimulatory 
effects induced by IL-1F6, -F8 and -F9 (IL-36α, -β and -γ, respectively) in bone 
marrow-derived DCs and CD4
+
 T cells were antagonised by IL-1F5 in a dose-dependent 
manner (Vigne, Palmer et al. 2011). An additional study (alluded to in Vigne, Palmer et 
al. (2011)) has also characterised IL-1F5 and observed the same general effect (Towne, 
unpublished). These studies indicate that chicken orthologues of the mammalian IL-36 
ligands are needed, should they exist, to assess the function of chIL-36RN.  
As previously discussed, these genes have not been found in the chicken genome 
or EST libraries. Intuitively, a receptor antagonist would be expected to be expressed in 
the same tissues that express the agonists. This is clearly the case for IL-1RN, which is 
detectable in all tissues that express IL-1β and IL-1α. The EST library containing chIL-
1F5 was made from the liver so it is not unreasonable to presume this tissue may also 
express IL-36α, -β and -γ, although they were not apparent. Interestingly, the liver cells 
that were used to make this EST library were unstimulated. Whilst we have shown the 
expression of the biologically inert IL-36RN is constitutive in all chicken tissues 
examined, this may not extend to IL-1RL2 agonists capable of multiple stimulatory 
effects. If the chicken does possess IL-36α, -β and -γ, these may be inducible genes so 
may not be expressed in an unstimulated tissue. Previous studies have consistently 
shown that IL-36α, -β and -γ expression is not constitutive in many tissues (Busfield, 
Comrack et al. 2000; Kumar, McDonnell et al. 2000; Smith, Renshaw et al. 2000; 
Debets, Timans et al. 2001); most tellingly IL-36α and IL-36β were not constitutively 
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expressed in the liver in one of these studies (Smith, Renshaw et al. 2000). In the study 
discussed above (Vigne, Palmer et al. 2011) real-time qRT-PCR showed that the IL-
1RL2 ligands were not expressed constitutively in all cells. The presence of IL-1RL2 
and its antagonist IL-36RN in the chicken strongly suggest the agonist ligand genes may 
also be present. There is of course the possibility that these ligand genes were formed in 
an ancient ancestor, present in the earliest birds and then lost during evolution. For this 
to happen, the robustness of the bird would have to be maintained by genetic 
redundancy whereby other genes, presumably IL-1 paralogues, performed the same set 
of functions. These paralogues would then be able to compensate for the loss of 
dispensable IL-1RL2 ligands. This would certainly fit with the pattern of a reduced gene 
repertoire in the minimalist avian immune genome; however, if minimalism is the 
prevailing genetic hallmark of birds, it would not explain why the genes for IL-1RL2 
and IL-36RN are maintained. Given the increasingly apparent importance of IL-36α, -β 
and -γ in mammals, it seems likely their deletion without functional compensation 
would seriously compromise the fitness of any species, including birds.  
  Prior to the commencement of this study, only two of the IL-1 family agonist 
ligands and six of the IL-1 receptor genes found in man had been identified in the 
chicken. The findings of this study have shown the IL-1 receptor family is completely 
conserved in the chicken genome. These chicken genes presumably retain similar 
functions as part of the essential signalling network of the IL-1 family. The number of 
known IL-1 ligand genes in the chicken has also been expanded following the 
identification of both receptor antagonists, IL-1RN and IL-36RN, found in humans. 
Before this study began, IL-1RN was thought to be confined to mammals; however, this 
gene has since been found in rainbow trout and now the chicken. This has demonstrated 
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that regulation in the IL-1 cytokine family is a fundamental requirement, with the IL-
1RN gene having been maintained in these two species despite millions of years of 
separate evolution and a significant amount of genomic reorganisation. The extent of 
this rearrangement within the chicken genome is clearly reflected in the observable 
differences between chIL-1RN and its mammalian orthologues. For example, chIL-1RN 
is separated from IL-1β, appears to lack a secretory-specific promoter and appears to be 
differentially regulated through splice variant formation. It is more than likely there are 
other non-mammalian species, containing an IL-1β gene, that also possess IL-1RN. 
Identification of chIL-36RN has provided further evidence of the need to regulate IL-1 
activity and has also shown that predictions of greater functional complexity in the IL-1 
family being confined to mammals (Mulero, Nelken et al. 2000) may have been 
overstated.  
This study has added two new cytokines to the growing number identified in 
birds which have previously been found in humans. A total of 27 interleukins have now 
been discovered in the chicken, compared with 41 in man. Although the minimalist 
immune genome is at present the accepted paradigm in the chicken, this is beginning to 
look less minimalist as more avian cytokine orthologues are being discovered. This is 
also expanding our understanding of the functional complexity of the immune system in 
the chicken. It remains to be seen how many of the 41 mammalian interleukins are 
actually present in this species. 
This study has also raised many questions concerning the extent to which the 
genetic and functional repertoires of the IL-1 family in man and mouse are conserved in 
birds. For instance, in humans IL-1α regulates transcription of icIL-1RN by controlling 
its promoter (La and Fischer 2001). A single report has also shown a degree of 
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regulation of IL-1α by icIL-1RN (Merhi-Soussi, Berti et al. 2005). As icIL-1RN has 
been identified in the chicken, this raises the possibility of the existence of IL-1α in the 
chicken. Alternatively, it may have lost this function, never had it in the first place or it 
may have been conserved in a paralogue. Only a single intracellular variant of icIL-1RN 
was found in the chicken, but further variants may exist. The genomic structure suggests 
icIL-1RN2 may be missing in birds; however, icIL-1RN3, formed through alternative 
translation initiation may be present. 
As discussed previously, the large discrepancy between the number of chIL-1 
receptor and ligand genes currently annotated in the genome may not be true, as the 
chicken genome may contain all of the ligands in as yet unsequenced regions. 
Identifying the genomic location of IL-1RN and IL-36RN may be a catalyst for finding 
some of these. 
 
8.2 Future work   
There are a number of ways this project could have been improved, as well as 
several other approaches which could be attempted to find further novel IL-1 genes in 
the chicken. 
Although the chIL-1F5 bioassay was possibly flawed (if the chicken orthologue 
is, as in mammals, a receptor antagonist) there are several improvements and alternative 
strategies which could be attempted to prove functionality. To establish whether the 
recombinant chIL-1F5 was correctly refolded, the protein could be analysed by nuclear 
magnetic resonance (NMR) spectroscopy.  
To overcome problems associated with mis-folded or precipitated recombinant 
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chIL-1F5, HD11 cells could be transfected with an expression vector containing the 
chIL-1F5 cDNA (alongside mock-transfected cells). Both groups of transfected cells 
could then be subsequently stimulated with IL-1β or LPS. Alternatively, siRNA 
knockdown of IL-1F5 alongside a scrambled siRNA control could be attempted in 
leukocytes. Cells could then be stimulated with LPS or IL-1β to establish if this leads to 
enhanced responses in the IL-1F5 knockdowns. This may also overcome problems with 
mis-folded protein and confirm if chIL-1F5 possesses endogenous anti-inflammatory 
activity. Unpublished observations (discussed in Sims and Smith (2010)) have also 
indicated that human IL-1F5 truncated at the NH2-terminus has increased biological 
activity. The transfection strategy outlined above could therefore also be attempted with 
a series of NH2-terminal truncation mutants of chIL-1F5. Cloning chIL-1F5 into an 
expression vector containing a GFP-tag prior to transfection would allow the movement 
of the protein to be monitored using laser scanning confocal microscopy. This may 
provide an insight into whether this protein is translocated to the nucleus and if it is 
subsequently exported as free ligand. This could reveal a role for the putative nuclear 
export sequence discussed in Chapter 6, section 6.3.4. 
None of the chIL-1RN splice variants appeared to be bioactive in the assays 
carried out. This could be a genuine effect or could be due to problems with translation 
or correct folding of the proteins. The efficiency of mRNA translation can be measured 
by the extent to which transcripts associate with ribosomes. Those mRNAs which are 
being efficiently translated are physically bound by numerous ribosomes (polysomes), 
whereas mRNAs being inadequately translated are associated with a single ribosome 
(monosome) (Ingolia, Ghaemmaghami et al. 2009; Esposito, Mateyak et al. 2010). 
These distinct pools of ribosome-bound mRNAs can be separated and then analysed by 
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Northern blotting. A polysome profile of the COS cells transfected with IL-1RN splice 
variant cDNAs could thus be carried out alongside a profile of cells transfected with full 
length IL-1RN.    
Chickens which are either resistant (line 61) or susceptible (BrL) to infectious 
bursal disease virus (IBDV) were challenged with the virus as outlined in Chapter 2, 
section 2.4.1.2. As discussed in Chapter 7, section 7.3.4.1, this led to a noticeable 
decrease in IL-1F5 mRNA expression in both lines throughout the entire experiment. In 
the BrL line, the differences in expression between infected and uninfected birds were 
much greater than differences in line 61. The IL-1F5 gene in BrL birds may contain 
SNPs which affect the amount of mRNA produced, or mRNA half-life, and thus 
contribute to disease susceptibility. It would therefore be interesting to fully sequence 
the coding region, 5′ UTR, 3′ UTR and putative promoter of the IL-1F5 gene in both 
lines to identify possible differences.  
It may be possible that further variants of icIL-1RN exist in the chicken. As 
icIL-1RN3 is formed through alternative translation initiation and has 100% nucleotide 
sequence identity with other intracellular isoforms, a molecular biology approach is not 
feasible. Raising a monoclonal antibody to chicken icIL-1RN should permit detection of 
all potential isoforms of this variant, if targeted against a region of the protein likely to 
be present in all isoforms. As any equivalent icIL-1RN3 isoform would have a much 
lower molecular weight than the isoforms created through alternative transcriptional 
splicing, distinguishing between the isoforms could then be possible using western 
blotting. Avian equivalents of the cell types which predominantly express icIL-1RN3 in 
mammals would be the first cells to test.   
 The genomic locations of chIL-1RN and chIL-1F5 were not identified during 
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this study. An alternative approach to those tried would be to use fluorescence in situ 
hybridisation (FISH). Generating probes as close as possible in length to both full 
length gene sequences would be required to achieve specific hybridization. 
A number of possible strategies could be attempted to uncover novel IL-1 
ligands in the chicken. Firstly, all IL-1 ligands in mammals have several regions within 
their cDNA sequences which are highly similar. These include the three common final 
exons in every transcript; the areas which correspond to the β-sheets of the protein 
secondary structure and the region containing the IL-1 family signature motif which has 
the highest homology between paralogues. For each IL-1 gene, cDNA and amino acid 
alignments should be created between all species possessing that orthologue. Regions 
with the highest homology between species would then be identified and degenerate 
primers designed against these regions. Multiple degenerate primers can then be used to 
attempt to amplify IL-1 ligand genes in the chicken. Although avian cytokines typically 
share 25-40% sequence identity with their mammalian equivalents, both chIL-1F5 and 
IL-1RN contain a number of short regions with 80-100% identity with the mammalian 
sequences. These are visible in Chapter 4, Figure 4.9 and Chapter 6, Figure 6.3. It is 
also apparent that, for any particular IL-1 gene, the signature motif is highly conserved 
between all species. For example, the motif in IL-1β is well conserved in mammals, 
birds, fish and amphibians (Bird, Zou et al. 2002). When attempting to amplify novel 
chicken orthologues, it would be prudent to design the reverse primers in the signature 
motif region. 
A proteomic screen of supernatants from stimulated avian cells may be useful 
for identifying novel chicken IL-1 ligands. In murine macrophage cultures stimulated 
with LPS and ATP, IL-1F6 was released into the supernatant (Martin, Scholler et al. 
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2009). This has also been repeatedly shown to induce IL-1β secretion into cell culture 
supernatants. The underlying mechanism is that of passive release following activation 
of the P2X7 receptor on the cell surface. A similar experiment could be attempted with 
avian macrophages that express the P2X7 receptor. These cells could be similarly 
stimulated with LPS and ATP and pools of proteins in the supernatants could be 
detected by mass spectrometry. It may be possible to identify passively secreted novel 
IL-1 proteins by de novo peptide sequencing of the entire pool of secreted proteins.  
At present, the chicken genome sequence is incomplete and poorly annotated 
throughout. The majority of chromosomes contain sequence gaps, some of which are 
likely to contain missing genes. With higher sequencing throughput, reduced costs and 
better chemistries, this may improve the overall sequence coverage, potentially 
uncovering many novel genes. This may lead to identification of further IL-1 family 
members in the chicken.   
 
8.3 Conclusion 
In summary, the chicken orthologues of IL-1RN and IL-36RN have been 
identified. Functionally, chIL-1RN exhibited biological activity resembling that of its 
mammalian homologues; however, the function of chIL-36RN remained undetermined. 
The expression of both genes was increased following bacterial infection; however, 
chIL-36RN mRNA expression decreased whilst chIL-1RN expression increased in a 
viral challenge model. Attempts to identify the genomic locations of both genes 
revealed they were not clustered at a conserved locus with chIL-1β. Although their 
exact locations were not identified, the absence of an IL-1 gene cluster similar to the 
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one found in humans suggested the evolution of the chIL-1 family has been distinctly 
different to that in mammals.  
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Appendices 
 
Appendix I: BLAST results 
 
TBLASTN searches were performed in Chapter 4, section 4.3.1 and Chapter 6, section 
6.3.1 against all 39 eukaryotic genomes present in ENSEMBL release 50 (July 2008). 
These 39 species are: Primates: Bushbaby, Chimpanzee, Human, Macaque, Mouse 
Lemur, Orangutan; Rodents: Guinea pig, Mouse, Pika, Rabbit, Rat, Squirrel, Tree 
shrew; Laurasiatheria: Cat, Cow, Dog, Hedgehog, Horse, Microbat, Shrew; Afrotheria: 
Elephant, Lesser hedgehog tenrec; Xenarthra: Armadillo; Marsupials and Monotremes: 
Opossum, Platypus; Birds: Chicken; Reptiles and Amphibians: X. tropicalis; Fish: 
Fugu, Medaka, Stickleback, Tetraodon, Zebrafish; Other chordates: C. intestinalis, C. 
savignyi; Other eukaryotes: Aedes, Anopheles, C. elegans, Fruitfly, S. cerevisiae.  
BLAST results are in Tables I and III.  
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Table I 
Species Genomic location Statistics 
score 
E-value % 
amino 
acid 
identity 
Length Gene 
Megabat GeneScaffold_1674       274 4.0e-21   41.59 113 IL-1RN 
Kangaroo 
Rat      
GeneScaffold_3082   223 1.1e-23   42.67   75 IL-1RN 
Horse  Chr:15   231 5.1e-16   34.82   112 IL-1RN 
Hedgehog  GeneScaffold_4042   239 8.3e-22   44.59   74 IL-1RN 
Lesser 
hedgehog 
tenrec 
GeneScaffold_3935       255 1.4e-26   37.65   85 IL-1RN 
Cat GeneScaffold_4437 262     9.2e-17   46.74   92 IL-1RN 
Human Chr:2       228 9.9e-19   41.67   84 IL-1RN 
Elephant scaffold_21082 278 4.5e-17   48.89   90 IL-1F5 
Macaque Chr:13   229 5.8e-20   43.42   76 IL-1RN 
Opossum Chr:1     254 6.2e-21   45.45   77 IL-1RN 
Mouse Chr:2           283 1.0e-14   48.45   97 IL-1F5 
Microbat GeneScaffold_2623       263 6.5e-30   40.62   96 IL-1RN 
Pika GeneScaffold_4797       247 1.1e-25   40.66   91 IL-1RN 
Platypus Contig1254       253 5.2e-27   41.67   84 IL-1RN 
Bushbaby GeneScaffold_2376       251 6.8e-20   48.68   76 IL-1RN 
Rabbit GeneScaffold_3038       248 1.0e-27 43.37 83 IL-1RN 
Chimpanzee Chr:2a 236   1.5e-22   42.86   84 IL-1RN 
Orangutan Chr:2a      235 1.0e-21   40.24   82 IL-1RN 
Hyrax
a
 scaffold_40202 243 2.8e-13   41.57   89 IL-1RN 
Rat Chr:3       228 1.7e-17   40.22   92 IL-1RN 
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Shrew scaffold_223412  274 1.7e-16   43.00   100 IL-1RN 
Squirrel scaffold_127907      251 5.9e-27   40.71   113 IL-1RN 
Tarsier scaffold_22964 232 2.3e-25 41.58 101 IL-1RN 
Tree shrew scaffold_109510         318 5.3e-21 48.91 92 IL-1RN 
Dolphin scaffold_102460  257 1.3e-17   38.89 126 IL-1F5 
Dog   Chr:17   271 1.3e-21   49.45   91 IL-1F5 
Cow    Chr:11   280 8.6e-15 46.67   90 IL-1F5 
 
Table II 
Chicken IL-1 family ESTs identified by reciprocal BLASTP analysis. 
NCBI I.D. Length (bp) Aa identity 
(%) 
BLAST result 
e-value 
Gene identity 
CK615408.1 432 98 8e-77 IL-1RN 
BU214831.1 669 82 2e-70 IL-1RN 
CK607391.1 364 100 4e-63 IL-1RN 
BX257556.3 526 100 2e-36 IL-1RN 
CN778914.1 709 33 3e-13 IL-1β 
BU432992.1 612 36 2e-10 IL-1β 
CK615181.1 291 39 1e-08 IL-1β 
CN231756.1 781 62 4e-07 IL-1RN* 
CK615098.1 459 47 3e-06 IL-1β 
CK613911.1 426 47 3e-06 IL-1β 
BU455380.1 880 34 0.001 IL-1β 
CK615049.1 416 43 0.002 IL-1β 
 
*This EST is a composite of the 5’end of sIL-1RN joined to Tmed4 with NotI linkers, which 
explains the apparent contradiction between the relatively high % aa identity with a high e-value 
from the BLAST analysis.  
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Table III 
Species Genomic location Statistic
s score 
E-value % amino 
acid 
identity 
Length Gene 
Cow Chr:11        186 3.5e-05 55.81 43 IL-1F5 
Dog Chr:17         197 1.3e-05 58.14 43 IL-1F5 
Kangaroo 
Rat 
scaffold_29650 182 1.0e-06   55.81 43 IL-1F5 
Horse Chr:15 202 7.8e-07 42.22 90 IL-1F5 
Hedgehog scaffold_296053           159 1.3e-05 42.86 63 IL-1F5 
Human Chr:2         186 0.0013 55.32 47 IL-1F5 
Elephant scaffold_21082         209 1.9e-09 50.85 59 IL-1F5 
Macaque Chr:13       181 0.00034   43.33 90 IL-1F5 
Opossum
a
 Chr:1 148     0.17 47.62 42 IL-1F5 
Mouse
b
 Chr:2         172 0.017 42.11 76 IL-1F5 
Pika GeneScaffold_4797       184 6.2e-06 55.81 43 IL-1F5 
Platypus
c
 Contig1254            156 0.0012 45.45 44 IL-1F5 
Rabbit GeneScaffold_6992         189 1.6e-07 39.82 113 IL-1F5 
Bushbaby GeneScaffold_2376         183 1.7e-06 50.00 54 IL-1F5 
Orangutan
d
 Chr:2a         197 0.068 40.35 114 IL-1F5 
Hyrax
e
 GeneScaffold_3408       161 1.6e-06 32.97 91 IL-
1F10 
Rat Chr:3           186 6.8e-05 51.67 60 IL-1F5 
Dolphin
f
 scaffold_102460             188 6.0e-06 41.67 84 IL-1F5 
Shrew GeneScaffold_3283       211 9.5e-10   35.77 137 IL-1F5 
Tarsier scaffold_119097 204 8.2e-09 52.46 61 IL-1F5 
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Appendix II: Primers 
 
Table I: Primers used in RT-PCR and PCR amplification of chIL-1 cytokines 
Primer name Target for amplification Sequence (5′-3′) 
sIL-1RN F sIL-1RN cDNA ATGGCGCTCACCATCGCCCT 
IL-1RN R sIL-1RN/icIL-1RN cDNAs GCTCAGCACAGCTGGAAGTA 
sIL-1RNpHL F Mature sIL-1RN. Includes 
AgeI restriction site. 
GAGAGAaccggtGTGCCGTGCCGCGCGCCCGC 
sIL-1RNpHL R Includes KpnI restriction 
site. 
GAGAGAggtaccGCACAGCTGGAAGTAGAAAT 
icIL-1RN F icIL-1RN cDNA GGCATCTCATGGGTGAGG 
icIL-1RNpHL F icIL-1RN cDNA. Includes 
AgeI restriction site. 
GAGAGAaccggtGGTGAGGCTGCCGGATCGGT 
icIL-1RNpHL 
R 
Includes KpnI restriction 
site. 
GAGAGAggtaccGCACAGCTGGAAGTAGAAAT 
IL-1RN ex5 F IL-1RN. Used with IL-1RN 
R to amplify TAM32-21N6 
DNA. 
TCACCTTCTTCCGCACCTAT 
IL-1β/1 IL-1β. Used with IL-1β/2 to 
amplify TAM32-21N6 
DNA 
CTTCACCTTCAGCTTTCACG 
IL-1β/2 IL-1β. Used with IL-1β/1 to 
amplify TAM32-21N6 
DNA 
GCACGTCCACTGTGGTGTGC 
IL-1RN Int2-3 
F 
IL-1RN intron 2  GCTGCAAACCAAAGTCTTCA 
IL-1RN Int2-3 
R 
IL-1RN intron 2 GCGACTGCTGGTTCATATCC 
IL-1Ra Int3-4 F IL-1RN intron 3 AACCAGCAGTCGCTGTACCT 
IL-1Ra Int3-4 R IL-1RN intron 3 GCAGCTCGTGCTTGAAGAAG 
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IL-1Ra Int1-2 F IL-1RN intron 4 CTCCATTGGGGCATCTCAT 
IL-1Ra 130bp R IL-1RN intron 4 GGGCAGCTCCGTGATGTC 
IL-1RN 5′ 
RACE R 
5′ end of IL-1RN cDNA ACAGCCCGTCCTTATAGGTGCGGAAGA 
IL-1F5 pHL F IL-1F5 cDNA. Includes 
AgeI restriction site. 
GAGAGAaccggtGTGGCGCTGTTCGATGAGTT 
IL-1F5 pHL R Includes KpnI restriction 
site. 
GAGAGAggtaccCCGGCGCCGCAGGTAGAAGG 
IL-1F5 fl F IL-1F5 cDNA ATGGTGGCGCTGTTCGAT 
IL-1F5 fl R22 IL-1F5 cDNA TCACCGGCGCCGCAGGTAGAAG 
IL-1F5 Int1 F IL-1F5 intron 1 CCCACATCCCGTCACCTC 
IL-1F5 Int1 R IL-1F5 intron 1 GTCCGGACACGAAGGACAT 
IL-1F5 332bp L IL-1F5 intron 4, and to 
amplify TAM32-21N6 
DNA 
GAGAGCTCAGCCGTACCACTA 
IL-1F5 437bp R IL-1F5 intron 4, and to 
amplify TAM32-21N6 
DNA 
GCACGACAGCGCCTTATT 
IL-1F5 Int5 F IL-1F5 intron 5 GCAATAAGGCGCTGTCGT 
IL-1F5 Int5 R IL-1F5 intron 5 TCTTATAGAACGTGTAGGGAACG 
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Table II: Primers and probes used for real-time qRT-PCR (TaqMan®) quantification 
of chicken mRNA 
Target Sequence (5′-3′) Standard Primer 
conc. 
(µM) 
IL-1RN F: CGCTGGAGGAGAAGGTGTTTT 
R: GATGTCGGCGTCCTGGAG  
P: CCCAACCGCTTCTTCAAGCACGA 
ex-COS IL-1RN 
mRNA 
0.4 
IL-1RN 
SV1 
F: ACCAAAGTCTTCAAATACCAGAAGGT  
R: GCGGATGCCCATGATGAC  
P: CGCTTCTTCAAGCACGAG 
ex-COS IL-1RN 
SV1 mRNA 
0.4 
IL-1RN 
SV2 
F: CCCACAGCCCACCCT  
R: GGAGGTGCAGAGGAACCAT  
P
a
: CCGTCCTGGAGCTGC 
ex-COS IL-1RN 
SV2 mRNA 
0.9 
IL-1F5 F: GCCCCCGAAGGTCTTATAGAA  
R: GCTGGAGGAGGTGAAGCTGTT  
P
a
: AACGGCCGCGTCC 
ex-COS IL-1F5 
mRNA 
0.6 
IL-1β F: GCTCTACATGTCGTGTGTGATGAG  
R: TGTCGATGTCCCGCATGA  
P: CCACACTGCAGCTGGAGGAAGCC 
ex-COS IL-1β 
mRNA 
0.4 
iNOS F: TTGGAAACCAAAGTGTGTAATATCTTG  
R: CCCTGGCCATGCGTACAT  
P: TCCACAGACATACAGATGCCCTTCCTCTTT 
LPS-stimulated 
HD11 mRNA 
0.2 
28S F: GGCGAAGCCAGAGGAAACT 
R: GACGACCGATTTGCACGTC  
P: AGGACCGCTACGGACCTCCACCA 
LPS-stimulated 
HD11 mRNA 
0.6 
 
a
 Indicates MGB probe. 
F = forward primer; R = reverse primer; P = probe. 
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Table III: Primers used for sequencing vector DNA inserts 
Primer name Plasmid Sequence (5′-3′) 
T3 pCI-neo ATTAACCCTCACTAAAGGGA 
T7 pTargeT™ or 
pGEM®-T Easy 
TAATACGACTCACTATAGGG 
T7 (reverse) pTargeT™ TTACGCCAAGTTATTTAGGTGACA 
SP6 pGEM®-T Easy TATTTAGGTGACACTATAG 
pHLSec F pHLSec GCTGGTTGTTGTGCTGTCTCATC 
pHLSec R pHLSec CACCAGCCACCACCTTCTGATAG 
M13 forward (-40) pBluescript II KS(+) GTTTTCCCAGTCACGAC 
M13 reverse pBluescript II KS(+) CAGGAAACAGCTATGAC 
 
 
Appendix III: Buffers 
 
Restriction enzyme buffers 
 
Buffers from Invitrogen unless stated otherwise. 
 
1X REact® 2:  50 mM Tris-HCl (pH 8.0)  
10 mM MgCl2  
50 mM NaCl 
 
1X REact® 3:  50 mM Tris-HCl (pH 8.0)  
10 mM MgCl2  
100 mM NaCl 
 
1X REact® 4:  20 mM Tris-HCl (pH 7.4)  
5 mM MgCl2  
50 mM KCl 
 
1X REact® 10:  100 mM Tris-HCl (pH 7.6)  
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10 mM MgCl2  
150 mM NaCl 
1X NEBuffer 1:  10 mM Bis-Tris-Propane-HCl  
(NEB)   10 mM MgCl2  
1 mM Dithiothreitol 
pH 7.0 @ 25°C 
 
Buffer H:   50 mM Tris-HCl (pH 7.5)  
(Roche)  10 mM MgCl2  
   100 mM NaCl 
   1 mM Dithioerythritol 
pH 7.5 @ 37°C 
 
 
Qiagen molecular biology kit buffers 
 
Details of most buffers supplied in nucleotide purification kits are not provided by 
Qiagen.  
 
RNAlater®  Details not supplied 
 
RNeasy Mini Kit 
 
Buffer RLT  contains guanidine thiocyanate 
Buffer RW1  contains guanidine thiocyanate and ethanol 
Buffer RPE  contains ethanol 
 
DNeasy Blood & Tissue Kit 
  
Buffer AL  contains guanidine hydrochloride 
Buffer AW1  contains guanidine hydrochloride and ethanol 
Buffer AW2  contains sodium azide and ethanol 
 
QIAquick PCR Purification Kit 
 
Buffer PB  contains guanidine hydrochloride and isopropanol 
Buffer PE  contains ethanol 
Buffer EB  10 mM Tris-Cl, pH 8.5 
 
QIAquick Gel Extraction Kit 
 
Buffer QG  contains guanidine thiocyanate 
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Buffer PE  contains ethanol 
Buffer EB  as above 
QIAprep Spin Miniprep Kit 
 
Buffer P1  50 mM Tris-Cl (pH 8.0)  
10 mM EDTA  
100 µg/ml RNase A 
 
Buffer P2  200 mM NaOH  
1% SDS (w/v) 
Buffer N3  contains guanidine hydrochloride 
Buffer PB  as above 
Buffer PE  as above 
 
EndoFree® Plasmid Purification Kits (Maxi/Mega)  
 
Buffer P1  as above 
Buffer P2  as above 
Buffer P3  3 M potassium acetate (CH3CO2K), pH 5.5 
Buffer FWB2  1 M CH3CO2K, pH 5.0 
Buffer QBT  750 mM NaCl 
   50 mM MOPS, pH 7.0 
   15% isopropanol (v/v) 
   0.15% Triton® X-100 
Buffer QC  1 M NaCl 
   50 mM MOPS, pH 7.0 
   15% isopropanol (v/v) 
Buffer QN  1.6 M NaCl 
   50 mM MOPS, pH 7.0 
   15% isopropanol (v/v) 
Buffer ER  contains isopropanol and polyethylene glycol octylphenyl ether 
Buffer TE  10 mM Tris-Cl (pH 8.0) 
   1 mM EDTA 
 
 
Macherey-Nagel molecular biology kit buffers 
 
NucleoBond® BAC 100 kit 
 
Buffer S1  50 mM Tris-HCl  
10 mM EDTA  
100 μg/mL RNase A, pH 8.0 
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Buffer S2  200 mM NaOH 
   1% SDS 
Buffer S3  2.8 M CH3CO2K, pH 5.1 
Buffer N2  100 mM Tris 
   15% Ethanol 
   900 mM KCl 
   0.15% Triton® X-100  
adjusted to pH 6.3 with H3PO4 
Buffer N3  100 mM Tris 
   15% Ethanol 
   1.15 M KCl 
   adjusted to pH 6.3 with H3PO4 
Buffer N5  100 mM Tris 
   15% Ethanol 
   1 M KCl 
   adjusted to pH 8.5 with H3PO4 
 
 
General buffers 
 
Pre-hybridisation solution 200 μg per ml DNA in  
10X SSC (1.5 M NaCl, 150 mM Na3C6H5O7) 
10X Denhardt's solution (20 g Ficoll, 20 g 
Polyvinylpyrrolidone, 20 g BSA) 
 
TBS buffer   10 mM Tris·Cl, pH 7.5 
150 mM NaCl 
 
TBS-Tween/Triton buffer 20 mM Tris·Cl, pH 7.5 
500 mM NaCl 
0.05% (v/v) Tween 20 
 
10X TBE   890mM Tris-borate  
890mM boric acid  
20mM EDTA 
pH 8.3 
 
PBSa    10.0g NaCl 
0.25g KCl 
1.437g Na2HPO4 
0.25g KH2PO4 
H2O to 1 l 
    pH 7.2 
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Versene   0.25g KCl 
1.437g Na2HPO4 
0.25g KH2PO4 
0.2g EDTA 
H2O to 1 l 
    pH 7.2 
 
 
Appendix IV: Cell culture reagents 
 
HD11 cell growth media 
 
10x RPMI 1640    50 ml    
tryptose phosphate broth (TPB) 50 ml      
FCS (2.5%)    12.5 ml   
Chick serum (2.5%)   12.5 ml  
7.5% NaHCO3   15 ml   
200 mM L-glutamine   5 ml   
1000X Penicillin/streptomycin 500 µl  
5 M NaOH    ~1 ml   
H2O      to 500 ml 
 
 
COS-7 cell growth media  
 
DMEM     
10% Foetal calf serum (FCS) (10%)  
1% 200 mM L-glutamine 
400 µl 1000X Penicillin/streptomycin    
4.0 ml 100X Non-essential amino acids  
 
Serum-free COS-7 cell growth media as above minus FCS. 
 
 
HEK293T growth media  
 
The same as COS-7 cell growth media. Both serum-free and 2% serum-containing 
HEK293T media are also the same as above, minus FCS and with 2% FCS, 
respectively. 
